{
 "nbformat": 4,
 "nbformat_minor": 0,
 "metadata": {
  "colab": {
   "provenance": []
  },
  "kernelspec": {
   "name": "python3",
   "display_name": "Python 3"
  },
  "language_info": {
   "name": "python"
  }
 },
 "cells": [
  {
   "cell_type": "markdown",
   "source": [
    "## Integrantes\n",
    "### Fernando Valencia"
   ],
   "metadata": {
    "id": "BZmWmFwz_woS"
   }
  },
  {
   "cell_type": "markdown",
   "source": [
    "# \ud83d\udccc Entregable 1 \u2013 Extracci\u00f3n de Entidades con Modelo NER de C\u00e1ncer de Mama\n",
    "\n",
    "Se implementa un script en Python que carga el modelo preentrenado [`anvorja/breast-cancer-biomedical-ner-sp-1`](https://huggingface.co/anvorja/breast-cancer-biomedical-ner-sp-1) para detectar entidades cl\u00ednicas en historias de c\u00e1ncer de mama. Las historias cl\u00ednicas son le\u00eddas desde archivos de texto y procesadas l\u00ednea por l\u00ednea usando un pipeline de NER con Hugging Face.\n",
    "\n"
   ],
   "metadata": {
    "id": "K6cG492BWwOv"
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "bQYH-gkMDCnb",
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "outputId": "e8ff0bef-84d8-43b2-dd7a-34f4e5b66616"
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "text": [
      "Requirement already satisfied: transformers in /usr/local/lib/python3.11/dist-packages (4.53.0)\n",
      "Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from transformers) (3.18.0)\n",
      "Requirement already satisfied: huggingface-hub<1.0,>=0.30.0 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.33.1)\n",
      "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.11/dist-packages (from transformers) (2.0.2)\n",
      "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.11/dist-packages (from transformers) (24.2)\n",
      "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.11/dist-packages (from transformers) (6.0.2)\n",
      "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.11/dist-packages (from transformers) (2024.11.6)\n",
      "Requirement already satisfied: requests in /usr/local/lib/python3.11/dist-packages (from transformers) (2.32.3)\n",
      "Requirement already satisfied: tokenizers<0.22,>=0.21 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.21.2)\n",
      "Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.5.3)\n",
      "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.11/dist-packages (from transformers) (4.67.1)\n",
      "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (2025.3.2)\n",
      "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (4.14.0)\n",
      "Requirement already satisfied: hf-xet<2.0.0,>=1.1.2 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub<1.0,>=0.30.0->transformers) (1.1.5)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests->transformers) (3.4.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.11/dist-packages (from requests->transformers) (3.10)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests->transformers) (2.4.0)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.11/dist-packages (from requests->transformers) (2025.6.15)\n",
      "Requirement already satisfied: torch in /usr/local/lib/python3.11/dist-packages (2.6.0+cu124)\n",
      "Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from torch) (3.18.0)\n",
      "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.11/dist-packages (from torch) (4.14.0)\n",
      "Requirement already satisfied: networkx in /usr/local/lib/python3.11/dist-packages (from torch) (3.5)\n",
      "Requirement already satisfied: jinja2 in /usr/local/lib/python3.11/dist-packages (from torch) (3.1.6)\n",
      "Requirement already satisfied: fsspec in /usr/local/lib/python3.11/dist-packages (from torch) (2025.3.2)\n",
      "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.127)\n",
      "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.127)\n",
      "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.127)\n",
      "Requirement already satisfied: nvidia-cudnn-cu12==9.1.0.70 in /usr/local/lib/python3.11/dist-packages (from torch) (9.1.0.70)\n",
      "Requirement already satisfied: nvidia-cublas-cu12==12.4.5.8 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.5.8)\n",
      "Requirement already satisfied: nvidia-cufft-cu12==11.2.1.3 in /usr/local/lib/python3.11/dist-packages (from torch) (11.2.1.3)\n",
      "Requirement already satisfied: nvidia-curand-cu12==10.3.5.147 in /usr/local/lib/python3.11/dist-packages (from torch) (10.3.5.147)\n",
      "Requirement already satisfied: nvidia-cusolver-cu12==11.6.1.9 in /usr/local/lib/python3.11/dist-packages (from torch) (11.6.1.9)\n",
      "Requirement already satisfied: nvidia-cusparse-cu12==12.3.1.170 in /usr/local/lib/python3.11/dist-packages (from torch) (12.3.1.170)\n",
      "Requirement already satisfied: nvidia-cusparselt-cu12==0.6.2 in /usr/local/lib/python3.11/dist-packages (from torch) (0.6.2)\n",
      "Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /usr/local/lib/python3.11/dist-packages (from torch) (2.21.5)\n",
      "Requirement already satisfied: nvidia-nvtx-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.127)\n",
      "Requirement already satisfied: nvidia-nvjitlink-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch) (12.4.127)\n",
      "Requirement already satisfied: triton==3.2.0 in /usr/local/lib/python3.11/dist-packages (from torch) (3.2.0)\n",
      "Requirement already satisfied: sympy==1.13.1 in /usr/local/lib/python3.11/dist-packages (from torch) (1.13.1)\n",
      "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.11/dist-packages (from sympy==1.13.1->torch) (1.3.0)\n",
      "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2->torch) (3.0.2)\n"
     ]
    }
   ],
   "source": [
    "# Instalaci\u00f3n de librer\u00edas necesarias\n",
    "!pip install -U transformers\n",
    "!pip install torch"
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "# \ud83d\udcc2 Carga de historias cl\u00ednicas desde Google Drive\n",
    "\n",
    "Se monta Google Drive en el entorno de Colab y se accede a la carpeta que contiene los archivos de texto con historias cl\u00ednicas. Cada archivo es le\u00eddo l\u00ednea por l\u00ednea, y se almacenan \u00fanicamente las l\u00edneas no vac\u00edas en la lista `historias`, la cual contiene todas las frases que ser\u00e1n procesadas posteriormente por los modelos de an\u00e1lisis.\n"
   ],
   "metadata": {
    "id": "sHIOFcHJD8vq"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "from google.colab import drive\n",
    "drive.mount('/content/drive')"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "zPEuqqmlLmKw",
    "outputId": "8ee2cb44-6e9a-44c9-aa60-05853c336b2d"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "text": [
      "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
     ]
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [
    "import os\n",
    "carpeta_historias = \"/content/drive/MyDrive/Analitica en Salud/Negaci\u00f3n\""
   ],
   "metadata": {
    "id": "kgsOwVGLL9BV"
   },
   "execution_count": null,
   "outputs": []
  },
  {
   "cell_type": "code",
   "source": [
    "archivos = os.listdir(carpeta_historias)\n",
    "print(len(archivos))"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "efCp5zEFMShT",
    "outputId": "e67d02c2-6512-418c-e503-8226ae791ed6"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "text": [
      "106\n"
     ]
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [
    "historias = []\n",
    "for archivo in archivos:\n",
    "  ruta_completa = os.path.join(carpeta_historias, archivo)\n",
    "  with open(ruta_completa, \"r\") as f:\n",
    "    for linea in f:\n",
    "      if linea.strip():\n",
    "        historias.append(linea.strip())"
   ],
   "metadata": {
    "id": "EjWTdgL0WmIA"
   },
   "execution_count": null,
   "outputs": []
  },
  {
   "cell_type": "code",
   "source": [
    "historias[0:10]"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "RA46Eb8iW2yI",
    "outputId": "0d9557d8-4d46-4604-a9e5-8aae5fac549f"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       "['PRIMERA CONSULTA DE ONCOLOG\u00cdA M\u00c9DICA.',\n",
       " 'Antecedentes Personales:- Alergia a Fluconazol.',\n",
       " '- No HTA.',\n",
       " 'No DM.',\n",
       " 'No DL.',\n",
       " '- Niega habitos toxicos.- Candidiasis recurrentes- Iqx: ninguna.',\n",
       " 'MEDICACI\u00d3N- No medicaci\u00f3n habitual.',\n",
       " 'Muje de 59 a\u00f1os remitida desde oncolog\u00eda con Adenocarcinoma ductal infiltrante de mama izquierda, moderadamente diferenciado de 2 cm, intervenido mediante mastectom\u00eda radical izquierda el 20/06/1991.',\n",
       " '-Carcinoma lobulillar in situ residual de 2 cm en mama dcha, intervenida el 16/04/2003 mediante mastectom\u00eda radical derecha.',\n",
       " 'Recidiva pulmonar y pleural confirmada con AP en el 2012.']"
      ]
     },
     "metadata": {},
     "execution_count": 68
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [
    "from huggingface_hub import login\n",
    "login()"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 212,
     "referenced_widgets": [
      "c3f2d37dcc5a4a03b413dff8697b0a33",
      "faf74b5941f9472d924162851fb687c2",
      "77675fa8194b4a408105c384fa3d3719",
      "007d2a3d72c74f70acd2698b5c5c4f83",
      "c4ecc82dfbfa4ffb8097f8a984685758",
      "db933007e69e4a0ba72870d7c9217bc1",
      "607b1e764e5b47cf92a5f8502994c2a9",
      "4115b506823b4a56895a377b5bbbd68b",
      "b01afe89d84645afa7c598b177747597",
      "855cdacb89dd46d2b8ccc5c60ac03d9b",
      "f07584931a1549cca775395f48d02767",
      "f2165dc98ede448e94f702da1f641320",
      "ed6955c1a0154468ad8cfd2c1fd255ef",
      "5a1429d164134168a66c01249205a2a7",
      "726e42f2f6dd443ba50f3439b152dcfb",
      "17891216203243b885e5bb115562671f",
      "cfbb81d719484249b3900b2bbf513b25",
      "f1d2c799b0da451eb0bc9f670f0d5dc1",
      "d414a91bc499411e9a12f4fe4a3c459c",
      "6647c575cab643a79cd92a0a542dfc23",
      "4acb52ea8a9143cbb772198a94bd604b",
      "dcee61025fde4c0ca0dc067750a97cd6",
      "181b1006013047988601e1f014d45067",
      "1781d6055b76452b9deb0dfb4cda5fc8",
      "4edf61ed87724d34bdbb0e313e4420f4",
      "ffa3eb8e650e4007a1ea4b11abb51ebe",
      "dca198c2faa34852900053e9275cbed8",
      "474dd095fd9f4510aa81f19c95dfde71",
      "e1a3c1deb6894277b2a1c71793d9c56d",
      "c53086326b5b4e519e47aa7f9d08381c",
      "1fa3095351464808bd560eff7f31ce85",
      "1ec7606d4a5b49edb7ad03855e84b340",
      "cd2ee107e6fe43669573924ee38c3cf5",
      "7927e63a094345c3ab05d94cf54fe442",
      "d95e8832ca614a469369c6cac63f7e8d"
     ]
    },
    "id": "CIVNLGd7NICX",
    "outputId": "3d6bcb43-447e-47e0-b724-c6d0685eb8da"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "display_data",
     "data": {
      "text/plain": [
       "VBox(children=(HTML(value='<center> <img\\nsrc=https://huggingface.co/front/assets/huggingface_logo-noborder.sv\u2026"
      ],
      "application/vnd.jupyter.widget-view+json": {
       "version_major": 2,
       "version_minor": 0,
       "model_id": "c3f2d37dcc5a4a03b413dff8697b0a33"
      }
     },
     "metadata": {}
    },
    {
     "output_type": "stream",
     "name": "stderr",
     "text": [
      "Token has not been saved to git credential helper.\n",
      "WARNING:huggingface_hub._login:Token has not been saved to git credential helper.\n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "# \ud83e\udd16 Carga del modelo NER de c\u00e1ncer de mama\n",
    "\n",
    "Se carga el modelo preentrenado `anvorja/breast-cancer-biomedical-ner-sp-1` desde Hugging Face, dise\u00f1ado para reconocer entidades biom\u00e9dicas en textos relacionados con c\u00e1ncer de mama. Se inicializa un pipeline de reconocimiento de entidades nombradas (NER), utilizando una estrategia de agregaci\u00f3n `\"simple\"` para combinar tokens subpalabra en entidades completas.\n"
   ],
   "metadata": {
    "id": "OVOmfwq0FrTA"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "from transformers import AutoTokenizer, AutoModelForTokenClassification, pipeline\n",
    "\n",
    "# Cargar el tokenizer y el modelo\n",
    "model_name = \"anvorja/breast-cancer-biomedical-ner-sp-1\"\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "model = AutoModelForTokenClassification.from_pretrained(model_name)\n",
    "\n",
    "# Crear pipeline de NER\n",
    "ner_pipeline = pipeline(\"ner\", model=model, tokenizer=tokenizer, aggregation_strategy=\"simple\")\n"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "KZHoATSIuJNl",
    "outputId": "42db6f7f-e78b-42c0-f496-ed9ba3269d5c"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "stream",
     "name": "stderr",
     "text": [
      "Device set to use cpu\n"
     ]
    }
   ]
  },
  {
   "cell_type": "markdown",
   "source": [
    "# \ud83e\uddfe Extracci\u00f3n de entidades con el modelo NER\n",
    "\n",
    "Se procesan las historias cl\u00ednicas utilizando el pipeline de NER previamente cargado. Para cada l\u00ednea del texto, se extraen las entidades reconocidas y se almacenan junto con la l\u00ednea original en una lista llamada `resultados_ner`, que contiene los resultados estructurados para su an\u00e1lisis posterior.\n"
   ],
   "metadata": {
    "id": "MC18cOYXGhgm"
   }
  },
  {
   "cell_type": "code",
   "source": [
    "# Procesar las historias cl\u00ednicas con el modelo NER\n",
    "resultados_ner = []\n",
    "\n",
    "for i, historia in enumerate(historias):\n",
    "    entidades = ner_pipeline(historia)\n",
    "    resultados_ner.append({\n",
    "        \"linea\": historia,\n",
    "        \"entidades\": entidades\n",
    "    })"
   ],
   "metadata": {
    "id": "Xx-mjpw4I6m0"
   },
   "execution_count": null,
   "outputs": []
  },
  {
   "cell_type": "code",
   "source": [
    "for r in resultados_ner:\n",
    "    print(f\"\\nTexto: {r['linea']}\")\n",
    "    for ent in r['entidades']:\n",
    "        print(f\"  \u2192 {ent['word']} ({ent['entity_group']}) [{ent['start']}-{ent['end']}]\")\n"
   ],
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "EBYYZjR9WBe1",
    "outputId": "f5f8c640-b5ca-4f38-9e38-0b577579a843"
   },
   "execution_count": null,
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "text": [
      "\n",
      "Texto: PRIMERA CONSULTA DE ONCOLOG\u00cdA M\u00c9DICA.\n",
      "  \u2192 ONCOLOG\u00cdA M\u00c9DICA (CLINICAL_SERVICE) [20-36]\n",
      "\n",
      "Texto: Antecedentes Personales:- Alergia a Fluconazol.\n",
      "  \u2192 Alergia a Fluconazol (ALLERGIES) [26-46]\n",
      "\n",
      "Texto: - No HTA.\n",
      "  \u2192 No HTA (COMORBIDITY) [2-8]\n",
      "\n",
      "Texto: No DM.\n",
      "  \u2192 No DM (COMORBIDITY) [0-5]\n",
      "\n",
      "Texto: No DL.\n",
      "  \u2192 No DL (COMORBIDITY) [0-5]\n",
      "\n",
      "Texto: - Niega habitos toxicos.- Candidiasis recurrentes- Iqx: ninguna.\n",
      "  \u2192 Candidiasis recurrentes (GINECOLOGICAL_HISTORY) [26-49]\n",
      "\n",
      "Texto: MEDICACI\u00d3N- No medicaci\u00f3n habitual.\n",
      "\n",
      "Texto: Muje de 59 a\u00f1os remitida desde oncolog\u00eda con Adenocarcinoma ductal infiltrante de mama izquierda, moderadamente diferenciado de 2 cm, intervenido mediante mastectom\u00eda radical izquierda el 20/06/1991.\n",
      "  \u2192 59 a\u00f1os (AGE) [8-15]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [16-24]\n",
      "  \u2192 oncolog\u00eda (CLINICAL_SERVICE) [31-40]\n",
      "  \u2192 Adenocarcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [45-96]\n",
      "  \u2192 intervenido (OCURRENCE_EVENT) [134-145]\n",
      "  \u2192 mastectom\u00eda radical izquierda (SURGERY) [155-184]\n",
      "  \u2192 20/06/1991 (DATE) [188-198]\n",
      "\n",
      "Texto: -Carcinoma lobulillar in situ residual de 2 cm en mama dcha, intervenida el 16/04/2003 mediante mastectom\u00eda radical derecha.\n",
      "  \u2192 Carcinoma lobulillar in situ residual (CANCER_CONCEPT) [1-38]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [61-72]\n",
      "  \u2192 16/04/2003 (DATE) [76-86]\n",
      "  \u2192 mastectom\u00eda radical derecha (SURGERY) [96-123]\n",
      "\n",
      "Texto: Recidiva pulmonar y pleural confirmada con AP en el 2012.\n",
      "  \u2192 Recidiva pulmonar y pleural (PROGRESION) [0-27]\n",
      "  \u2192 2012. (DATE) [52-57]\n",
      "\n",
      "Texto: \u00daltima revisi\u00f3n en OM el 06/02/14, programando anal\u00edtica, TAC y GGO en 3 meses.\n",
      "  \u2192 OM (CLINICAL_SERVICE) [19-21]\n",
      "  \u2192 06/02/14 (DATE) [25-33]\n",
      "  \u2192 3 meses (IMPLICIT_DATE) [71-78]\n",
      "\n",
      "Texto: Acudi\u00f3 fuera de cita el 04/04/14 por dolor lumbar y le pidieron RM lumbar que se va a realizar el 25/04/14.\n",
      "  \u2192 04/04/14 (DATE) [24-32]\n",
      "  \u2192 25/04/14 (DATE) [98-106]\n",
      "\n",
      "Texto: Tratamiento Habitual: Omeprazol 2 mg 0-0-1, Enalapril de 5 g 1-0-0.\n",
      "  \u2192 Omeprazol (DRUG) [22-31]\n",
      "  \u2192 2 mg (DOSE) [32-36]\n",
      "  \u2192 0-0-1 (FREQ) [37-42]\n",
      "  \u2192 Enalapril (DRUG) [44-53]\n",
      "  \u2192 5 g (DOSE) [57-60]\n",
      "  \u2192 1-0-0 (FREQ) [61-66]\n",
      "\n",
      "Texto: Enfermedad Actual: Mujer de 59 a\u00f1os con Ca de mama en tratamiento con BKM 120 (ensayo cl\u00ednico), en tratamiento desde hace 1 mes y medio (1 comprimido cada 12horas) y fulvesartrant 5 mg (antiestr\u00f3geno)(lleva 3 inyecciones, 1 dosis cada 15 d\u00edas, aunque actualmente 1 inyecci\u00f3n al mes).\n",
      "  \u2192 59 a\u00f1os (AGE) [28-35]\n",
      "  \u2192 Ca de mama (CANCER_CONCEPT) [40-50]\n",
      "  \u2192 BKM 120 (DRUG) [70-77]\n",
      "  \u2192 hace 1 mes y medio (IMPLICIT_DATE) [117-135]\n",
      "  \u2192 (1 comprimido (DOSE) [136-149]\n",
      "  \u2192 cada 12horas (FREQ) [150-162]\n",
      "  \u2192 fulvesartrant (DRUG) [166-179]\n",
      "  \u2192 5 mg (DOSE) [180-184]\n",
      "  \u2192 1 dosis (DOSE) [222-229]\n",
      "  \u2192 cada 15 d\u00edas (FREQ) [230-242]\n",
      "\n",
      "Texto: Presenta desde hace 7 d\u00edas, exantema en escote, abdomen y miembros inferiores, pruriginoso.Se administr\u00f3 la \u00faltima dosis de fulvestrantel 30 de Julio.\n",
      "  \u2192 hace 7 d\u00edas (IMPLICIT_DATE) [15-26]\n",
      "  \u2192 \u00faltima (OCURRENCE_EVENT) [108-114]\n",
      "  \u2192 fulvestrantel (DRUG) [124-137]\n",
      "  \u2192 30 de Julio (DATE) [138-149]\n",
      "\n",
      "Texto: No ha presentado cl\u00ednica inmediata tras la administraci\u00f3n de las inyecciones.\n",
      "\n",
      "Texto: Actualmente mantiene tratamiento con polaramine 2 mg al d\u00eda y ha cumplido tratamiento con prednisona 3 mg durante 5 d\u00edas.\n",
      "  \u2192 polaramine (DRUG) [37-47]\n",
      "  \u2192 2 mg (DOSE) [48-52]\n",
      "  \u2192 al d\u00eda (FREQ) [53-59]\n",
      "  \u2192 prednisona (DRUG) [90-100]\n",
      "  \u2192 3 mg (DOSE) [101-105]\n",
      "  \u2192 durante 5 d\u00edas (DURATION) [106-120]\n",
      "\n",
      "Texto: Suspendi\u00f3 el tratamiento con BKM 120 hace 5 d\u00edas con empeoramiento del cuadro.\n",
      "  \u2192 Suspendi\u00f3 el tratamiento (OCURRENCE_EVENT) [0-24]\n",
      "  \u2192 BKM 120 (DRUG) [29-36]\n",
      "  \u2192 hace 5 d\u00edas (IMPLICIT_DATE) [37-48]\n",
      "\n",
      "Texto: Exploraci\u00f3n F\u00edsica: Actualmente presenta exantema micropapular en abdomen, t\u00f3rax y extremidades, sin afectaci\u00f3n de mucosas ni descamaci\u00f3n.\n",
      "\n",
      "Texto: Impresi\u00f3n Diagn\u00f3stica: Exantema de probable origen medicamentoso.\n",
      "\n",
      "Texto: Mujer de 59 a\u00f1os remitida desde oncolog\u00eda m\u00e9dica con Adenocarcinoma ductal infiltrante de mama izquierda.\n",
      "  \u2192 59 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [17-25]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [32-48]\n",
      "  \u2192 Adenocarcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [53-104]\n",
      "\n",
      "Texto: Paciente de 31 a\u00f1os con diagn\u00f3stico de carcinoma ductal infiltrante de mama izquierda ( regi\u00f3n periareolar hacia cuadrante infero - interno).\n",
      "  \u2192 31 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [24-35]\n",
      "  \u2192 carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [39-85]\n",
      "\n",
      "Texto: Multifocal 2 focos muy pr\u00f3ximos de 1 mm y 7 m.\n",
      "\n",
      "Texto: Con componente intraductal asociado de grado nuclear intermedio de patr\u00f3n s\u00f3lido, sin necrosis y cancerizaci\u00f3n ductal que representa aproximadamente el 255 de la masa tumoral total.\n",
      "  \u2192 masa tumoral (CANCER_CONCEPT) [162-174]\n",
      "\n",
      "Texto: Infiltra dermis sin ulcerar epidermis.\n",
      "\n",
      "Texto: No se observa afectaci\u00f3n de la areola.\n",
      "\n",
      "Texto: No se identifican im\u00e1genes de invasi\u00f3n linfovascular.\n",
      "\n",
      "Texto: Se observa invasi\u00f3n perineural.-Bordes quir\u00fargicos definitivos: LIBRES DE AFECTACI\u00d3N: borde quir\u00fargico superficial (no cubierto por piel, CII) afecto en la pieza de mastectom\u00eda (borde libre en pieza de ampliaci\u00f3n: B13-20160).\n",
      "  \u2192 mastectom\u00eda (SURGERY) [165-176]\n",
      "\n",
      "Texto: Resto de m\u00e1rgenes a m\u00e1s de 1 cm.\n",
      "\n",
      "Texto: -ESTADIO GANGLIONAR: MACROMET\u00c1STASIS en ganglio centinela (B13-20154) (1/1sn: resultado OSNA).\n",
      "  \u2192 MACROMET\u00c1STASIS en ganglio centinela (CANCER_CONCEPT) [21-57]\n",
      "\n",
      "Texto: Ausencia de met\u00e1stasis en 15 ganglios aislados en pieza de linfadenectom\u00eda (B13-20161).\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [12-22]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [59-74]\n",
      "\n",
      "Texto: TOTAL GANGLIONAR (1/16)Estadio pTNM, (7\u00aa Ed.): pT1c(m); pN1a (1/16)ESTUDIO IHQ:- receptores de estr\u00f3genos: positivo en el 100 % de las c\u00e9lulas tumorales.\n",
      "  \u2192 pTNM (TNM) [31-35]\n",
      "  \u2192 pT1c(m); (TNM) [47-55]\n",
      "  \u2192 pN1a (TNM) [56-60]\n",
      "  \u2192 receptores de estr\u00f3genos: positivo en el 100 % (BIOMARKER) [81-127]\n",
      "  \u2192 c\u00e9lulas tumorales (CANCER_CONCEPT) [135-152]\n",
      "\n",
      "Texto: Receptores de progesterona: positivo en el 100 % de las c\u00e9lulas tumorales- CK19: positivo- Ki67: \u00edndice proliferativo de 200.\n",
      "  \u2192 Receptores de progesterona: positivo en el 100 % (BIOMARKER) [0-48]\n",
      "  \u2192 c\u00e9lulas tumorales (CANCER_CONCEPT) [56-73]\n",
      "  \u2192 CK19: positivo (BIOMARKER) [75-89]\n",
      "  \u2192 Ki67: \u00edndice proliferativo de 200 (BIOMARKER) [91-124]\n",
      "\n",
      "Texto: Herceptest: Negativo (0) Mastectom\u00eda ahorradora con ampliaci\u00f3n de margen superficial , BSGC y LA.AC x 4 - taxanos semanal por 12 .\n",
      "  \u2192 Herceptest: Negativo (0) (BIOMARKER) [0-24]\n",
      "  \u2192 Mastectom\u00eda ahorradora con ampliaci\u00f3n de margen superficial (SURGERY) [25-84]\n",
      "  \u2192 LA.AC (SURGERY) [94-99]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [100-103]\n",
      "  \u2192 taxanos (DRUG) [106-113]\n",
      "  \u2192 semanal (FREQ) [114-121]\n",
      "  \u2192 por 12 (LINE_CICLE_NUMBER) [122-128]\n",
      "\n",
      "Texto: No disnea. No sibilancias, no toma BD.\n",
      "\n",
      "Texto: Espirometr\u00eda, vol\u00famenes pulmonares y difusi\u00f3n dentro de la normalidad.\n",
      "\n",
      "Texto: Exploraci\u00f3n: eritema moderado cobn zona de descamaci\u00f3n h\u00fameda en axila.\n",
      "\n",
      "Texto: Plan: revsii\u00f3n en 3 meses o antes si precisase nueva valoraci\u00f3n.\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, T2N1M0, RE 8 % , RP 2 % , Ki 4 % , Her2 positivo, tratado con mastectom\u00eda + linfadenectom\u00eda axilar en OCTUBRE del 2014 , en mujer premenop\u00e1usica (Servicio CGD).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [0-59]\n",
      "  \u2192 T2N1M0 (TNM) [61-67]\n",
      "  \u2192 RE 8 % (BIOMARKER) [69-75]\n",
      "  \u2192 RP 2 % (BIOMARKER) [78-84]\n",
      "  \u2192 Ki 4 % (BIOMARKER) [87-93]\n",
      "  \u2192 Her2 positivo (BIOMARKER) [96-109]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [111-118]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [123-134]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [137-159]\n",
      "  \u2192 OCTUBRE del 2014 (DATE) [163-179]\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [191-205]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, T2N1M0, Her2 positivo, tratado con mastectom\u00eda + linfadenectom\u00eda axilar en OCTUBRE del 2014 , en mujer premenop\u00e1usica (Servicio CGD).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [0-59]\n",
      "  \u2192 T2N1M0 (TNM) [61-67]\n",
      "  \u2192 Her2 positivo (BIOMARKER) [69-82]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [84-91]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [96-107]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [110-132]\n",
      "  \u2192 OCTUBRE del 2014 (DATE) [136-152]\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [164-178]\n",
      "\n",
      "Texto: HA recibido tto con AC - Paclitaxel + herceptin.\n",
      "  \u2192 AC (DRUG) [20-22]\n",
      "  \u2192 Paclitaxel (DRUG) [25-35]\n",
      "  \u2192 herceptin (DRUG) [38-47]\n",
      "\n",
      "Texto: Ha recibido RT . Finalizada la quimioterapia en Mayo del 2015 y Finalizado Herceptin en ENERO 2016.\n",
      "  \u2192 RT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 Finalizada (OCURRENCE_EVENT) [17-27]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [31-44]\n",
      "  \u2192 Mayo del 2015 (DATE) [48-61]\n",
      "  \u2192 Finalizado (OCURRENCE_EVENT) [64-74]\n",
      "  \u2192 Herceptin (DRUG) [75-84]\n",
      "  \u2192 ENERO 2016. (DATE) [88-99]\n",
      "\n",
      "Texto: Tratamiento con TAMOXIFENO desde agosto de 2015, sustituido en diciembre de 2017 por Letrozol.\n",
      "  \u2192 TAMOXIFENO (DRUG) [16-26]\n",
      "  \u2192 agosto de 2015, (DATE) [33-48]\n",
      "  \u2192 sustituido (OCURRENCE_EVENT) [49-59]\n",
      "  \u2192 diciembre de 2017 (DATE) [63-80]\n",
      "  \u2192 Letrozol (DRUG) [85-93]\n",
      "\n",
      "Texto: Presenta dolor intenso en la zona dorsal se ha relaixzado RMN cervical que evidencia patologia degenerativa y contractura del dorsal.\n",
      "  \u2192 patologia degenerativa (COMORBIDITY) [85-107]\n",
      "\n",
      "Texto: No otra clinica EXPLORACION Mastectomia derecha.\n",
      "  \u2192 Mastectomia derecha (SURGERY) [28-47]\n",
      "\n",
      "Texto: No adenoptias .\n",
      "  \u2192 No adenoptias (COMORBIDITY) [0-13]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha G2/3, pT2 pN1a cM0.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 G2/3 (STAGE) [45-49]\n",
      "  \u2192 pT2 pN1a cM0 (TNM) [51-63]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha G2/3, pT2 pN1a cM0.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 G2/3 (STAGE) [45-49]\n",
      "  \u2192 pT2 pN1a cM0 (TNM) [51-63]\n",
      "\n",
      "Texto: RH positivos, Her2 negativo.\n",
      "  \u2192 RH positivos (BIOMARKER) [0-12]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [14-27]\n",
      "\n",
      "Texto: Tratado con cuadrantectom\u00eda en AGOSTO del 2014.\n",
      "  \u2192 Tratado (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [12-27]\n",
      "  \u2192 AGOSTO del 2014. (DATE) [31-47]\n",
      "\n",
      "Texto: Ha recibico AC - Paclitaxel , RT y TAMOXIFENO desde Julio del 2015.\n",
      "  \u2192 AC (DRUG) [12-14]\n",
      "  \u2192 Paclitaxel (DRUG) [17-27]\n",
      "  \u2192 RT (TREATMENT_NAME) [30-32]\n",
      "  \u2192 TAMOXIFENO (DRUG) [35-45]\n",
      "  \u2192 Julio del 2015. (DATE) [52-67]\n",
      "\n",
      "Texto: En tto con ZOLADEX + EXEMESTANO desde Julio del 2016.\n",
      "  \u2192 ZOLADEX (DRUG) [11-18]\n",
      "  \u2192 EXEMESTANO (DRUG) [21-31]\n",
      "  \u2192 Julio del 2016. (DATE) [38-53]\n",
      "\n",
      "Texto: Suspendido ZOLADEX en Agosto del 2018.\n",
      "  \u2192 Suspendido (OCURRENCE_EVENT) [0-10]\n",
      "  \u2192 ZOLADEX (DRUG) [11-18]\n",
      "  \u2192 Agosto del 2018. (DATE) [22-38]\n",
      "\n",
      "Texto: En tto con exemestano que sustituyo por TAMOXIFENo ya que ha comenzado a tener menstruaciones irregilares.\n",
      "  \u2192 exemestano (DRUG) [11-21]\n",
      "  \u2192 sustituyo (OCURRENCE_EVENT) [26-35]\n",
      "  \u2192 TAMOXIFENo (DRUG) [40-50]\n",
      "  \u2192 menstruaciones irregilares (GINECOLOGICAL_HISTORY) [79-105]\n",
      "\n",
      "Texto: Menstruaciones irregulares.\n",
      "  \u2192 Menstruaciones irregulares (GINECOLOGICAL_HISTORY) [0-26]\n",
      "\n",
      "Texto: Paciente de 49 a\u00f1os que ha sido diagnosticada de Carcinoma ductal infiltrante de mama izquierda , RE 95 % RPG 50 % HER2 negativo, cT2,cN2,cM1 estadio IV en contexto de lesi\u00f3n vertebral.\n",
      "  \u2192 49 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [49-95]\n",
      "  \u2192 RE 95 % (BIOMARKER) [98-105]\n",
      "  \u2192 RPG 50 % (BIOMARKER) [106-114]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [115-128]\n",
      "  \u2192 cT2,cN2,cM1 (TNM) [130-141]\n",
      "  \u2192 estadio IV (STAGE) [142-152]\n",
      "\n",
      "Texto: PET:HALLAZGOS SUGERENTES DE MALIGNIDAD EN MAMA DERECHA, ADENOPAT\u00cdAS AXILARES Y EN CADENA MAMARIA INTERNA DERECHAS Y EN LESI\u00d3N \u00d3SEA.\n",
      "  \u2192 MALIGNIDAD (COMORBIDITY) [28-38]\n",
      "  \u2192 ADENOPAT\u00cdAS AXILARES (COMORBIDITY) [56-76]\n",
      "\n",
      "Texto: LESI\u00d3N CEREBRAL QUE RECOMENDAMOS VALORAR COMPLEMENTARIAMENTE.\n",
      "\n",
      "Texto: Captaci\u00f3n focal patol\u00f3gica en hemicuerpo izquierdo de T9, coincidente con una lesi\u00f3n mal definida, levemente esclerosa, sugerente de malignidad RM cerebral:2019-12-12 Sin anomal\u00edas en uni\u00f3n craneocervical.\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [133-143]\n",
      "  \u2192 2019-12-12 (DATE) [156-166]\n",
      "\n",
      "Texto: En el compartimento infratentorial no se identifican lesiones en el cerebelo ni el tronco del enc\u00e9falo, de morfolog\u00eda conservada.\n",
      "\n",
      "Texto: Paciente de 49 a\u00f1os que ha sido diagnosticada de Carcinoma ductal infiltrante de mama izquierda HER2 negativo, cT2,cN2,cM1 estadio IV en contexto de lesi\u00f3n vertebral.\n",
      "  \u2192 49 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [49-95]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [96-109]\n",
      "  \u2192 cT2,cN2,cM1 (TNM) [111-122]\n",
      "  \u2192 estadio IV (STAGE) [123-133]\n",
      "\n",
      "Texto: El compartimento supratentorial llama la atenci\u00f3n la presencia de m\u00faltiples estructuras con vac\u00edo de se\u00f1al, de distintos calibres ,que adoptan morfolog\u00eda tortuosa y serpiginosa sugestivos de MAV pial situada en sustancia blanca subcortical parietal izquierda, cuyo l\u00edmite anterosuperior de estructuras vasculares alcanza la circunvoluci\u00f3n posrol\u00e1ndica y que en profundidad se dirige al atrio del VL izquierdo con componente intraventricular.\n",
      "\n",
      "Texto: Paciente de 49 a\u00f1os que ha sido diagnosticada de Carcinoma ductal infiltrante de mama izquierda cT2,cN2,cM1 estadio IV en contexto de lesi\u00f3n vertebral.\n",
      "  \u2192 49 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [49-95]\n",
      "  \u2192 cT2,cN2,cM1 (TNM) [96-107]\n",
      "  \u2192 estadio IV (STAGE) [108-118]\n",
      "\n",
      "Texto: El nidus malformativo supera los 3 cent\u00edmetros de di\u00e1metro, cuya medida est\u00e1 dificultada por la interposici\u00f3n de prominente vena de drenaje que se dirige hacia la porci\u00f3n posterior del seno sagital superior y tambi\u00e9n se observan elementos vasculares prominentes que se dirigen hacia el sistema venoso profundo en las proximidades de la cisterna supravermiana.\n",
      "\n",
      "Texto: Paciente de 49 a\u00f1os que ha sido diagnosticada de Carcinoma ductal infiltrante de mama izquierda cT2,cN2,cM1 estadio IV en contexto de lesi\u00f3n vertebral.\n",
      "  \u2192 49 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [49-95]\n",
      "  \u2192 cT2,cN2,cM1 (TNM) [96-107]\n",
      "  \u2192 estadio IV (STAGE) [108-118]\n",
      "\n",
      "Texto: El aporte arterial podr\u00eda depender de la ACM izquierda ya que se objetivan elementos vasculares prominentes en la cisura de Silvio izquierda, sin poder descartar componente dependiente de la arteria cerebral posterior izquierda.\n",
      "\n",
      "Texto: Se identifican hiperse\u00f1al hiperse\u00f1al en T2/Flair en el escaso par\u00e9nquima encef\u00e1lico interpuesto que podr\u00eda corresponder a gliosis, se aprecia hiperse\u00f1al en secuencias potenciadas en T1 que no presenta artefacto en el estudio de difusi\u00f3n , hallazgo esperable si se tratase de componente hem\u00e1tico.\n",
      "  \u2192 gliosis (COMORBIDITY) [122-129]\n",
      "\n",
      "Texto: No se identifican focos de restricci\u00f3n a la difusi\u00f3n tampoco como expresi\u00f3n de lesiones isqu\u00e9micas agudas ni otras alteraciones en el par\u00e9nquima encef\u00e1lico perilesional sugestivas de edema perilesional como datos de complicaci\u00f3n.\n",
      "\n",
      "Texto: No se detectan otras alteraciones de intensidad de se\u00f1al en el par\u00e9nquima encef\u00e1lico ni se identifican otros realces patol\u00f3gicos intra ni extraaxiales en compartimento infra ni supratentorial.\n",
      "\n",
      "Texto: Sistema ventricular de tama\u00f1o, situaci\u00f3n y morfolog\u00eda conservada.\n",
      "\n",
      "Texto: Probable quiste de retenci\u00f3n mucoso en antro maxilar izquierdo.\n",
      "\n",
      "Texto: Mujer de 44 a\u00f1os que acude por diarrea.\n",
      "  \u2192 44 a\u00f1os (AGE) [9-16]\n",
      "\n",
      "Texto: Antecedentes personales- RAMc: alergia a penicilina.\n",
      "  \u2192 RAMc (ALLERGIES) [25-29]\n",
      "  \u2192 alergia a penicilina (ALLERGIES) [31-51]\n",
      "\n",
      "Texto: Tras descartarse en Alergia en el \u00faltimo parto tras administrar penicilina presenta reacci\u00f3n urticariforme de nuevo.\n",
      "  \u2192 Tras descartarse (OCURRENCE_EVENT) [0-16]\n",
      "  \u2192 \u00faltimo parto (GINE_OBSTETRICS) [34-46]\n",
      "  \u2192 tras administrar (OCURRENCE_EVENT) [47-63]\n",
      "  \u2192 penicilina (DRUG) [64-74]\n",
      "\n",
      "Texto: - Par\u00e1lisis facial.\n",
      "  \u2192 Par\u00e1lisis facial (COMORBIDITY) [2-18]\n",
      "\n",
      "Texto: -H\u00e1bitos t\u00f3xicos: Fumadora 4-5 cig/d\u00eda desde los 18 a\u00f1os.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [18-26]\n",
      "  \u2192 4-5 cig (HABIT-QUANTITY) [27-34]\n",
      "  \u2192 d\u00eda (FREQ) [35-38]\n",
      "  \u2192 desde los 18 a\u00f1os (DURATION) [39-56]\n",
      "\n",
      "Texto: No bebedora.\n",
      "  \u2192 No bebedora (TOXIC_HABITS) [0-11]\n",
      "\n",
      "Texto: Tratamiento habitual: Dumirox.\n",
      "  \u2192 Dumirox (DRUG) [22-29]\n",
      "\n",
      "Texto: Resumen de historia oncol\u00f3gica: Diagnosticada de Carcinoma ductal infiltrante de mama izquierda cT2 pN1cMx0, Her2 Positivo.\n",
      "  \u2192 Diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [49-95]\n",
      "  \u2192 cT2 pN1cMx0 (TNM) [96-107]\n",
      "  \u2192 Her2 Positivo (BIOMARKER) [109-122]\n",
      "\n",
      "Texto: Inicia quimioterapia ensayo clinico con Trastuzumab + Paclitaxel con repuesta parcial el 17.02.2015.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [7-20]\n",
      "  \u2192 Trastuzumab (DRUG) [40-51]\n",
      "  \u2192 Paclitaxel (DRUG) [54-64]\n",
      "  \u2192 17.02.2015 (DATE) [89-99]\n",
      "\n",
      "Texto: Mastectom\u00eda izda + linfadenectom\u00eda izda ypT1ypN0+M0.\n",
      "  \u2192 Mastectom\u00eda izda (SURGERY) [0-16]\n",
      "  \u2192 linfadenectom\u00eda izda (SURGERY) [19-39]\n",
      "  \u2192 ypT1ypN0+M0 (TNM) [40-51]\n",
      "\n",
      "Texto: Mujer diagnosticada de metastasis hepatica y osea de ca mama HER2 + en FEBRERO del 2018 .\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 metastasis hepatica y osea (CANCER_CONCEPT) [23-49]\n",
      "  \u2192 ca mama (CANCER_CONCEPT) [53-60]\n",
      "  \u2192 HER2 + (BIOMARKER) [61-67]\n",
      "  \u2192 FEBRERO del 2018 (DATE) [71-87]\n",
      "\n",
      "Texto: Inicia tratamiento con PERTUZUMAB, TRASTUZUMAB y DOCETAXEL hace un mes.\n",
      "  \u2192 Inicia tratamiento (OCURRENCE_EVENT) [0-18]\n",
      "  \u2192 PERTUZUMAB (DRUG) [23-33]\n",
      "  \u2192 TRASTUZUMAB (DRUG) [35-46]\n",
      "  \u2192 DOCETAXEL (DRUG) [49-58]\n",
      "  \u2192 hace un mes (IMPLICIT_DATE) [59-70]\n",
      "\n",
      "Texto: Mujer de 44 a\u00f1os que acude por diarrea de 6 desposiciones diarias desde hace 2 d\u00edas, sin fiebre ni tiritona.\n",
      "  \u2192 44 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diarias (FREQ) [58-65]\n",
      "  \u2192 hace 2 d\u00edas (IMPLICIT_DATE) [72-83]\n",
      "\n",
      "Texto: Pacientede 37 a\u00f1os a la que se le realizo en junio de 2011 una ecograf\u00eda mamaria por notarse una tumoraci\u00f3n en mama derecha objetiv\u00e1ndose una lesi\u00f3n de 16 x 7 mm.\n",
      "  \u2192 37 a\u00f1os (AGE) [11-18]\n",
      "  \u2192 junio de 2011 (DATE) [45-58]\n",
      "  \u2192 tumoraci\u00f3n en mama derecha (CANCER_CONCEPT) [97-123]\n",
      "\n",
      "Texto: Niega HTA, DM2 o Dislipemias.\n",
      "  \u2192 Niega HTA, DM2 o Dislipemias (COMORBIDITY) [0-28]\n",
      "\n",
      "Texto: Fumadora de 8 cigarrillos al d\u00eda.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [0-8]\n",
      "  \u2192 8 cigarrillos (HABIT-QUANTITY) [12-25]\n",
      "  \u2192 al d\u00eda (FREQ) [26-32]\n",
      "\n",
      "Texto: Medicaci\u00f3n habitual: Lormetazepam 0-0-1, escitalopram 1-0-0.\n",
      "  \u2192 Lormetazepam (DRUG) [21-33]\n",
      "  \u2192 0-0-1 (FREQ) [34-39]\n",
      "  \u2192 escitalopram (DRUG) [41-53]\n",
      "  \u2192 1-0-0 (FREQ) [54-59]\n",
      "\n",
      "Texto: Antecedentes familiares oncol\u00f3gicos: Madre con ca g\u00e1strico.\n",
      "  \u2192 Madre (FAMILY) [37-42]\n",
      "  \u2192 ca g\u00e1strico (CANCER_CONCEPT) [47-58]\n",
      "\n",
      "Texto: T\u00eda con ca de mama a los 52 a\u00f1os.\n",
      "  \u2192 T\u00eda (FAMILY) [0-3]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [8-18]\n",
      "  \u2192 52 a\u00f1os (AGE) [25-32]\n",
      "\n",
      "Texto: H\u00e1bitos t\u00f3xicos: Fumadora de 8 cigarros diarios.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [17-25]\n",
      "  \u2192 8 cigarros (HABIT-QUANTITY) [29-39]\n",
      "  \u2192 diarios (FREQ) [40-47]\n",
      "\n",
      "Texto: Antedentes familiares: Madre diagnosticada con ca de mama hace 5 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [23-28]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [29-42]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [47-57]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [58-69]\n",
      "\n",
      "Texto: En agosto de 2011 se realiza BAG: incluye un lobulillo con fibrosis, sin otras lesiones significativas.\n",
      "  \u2192 agosto de 2011 (DATE) [3-17]\n",
      "\n",
      "Texto: No se identifica infiltraci\u00f3n tumoral.\n",
      "  \u2192 infiltraci\u00f3n (CANCER_CONCEPT) [17-29]\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [30-37]\n",
      "\n",
      "Texto: Se cita en 6 meses para nueva mamograf\u00eda que se realiza el 15/02/2012.\n",
      "  \u2192 15/02/2012 (DATE) [59-69]\n",
      "\n",
      "Texto: Se realiza punci\u00f3n con fecha 15/02/2011.\n",
      "  \u2192 15/02/2011 (DATE) [29-39]\n",
      "\n",
      "Texto: Tiene realizada punci\u00f3n previa en julio de 2011.\n",
      "  \u2192 julio de 2011. (DATE) [34-48]\n",
      "\n",
      "Texto: Cilindro de mama con CARCINOMA LOBULILLAR INFILTRANTE, que expresa el siguiente inmunofenotipo:- CK19 positiva, Receptores de estr\u00f3genos: positividad del 90 % .\n",
      "  \u2192 CARCINOMA LOBULILLAR INFILTRANTE (CANCER_CONCEPT) [21-53]\n",
      "  \u2192 CK19 positiva (BIOMARKER) [97-110]\n",
      "  \u2192 Receptores de estr\u00f3genos: positividad del 90 % (BIOMARKER) [112-158]\n",
      "\n",
      "Texto: Receptores de progesterona: positividad del 75 %, HER2 negativo.\n",
      "  \u2192 Receptores de progesterona: positividad del 75 % (BIOMARKER) [0-48]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [50-63]\n",
      "\n",
      "Texto: Diagnostico con HER2 negativo.\n",
      "  \u2192 Diagnostico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [16-29]\n",
      "\n",
      "Texto: Diagnostico con HER2 negativo.\n",
      "  \u2192 Diagnostico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [16-29]\n",
      "\n",
      "Texto: Pieza correspondiente a mama derecha con CARCINOMA INFILTRANTE DE PATR\u00d3N LOBULILLAR de 4,3 cm.\n",
      "  \u2192 CARCINOMA INFILTRANTE DE PATR\u00d3N LOBULILLAR (CANCER_CONCEPT) [41-83]\n",
      "\n",
      "Texto: Carcinoma lobulillar infiltrante pT3 (m) N1a (1 +) M0.\n",
      "  \u2192 Carcinoma lobulillar infiltrante (CANCER_CONCEPT) [0-32]\n",
      "  \u2192 pT3 (TNM) [33-36]\n",
      "  \u2192 N1a (TNM) [41-44]\n",
      "  \u2192 M0 (TNM) [51-53]\n",
      "\n",
      "Texto: Estadio IIIA.\n",
      "  \u2192 Estadio IIIA (STAGE) [0-12]\n",
      "\n",
      "Texto: RE 2 %, RP -, HER2 0(negativo).\n",
      "  \u2192 RE 2 % (BIOMARKER) [0-6]\n",
      "  \u2192 RP - (BIOMARKER) [8-12]\n",
      "  \u2192 HER2 0(negativo (BIOMARKER) [14-29]\n",
      "\n",
      "Texto: Carcinoma lobulillar in situ.\n",
      "  \u2192 Carcinoma lobulillar in situ (CANCER_CONCEPT) [0-28]\n",
      "\n",
      "Texto: Bordes libres.\n",
      "\n",
      "Texto: Tratamiento quimioter\u00e1pico adyuvante con AC-T (Doxorrubicina 60 mg/m2, ciclofosfamida 600 mg/m2 cada 21 d\u00edas 4 ciclos.\n",
      "  \u2192 Tratamiento quimioter\u00e1pico adyuvante (TREATMENT_NAME) [0-36]\n",
      "  \u2192 AC-T (DRUG) [41-45]\n",
      "  \u2192 Doxorrubicina (DRUG) [47-60]\n",
      "  \u2192 60 mg/m2 (DOSE) [61-69]\n",
      "  \u2192 ciclofosfamida (DRUG) [71-85]\n",
      "  \u2192 600 mg/m2 (DOSE) [86-95]\n",
      "  \u2192 cada 21 d\u00edas (FREQ) [96-108]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [109-117]\n",
      "\n",
      "Texto: Seguido de Taxol semanal, 12 ciclos que finaliza en ABRIL del 2017.\n",
      "  \u2192 Segui (OCURRENCE_EVENT) [0-5]\n",
      "  \u2192 Taxol (DRUG) [11-16]\n",
      "  \u2192 semanal (FREQ) [17-24]\n",
      "  \u2192 12 ciclos (LINE_CICLE_NUMBER) [26-35]\n",
      "  \u2192 finaliza (OCURRENCE_EVENT) [40-48]\n",
      "  \u2192 ABRIL del 2017. (DATE) [52-67]\n",
      "\n",
      "Texto: RT hasta Junio del 2017, Inicia tratamiento hormonal en Agosto del 2017 con LETROZOL + PALBOCICLIBHA tenido una infeccion de orina por Proteus mirabilis tratada con antibioticos ( fosfomicina 2 dosis).\n",
      "  \u2192 RT (TREATMENT_NAME) [0-2]\n",
      "  \u2192 Junio del 2017 (DATE) [9-23]\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [25-31]\n",
      "  \u2192 tratamiento hormonal (TREATMENT_NAME) [32-52]\n",
      "  \u2192 Agosto del 2017 (DATE) [56-71]\n",
      "  \u2192 LETROZOL (DRUG) [76-84]\n",
      "  \u2192 PALBOCICLIBHA (DRUG) [87-100]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [153-160]\n",
      "  \u2192 fosfomicina (DRUG) [180-191]\n",
      "  \u2192 2 dosis (DOSE) [192-199]\n",
      "\n",
      "Texto: Infeccion de vias altas sin fiebre.\n",
      "\n",
      "Texto: Paciente de 37 a\u00f1os a la que se le realizo en junio de 2011 una ecograf\u00eda mamaria por notarse una tumoraci\u00f3n en mama derecha objetiv\u00e1ndose una lesi\u00f3n de 16 x 7 mm.\n",
      "  \u2192 37 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 junio de 2011 (DATE) [46-59]\n",
      "  \u2192 tumoraci\u00f3n en mama derecha (CANCER_CONCEPT) [98-124]\n",
      "\n",
      "Texto: En agosto de 2011 se realiza BAG: incluye un lobulillo con fibrosis, sin otras lesiones significativas.\n",
      "  \u2192 agosto de 2011 (DATE) [3-17]\n",
      "\n",
      "Texto: No se identifica infiltraci\u00f3n tumoral.\n",
      "  \u2192 infiltraci\u00f3n (CANCER_CONCEPT) [17-29]\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [30-37]\n",
      "\n",
      "Texto: Se cita en 6 meses para nueva mamograf\u00eda que se realiza el 15/02/2012.\n",
      "  \u2192 15/02/2012 (DATE) [59-69]\n",
      "\n",
      "Texto: Mamograf\u00eda bilateral y ecograf\u00eda de mama derecha: tumoraci\u00f3n de mama.\n",
      "  \u2192 tumoraci\u00f3n de mama (CANCER_CONCEPT) [50-68]\n",
      "\n",
      "Texto: Se realiza punci\u00f3n con fecha 15/02/2011.\n",
      "  \u2192 15/02/2011 (DATE) [29-39]\n",
      "\n",
      "Texto: Tiene realizada punci\u00f3n previa en julio de 2011.\n",
      "  \u2192 julio de 2011. (DATE) [34-48]\n",
      "\n",
      "Texto: Caracter\u00edsticas de corresponder probablemente a TUMOR FILODES.\n",
      "  \u2192 TUMOR FILODES (CANCER_CONCEPT) [48-61]\n",
      "\n",
      "Texto: Se realiza BAG de la lesi\u00f3n ese mismo d\u00eda: Cilindro de mama con CARCINOMA LOBULILLAR INFILTRANTE, que expresa el siguiente inmunofenotipo: - CK19 positiva, Receptores de estr\u00f3genos: positividad del 90 p.\n",
      "  \u2192 CARCINOMA LOBULILLAR INFILTRANTE (CANCER_CONCEPT) [64-96]\n",
      "  \u2192 CK19 positiva (BIOMARKER) [141-154]\n",
      "  \u2192 Receptores de estr\u00f3genos: positividad del 90 p (BIOMARKER) [156-202]\n",
      "\n",
      "Texto: - Receptores de progesterona: positividad del 75 %.\n",
      "  \u2192 Receptores de progesterona: positividad del 75 %. (BIOMARKER) [2-51]\n",
      "\n",
      "Texto: Indice de proliferaci\u00f3n medido con ki-67 : 25 % , HER2 negativo.\n",
      "  \u2192 ki-67 : 25 % (BIOMARKER) [35-47]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [50-63]\n",
      "\n",
      "Texto: Estudio de extensi\u00f3n ( ecograf\u00eda de abdomen, Rx t\u00f3rax y GGO) sin hallazgos.\n",
      "\n",
      "Texto: Se realiza mastectom\u00eda + BSGC + reconstrucci\u00f3n inmediata el 15/03/2012.\n",
      "  \u2192 mastectom\u00eda (SURGERY) [11-22]\n",
      "  \u2192 BSGC (SURGERY) [25-29]\n",
      "  \u2192 reconstrucci\u00f3n inmediata (SURGERY) [32-56]\n",
      "  \u2192 15/03/2012 (DATE) [60-70]\n",
      "\n",
      "Texto: Pieza correspondiente a mama derecha con CARCINOMA INFILTRANTE DE PATR\u00d3N LOBULILLAR de 4,3 cm que se dispone a 1 mm del margen quir\u00fargico profundo.\n",
      "  \u2192 CARCINOMA INFILTRANTE DE PATR\u00d3N LOBULILLAR (CANCER_CONCEPT) [41-83]\n",
      "\n",
      "Texto: Mide 4,3 cms y muestra im\u00e1genes focales de invasi\u00f3n linfo-vascular.\n",
      "\n",
      "Texto: Par\u00e9nquima mamario con cambios de mastopat\u00eda fibroqu\u00edstica.\n",
      "  \u2192 mastopat\u00eda fibroqu\u00edstica (COMORBIDITY) [34-58]\n",
      "\n",
      "Texto: Ganglios linf\u00e1ticos ( los centinelas) con MET\u00c1STASIS.\n",
      "  \u2192 MET\u00c1STASIS (CANCER_CONCEPT) [42-52]\n",
      "\n",
      "Texto: Paciente tratada con Linfadenectom\u00eda hace 2 meses.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Linfadenectom\u00eda (SURGERY) [21-36]\n",
      "  \u2192 hace 2 meses (IMPLICIT_DATE) [37-49]\n",
      "\n",
      "Texto: Paciente tratada con Linfadenectom\u00eda hace 2 meses.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Linfadenectom\u00eda (SURGERY) [21-36]\n",
      "  \u2192 hace 2 meses (IMPLICIT_DATE) [37-49]\n",
      "\n",
      "Texto: Env\u00edan a la paciente para valorar adyuvancia.\n",
      "  \u2192 adyuvancia (TREATMENT_NAME) [34-44]\n",
      "\n",
      "Texto: Indice de proliferaci\u00f3n medido con ki-67 25 %, HER2 negativo.\n",
      "  \u2192 ki-67 25 % (BIOMARKER) [35-45]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [47-60]\n",
      "\n",
      "Texto: PRIMERA CONSULTA ONCOLOG\u00cdA M\u00c9DICA.\n",
      "  \u2192 ONCOLOG\u00cdA M\u00c9DICA (CLINICAL_SERVICE) [17-33]\n",
      "\n",
      "Texto: Mujer de 36 a\u00f1os con dx de carcinoma de mama, aacude a consulta para valoraci\u00f3n de tratamiento neoadyuvante.\n",
      "  \u2192 36 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 dx (OCURRENCE_EVENT) [21-23]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [27-44]\n",
      "  \u2192 tratamiento neoadyuvante (TREATMENT_NAME) [83-107]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES: No RAMC.\n",
      "  \u2192 No RAMC (ALLERGIES) [25-32]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: Niega h\u00e1bitos t\u00f3xicos.\n",
      "\n",
      "Texto: Antecedentes ginecol\u00f3gicos: menarquia 10-11 a\u00f1os, no gestaciones ni abortos.\n",
      "  \u2192 menarquia (GINECOLOGICAL_HISTORY) [28-37]\n",
      "  \u2192 10-11 a\u00f1os (AGE) [38-48]\n",
      "  \u2192 gestaciones (GINE_OBSTETRICS) [53-64]\n",
      "  \u2192 abortos (GINE_OBSTETRICS) [68-75]\n",
      "\n",
      "Texto: No tratamiento habitual.\n",
      "\n",
      "Texto: No refiere antecedentes familiares oncol\u00f3gicos.\n",
      "\n",
      "Texto: Mujer de 49 a\u00f1os que acude a control anual en ginecolog\u00eda.\n",
      "  \u2192 49 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 anual (FREQ) [37-42]\n",
      "  \u2192 ginecolog\u00eda (CLINICAL_SERVICE) [46-57]\n",
      "\n",
      "Texto: AP:- Hipotiroidismo quir\u00fargico en 2012,, CARCINOMA DUCTAL INFILTRANTE / Grado1 .\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [5-19]\n",
      "  \u2192 CARCINOMA DUCTAL INFILTRANTE (CANCER_CONCEPT) [41-69]\n",
      "  \u2192 Grado1 (STAGE) [72-78]\n",
      "\n",
      "Texto: Mujer de 49 a\u00f1os con Carcinoma Ductual infiltrante y omponente intraductal asociado de grado nuclear intermedio pT2 N1mi Mx.\n",
      "  \u2192 49 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 Carcinoma Ductual infiltrante y omponente intraductal (CANCER_CONCEPT) [21-74]\n",
      "  \u2192 pT2 N1mi Mx (TNM) [112-123]\n",
      "\n",
      "Texto: Invasi\u00f3n linfovascular + perineural.\n",
      "\n",
      "Texto: Her2 negativo.\n",
      "  \u2192 Her2 negativo (BIOMARKER) [0-13]\n",
      "\n",
      "Texto: (24/04/2012) mastectomia derecha ahorradora de piel + LA + reconstrucci\u00f3n con colgajo libre gracilis y posterior DA-QMT: AC-T hasta oct 2012.\n",
      "  \u2192 (24/04/2012 (DATE) [0-11]\n",
      "  \u2192 mastectomia derecha ahorradora de piel (SURGERY) [13-51]\n",
      "  \u2192 LA (SURGERY) [54-56]\n",
      "  \u2192 reconstrucci\u00f3n con colgajo (SURGERY) [59-85]\n",
      "  \u2192 DA-QMT: AC-T (TREATMENT_NAME) [113-125]\n",
      "  \u2192 oct 2012. (DATE) [132-141]\n",
      "\n",
      "Texto: -RDT-HMT: Tamoxifeno 5 a\u00f1os, Se encuentra bien, refiere que ha estado sin reglas desde diciembre hasta abril que ha tenido su FUR 30/03/2018.\n",
      "  \u2192 Tamoxifeno (DRUG) [10-20]\n",
      "  \u2192 5 a\u00f1os (DURATION) [21-27]\n",
      "  \u2192 reglas (GINECOLOGICAL_HISTORY) [74-80]\n",
      "  \u2192 diciembre (DATE) [87-96]\n",
      "  \u2192 abril (DATE) [103-108]\n",
      "  \u2192 FUR (GINECOLOGICAL_HISTORY) [126-129]\n",
      "  \u2192 30/03/2018 (DATE) [130-140]\n",
      "\n",
      "Texto: Molestias vaginales pese a lubricantes e hidratantes (pero que solo usa cuando tiene molestias no de forma regular).\n",
      "  \u2192 Molestias vaginales (GINECOLOGICAL_HISTORY) [0-19]\n",
      "\n",
      "Texto: Ha terminado el tratamiento con tamoxifeno, Refiere que le han dado de alta desde oncologia medica.\n",
      "  \u2192 terminado el tratamiento (OCURRENCE_EVENT) [3-27]\n",
      "  \u2192 tamoxifeno (DRUG) [32-42]\n",
      "  \u2192 dado de alta (OCURRENCE_EVENT) [63-75]\n",
      "  \u2192 oncologia medica (CLINICAL_SERVICE) [82-98]\n",
      "\n",
      "Texto: No leucorrea.\n",
      "\n",
      "Texto: Eco TV: Utero normal con DIU normoinserto. imagen econegativa sin tabiques ni papilas de 26 mm de aspecto funcional.\n",
      "  \u2192 DIU normoinserto (GINECOLOGICAL_HISTORY) [25-41]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante T2N0M0, receptores hormonales positivos, HER2 negativo.\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 T2N0M0 (TNM) [29-35]\n",
      "  \u2192 receptores hormonales positivos (BIOMARKER) [37-68]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [70-83]\n",
      "\n",
      "Texto: Mujer Premenopausica tratada con Mastectomia en Julio del 2009.\n",
      "  \u2192 Premenopausica (GINECOLOGICAL_HISTORY) [6-20]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [21-28]\n",
      "  \u2192 Mastectomia (SURGERY) [33-44]\n",
      "  \u2192 Julio del 2009. (DATE) [48-63]\n",
      "\n",
      "Texto: En tratamiento con QUIMIOTERAPIA tipo AC por 4 y TAMOXIFENO posterior.\n",
      "  \u2192 QUIMIOTERAPIA (TREATMENT_NAME) [19-32]\n",
      "  \u2192 AC (DRUG) [38-40]\n",
      "  \u2192 por 4 (LINE_CICLE_NUMBER) [41-46]\n",
      "  \u2192 TAMOXIFENO (DRUG) [49-59]\n",
      "\n",
      "Texto: Recaida local en el lecho de mastectom\u00eda en Agosto del 2010.\n",
      "  \u2192 Recaida local (PROGRESION) [0-13]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [29-40]\n",
      "  \u2192 Agosto del 2010. (DATE) [44-60]\n",
      "\n",
      "Texto: Entre los d\u00edas 21-12-2010 y 07-01-2011, se procedi\u00f3 a irradiaci\u00f3n de pared tor\u00e1cica izquierda, de \u00e1reas ganglionares supraclaviculares, interpectorales, infraclaviculares y niveles ganglionares axilares.\n",
      "  \u2192 21-12-2010 (DATE) [15-25]\n",
      "  \u2192 07-01-2011 (DATE) [28-38]\n",
      "\n",
      "Texto: En Enero del 2011 iniica bloqueo hormonal completo con ZOLADEX + Tamoxifeno, sustituido por LETROZOL al mes siguiente.\n",
      "  \u2192 Enero del 2011 (DATE) [3-17]\n",
      "  \u2192 bloqueo hormonal (TREATMENT_NAME) [25-41]\n",
      "  \u2192 ZOLADEX (DRUG) [55-62]\n",
      "  \u2192 Tamoxifeno (DRUG) [65-75]\n",
      "  \u2192 sustituido (OCURRENCE_EVENT) [77-87]\n",
      "  \u2192 LETROZOL (DRUG) [92-100]\n",
      "\n",
      "Texto: Metastasis tratada con cirugia y RADIOTERAPIA.\n",
      "  \u2192 Metastasis (CANCER_CONCEPT) [0-10]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [11-18]\n",
      "  \u2192 RADIOTERAPIA (TREATMENT_NAME) [33-45]\n",
      "\n",
      "Texto: Inicio de 1ra l\u00ednea de tratamiento quimioter\u00e1pico para met\u00e1stasis con Gemcitabina 2500 mg/m2 y Carboplatino AUC 2,5.\n",
      "  \u2192 Inicio (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 1ra l\u00ednea (LINE_CICLE_NUMBER) [10-19]\n",
      "  \u2192 tratamiento quimioter\u00e1pico (TREATMENT_NAME) [23-49]\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [55-65]\n",
      "  \u2192 Gemcitabina (DRUG) [70-81]\n",
      "  \u2192 2500 mg/m2 (DOSE) [82-92]\n",
      "  \u2192 Carboplatino (DRUG) [95-107]\n",
      "  \u2192 AUC 2,5 (DOSE) [108-115]\n",
      "\n",
      "Texto: Mujer diagnosticada Carcinoma infiltrante de mama derecha en diciembre de 2010, pTxN0M0, estadio IA.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 Carcinoma infiltrante de mama derecha (CANCER_CONCEPT) [20-57]\n",
      "  \u2192 diciembre de 2010, (DATE) [61-79]\n",
      "  \u2192 pTxN0M0 (TNM) [80-87]\n",
      "  \u2192 estadio IA (STAGE) [89-99]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre con cancer de prostata hace 10 a\u00f1os.\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 cancer de prostata (CANCER_CONCEPT) [35-53]\n",
      "  \u2192 hace 10 a\u00f1os (IMPLICIT_DATE) [54-66]\n",
      "\n",
      "Texto: Mujer con cancer de mama, EGFR no mutado, HER2 negativo.\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [10-24]\n",
      "  \u2192 EGFR no mutado (BIOMARKER) [26-40]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [42-55]\n",
      "\n",
      "Texto: Mujer de 44 a\u00f1os diagnosticada de Carcinoma ductal infiltrante de mama derecha cT2N0M0 (estadio IIA) G2.\n",
      "  \u2192 44 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [34-78]\n",
      "  \u2192 cT2N0M0 (TNM) [79-86]\n",
      "  \u2192 estadio IIA (STAGE) [88-99]\n",
      "  \u2192 G2. (STAGE) [101-104]\n",
      "\n",
      "Texto: RE 100% RP < 5% KI 70% HER2 + en diciembre de 2016.\n",
      "  \u2192 RE 100% (BIOMARKER) [0-7]\n",
      "  \u2192 RP < 5% (BIOMARKER) [8-15]\n",
      "  \u2192 KI 70% (BIOMARKER) [16-22]\n",
      "  \u2192 HER2 + (BIOMARKER) [23-29]\n",
      "  \u2192 diciembre de 2016. (DATE) [33-51]\n",
      "\n",
      "Texto: *Neoadyuvancia con AC x 4 (21.12 al 22-02-2017) con soporte con factores.\n",
      "  \u2192 Neoadyuvancia (TREATMENT_NAME) [1-14]\n",
      "  \u2192 AC (DRUG) [19-21]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [22-25]\n",
      "  \u2192 (21.12 (DATE) [26-32]\n",
      "  \u2192 22-02-2017 (DATE) [36-46]\n",
      "\n",
      "Texto: RMN tras 4 ciclos respuesta parcial mayor + Paclitaxel por 12 ciclos + Herceptin 4 dosis sc( reducido al 80, por neuropat\u00eda G2 y con soporte conG-CSF) del 15-03 hasta mayo 2017.\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [9-17]\n",
      "  \u2192 Paclitaxel (DRUG) [44-54]\n",
      "  \u2192 12 ciclos (LINE_CICLE_NUMBER) [59-68]\n",
      "  \u2192 Herceptin (DRUG) [71-80]\n",
      "  \u2192 4 dosis (DOSE) [81-88]\n",
      "  \u2192 neuropat\u00eda G2 (COMORBIDITY) [113-126]\n",
      "  \u2192 15-03 (DATE) [155-160]\n",
      "  \u2192 mayo 2017. (DATE) [167-177]\n",
      "\n",
      "Texto: RMN tras 4 ciclos respuesta parcial mayor + Paclitaxel por 12 ciclos + Herceptin 4 dosis sc( reducido al 80, por neuropat\u00eda G2 y con soporte conG-CSF) del 15-03 hasta mayo 2017.\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [9-17]\n",
      "  \u2192 Paclitaxel (DRUG) [44-54]\n",
      "  \u2192 12 ciclos (LINE_CICLE_NUMBER) [59-68]\n",
      "  \u2192 Herceptin (DRUG) [71-80]\n",
      "  \u2192 4 dosis (DOSE) [81-88]\n",
      "  \u2192 neuropat\u00eda G2 (COMORBIDITY) [113-126]\n",
      "  \u2192 15-03 (DATE) [155-160]\n",
      "  \u2192 mayo 2017. (DATE) [167-177]\n",
      "\n",
      "Texto: Mujer de 44 a\u00f1os diagnosticada de Carcinoma ductal infiltrante de mama derecha cT2N0M0 (estadio IIA) G2.\n",
      "  \u2192 44 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [34-78]\n",
      "  \u2192 cT2N0M0 (TNM) [79-86]\n",
      "  \u2192 estadio IIA (STAGE) [88-99]\n",
      "  \u2192 G2. (STAGE) [101-104]\n",
      "\n",
      "Texto: Mastectom\u00eda derecha el 26-06-2017.\n",
      "  \u2192 Mastectom\u00eda derecha (SURGERY) [0-19]\n",
      "  \u2192 26-06-2017 (DATE) [23-33]\n",
      "\n",
      "Texto: AP respuesta patol\u00f3gica completa(y)pT0; (y)pN0\n",
      "  \u2192 (y)pT0 (TNM) [32-38]\n",
      "  \u2192 (y)pN0 (TNM) [40-46]\n",
      "\n",
      "Texto: Radioterapia: mastectom\u00eda derecha, axila y regi\u00f3n supraclavicular derecha 50 Gy, Inicia TAMOXIFENO en Octubre del 2017 Finaliza HERCEPTIN en MArzo del 2018 Amenorrea desde el tratamietno .\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [0-12]\n",
      "  \u2192 mastectom\u00eda derecha (SURGERY) [14-33]\n",
      "  \u2192 50 Gy (DOSE) [74-79]\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [81-87]\n",
      "  \u2192 TAMOXIFENO (DRUG) [88-98]\n",
      "  \u2192  (DRUG) [102-103]\n",
      "  \u2192 Octubre del 2017 (DATE) [102-118]\n",
      "  \u2192 Finaliza (OCURRENCE_EVENT) [119-127]\n",
      "  \u2192 HERCEPTIN (DRUG) [128-137]\n",
      "  \u2192 MArzo del 2018 (DATE) [141-155]\n",
      "  \u2192 Amenorrea (GINECOLOGICAL_HISTORY) [156-165]\n",
      "\n",
      "Texto: SofocosTiene solicitada mamaografia para JUnio a\u00f1ado SE BQ analisis hormonal y cita para revison\n",
      "  \u2192 JUnio (DATE) [41-46]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os de edad, que ingresa con diagn\u00f3stico de:- Carcinoma de mama diagnosticado en 2005, pT2N0M0 , RH +, HER 2 desconocido tratada con tumorectom\u00eda + LA + RT + QT + HT posterior.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [42-53]\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [59-76]\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [77-90]\n",
      "  \u2192 2005, (DATE) [94-99]\n",
      "  \u2192 pT2N0M0 (TNM) [100-107]\n",
      "  \u2192 RH + (BIOMARKER) [110-114]\n",
      "  \u2192 HER 2 desconocido (BIOMARKER) [116-133]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [134-141]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [146-158]\n",
      "  \u2192 LA (SURGERY) [161-163]\n",
      "  \u2192 RT (TREATMENT_NAME) [166-168]\n",
      "  \u2192 QT (TREATMENT_NAME) [171-173]\n",
      "  \u2192 HT (TREATMENT_NAME) [176-178]\n",
      "\n",
      "Texto: Mastectom\u00eda bilateral + reconstrucci\u00f3n en mayo de 2014.\n",
      "  \u2192 Mastectom\u00eda bilateral (SURGERY) [0-21]\n",
      "  \u2192 reconstrucci\u00f3n (SURGERY) [24-38]\n",
      "  \u2192 mayo de 2014. (DATE) [42-55]\n",
      "\n",
      "Texto: (AP sin alteraciones).\n",
      "\n",
      "Texto: - Progresi\u00f3n \u00f3sea en octubre de 2014, con fractura patol\u00f3gica del cuerpo vertebral L2 desplasada, intervenida con vertebroplastia, tom\u00e1ndose biopsia de la lesi\u00f3n cuyos resultados son de material hem\u00e1tico sin datos de infiltraci\u00f3n tumoral.\n",
      "  \u2192 Progresi\u00f3n \u00f3sea (PROGRESION) [2-17]\n",
      "  \u2192 octubre de 2014, (DATE) [21-37]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [98-109]\n",
      "  \u2192 vertebroplastia (SURGERY) [114-129]\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [230-237]\n",
      "\n",
      "Texto: FECHA VAL: 2014-10-27\n",
      "  \u2192 2014-10-27 (DATE) [11-21]\n",
      "\n",
      "Texto: ESTUDIOS DE IMAGEN FUNCIONAL CON RADIOTRAZADORESGAMMAGRAFIA OSEA \u00d3rgano estudiado: Cuerpo Completo Radiotrazador: HDP-99mTc Dosis: 830 MBq Administrado v\u00eda I.V.\n",
      "  \u2192 HDP-99mTc (TNM) [114-123]\n",
      "  \u2192 830 MBq (DOSE) [131-138]\n",
      "\n",
      "Texto: Equipo empleado: Gammac\u00e1mara SPECT -1DESCRIPCION DE LOS HALLAZGOSSe ha realizado el estudio de la distribuci\u00f3n del radiof\u00e1rmaco arriba mencionado a nivel de esqueleto, realizando rastreo de cuerpo completo en proyecciones anterior y posterior.\n",
      "\n",
      "Texto: Se observan dep\u00f3sitos patol\u00f3gicos en cuerpos vertebrales de C5-C6, dorsolumbar, L1-2 NO muestra patr\u00f3n de aplastamiento osteopor\u00f3tico, pelvis , f\u00e9mur proximal derecho y parrilla costal bilateral.\n",
      "\n",
      "Texto: Captaci\u00f3n focal en calota RESUMEN E INTERPRETACION CLINICA Diseminaci\u00f3n \u00f3sea secundaria extensa.\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os de edad, que ingresa con diagn\u00f3stico de:- Carcinoma de mama diagnosticado en 2005, pT2N0M0 , RH +, HER 2 desconocido tratada con tumorectom\u00eda + LA + RT + QT + HT posteriorr .\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [42-53]\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [59-76]\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [77-90]\n",
      "  \u2192 2005, (DATE) [94-99]\n",
      "  \u2192 pT2N0M0 (TNM) [100-107]\n",
      "  \u2192 RH + (BIOMARKER) [110-114]\n",
      "  \u2192 HER 2 desconocido (BIOMARKER) [116-133]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [134-141]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [146-158]\n",
      "  \u2192 LA (SURGERY) [161-163]\n",
      "  \u2192 RT (TREATMENT_NAME) [166-168]\n",
      "  \u2192 QT (TREATMENT_NAME) [171-173]\n",
      "  \u2192 HT (TREATMENT_NAME) [176-178]\n",
      "\n",
      "Texto: FECHA VAL: 2014-10-19 Se realiza estudio de columna completa obteni\u00e9ndose im\u00e1genes en plano sagital y axial con secuencias potenciadas en T1 y T2 y secuencias STIR.\n",
      "  \u2192 2014-10-19 (DATE) [11-21]\n",
      "\n",
      "Texto: Adquisici\u00f3n coronal T2 de columna lumbar.\n",
      "\n",
      "Texto: Afectaci\u00f3n difusa del esqueleto axial visible por lesiones focales que comportamiento predominantemente hipointenso en secuencias T1 y T2, sugestivas de lesiones con origen metast\u00e1sico como primera posibilidad.\n",
      "  \u2192 metast\u00e1sico (CANCER_CONCEPT) [173-184]\n",
      "\n",
      "Texto: Conclusi\u00f3n:Hallazgos sugestivos de afectaci\u00f3n metast\u00e1sica difusa del esqueleto axial visible,destacando fractura patol\u00f3gica del cuerpo vertebral de L2 con desplazamiento de muro posterior que condiciona estenosis del receso lateral izquierdo y margen anterior del canal central.\n",
      "  \u2192 afectaci\u00f3n metast\u00e1sica difusa (CANCER_CONCEPT) [35-64]\n",
      "\n",
      "Texto: Mujer de 56 a\u00f1os con carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, G3, RE 00; RP 10; HER2 neg.\n",
      "  \u2192 56 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [21-80]\n",
      "  \u2192 G3 (STAGE) [82-84]\n",
      "  \u2192 RE 00 (BIOMARKER) [86-91]\n",
      "  \u2192 RP 10 (BIOMARKER) [93-98]\n",
      "  \u2192 HER2 neg (BIOMARKER) [100-108]\n",
      "\n",
      "Texto: cT2N1.\n",
      "  \u2192 cT2N1 (TNM) [0-5]\n",
      "\n",
      "Texto: BSCG (1 +/2 gg con extensi\u00f3n extracapsular).\n",
      "\n",
      "Texto: QT neoadyuvante: AC x 4 ciclos + Taxol x 10 ciclos.\n",
      "  \u2192 QT neoadyuvante (TREATMENT_NAME) [0-15]\n",
      "  \u2192 AC (DRUG) [17-19]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [20-30]\n",
      "  \u2192 Taxol (DRUG) [33-38]\n",
      "  \u2192 x 10 ciclos (LINE_CICLE_NUMBER) [39-50]\n",
      "\n",
      "Texto: Noviembre de 2017 Neumonitis por docetaxel.\n",
      "  \u2192 Noviembre de 2017 (DATE) [0-17]\n",
      "  \u2192 Neumonitis (COMORBIDITY) [18-28]\n",
      "  \u2192 docetaxel (DRUG) [33-42]\n",
      "\n",
      "Texto: Mastectom\u00eda radical modificada, ypT0N0.\n",
      "  \u2192 Mastectom\u00eda radical modificada (SURGERY) [0-30]\n",
      "  \u2192 ypT0N0 (TNM) [32-38]\n",
      "\n",
      "Texto: - RT Pared tor\u00e1cica y Axilo-supraclavicular derecho 50 Gy del 04/04/18 a 10/05/18.\n",
      "  \u2192 RT (TREATMENT_NAME) [2-4]\n",
      "  \u2192 50 Gy (DOSE) [52-57]\n",
      "  \u2192 04/04/18 (DATE) [62-70]\n",
      "  \u2192 10/05/18 (DATE) [73-81]\n",
      "\n",
      "Texto: - Met\u00e1stasis cerebelosa intervenida + RTEhF 10 x 4 Gy del 27/12/2018 y 14/1/2019.\n",
      "  \u2192 Met\u00e1stasis cerebelosa (CANCER_CONCEPT) [2-23]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [24-35]\n",
      "  \u2192 RTEhF (DRUG) [38-43]\n",
      "  \u2192 10 x 4 Gy (DOSE) [44-53]\n",
      "  \u2192 27/12/2018 (DATE) [58-68]\n",
      "  \u2192 14/1/2019 (DATE) [71-80]\n",
      "\n",
      "Texto: El 04/09/19 acudi\u00f3 a urgencias por dolor tipo pinchazo infracostal anterior izdo. Dolor de espalda.\n",
      "  \u2192 04/09/19 (DATE) [3-11]\n",
      "  \u2192 urgencias (CLINICAL_SERVICE) [21-30]\n",
      "\n",
      "Texto: Asintom\u00e1tica neurol\u00f3gicamente.\n",
      "\n",
      "Texto: Mujer de 56 a\u00f1os con carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, G3, RE 0%; RP 1%; HER2 neg.\n",
      "  \u2192 56 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [21-80]\n",
      "  \u2192 G3 (STAGE) [82-84]\n",
      "  \u2192 RE 0% (BIOMARKER) [86-91]\n",
      "  \u2192 RP 1% (BIOMARKER) [93-98]\n",
      "  \u2192 HER2 neg (BIOMARKER) [100-108]\n",
      "\n",
      "Texto: Mujer de 56 a\u00f1os con carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, G3, RE 0%; RP 1%; HER2 neg.\n",
      "  \u2192 56 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [21-80]\n",
      "  \u2192 G3 (STAGE) [82-84]\n",
      "  \u2192 RE 0% (BIOMARKER) [86-91]\n",
      "  \u2192 RP 1% (BIOMARKER) [93-98]\n",
      "  \u2192 HER2 neg (BIOMARKER) [100-108]\n",
      "\n",
      "Texto: RM CR\u00c1NEO (27/08/2019): Se dispone estudios previos, m\u00e1s reciente de Mayo de 2019.\n",
      "  \u2192 (27/08/2019 (DATE) [10-21]\n",
      "  \u2192 Mayo de 2019. (DATE) [69-82]\n",
      "\n",
      "Texto: Mujer de 56 a\u00f1os con carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico, G3, RE 0%; RP 1%; HER2 neg.\n",
      "  \u2192 56 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 carcinoma ductal infiltrante de mama derecha, multic\u00e9ntrico (CANCER_CONCEPT) [21-80]\n",
      "  \u2192 G3 (STAGE) [82-84]\n",
      "  \u2192 RE 0% (BIOMARKER) [86-91]\n",
      "  \u2192 RP 1% (BIOMARKER) [93-98]\n",
      "  \u2192 HER2 neg (BIOMARKER) [100-108]\n",
      "\n",
      "Texto: - Cambios posquir\u00fargicos de craniectom\u00eda occipital izquierda en relaci\u00f3n a resecci\u00f3n quir\u00fargica de lesi\u00f3n metast\u00e1sica intraparenquimatosa en hemisferio cerebeloso izquierdo, ya tratada.\n",
      "  \u2192 craniectom\u00eda occipital izquierda (SURGERY) [28-60]\n",
      "  \u2192 lesi\u00f3n metast\u00e1sica intraparenquimatosa (CANCER_CONCEPT) [99-137]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [177-184]\n",
      "\n",
      "Texto: En el lecho quir\u00fargico se observa un \u00e1rea con cambios gli\u00f3ticomal\u00e1cicos de aspecto retractil y dep\u00f3sitos hemosider\u00ednicos por metabolismo de restos hem\u00e1ticos.\n",
      "\n",
      "Texto: No muestra cambios significativos respecto estudio previo m\u00e1s reciente y es significativamente menor extensi\u00f3n que en estudio de diciembre de 2018.\n",
      "  \u2192 diciembre de 2018. (DATE) [129-147]\n",
      "\n",
      "Texto: No se aprecian nuevos efectos de masa ni nodularidad.\n",
      "\n",
      "Texto: Mantiene algunos focos de sutil realce puntiforme en su interior.\n",
      "\n",
      "Texto: No asocia alteraciones de intensidad de se\u00f1al perilesionales significativas as\u00ed como tampoco efecto de masa sobre las estructuras adyacentes.\n",
      "\n",
      "Texto: - Como hallazgos de nueva aparici\u00f3n:Se observa en regi\u00f3n posteroinferior del n\u00facleo p\u00e1lido derecho la presencia de una lesi\u00f3n nodular, con restricci\u00f3n a la difusi\u00f3n y realce tras administraci\u00f3n de CI. Asocia edema vasog\u00e9nico perilesional en la regi\u00f3n gangliocapsular derecha.\n",
      "\n",
      "Texto: En sugestivo de nueva lesi\u00f3n metast\u00e1sica intraparenquimatosa.\n",
      "  \u2192 lesi\u00f3n metast\u00e1sica intraparenquimatosa (CANCER_CONCEPT) [22-60]\n",
      "\n",
      "Texto: En el compartimento infratentorial tambi\u00e9n se observa otra lesi\u00f3n en regi\u00f3n anterior del hemisferio cerebeloso derecho inferolateral al fl\u00f3culo, con caracter\u00edsticas de se\u00f1al similares a la descrita previamente y realce tras administraci\u00f3n CIV.\n",
      "\n",
      "Texto: No asocia edema vasog\u00e9nico perilesional significativo. Tambi\u00e9n sugestiva de nueva lesi\u00f3n metast\u00e1sica intraparenquimatosa.- Se mantienen escasas lesiones hiperintensas en T2 / Flair en sustancia blanca supratentorial distribuci\u00f3n subcortical frontal bilateral de caracter\u00edsticas inespec\u00edficas.\n",
      "  \u2192 nueva (CANCER_CONCEPT) [76-81]\n",
      "  \u2192 lesi\u00f3n metast\u00e1sica intraparenquimatosa (CANCER_CONCEPT) [82-120]\n",
      "\n",
      "Texto: - Anomal\u00eda venosa del desarrollo parietal parasagital profunda derecha en proximidades de rodete del cuerpo calloso.\n",
      "\n",
      "Texto: - No se identifican otros focos de realce patol\u00f3gicos intra ni extraaxiales en compartimento infra ni supratentorial.\n",
      "\n",
      "Texto: Persiste discreta ocupaci\u00f3n aspecto mastoideo izquierdo.\n",
      "\n",
      "Texto: - No se observan cambios significativos en la lesi\u00f3n nodular epicraneal en tejido celular subcut\u00e1neo epicraneal parietal derecho sugestiva de quiste seb\u00e1ceo, parcialmente calcificado.\n",
      "\n",
      "Texto: Resumen-Estudio control de lesi\u00f3n intraparenquimatosa metast\u00e1sica en hemisferio cerebeloso izquierdo, ya tratada, estable respecto a estudio previo m\u00e1s reciente.\n",
      "  \u2192 lesi\u00f3n intraparenquimatosa metast\u00e1sica en hemisferio cerebeloso izquierdo (CANCER_CONCEPT) [27-100]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [105-112]\n",
      "\n",
      "Texto: -Como hallazgos de nueva aparici\u00f3n: Dos lesiones sugestivas de afectaci\u00f3n metast\u00e1sica intraparenquimatosa supra e infratentorial situadas respectivamente en n\u00facleo p\u00e1lido derecho e hemisferio cerebeloso derecho.\n",
      "  \u2192 afectaci\u00f3n metast\u00e1sica intraparenquimatosa supra e infratentorial (CANCER_CONCEPT) [63-128]\n",
      "\n",
      "Texto: Servicio de ONCOLOG\u00cdA M\u00c9DICA : Mujerr de 42 a\u00f1os con ADENOCARCINOMA INVASIVO TRIPLE NEGATIVO DE MAMA DERECHA.\n",
      "  \u2192 ONCOLOG\u00cdA M\u00c9DICA (CLINICAL_SERVICE) [12-28]\n",
      "  \u2192 42 a\u00f1os (AGE) [41-48]\n",
      "  \u2192 ADENOCARCINOMA INVASIVO TRIPLE NEGATIVO DE MAMA DERECHA (CANCER_CONCEPT) [53-108]\n",
      "\n",
      "Texto: Anteccedentes familiares: Madre diagnosticada con c\u00e1ncer mamario.\n",
      "  \u2192 Madre (FAMILY) [26-31]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [32-45]\n",
      "  \u2192 c\u00e1ncer mamario (CANCER_CONCEPT) [50-64]\n",
      "\n",
      "Texto: Padre con varios antecedentes oncol\u00f3gicos: c\u00e1ncer de colon, cancer de pr\u00f3stata y pulm\u00f3n (todos ellos curados).\n",
      "  \u2192 Padre (FAMILY) [0-5]\n",
      "  \u2192 c\u00e1ncer de colon (CANCER_CONCEPT) [43-58]\n",
      "  \u2192 cancer de pr\u00f3stata y pulm\u00f3n (CANCER_CONCEPT) [60-87]\n",
      "\n",
      "Texto: Antecedentes Personales: no HTA, No dislipemia.\n",
      "  \u2192 no HTA (COMORBIDITY) [25-31]\n",
      "  \u2192 No dislipemia (COMORBIDITY) [33-46]\n",
      "\n",
      "Texto: No diabetes mellitus.\n",
      "  \u2192 No diabetes mellitus (COMORBIDITY) [0-20]\n",
      "\n",
      "Texto: Tratamiento quimioter\u00e1pico con 4 ciclos de Adriamicina y Ciclofosfamida y cuatro ciclos de Docetaxel trisemanal.\n",
      "  \u2192 Tratamiento quimioter\u00e1pico (TREATMENT_NAME) [0-26]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [31-39]\n",
      "  \u2192 Adriamicina (DRUG) [43-54]\n",
      "  \u2192 Ciclofosfamida (DRUG) [57-71]\n",
      "  \u2192 cuatro ciclos (LINE_CICLE_NUMBER) [74-87]\n",
      "  \u2192 Docetaxel (DRUG) [91-100]\n",
      "  \u2192 trisemanal (FREQ) [101-111]\n",
      "\n",
      "Texto: Tratamiento de quimiotrapia con Carboplatino y Paclitaxel.\n",
      "  \u2192 quimiotrapia (TREATMENT_NAME) [15-27]\n",
      "  \u2192 Carboplatino (DRUG) [32-44]\n",
      "  \u2192 Paclitaxel (DRUG) [47-57]\n",
      "\n",
      "Texto: Diagnosticada en julio de 2019 de cancer de mama cT4cN2cM0, (estadio IIIB).\n",
      "  \u2192 Diagnosticada (OCURRENCE_EVENT) [0-13]\n",
      "  \u2192 julio de 2019 (DATE) [17-30]\n",
      "  \u2192 cancer de mama cT4cN2cM0 (CANCER_CONCEPT) [34-58]\n",
      "  \u2192 estadio IIIB (STAGE) [61-73]\n",
      "\n",
      "Texto: PD-L1 Positivo al 97 %, HER 2 negativo.\n",
      "  \u2192 PD-L1 Positivo al 97 % (BIOMARKER) [0-22]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [24-38]\n",
      "\n",
      "Texto: Acude con excelente estado general, se ha resuelto completamente la disnea y la tos.\n",
      "\n",
      "Texto: Ha estado de vacaciones en Israel y no ha tenido incidencias.\n",
      "\n",
      "Texto: Mujer de 59 a\u00f1os diagnosticada en julio de 2019 de cancer de mama cT4cN2cM0, (estadio IIIB).\n",
      "  \u2192 59 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 julio de 2019 (DATE) [34-47]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [51-65]\n",
      "  \u2192 c (TNM) [66-67]\n",
      "  \u2192 T4 (CANCER_CONCEPT) [67-69]\n",
      "  \u2192 cN2cM0 (TNM) [69-75]\n",
      "  \u2192 estadio IIIB (STAGE) [78-90]\n",
      "\n",
      "Texto: Mujer de 40 a\u00f1os con c\u00e1ncer de mama izquierda estad\u00edo IV que que acude a Urgencias por mal control del dolor.\n",
      "  \u2192 40 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 c\u00e1ncer de mama izquierda (CANCER_CONCEPT) [21-45]\n",
      "  \u2192 estad\u00edo IV (STAGE) [46-56]\n",
      "  \u2192 Urgencias (CLINICAL_SERVICE) [73-82]\n",
      "\n",
      "Texto: Su hermana hab\u00eda venido a lo largo de la tarde del 3/08/2013 a por medicaci\u00f3n analg\u00e9sica, pero no se ha controlado con eso.\n",
      "  \u2192 hermana (FAMILY) [3-10]\n",
      "  \u2192 3/08/2013 (DATE) [51-60]\n",
      "\n",
      "Texto: No ha presentado fiebre ni otra sintomatolog\u00eda acompa\u00f1ante.\n",
      "\n",
      "Texto: Ven\u00eda desaturada y taquipneica, se ha realizado ANGIOTAC para descartar TEP.\n",
      "\n",
      "Texto: No se visualiza, pero se objetiva derrame pleural izquierdo (tambi\u00e9n visualizado en RX t\u00f3rax actual).\n",
      "\n",
      "Texto: Vista el 01 de agosto en Oncologia m\u00e9dica, se aumentan los parches de Durogesic de 50 a 75 mg cada 72 horas y la dosis de rescate de Effentora de 100 a 200 con regular control del dolor.\n",
      "  \u2192 01 de agosto (DATE) [9-21]\n",
      "  \u2192 Oncologia m\u00e9dica (CLINICAL_SERVICE) [25-41]\n",
      "  \u2192 parches de Durogesic (DRUG) [59-79]\n",
      "  \u2192 50 a 75 mg (DOSE) [83-93]\n",
      "  \u2192 cada 72 horas (FREQ) [94-107]\n",
      "  \u2192 Effentora (DRUG) [133-142]\n",
      "  \u2192 100 a 200 (DOSE) [146-155]\n",
      "\n",
      "Texto: En urgencias se realiza toracocentesis.\n",
      "  \u2192 urgencias (CLINICAL_SERVICE) [3-12]\n",
      "\n",
      "Texto: Pendientes citologia.\n",
      "\n",
      "Texto: Antecedentes: T\u00eda materna: fallecida de c\u00e1ncer linfatico a los 56 a\u00f1os\n",
      "  \u2192 T\u00eda materna (FAMILY) [14-25]\n",
      "  \u2192 fallecida (OCURRENCE_EVENT) [27-36]\n",
      "  \u2192 c\u00e1ncer linfatico (CANCER_CONCEPT) [40-56]\n",
      "  \u2192 56 a\u00f1os (AGE) [63-70]\n",
      "\n",
      "Texto: Mujer diagnosticada de Carcinoma ductal infiltrante en Mayo de 2016, estadio II.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [23-51]\n",
      "  \u2192 Mayo de 2016, (DATE) [55-68]\n",
      "  \u2192 estadio II (STAGE) [69-79]\n",
      "\n",
      "Texto: Paciente con RH positivos, HER2 negativo.\n",
      "  \u2192 RH positivos (BIOMARKER) [13-25]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [27-40]\n",
      "\n",
      "Texto: Menarquia a los 13 a\u00f1os y menopausia a los 50 a\u00f1os.\n",
      "  \u2192 Menarquia (GINECOLOGICAL_HISTORY) [0-9]\n",
      "  \u2192 13 a\u00f1os (AGE) [16-23]\n",
      "  \u2192 menopausia (GINECOLOGICAL_HISTORY) [26-36]\n",
      "  \u2192 50 a\u00f1os (AGE) [43-50]\n",
      "\n",
      "Texto: Recibe tratamiento con Mastectom\u00eda y linfadenectom\u00eda el 20-8-2016, pT1cpN0\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [23-34]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [37-52]\n",
      "  \u2192 20-8-2016 (DATE) [56-65]\n",
      "  \u2192 pT1cpN0 (TNM) [67-74]\n",
      "\n",
      "Texto: El 1 de octubre de 2017 inicia quimioterapia con Adriamicina, Ciclofosfamida y Docetaxel recibiendo 6 ciclos.\n",
      "  \u2192 1 de octubre de 2017 (DATE) [3-23]\n",
      "  \u2192 inicia (OCURRENCE_EVENT) [24-30]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [31-44]\n",
      "  \u2192 Adriamicina (DRUG) [49-60]\n",
      "  \u2192 Ciclofosfamida (DRUG) [62-76]\n",
      "  \u2192 Docetaxel (DRUG) [79-88]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [100-108]\n",
      "\n",
      "Texto: Inicia tratamiento con Lapatinib 250 mg y Docetaxel.\n",
      "  \u2192 Inicia tratamiento (OCURRENCE_EVENT) [0-18]\n",
      "  \u2192 Lapatinib (DRUG) [23-32]\n",
      "  \u2192 250 mg (DOSE) [33-39]\n",
      "  \u2192 Docetaxel (DRUG) [42-51]\n",
      "\n",
      "Texto: Carcinoma lobulillar infiltrante mama derecha RE 7 %, RP 55, HER2 negativo con afectaci\u00f3n axilar cT3 cN2a cM0 (IIIA).\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [0-45]\n",
      "  \u2192 RE 7 % (BIOMARKER) [46-52]\n",
      "  \u2192 RP 55 (BIOMARKER) [54-59]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [61-74]\n",
      "  \u2192 cT3 cN2a cM0 (TNM) [97-109]\n",
      "  \u2192 ( (STAGE) [110-111]\n",
      "  \u2192 IIIA (STAGE) [111-115]\n",
      "\n",
      "Texto: Carcinoma lobulillar infiltrante mama derecha RE 7 %, RP 55, HER2 negativo con afectaci\u00f3n axilar cT3 cN2a cM0 (IIIA ).\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [0-45]\n",
      "  \u2192 RE 7 % (BIOMARKER) [46-52]\n",
      "  \u2192 RP 55 (BIOMARKER) [54-59]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [61-74]\n",
      "  \u2192 cT3 cN2a cM0 (TNM) [97-109]\n",
      "  \u2192 ( (STAGE) [110-111]\n",
      "  \u2192 IIIA (STAGE) [111-115]\n",
      "\n",
      "Texto: Carcinoma lobulillar infiltrante mama derecha RE 7 %, RP 55, HER2 negativo con afectaci\u00f3n axilar cT3 cN2a cM0 (IIIA ).\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [0-45]\n",
      "  \u2192 RE 7 % (BIOMARKER) [46-52]\n",
      "  \u2192 RP 55 (BIOMARKER) [54-59]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [61-74]\n",
      "  \u2192 cT3 cN2a cM0 (TNM) [97-109]\n",
      "  \u2192 ( (STAGE) [110-111]\n",
      "  \u2192 IIIA (STAGE) [111-115]\n",
      "\n",
      "Texto: Premenop\u00e1usica.\n",
      "  \u2192 Premenop\u00e1usica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "\n",
      "Texto: QMT neoadyuvante: AC x 4, Paclitaxel semanal x 3, sin respuesta objetiva.\n",
      "  \u2192 QMT neoadyuvante (TREATMENT_NAME) [0-16]\n",
      "  \u2192 AC (DRUG) [18-20]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [21-24]\n",
      "  \u2192 Paclitaxel (DRUG) [26-36]\n",
      "  \u2192 semanal (FREQ) [37-44]\n",
      "  \u2192 x 3 (LINE_CICLE_NUMBER) [45-48]\n",
      "\n",
      "Texto: * Mastectomia + linfadenectomia, ypT3 pN3b cMx (estadio IIIC).\n",
      "  \u2192 Mastectomia (SURGERY) [2-13]\n",
      "  \u2192 linfadenectomia (SURGERY) [16-31]\n",
      "  \u2192 ypT3 pN3b cMx (TNM) [33-46]\n",
      "  \u2192 estadio IIIC (STAGE) [48-60]\n",
      "\n",
      "Texto: * ZOLADEX-LETROZOL desde diciembre del 2018, con regular tolerancia por dolores articulares.\n",
      "  \u2192 ZOLADEX-LETROZOL (DRUG) [2-18]\n",
      "  \u2192 diciembre del 2018 (DATE) [25-43]\n",
      "\n",
      "Texto: *RT: pared tor\u00e1cica derecha y \u00e1reas ganglionares supraclaviculares, infraclaviculares, axilares y cadena mamaria interna, 50 Gy , cadena mamaria interna afecta inicialmente (primer y segundo espacio intercostal) administrando una dosis adicional de 10 Gy en fracciones de 2 Gy, del 07-03-2019 al 13-03-2019.\n",
      "  \u2192 RT (TREATMENT_NAME) [1-3]\n",
      "  \u2192 50 Gy (DOSE) [122-127]\n",
      "  \u2192 10 Gy (DOSE) [249-254]\n",
      "  \u2192 2 Gy (DOSE) [272-276]\n",
      "  \u2192 07-03-2019 (DATE) [282-292]\n",
      "  \u2192 13-03-2019 (DATE) [296-306]\n",
      "\n",
      "Texto: Progresi\u00f3n axilar contralateral, \u00f3sea y supraclavicular ipsilateral, biopsiada con el resultado de triple negativo.\n",
      "  \u2192 Progresi\u00f3n axilar contralateral, \u00f3sea y supraclavicular ipsilateral (PROGRESION) [0-67]\n",
      "  \u2192 triple negativo (CANCER_CONCEPT) [99-114]\n",
      "\n",
      "Texto: - Celulitis en miembro superior derecho-\n",
      "  \u2192 Celulitis en miembro superior (COMORBIDITY) [2-31]\n",
      "\n",
      "Texto: Fecha: 09/08/2019 17:28 - Ambulatoria - Ubicaci\u00f3n: QUIMIOTERAPIA Procedimientos de enfermer\u00eda - AUXILIAR DE ENFERMERIAEXAMEN F\u00cdSICO Presi\u00f3n arterial (mmHg): 120/70, Presi\u00f3n arterial media(mmhg): 86 Frecuencia cardiaca(Lat/min): 90 Temperatura(\u00b0C): 36. 7.\n",
      "  \u2192 09/08/2019 (DATE) [7-17]\n",
      "  \u2192 QUIMIOTERAPIA (TREATMENT_NAME) [51-64]\n",
      "  \u2192 enfermer\u00eda (CLINICAL_SERVICE) [83-93]\n",
      "\n",
      "Texto: Procedimientos despu\u00e9s de la nota: PP992505 - P992505 Politerapia Antineoplasica de Alto Toxiciidad .\n",
      "  \u2192 Politerapia Antineoplasica (TREATMENT_NAME) [54-80]\n",
      "\n",
      "Texto: Nota: Igresa paciente a la unidad de quimioterapia en compa\u00f1\u00eda del familiar conciente orientada en tiempo lugar y persona femenina de 70 a\u00f1os con DX:Tumor maligno de mama.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [37-50]\n",
      "  \u2192 70 a\u00f1os (AGE) [134-141]\n",
      "  \u2192 DX (OCURRENCE_EVENT) [146-148]\n",
      "  \u2192 Tumor maligno de mama (CANCER_CONCEPT) [149-170]\n",
      "\n",
      "Texto: Se canaliza vena periferica en miembro superior derecho recibe tratamiento 2 ciclo dia 15 con ondasetron 16 mg dexametasona 8 mg carboplatino 195 mg paclitaxel 130 mg endovenoso hidroxicina 100 mg intramuscular paciente que no presenta reaccion adversa al medicamento sale de la unidad en compa\u00f1\u00eda del familiar conciente por sus propios medios y en buenas condiciones generales.\n",
      "  \u2192 2 ciclo (LINE_CICLE_NUMBER) [75-82]\n",
      "  \u2192 ondasetron (DRUG) [94-104]\n",
      "  \u2192 16 mg (DOSE) [105-110]\n",
      "  \u2192 dexametasona (DRUG) [111-123]\n",
      "  \u2192 8 mg (DOSE) [124-128]\n",
      "  \u2192 carboplatino (DRUG) [129-141]\n",
      "  \u2192 195 mg (DOSE) [142-148]\n",
      "  \u2192 paclitaxel (DRUG) [149-159]\n",
      "  \u2192 130 mg (DOSE) [160-166]\n",
      "  \u2192 hidroxicina (DRUG) [178-189]\n",
      "  \u2192 100 mg (DOSE) [190-196]\n",
      "\n",
      "Texto: Acude tras la radioterapia para inicio de hormona.\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [14-26]\n",
      "  \u2192 inicio (OCURRENCE_EVENT) [32-38]\n",
      "  \u2192 hormona (TREATMENT_NAME) [42-49]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante mama derecha cT2 pN1a (1/13) Mx G2 RE 8/8, RP 8/8, HER 2 equivoco, FISH no amplificado, Ki-67 10.\n",
      "  \u2192 Carcinoma ductal infiltrante mama derecha (CANCER_CONCEPT) [0-41]\n",
      "  \u2192 cT2 pN1a (TNM) [42-50]\n",
      "  \u2192 Mx (TNM) [58-60]\n",
      "  \u2192 G2 (STAGE) [61-63]\n",
      "  \u2192 RE 8/8 (BIOMARKER) [64-70]\n",
      "  \u2192 RP 8/8 (BIOMARKER) [72-78]\n",
      "  \u2192 HER 2 equivoco (BIOMARKER) [80-94]\n",
      "  \u2192 FISH no amplificado (BIOMARKER) [96-115]\n",
      "  \u2192 Ki-67 10. (BIOMARKER) [117-126]\n",
      "\n",
      "Texto: Tumorectom\u00eda (margen posterior a 1 mm)+ BSGC + linfadenectom\u00eda 05/07/18.\n",
      "  \u2192 Tumorectom\u00eda (SURGERY) [0-12]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [47-62]\n",
      "  \u2192 05/07/18 (DATE) [63-71]\n",
      "\n",
      "Texto: Inicia AC el 20/7/2018 Adyuvancia con AC- Paclitaxel con toxicidad hematologica grado II que ha precisado factores y reduccion de dosis.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 AC (DRUG) [7-9]\n",
      "  \u2192 20/7/2018 (DATE) [13-22]\n",
      "  \u2192 Adyuvancia (TREATMENT_NAME) [23-33]\n",
      "  \u2192 AC- (DRUG) [38-41]\n",
      "  \u2192 Paclitaxel (DRUG) [42-52]\n",
      "\n",
      "Texto: Finaliza la QT en Enero del 2019.\n",
      "  \u2192 Finaliza (OCURRENCE_EVENT) [0-8]\n",
      "  \u2192 QT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 Enero del 2019. (DATE) [18-33]\n",
      "\n",
      "Texto: RT 26.2 al 14.4.\n",
      "  \u2192 RT (TREATMENT_NAME) [0-2]\n",
      "  \u2192 26.2 (DATE) [3-7]\n",
      "  \u2192 14.4. (DATE) [11-16]\n",
      "\n",
      "Texto: Acude despues de la Rt.\n",
      "\n",
      "Texto: Radioepiermitis G 1. Buen estado general. Sin otra cl\u00ednica.\n",
      "\n",
      "Texto: PLAN:Inicio zoladex + tamoxifeno.\n",
      "  \u2192 Ini (OCURRENCE_EVENT) [5-8]\n",
      "  \u2192 zoladex (DRUG) [12-19]\n",
      "  \u2192 tamoxifeno (DRUG) [22-32]\n",
      "\n",
      "Texto: Explico los posibles efectos adversos.\n",
      "\n",
      "Texto: Comprende.\n",
      "\n",
      "Texto: Acuidr\u00e1 en 3 meses a control.\n",
      "\n",
      "Texto: Desea tener m\u00e1s hijos, recomiendo bloqueo 2 a\u00f1os y ver.\n",
      "  \u2192 hijos (GINE_OBSTETRICS) [16-21]\n",
      "  \u2192 2 a\u00f1os (DURATION) [42-48]\n",
      "\n",
      "Texto: La paciente se qued\u00f3 embarazada por FIV.\n",
      "  \u2192 embarazada (GINE_OBSTETRICS) [21-31]\n",
      "  \u2192 FIV (GINE_OBSTETRICS) [36-39]\n",
      "\n",
      "Texto: Motivo de consulta: Paciente no asiste a quimioterapia.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [41-54]\n",
      "\n",
      "Texto: Enfermedad actual: Diagnosticos: CA DE MAMA DUCTAL INFILTRANTE DE MAMA IZQUIERDA, pT2N2M0, Estadio IIIA, RECEPTORES HORMONALES POSITIVOS, HER 2 POSITIVO.\n",
      "  \u2192 Diagnosticos (OCURRENCE_EVENT) [19-31]\n",
      "  \u2192 CA DE MAMA DUCTAL INFILTRANTE DE MAMA IZQUIERDA (CANCER_CONCEPT) [33-80]\n",
      "  \u2192 pT2N2M0 (TNM) [82-89]\n",
      "  \u2192 Estadio IIIA (STAGE) [91-103]\n",
      "  \u2192 RECEPTORES HORMONALES POSITIVOS (BIOMARKER) [105-136]\n",
      "  \u2192 HER 2 POSITIVO (BIOMARKER) [138-152]\n",
      "\n",
      "Texto: Mujer con cancer de mama izquierda, estadio IIIA.\n",
      "  \u2192 cancer de mama izquierda (CANCER_CONCEPT) [10-34]\n",
      "  \u2192 estadio IIIA (STAGE) [36-48]\n",
      "\n",
      "Texto: Carcinoma ductual infiltrante, estadio IIIA, HER 2 positivo y KI67 DEL 90 %.\n",
      "  \u2192 Carcinoma ductual infiltrante (CANCER_CONCEPT) [0-29]\n",
      "  \u2192 estadio IIIA (STAGE) [31-43]\n",
      "  \u2192 HER 2 positivo (BIOMARKER) [45-59]\n",
      "  \u2192 KI67 DEL 90 %. (BIOMARKER) [62-76]\n",
      "\n",
      "Texto: Tratamiento: 10 ciclos con Trastuzumab 600 mg cada 21 dias.\n",
      "  \u2192 10 ciclos (LINE_CICLE_NUMBER) [13-22]\n",
      "  \u2192 Trastuzumab (DRUG) [27-38]\n",
      "  \u2192 600 mg (DOSE) [39-45]\n",
      "  \u2192 cada 21 dias (FREQ) [46-58]\n",
      "\n",
      "Texto: Tamoxifeno 20 mg cada dia.\n",
      "  \u2192 Tamoxifeno (DRUG) [0-10]\n",
      "  \u2192 20 mg (DOSE) [11-16]\n",
      "  \u2192 cada dia (FREQ) [17-25]\n",
      "\n",
      "Texto: TUMOR MALIGNO DE LA PROLONGACION AXILAR DE LA MAMA, Origen: Primario .\n",
      "  \u2192 TUMOR MALIGNO DE LA PROLONGACION AXILAR DE LA MAMA (CANCER_CONCEPT) [0-50]\n",
      "  \u2192 Primario (CANCER_CONCEPT) [60-68]\n",
      "\n",
      "Texto: An\u00e1lisis del caso: Paciente quien debia asistir a sesion de quimioterapia programada para el dia de hoy, para lo cual se intenta informarle por via telefonica, pero no es posible contactarla en los numeros telefonicos suministrados por la paciente.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [60-73]\n",
      "  \u2192 hoy (IMPLICIT_DATE) [100-103]\n",
      "\n",
      "Texto: Plan de manejo: Paciente no asiste a quimioterapia.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [37-50]\n",
      "\n",
      "Texto: Tratamiento de quimiotrapia con Carboplatino y Paclitaxel.\n",
      "  \u2192 quimiotrapia (TREATMENT_NAME) [15-27]\n",
      "  \u2192 Carboplatino (DRUG) [32-44]\n",
      "  \u2192 Paclitaxel (DRUG) [47-57]\n",
      "\n",
      "Texto: Mujer premenop\u00e1usica con Cancer ductal infiltrante de mama izquierda, G3, pT2 (2.3 cm) N0 (2 GC mamaria interna) M0.\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [6-20]\n",
      "  \u2192 Cancer ductal infiltrante de mama izquierda (CANCER_CONCEPT) [25-68]\n",
      "  \u2192 G3 (STAGE) [70-72]\n",
      "  \u2192 pT2 (TNM) [74-77]\n",
      "  \u2192 N0 (TNM) [87-89]\n",
      "  \u2192 M0 (TNM) [113-115]\n",
      "\n",
      "Texto: Tratada mediante cuadrantectom\u00eda con posterior ampliaci\u00f3n de m\u00e1rgenes y borde quir\u00fargico definitivo libre de afectaci\u00f3n tumoral.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [17-32]\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [120-127]\n",
      "\n",
      "Texto: Mujer de 47 a\u00f1os que acude a control.\n",
      "  \u2192 47 a\u00f1os (AGE) [9-16]\n",
      "\n",
      "Texto: AP:- Carcinoma de mama izquierda T2N0M0 (ganglio centinela negativo. Estad\u00edo IIA) grado3, RH+, HER2 negativo en mujer premenop\u00e1usica.\n",
      "  \u2192 Carcinoma de mama izquierda (CANCER_CONCEPT) [5-32]\n",
      "  \u2192 T2N0M0 (TNM) [33-39]\n",
      "  \u2192 Estad\u00edo IIA (STAGE) [69-80]\n",
      "  \u2192 grado3 (STAGE) [82-88]\n",
      "  \u2192 RH+ (BIOMARKER) [90-93]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [95-108]\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [118-132]\n",
      "\n",
      "Texto: Diagn\u00f3stico en 2010.\n",
      "  \u2192 Diagn\u00f3stico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 2010. (DATE) [15-20]\n",
      "\n",
      "Texto: Tratada con cirug\u00eda- RDT sobre la mama hasta 50 Gy entre el 3/02/11 y finaliz\u00f3 17/03/11.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 RDT (TREATMENT_NAME) [21-24]\n",
      "  \u2192 50 Gy (DOSE) [45-50]\n",
      "  \u2192 3/02/11 (DATE) [60-67]\n",
      "  \u2192 finaliz\u00f3 (OCURRENCE_EVENT) [70-78]\n",
      "  \u2192 17/03/11 (DATE) [79-87]\n",
      "\n",
      "Texto: -HMT tamoxifeno desde 12/2010.\n",
      "  \u2192 tamoxifeno (DRUG) [5-15]\n",
      "  \u2192 12/2010 (DATE) [22-29]\n",
      "\n",
      "Texto: - En febrero de 2015 recidiva pulmonar tratado con taxol semanal por 12 ciclos.\n",
      "  \u2192 febrero de 2015 (DATE) [5-20]\n",
      "  \u2192 recidiva pulmonar (PROGRESION) [21-38]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [39-46]\n",
      "  \u2192 taxol (DRUG) [51-56]\n",
      "  \u2192 semanal (FREQ) [57-64]\n",
      "  \u2192 12 ciclos (LINE_CICLE_NUMBER) [69-78]\n",
      "\n",
      "Texto: -En diciembre de 2015 inicia bloqueo hormonal con ANASTROZOL.\n",
      "  \u2192 diciembre de 2015 (DATE) [4-21]\n",
      "  \u2192 inicia (OCURRENCE_EVENT) [22-28]\n",
      "  \u2192 bloqueo hormonal (TREATMENT_NAME) [29-45]\n",
      "  \u2192 ANASTROZOL (DRUG) [50-60]\n",
      "\n",
      "Texto: -Por mala tolerancia se cambia a LETROZOL en febrero 2016.\n",
      "  \u2192 se cambia a (OCURRENCE_EVENT) [21-32]\n",
      "  \u2192 LETROZOL (DRUG) [33-41]\n",
      "  \u2192 febrero 2016. (DATE) [45-58]\n",
      "\n",
      "Texto: Tambien con zoladex por sangrado -En remisi\u00f3n en ultimo pet.\n",
      "  \u2192 zoladex (DRUG) [12-19]\n",
      "\n",
      "Texto: -No candidata a Tx renal, esta con dialisis peritoneal.\n",
      "\n",
      "Texto: Se encuentra bien, pero con mucha clinica vasomotora.\n",
      "\n",
      "Texto: Refiere estar mejor de las molestias tras tto con colageno o hialuronico vesical.\n",
      "  \u2192 colageno (DRUG) [50-58]\n",
      "  \u2192 hialuronico (DRUG) [61-72]\n",
      "\n",
      "Texto: CICLO 1 - PEMBROLIZUMAB 2 MG/M2.\n",
      "  \u2192 CICLO 1 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 PEMBROLIZUMAB (DRUG) [10-23]\n",
      "  \u2192 2 MG/M2. (DOSE) [24-32]\n",
      "\n",
      "Texto: En resumen, se trata de una paciente mujer de 51 a\u00f1os de edad con antecedentes de posible espondilitis y fumadora de 15 cigarrillos/d\u00eda.\n",
      "  \u2192 51 a\u00f1os (AGE) [46-53]\n",
      "  \u2192 posible (COMORBIDITY) [82-89]\n",
      "  \u2192 espondilitis (COMORBIDITY) [90-102]\n",
      "  \u2192 fumadora (TOXIC_HABITS) [105-113]\n",
      "  \u2192 15 cigarrillos (HABIT-QUANTITY) [117-131]\n",
      "  \u2192 d\u00eda (FREQ) [132-135]\n",
      "\n",
      "Texto: Tratamiento habitual: Spiriva 2,5 mcg / d\u00eda, Lormetazepam 1,5 mg / noche, Zaldiar cada 8 horas, Metamizol 575 mg C/8 horas.\n",
      "  \u2192 Spiriva (DRUG) [22-29]\n",
      "  \u2192 2,5 mcg (DOSE) [30-37]\n",
      "  \u2192 d\u00eda (FREQ) [40-43]\n",
      "  \u2192 Lormetazepam (DRUG) [45-57]\n",
      "  \u2192 1,5 mg (DOSE) [58-64]\n",
      "  \u2192 noche (FREQ) [67-72]\n",
      "  \u2192 Zaldiar (DRUG) [74-81]\n",
      "  \u2192 cada 8 horas (FREQ) [82-94]\n",
      "  \u2192 Metamizol (DRUG) [96-105]\n",
      "  \u2192 575 mg (DOSE) [106-112]\n",
      "  \u2192 C/8 horas (FREQ) [113-122]\n",
      "\n",
      "Texto: Diagnosticada en julio de 2019 de Adenocarcinoma de pulm\u00f3n cT4cN2cM0 ( estadio IIIB ).\n",
      "  \u2192 Diagnosticada (OCURRENCE_EVENT) [0-13]\n",
      "  \u2192 julio de 2019 (DATE) [17-30]\n",
      "  \u2192 Adenocarcinoma de pulm\u00f3n (CANCER_CONCEPT) [34-58]\n",
      "  \u2192 cT4cN2cM0 (TNM) [59-68]\n",
      "  \u2192 estadio IIIB (STAGE) [71-83]\n",
      "\n",
      "Texto: Acude con aceptable estado general, limitada por la sensaci\u00f3n de disnea de moderados esfuerzos.\n",
      "\n",
      "Texto: El dolor a nivel tor\u00e1cico y en MSD que controla regular con la analgesia de primer escal\u00f3n.\n",
      "\n",
      "Texto: S\u00edntomas basales : Dolor en hemit\u00f3rax derecho irradiado a MSD.\n",
      "\n",
      "Texto: Tos escasamente productiva.\n",
      "\n",
      "Texto: ECOG: 1.\n",
      "\n",
      "Texto: Ara\u00f1as vasculares en t\u00f3rax.\n",
      "\n",
      "Texto: Mujer de 57 a\u00f1os MC: Hallazgos en PETEA: Remitida desde Oncolog\u00eda RT para valoraci\u00f3n por hallazgos en PET.\n",
      "  \u2192 57 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 Remitida (OCURRENCE_EVENT) [41-49]\n",
      "  \u2192 Oncolog\u00eda RT (CLINICAL_SERVICE) [56-68]\n",
      "\n",
      "Texto: Paciente con antecedente de ca mama tratado con QT, cirug\u00eda y RT con aumento de marcadores motivo por el que se le hace PET-TAC.\n",
      "  \u2192 ca mama (CANCER_CONCEPT) [28-35]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [36-43]\n",
      "  \u2192 QT (TREATMENT_NAME) [48-50]\n",
      "  \u2192 RT (TREATMENT_NAME) [62-64]\n",
      "\n",
      "Texto: Refiere disnea de moderados-grandes esfuerzos de siempre, algo de tos con expectoraci\u00f3n verdosa en ocasiones que mejora con antihistam\u00ednicos.\n",
      "\n",
      "Texto: No fiebre AP:- Trabaj\u00f3 como administrativa- No alergias conocidas- Nunca fumadora, Hipotiroidismo, Fibrosis.\n",
      "  \u2192 No alergias conocidas (ALLERGIES) [44-65]\n",
      "  \u2192 Nunca fumadora (TOXIC_HABITS) [67-81]\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [83-97]\n",
      "  \u2192 Fibrosis (COMORBIDITY) [99-107]\n",
      "\n",
      "Texto: Antecedente oncol\u00f3gico: 1993: Ca ductal infiltrante de mama izquierda tratada con mastectom\u00eda radical modificada izquierda.\n",
      "  \u2192 1993 (DATE) [24-28]\n",
      "  \u2192 Ca ductal infiltrante de mama izquierda (CANCER_CONCEPT) [30-69]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [70-77]\n",
      "  \u2192 mastectom\u00eda radical modificada izquierda (SURGERY) [82-122]\n",
      "\n",
      "Texto: Informe AP: Comedocarcinoma infiltrante de 3,8 cm con componente intraductal asociado con necrosis central.\n",
      "  \u2192 Comedocarcinoma infiltrante (CANCER_CONCEPT) [12-39]\n",
      "\n",
      "Texto: Tiene ganglios linf\u00e1ticos libres de metastasis pT2 N0 (0/9).\n",
      "  \u2192 metastasis (CANCER_CONCEPT) [36-46]\n",
      "  \u2192 pT2 N0 (TNM) [47-53]\n",
      "\n",
      "Texto: RE: 15 %, RP: positivo.\n",
      "  \u2192 RE: 15 % (BIOMARKER) [0-8]\n",
      "  \u2192 RP: positivo (BIOMARKER) [10-22]\n",
      "\n",
      "Texto: Her2: positivo.\n",
      "  \u2192 Her2: positivo (BIOMARKER) [0-14]\n",
      "\n",
      "Texto: No fiebre alta.\n",
      "\n",
      "Texto: Estaba embarazada coincidiendo con el diagn\u00f3stico por este motivo recibi\u00f3 tratamiento con quimioterapia exclusivamente con Adriamicina x 6 ciclos.\n",
      "  \u2192 embarazada (GINE_OBSTETRICS) [7-17]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [38-49]\n",
      "  \u2192 recibi\u00f3 (OCURRENCE_EVENT) [66-73]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [90-103]\n",
      "  \u2192 Adriamicina (DRUG) [123-134]\n",
      "  \u2192 x (LINE_CICLE_NUMBER) [135-136]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [137-145]\n",
      "\n",
      "Texto: Sigui\u00f3 revisiones posteriormente, no recibi\u00f3 tto con hormonoterapia inicialmente.\n",
      "  \u2192 recibi\u00f3 (OCURRENCE_EVENT) [37-44]\n",
      "  \u2192 hormonoterapia (TREATMENT_NAME) [53-67]\n",
      "\n",
      "Texto: Informe AP: segmento cut\u00e1neo de 4 x 1 cm con carcinoma ductal de borde profundo.\n",
      "  \u2192 carcinoma ductal de borde profundo (CANCER_CONCEPT) [45-79]\n",
      "\n",
      "Texto: Paciente de 45 a\u00f1os diagnosticada de c\u00e1ncer de mama, estadio IV, HER2 positivo hace tres semanas.\n",
      "  \u2192 45 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [20-33]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [37-51]\n",
      "  \u2192 estadio IV (STAGE) [53-63]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [65-78]\n",
      "  \u2192 hace tres semanas (IMPLICIT_DATE) [79-96]\n",
      "\n",
      "Texto: Mujer con Ca ductal infiltrante de mama izquierda T1N0Mx, postmenopa\u00fasicas, HER2 positivo.\n",
      "  \u2192 Ca ductal infiltrante de mama izquierda (CANCER_CONCEPT) [10-49]\n",
      "  \u2192 T1N0Mx (TNM) [50-56]\n",
      "  \u2192 postmenopa\u00fasicas (GINECOLOGICAL_HISTORY) [58-74]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [76-89]\n",
      "\n",
      "Texto: Intervenida mediante cuadrantectom\u00eda y VA en diciembre del 2008.\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [21-36]\n",
      "  \u2192 VA (SURGERY) [39-41]\n",
      "  \u2192 diciembre del 2008. (DATE) [45-64]\n",
      "\n",
      "Texto: Tratada con Doxorrubicina y Ciclofosfamida x 4 ciclos .\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 Doxorrubicina (DRUG) [12-25]\n",
      "  \u2192 Ciclofosfamida (DRUG) [28-42]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [43-53]\n",
      "\n",
      "Texto: Posteriormente tratada Radioterapia y Trastuzumab.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [15-22]\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [23-35]\n",
      "  \u2192 Trastuzumab (DRUG) [38-49]\n",
      "\n",
      "Texto: Tejido fibroadiposo con infiltraci\u00f3n por CARCINOMA de tipo histol\u00f3gico inespec\u00edfico y grado histol\u00f3gico de Nottinghammm por puntuaci\u00f3n de 8 (3-3-2).\n",
      "  \u2192 CARCINOMA de tipo histol\u00f3gico inespec\u00edfico (CANCER_CONCEPT) [41-83]\n",
      "  \u2192 grado histol\u00f3gico de Nottinghammm (STAGE) [86-119]\n",
      "\n",
      "Texto: Ha recibido tratamiento con CARBOPLATINO ( 2\u00ba linea de enferemedad metastasica) Por 10 ciclos con Enfermedad estable.\n",
      "  \u2192 CARBOPLATINO (DRUG) [28-40]\n",
      "  \u2192 2o linea (LINE_CICLE_NUMBER) [43-51]\n",
      "  \u2192 metastasica (CANCER_CONCEPT) [67-78]\n",
      "  \u2192 10 ciclos (LINE_CICLE_NUMBER) [84-93]\n",
      "\n",
      "Texto: Tratada con Carboplatino en mayo de 2009.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 Carboplatino (DRUG) [12-24]\n",
      "  \u2192 mayo de 2009. (DATE) [28-41]\n",
      "\n",
      "Texto: Mujer de 37 a\u00f1os que pasa a nivel I por derrame peric\u00e1rdico.\n",
      "  \u2192 37 a\u00f1os (AGE) [9-16]\n",
      "\n",
      "Texto: A su llegada TA 128/94, FC: 95 lpm, sat basal 100%\n",
      "\n",
      "Texto: CyC: No IYAC: R\u00edtmico. no ausculto soplos. AP: MVCAD: Sin hallazgos. EEII: No edema. PLAN: Observaci\u00f3n.\n",
      "  \u2192 no ausculto soplos (COMORBIDITY) [23-41]\n",
      "\n",
      "Texto: Pte de ingreso.\n",
      "\n",
      "Texto: Cardiolog\u00eda est\u00e1 al tanto del caso.\n",
      "  \u2192 Cardiolog\u00eda (CLINICAL_SERVICE) [0-11]\n",
      "\n",
      "Texto: Tras valoraci\u00f3n del caso por cardiolog\u00eda y la imposibilidad de realizar pericardiocentesis por parte de ellos aconsejan ingreso a oncolog\u00eda m\u00e9dica con seguimiento estrecho por su parte.\n",
      "  \u2192 cardiolog\u00eda (CLINICAL_SERVICE) [29-40]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [130-146]\n",
      "\n",
      "Texto: El lunes probablemente se realizar\u00e1 ventana peric\u00e1rdica por parte de cirug\u00eda cardiaca.\n",
      "  \u2192 cirug\u00eda cardiaca (CLINICAL_SERVICE) [69-85]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda pT2 N0 (GC).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 pT2 N0 (TNM) [47-53]\n",
      "\n",
      "Texto: Mujer con carcinoma ductal in situ dentro del tumor con patrones qu\u00edstico y comedocarcinoma y de alto grado nuclear.\n",
      "  \u2192 carcinoma ductal in situ (CANCER_CONCEPT) [10-34]\n",
      "  \u2192 tumor (CANCER_CONCEPT) [46-51]\n",
      "  \u2192 comedocarcinoma (CANCER_CONCEPT) [76-91]\n",
      "\n",
      "Texto: Posteriormente recibi\u00f3 QT.\n",
      "  \u2192 recibi\u00f3 (OCURRENCE_EVENT) [15-22]\n",
      "  \u2192 QT (TREATMENT_NAME) [23-25]\n",
      "\n",
      "Texto: RT sobre lecho de mastectom\u00eda izquierda y las cadenas ganglionares axiloclaviculares izquierdas.\n",
      "  \u2192 RT (TREATMENT_NAME) [0-2]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [18-39]\n",
      "\n",
      "Texto: Paciente con Hipotiroidismo en tto.\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [13-27]\n",
      "\n",
      "Texto: El 17/10/2018 se ha realizado tumorectom\u00eda guiada por arp\u00f3n.\n",
      "  \u2192 17/10/2018 (DATE) [3-13]\n",
      "  \u2192 tumorectom\u00eda guiada por arp\u00f3n (SURGERY) [30-59]\n",
      "\n",
      "Texto: JUICIO DIAGN\u00d3STICO: Carcinoma infiltrante triple negativo cT2 cN1 M0.\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [7-18]\n",
      "  \u2192 Carcinoma infiltrante triple negativo (CANCER_CONCEPT) [20-57]\n",
      "  \u2192 cT2 cN1 M0 (TNM) [58-68]\n",
      "\n",
      "Texto: Paciente tratada en Diciembre 2016 con QT con esquema EC x 4 y Carboplatino - Paclitaxel x 4 hasta Julio 2017.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Diciembre 2016 (DATE) [20-34]\n",
      "  \u2192 QT (TREATMENT_NAME) [39-41]\n",
      "  \u2192 esquema EC (DRUG) [46-56]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [57-60]\n",
      "  \u2192 Carboplatino (DRUG) [63-75]\n",
      "  \u2192 Paclitaxel (DRUG) [78-88]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [89-92]\n",
      "  \u2192 Julio 2017. (DATE) [99-110]\n",
      "\n",
      "Texto: Paciente tratada en Diciembre 2016 con QT con esquema EC x 4 y Carboplatino - Paclitaxel x 4 hasta Julio 2017.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Diciembre 2016 (DATE) [20-34]\n",
      "  \u2192 QT (TREATMENT_NAME) [39-41]\n",
      "  \u2192 esquema EC (DRUG) [46-56]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [57-60]\n",
      "  \u2192 Carboplatino (DRUG) [63-75]\n",
      "  \u2192 Paclitaxel (DRUG) [78-88]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [89-92]\n",
      "  \u2192 Julio 2017. (DATE) [99-110]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre con CARCINOMAS DE PR\u00d3STATA .\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 CARCINOMAS DE PR\u00d3STATA (CANCER_CONCEPT) [35-57]\n",
      "\n",
      "Texto: PRIMERA CONSULTA ONCOLOG\u00cdA M\u00c9DICA en mujer de 36 a\u00f1os que acude sola.\n",
      "  \u2192 ONCOLOG\u00cdA M\u00c9DICA (CLINICAL_SERVICE) [17-33]\n",
      "  \u2192 36 a\u00f1os (AGE) [46-53]\n",
      "\n",
      "Texto: PRIMERA CONSULTA ONCOLOG\u00cdA M\u00c9DICA.\n",
      "  \u2192 ONCOLOG\u00cdA M\u00c9DICA (CLINICAL_SERVICE) [17-33]\n",
      "\n",
      "Texto: Mujer de 36 a\u00f1os diagnosticada de carcinoma de mama, acude a consulta para valoraci\u00f3n de tratamiento neoadyuvante.\n",
      "  \u2192 36 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [34-51]\n",
      "  \u2192 tratamiento neoadyuvante (TREATMENT_NAME) [89-113]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES: No RAMC.\n",
      "  \u2192 No RAMC (ALLERGIES) [25-32]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: Niega h\u00e1bitos t\u00f3xicos.\n",
      "\n",
      "Texto: Antecedentes ginecol\u00f3gicos: menarquia 10-11 a\u00f1os, no gestaciones ni abortos, no ACO.\n",
      "  \u2192 menarquia (GINECOLOGICAL_HISTORY) [28-37]\n",
      "  \u2192 10-11 a\u00f1os (AGE) [38-48]\n",
      "  \u2192 gestaciones (GINE_OBSTETRICS) [53-64]\n",
      "  \u2192 abortos (GINE_OBSTETRICS) [68-75]\n",
      "  \u2192 ACO (GINECOLOGICAL_HISTORY) [80-83]\n",
      "\n",
      "Texto: No tratamiento habitual.\n",
      "\n",
      "Texto: Refiere antecedentess familiaress onncol\u00f3gicos.\n",
      "\n",
      "Texto: Paciente de 47 a\u00f1os remitida de su centro de salud por cefalea.\n",
      "  \u2192 47 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [20-28]\n",
      "\n",
      "Texto: Antecedentes personales- Niega reacciones al\u00e9rgicas o medicamentosas conocidas.\n",
      "  \u2192 Niega reacciones al\u00e9rgicas o medicamentosas conocidas (ALLERGIES) [25-78]\n",
      "\n",
      "Texto: - No t\u00f3xicos.\n",
      "\n",
      "Texto: No HTA, No DM2 ni Dislipemias.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 No DM2 (COMORBIDITY) [8-14]\n",
      "  \u2192 ni Dislipemias (COMORBIDITY) [15-29]\n",
      "\n",
      "Texto: Mujer con Carcinoma de mama pT1 (m) N0 M0 (estadio IA), diagnosticada hace un mes.\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [10-27]\n",
      "  \u2192 pT1 (TNM) [28-31]\n",
      "  \u2192 N0 M0 (TNM) [36-41]\n",
      "  \u2192 estadio IA (STAGE) [43-53]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [56-69]\n",
      "  \u2192 hace un mes (IMPLICIT_DATE) [70-81]\n",
      "\n",
      "Texto: Mujer con Carcinoma de mama, estadio IA, diagnosticada hace tres meses.\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [10-27]\n",
      "  \u2192 estadio IA (STAGE) [29-39]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [41-54]\n",
      "  \u2192 hace tres meses (IMPLICIT_DATE) [55-70]\n",
      "\n",
      "Texto: Mujer con Carcinoma de mama, estadio IA, diagnosticada hace tres meses.\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [10-27]\n",
      "  \u2192 estadio IA (STAGE) [29-39]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [41-54]\n",
      "  \u2192 hace tres meses (IMPLICIT_DATE) [55-70]\n",
      "\n",
      "Texto: Carcinoma de mama RE positivos, HER-2 negativo, Ki67: positivo.\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [0-17]\n",
      "  \u2192 RE positivos (BIOMARKER) [18-30]\n",
      "  \u2192 HER-2 negativo (BIOMARKER) [32-46]\n",
      "  \u2192 Ki67: positivo (BIOMARKER) [48-62]\n",
      "\n",
      "Texto: Motivo de consulta: Mujer de 40 a\u00f1os remitida desde el servicio de Ginecolog\u00eda con cancer de mama para valoraci\u00f3n de tratamiento .\n",
      "  \u2192 40 a\u00f1os (AGE) [29-36]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [37-45]\n",
      "  \u2192 Ginecolog\u00eda (CLINICAL_SERVICE) [67-78]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [83-97]\n",
      "\n",
      "Texto: No HTA, no dislipemia, no DM.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no dislipemia (COMORBIDITY) [8-21]\n",
      "  \u2192 no DM (COMORBIDITY) [23-28]\n",
      "\n",
      "Texto: No diabetes mellitus.\n",
      "  \u2192 No diabetes mellitus (COMORBIDITY) [0-20]\n",
      "\n",
      "Texto: Esofagitis por RGE.\n",
      "  \u2192 Esofagitis por RGE (COMORBIDITY) [0-18]\n",
      "\n",
      "Texto: Antecedentes gineco-obst\u00e9tricos: Menarquia a los 14 a\u00f1os.\n",
      "  \u2192 Menarquia (GINECOLOGICAL_HISTORY) [33-42]\n",
      "  \u2192 14 a\u00f1os (AGE) [49-56]\n",
      "\n",
      "Texto: Toxicol\u00f3gicos: Fumadora de 1-2 cig/d\u00eda desde los 18 a\u00f1os.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [15-23]\n",
      "  \u2192 1-2 cig (HABIT-QUANTITY) [27-34]\n",
      "  \u2192 d\u00eda (FREQ) [35-38]\n",
      "  \u2192 desde los 18 a\u00f1os (DURATION) [39-56]\n",
      "\n",
      "Texto: Tratamiento habitual: Esomeprazol 20 mg cada 12 horas, sertralina 100 mg cada 8 horas.\n",
      "  \u2192 Esomeprazol (DRUG) [22-33]\n",
      "  \u2192 20 mg (DOSE) [34-39]\n",
      "  \u2192 cada 12 horas (FREQ) [40-53]\n",
      "  \u2192 sertralina (DRUG) [55-65]\n",
      "  \u2192 100 mg (DOSE) [66-72]\n",
      "  \u2192 cada 8 horas (FREQ) [73-85]\n",
      "\n",
      "Texto: Antecedentes familiares oncol\u00f3gicos: T\u00eda materna: fallecida de c\u00e1ncer linfatico a los 56 a\u00f1os.\n",
      "  \u2192 T\u00eda materna (FAMILY) [37-48]\n",
      "  \u2192 fallecida (OCURRENCE_EVENT) [50-59]\n",
      "  \u2192 c\u00e1ncer linfatico (CANCER_CONCEPT) [63-79]\n",
      "  \u2192 56 a\u00f1os (AGE) [86-93]\n",
      "\n",
      "Texto: Abuela con c\u00e1ncer de colon a los 64 a\u00f1os, en tratamiento.\n",
      "  \u2192 Abuela (FAMILY) [0-6]\n",
      "  \u2192 c\u00e1ncer de colon (CANCER_CONCEPT) [11-26]\n",
      "  \u2192 64 a\u00f1os (AGE) [33-40]\n",
      "\n",
      "Texto: Tio materno operado de c\u00e1ncer de colon a los 75 a\u00f1os.\n",
      "  \u2192 Tio materno (FAMILY) [0-11]\n",
      "  \u2192 operado (OCURRENCE_EVENT) [12-19]\n",
      "  \u2192 c\u00e1ncer de colon (CANCER_CONCEPT) [23-38]\n",
      "  \u2192 75 a\u00f1os (AGE) [45-52]\n",
      "\n",
      "Texto: Madre intervenida de cancer de mama hace 5 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [0-5]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [6-17]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [21-35]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [36-47]\n",
      "\n",
      "Texto: Abuelo materno fallecido de c\u00e1ncer de pulm\u00f3n hace 20 a\u00f1os.\n",
      "  \u2192 Abuelo materno (FAMILY) [0-14]\n",
      "  \u2192 fallecido (OCURRENCE_EVENT) [15-24]\n",
      "  \u2192 c\u00e1ncer de pulm\u00f3n (CANCER_CONCEPT) [28-44]\n",
      "  \u2192 hace 20 a\u00f1os (IMPLICIT_DATE) [45-57]\n",
      "\n",
      "Texto: No HTA, no dislipemia, no DM.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no dislipemia (COMORBIDITY) [8-21]\n",
      "  \u2192 no DM (COMORBIDITY) [23-28]\n",
      "\n",
      "Texto: CICLO 3 ADRIAMICINA (60 mg/m2) - CICLOFOSFAMIDA (600 mg/m2) ADYUVANTE ++ Ciclofosfamida 1172 mg - Doxorrubicina 117 mg.\n",
      "  \u2192 CICLO 3 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 ADRIAMICINA (DRUG) [8-19]\n",
      "  \u2192 (60 mg/m2) (DOSE) [20-30]\n",
      "  \u2192 CICLOFOSFAMIDA (DRUG) [33-47]\n",
      "  \u2192 (600 mg/m2) (DOSE) [48-59]\n",
      "  \u2192 ADYUVANTE (TREATMENT_NAME) [60-69]\n",
      "  \u2192 Ciclofosfamida (DRUG) [73-87]\n",
      "  \u2192 1172 mg (DOSE) [88-95]\n",
      "  \u2192 Doxorrubicina (DRUG) [98-111]\n",
      "  \u2192 117 mg (DOSE) [112-118]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda, RE 90 % , RP 70 % , HER2 negativo, pT1c(m) pN1a(1/13) cM0 (al menos estadio IIA).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 RE 90 % (BIOMARKER) [48-55]\n",
      "  \u2192 RP 70 % (BIOMARKER) [58-65]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [68-81]\n",
      "  \u2192 pT1c(m) pN1a(1/13) (TNM) [83-101]\n",
      "  \u2192 cM0 (TNM) [102-105]\n",
      "  \u2192 estadio IIA (STAGE) [116-127]\n",
      "\n",
      "Texto: * Mastectomia izquierda + linfadenectomia 09/04/2019.\n",
      "  \u2192 Mastectomia izquierda (SURGERY) [2-23]\n",
      "  \u2192 linfadenectomia (SURGERY) [26-41]\n",
      "  \u2192 09/04/2019 (DATE) [42-52]\n",
      "\n",
      "Texto: Mejor de las nauseas y v\u00f3mitos respecto a ciclos previos.\n",
      "\n",
      "Texto: CICLO 1 DOXORRUBICINA 90 MG CICLOFOSFAMIDA 895 MG Carcinoma infiltrante tipo inespec\u00edfico, en CII de mama derecha.\n",
      "  \u2192 CICLO 1 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 DOXORRUBICINA (DRUG) [8-21]\n",
      "  \u2192 90 MG (DOSE) [22-27]\n",
      "  \u2192 CICLOFOSFAMIDA (DRUG) [28-42]\n",
      "  \u2192 895 MG (DOSE) [43-49]\n",
      "  \u2192 Carcinoma infiltrante tipo inespec\u00edfico (CANCER_CONCEPT) [50-89]\n",
      "  \u2192 CII de mama derecha (CANCER_CONCEPT) [94-113]\n",
      "\n",
      "Texto: Premenop\u00e1usica Carcinoma intraductal focal, Mastectom\u00eda + Linfadenectom\u00eda derechas 11/09/2017.\n",
      "  \u2192 Premenop\u00e1usica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "  \u2192 Carcinoma intraductal focal (CANCER_CONCEPT) [15-42]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [44-55]\n",
      "  \u2192 Linfadenectom\u00eda derechas (SURGERY) [58-82]\n",
      "  \u2192 11/09/2017 (DATE) [83-93]\n",
      "\n",
      "Texto: Doy informe completo y recetas.\n",
      "\n",
      "Texto: Resuelvo dudas.\n",
      "\n",
      "Texto: Acude acompa\u00f1ada con una amiga.\n",
      "\n",
      "Texto: Mastectom\u00eda con reconstrucci\u00f3n en buen estado, cicatrices cerradas, sin signos de complicaci\u00f3n.\n",
      "  \u2192 Mastectom\u00eda con reconstrucci\u00f3n (SURGERY) [0-30]\n",
      "\n",
      "Texto: 1er CICLO ADRIAMICINA - CICLOFOSFAMIDA neoadyuvantes, Doxorrubicina 92,8 mg y Ciclofosfamida 92 mg.\n",
      "  \u2192 1er CICLO (LINE_CICLE_NUMBER) [0-9]\n",
      "  \u2192 ADRIAMICINA (DRUG) [10-21]\n",
      "  \u2192 CICLOFOSFAMIDA (DRUG) [24-38]\n",
      "  \u2192 neoadyuvantes (TREATMENT_NAME) [39-52]\n",
      "  \u2192 Doxorrubicina (DRUG) [54-67]\n",
      "  \u2192 92,8 mg (DOSE) [68-75]\n",
      "  \u2192 Ciclofosfamida (DRUG) [78-92]\n",
      "  \u2192 92 mg (DOSE) [93-98]\n",
      "\n",
      "Texto: Se palpa n\u00f3dulo en IICC externos de mama izquierda de 3 x 3 cm.\n",
      "\n",
      "Texto: No palpo adenopatias axilares ni supraclaviculares.\n",
      "  \u2192 No palpo adenopatias axilares (COMORBIDITY) [0-29]\n",
      "\n",
      "Texto: ACR: ritmica sin soplos.\n",
      "  \u2192 sin soplos (COMORBIDITY) [13-23]\n",
      "\n",
      "Texto: Aporta anal\u00edtica normal de hace 1 mes.\n",
      "  \u2192 hace 1 mes (IMPLICIT_DATE) [27-37]\n",
      "\n",
      "Texto: CICLO 9 CAPECITABINA 1800 MG CADA 12 HORAS.\n",
      "  \u2192 CICLO 9 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 CAPECITABINA (DRUG) [8-20]\n",
      "  \u2192 1800 MG (DOSE) [21-28]\n",
      "  \u2192 CADA 12 HORAS (FREQ) [29-42]\n",
      "\n",
      "Texto: Se ha evidenciado anal\u00edtica normalizada y marcador ha bajdo de forma muy considerable .\n",
      "\n",
      "Texto: Se plantear\u00e1 pr\u00f3xima revisi\u00f3n con PET.\n",
      "\n",
      "Texto: CICLO 5 CAPECITABINA, Dolor en la planta de los pies que desaparece en los dias descanso y no ha tomado analgesia.\n",
      "  \u2192 CICLO 5 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 CAPECITABINA (DRUG) [8-20]\n",
      "\n",
      "Texto: Juicio cl\u00ednico: - Carcinoma infiltrante de mama derecha en 2010 pTxN0M0.\n",
      "  \u2192 Carcinoma infiltrante de mama derecha (CANCER_CONCEPT) [18-55]\n",
      "  \u2192 2010 (DATE) [59-63]\n",
      "  \u2192 pTxN0M0 (TNM) [64-71]\n",
      "\n",
      "Texto: - Carcinoma infiltrante de mama izquierda cT4b N2 M1 (estadio IV, por afectaci\u00f3n \u00f3sea y pulmonar).\n",
      "  \u2192 Carcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [2-41]\n",
      "  \u2192 cT4b N2 M1 (TNM) [42-52]\n",
      "  \u2192 estadio IV (STAGE) [54-64]\n",
      "  \u2192 afectaci\u00f3n \u00f3sea y pulmonar (PROGRESION) [70-96]\n",
      "\n",
      "Texto: Rc estr\u00f3genos negativo, Rc progesterona 40 %, HER2 negativo, Ki67 40 %.\n",
      "  \u2192 Rc estr\u00f3genos negativo (BIOMARKER) [0-22]\n",
      "  \u2192 Rc progesterona 40 % (BIOMARKER) [24-44]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [46-59]\n",
      "  \u2192 Ki67 40 %. (BIOMARKER) [61-71]\n",
      "\n",
      "Texto: Docetaxel + Capecitabina x 4 * Paclitaxel + Bevacizumab x 2 ciclos.\n",
      "  \u2192 Docetaxel (DRUG) [0-9]\n",
      "  \u2192 Capecitabina (DRUG) [12-24]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [25-28]\n",
      "  \u2192 Paclitaxel (DRUG) [31-41]\n",
      "  \u2192 Bevacizumab (DRUG) [44-55]\n",
      "  \u2192 x 2 ciclos (LINE_CICLE_NUMBER) [56-66]\n",
      "\n",
      "Texto: Mujer de 62 a\u00f1os diagnosticada de Carcinoma lobulillar y ductal infiltrante de mama izquierda, tratado mediante mastectom\u00eda + linfadenectom\u00eda axilar.\n",
      "  \u2192 62 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma lobulillar y ductal infiltrante de mama izquierda (CANCER_CONCEPT) [34-93]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [95-102]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [112-123]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [126-148]\n",
      "\n",
      "Texto: Mujer de 62 a\u00f1os con diagn\u00f3stico de Carcinoma lobulillar y ductal infiltrante de mama izquierda, tratado mediante mastectom\u00eda + linfadenectom\u00eda axilar.\n",
      "  \u2192 62 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 con diagn\u00f3stico (OCURRENCE_EVENT) [17-32]\n",
      "  \u2192 Carcinoma lobulillar y ductal infiltrante de mama izquierda (CANCER_CONCEPT) [36-95]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [97-104]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [114-125]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [128-150]\n",
      "\n",
      "Texto: ESTUDIO IHQ:- receptores de estr\u00f3genos: positivo en el 100 % de las c\u00e9lulas tumorales, CK19: positivo, Ki67 positivo, Her2: Negativo.\n",
      "  \u2192 receptores de estr\u00f3genos: positivo en el 100 % (BIOMARKER) [14-60]\n",
      "  \u2192 c\u00e9lulas tumorales (CANCER_CONCEPT) [68-85]\n",
      "  \u2192 CK19: positivo (BIOMARKER) [87-101]\n",
      "  \u2192 Ki67 positivo (BIOMARKER) [103-116]\n",
      "  \u2192 Her2: Negativo (BIOMARKER) [118-132]\n",
      "\n",
      "Texto: Her2 : Negativo.\n",
      "  \u2192 Her2 : Negativo (BIOMARKER) [0-15]\n",
      "\n",
      "Texto: Ver informe M16-04478.\n",
      "\n",
      "Texto: Plan:- Comentado en comit\u00e9 de tumores, se deriva a oncologia m\u00e9dica para tratamiento quir\u00fargico con BSGC.\n",
      "  \u2192 comit\u00e9 de tumores (CLINICAL_SERVICE) [20-37]\n",
      "  \u2192 se deriva (OCURRENCE_EVENT) [39-48]\n",
      "  \u2192 oncologia m\u00e9dica (CLINICAL_SERVICE) [51-67]\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA: Mujer de 35 a\u00f1os diagnosticada de c\u00e1ncer de mama derecha en Septiembre 2019.\n",
      "  \u2192 35 a\u00f1os (AGE) [30-37]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [38-51]\n",
      "  \u2192 c\u00e1ncer de mama derecha (CANCER_CONCEPT) [55-77]\n",
      "  \u2192 Septiembre 2019. (DATE) [81-97]\n",
      "\n",
      "Texto: En Agosto de 2019 se palpa un n\u00f3dulo en axila derecha y se inicia estudio.\n",
      "  \u2192 Agosto de 2019 (DATE) [3-17]\n",
      "  \u2192 inicia estudio (OCURRENCE_EVENT) [59-73]\n",
      "\n",
      "Texto: - Mamograf\u00eda Agosto 2019: mamas densas sin signos mamogr\u00e1ficos de malignidad.\n",
      "  \u2192 Agosto 2019 (DATE) [13-24]\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [66-76]\n",
      "\n",
      "Texto: Se decide iniciar tratamiento el 14/10/19 con Carboplatino AUC 1.5 y Paclitaxel 80 mg/m2 semanal en el Hospital de Santiago de Compostela.\n",
      "  \u2192 iniciar tratamiento (OCURRENCE_EVENT) [10-29]\n",
      "  \u2192 14/10/19 (DATE) [33-41]\n",
      "  \u2192 Carboplatino (DRUG) [46-58]\n",
      "  \u2192 AUC 1.5 (DOSE) [59-66]\n",
      "  \u2192 Paclitaxel (DRUG) [69-79]\n",
      "  \u2192 80 mg/m2 (DOSE) [80-88]\n",
      "  \u2192 semanal (FREQ) [89-96]\n",
      "\n",
      "Texto: En Octubre de 2019 se traslada a Madrid y contin\u00faa quimioterapia (tercer ciclo de Carboplatino AUC 2 + Paclitaxel 80 mg/m2 el 29/10/2019).\n",
      "  \u2192 Octubre de 2019 (DATE) [3-18]\n",
      "  \u2192 se traslada (OCURRENCE_EVENT) [19-30]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [51-64]\n",
      "  \u2192 tercer ciclo (LINE_CICLE_NUMBER) [66-78]\n",
      "  \u2192 Carboplatino (DRUG) [82-94]\n",
      "  \u2192 AUC 2 (DOSE) [95-100]\n",
      "  \u2192 Paclitaxel (DRUG) [103-113]\n",
      "  \u2192 80 mg/m2 (DOSE) [114-122]\n",
      "  \u2192 29/10/2019 (DATE) [126-136]\n",
      "\n",
      "Texto: Tras 6 ciclos se solicita PET de reevaluaci\u00f3n.\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [5-13]\n",
      "\n",
      "Texto: A GANGLIO LINFATICO (NEOM) Biopsia intraoperatoria, una biopsia.\n",
      "\n",
      "Texto: DESCRIPCI\u00d3N MACROSC\u00d3PICA: Ganglio linf\u00e1tico axilar centinela que en su conjunto miden 2,1 cm de di\u00e1metro m\u00e1ximo y pesan 1580 mg.\n",
      "\n",
      "Texto: Se divide en tres mitades.\n",
      "\n",
      "Texto: Se procesa mediante OSNA (amplificaci\u00f3n de \u00e1cido nucleico en un solo paso, con detecci\u00f3n semicuantitativa y cuantitativa del\n",
      "\n",
      "Texto: Biopsia intraoperatoria, una biopsia DESCRIPCI\u00d3N MACROSC\u00d3PICA Mama derecha: pieza de mastectom\u00eda simple ahorradora de piel, con areola y pez\u00f3n, que pesa 377 g y mide 21 x 17 x 3 cm, identificada con un hilo de sutura.\n",
      "  \u2192 mastectom\u00eda simple ahorradora de piel (SURGERY) [85-122]\n",
      "\n",
      "Texto: Borde anterior e intercuadrantes externos.\n",
      "\n",
      "Texto: A la seriaci\u00f3n en la zona del punto existe un tumor s\u00f3lido, bien delimitado, homog\u00e9neo y de color rosado que mide 3,6 x 2,7 cm.\n",
      "  \u2192 tumor s\u00f3lido (CANCER_CONCEPT) [46-58]\n",
      "\n",
      "Texto: Dista 4 mm del margen quir\u00fargico anterior y 7 mm del margen quir\u00fargico posterior.\n",
      "\n",
      "Texto: Pieza de mastectom\u00eda simple, ahorradora de piel, con areola y pez\u00f3n, con CARCINOMA DUCTAL INFILTRANTE, estadio III, HER 2 negativo.\n",
      "  \u2192 mastectom\u00eda simple, ahorradora de piel (SURGERY) [9-47]\n",
      "  \u2192 CARCINOMA DUCTAL INFILTRANTE (CANCER_CONCEPT) [73-101]\n",
      "  \u2192 estadio III (STAGE) [103-114]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [116-130]\n",
      "\n",
      "Texto: Unifocal, mide 36 x 27 mm - con Carcinoma ductal in situ de alto grado nuclear, s\u00f3lido, con comedonecrosis, que supone < 10 % del total del tumor.\n",
      "  \u2192 Carcinoma ductal in situ de alto grado nuclear (CANCER_CONCEPT) [32-78]\n",
      "  \u2192 tumor (CANCER_CONCEPT) [140-145]\n",
      "\n",
      "Texto: Con hallazgos morfol\u00f3gicos de Carcinoma medular, (tumor circunscrito, con intenso infiltrado linfo-plasmocitario, sin claro patr\u00f3n sincitial).\n",
      "  \u2192 Carcinoma medular (CANCER_CONCEPT) [30-47]\n",
      "  \u2192 tumor circunscrito (CANCER_CONCEPT) [50-68]\n",
      "\n",
      "Texto: Antecedentes familiares: Abuelo con cancer de de colon hace 30 a\u00f1os.\n",
      "  \u2192 Abuelo (FAMILY) [25-31]\n",
      "  \u2192 cancer de de colon (CANCER_CONCEPT) [36-54]\n",
      "  \u2192 hace 30 a\u00f1os (IMPLICIT_DATE) [55-67]\n",
      "\n",
      "Texto: Antecedentes personales: Paciente con hipotiroidismo diagnosticado hace 5 a\u00f1os.\n",
      "  \u2192 hipotiroidismo (COMORBIDITY) [38-52]\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [53-66]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [67-78]\n",
      "\n",
      "Texto: Mujer de 40 a\u00f1os diagnosticada con cancer de mama que acude a revisi\u00f3n.\n",
      "  \u2192 40 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [35-49]\n",
      "\n",
      "Texto: AP: Carcinoma indiferenciado de mama derecha localmente avanzado cT1 (multifocal) N3b (axilar derecha y cadena mamaria interna derecha) Mx.\n",
      "  \u2192 Carcinoma indiferenciado de mama derecha (CANCER_CONCEPT) [4-44]\n",
      "  \u2192 localmente (STAGE) [45-55]\n",
      "  \u2192 avanzado (STAGE) [56-64]\n",
      "  \u2192 cT1 (TNM) [65-68]\n",
      "  \u2192 N3b (TNM) [82-85]\n",
      "  \u2192 Mx (TNM) [136-138]\n",
      "\n",
      "Texto: Mujer con carcinoma de mama derecha.\n",
      "  \u2192 carcinoma de mama derecha (CANCER_CONCEPT) [10-35]\n",
      "\n",
      "Texto: - Octubre de 2014: Quimioterapia: TAC x 1.\n",
      "  \u2192 Octubre de 2014 (DATE) [2-17]\n",
      "  \u2192 Quimioterapia (TREATMENT_NAME) [19-32]\n",
      "  \u2192 TAC (DRUG) [34-37]\n",
      "  \u2192 x 1. (LINE_CICLE_NUMBER) [38-42]\n",
      "\n",
      "Texto: AC x 3 ciclos.\n",
      "  \u2192 AC (DRUG) [0-2]\n",
      "  \u2192 x 3 ciclos (LINE_CICLE_NUMBER) [3-13]\n",
      "\n",
      "Texto: Taxanos semanal (+ 9 ciclos).\n",
      "  \u2192 Taxanos (DRUG) [0-7]\n",
      "  \u2192 semanal (FREQ) [8-15]\n",
      "  \u2192 9 ciclos (LINE_CICLE_NUMBER) [19-27]\n",
      "\n",
      "Texto: El 7 de abril de 2015 se hace mastectom\u00eda radical modificada derecha: ypT0 N0.\n",
      "  \u2192 7 de abril de 2015 (DATE) [3-21]\n",
      "  \u2192 mastectom\u00eda radical modificada derecha (SURGERY) [30-68]\n",
      "  \u2192 ypT0 N0 (TNM) [70-77]\n",
      "\n",
      "Texto: Radioterapia: Mediante t\u00e9cnica de modulaci\u00f3n de intensidad (IMRT) sobre lecho de mastectom\u00eda derecha, cadenas ganglionares axilares, FSC y cadena mamaria interna derecha.\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [0-12]\n",
      "  \u2192 mastectom\u00eda derecha (SURGERY) [81-100]\n",
      "\n",
      "Texto: Dosis total: 50 Gy.\n",
      "  \u2192 Dosis total (DOSE) [0-11]\n",
      "  \u2192 50 Gy (DOSE) [13-18]\n",
      "\n",
      "Texto: Se hab\u00eda realizado Rx t\u00f3rax y eco mamaria hace dos semanas.\n",
      "  \u2192 hace dos semanas (IMPLICIT_DATE) [42-58]\n",
      "\n",
      "Texto: Al d\u00eda siguiente comienza con fiebre.\n",
      "\n",
      "Texto: Acude a Hospital de Montepr\u00edncipe y es estudiada por Medicina Interna, que solicit\u00f3 estudios: Ecograf\u00eda axilar (16 de julio de 2014): adenopat\u00eda patol\u00f3gica axilar derecha, ya conocida, sin identificar cambios significativos respecto al estudio previo de referencia.\n",
      "  \u2192 Medicina Interna (CLINICAL_SERVICE) [53-69]\n",
      "  \u2192 (16 de julio de 2014) (DATE) [111-132]\n",
      "  \u2192 adenopat\u00eda patol\u00f3gica axilar derecha (COMORBIDITY) [134-170]\n",
      "\n",
      "Texto: Corresponde a adenopat\u00eda de aproximadamente 2,2 x 4 cm, bien definida, con contornos lobulados, marcadamente hipoecog\u00e9nica, discretamente heterog\u00e9nea, sin evidencia de hilio central graso.\n",
      "  \u2192 adenopat\u00eda (COMORBIDITY) [14-24]\n",
      "\n",
      "Texto: Resto del estudio axilar sin otros hallazgos patol\u00f3gicos rese\u00f1ables.\n",
      "\n",
      "Texto: ANATOM\u00cdA PATOL\u00d3GICA: carcinoma pobremente diferenciado de celulas grandes con rasgos anapl\u00e1sicos a tipificar en estudio inmunohistoqu\u00edmico.\n",
      "  \u2192 carcinoma pobremente diferenciado de celulas grandes (CANCER_CONCEPT) [21-73]\n",
      "\n",
      "Texto: ALK1 negativo, RE negativos, Her2 negativo, CK 7 positivo focal. Her2 negativo.\n",
      "  \u2192 ALK1 negativo (BIOMARKER) [0-13]\n",
      "  \u2192 RE negativos (BIOMARKER) [15-27]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [29-42]\n",
      "  \u2192 CK 7 positivo focal (BIOMARKER) [44-63]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [65-78]\n",
      "\n",
      "Texto: ALK1 negativo, Her2 negativo.\n",
      "  \u2192 ALK1 negativo (BIOMARKER) [0-13]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [15-28]\n",
      "\n",
      "Texto: Mujer diagnostiada con carcinoma de mama hace 5 meses.\n",
      "  \u2192 diagnostiada (OCURRENCE_EVENT) [6-18]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [23-40]\n",
      "  \u2192 hace 5 meses (IMPLICIT_DATE) [41-53]\n",
      "\n",
      "Texto: Carcioma de mama pT2N0M0, en mujer premenopausica, receptores hormonales positivos, HER2 negativo intervenida mediante mastectom\u00eda con reconstrucci\u00f3n en Enero del 2011 .\n",
      "  \u2192 Carcioma de mama (CANCER_CONCEPT) [0-16]\n",
      "  \u2192 pT2N0M0 (TNM) [17-24]\n",
      "  \u2192 premenopausica (GINECOLOGICAL_HISTORY) [35-49]\n",
      "  \u2192 receptores hormonales positivos (BIOMARKER) [51-82]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [84-97]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [98-109]\n",
      "  \u2192 mastectom\u00eda con reconstrucci\u00f3n (SURGERY) [119-149]\n",
      "  \u2192 Enero del 2011 (DATE) [153-167]\n",
      "\n",
      "Texto: Mujer diagnosticada de cancer de mama, en tratamiento con Quimioterapia AC por 4 ciclos y Tamoxifeno posterior ( Junio del 2011).\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [23-37]\n",
      "  \u2192 Quimioterapia (TREATMENT_NAME) [58-71]\n",
      "  \u2192 AC (DRUG) [72-74]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [79-87]\n",
      "  \u2192 Tamoxifeno (DRUG) [90-100]\n",
      "  \u2192 Junio del 2011) (DATE) [113-128]\n",
      "\n",
      "Texto: JUICIO CL\u00cdNICO : Carcinoma infiltrante de tipo inespec\u00edfico de mama izquierda, pT1 pN0 (sn) cM0 (Estadio IA).\n",
      "  \u2192 Carcinoma infiltrante de tipo inespec\u00edfico de mama izquierda (CANCER_CONCEPT) [17-77]\n",
      "  \u2192 pT1 pN0 (TNM) [79-86]\n",
      "  \u2192 cM0 (TNM) [92-95]\n",
      "  \u2192 Estadio IA (STAGE) [97-107]\n",
      "\n",
      "Texto: RE 100 % , HER2 negativo, Ki67 5 % .\n",
      "  \u2192 RE 100 % (BIOMARKER) [0-8]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [11-24]\n",
      "  \u2192 Ki67 5 % (BIOMARKER) [26-34]\n",
      "\n",
      "Texto: Mujer de 40 a\u00f1os ingresada a urgencias con diagn\u00f3sticos m\u00e9dicos de:- CA mama bilateral estadio IV, Mama Izquierda: CDI ypT2 N2a.\n",
      "  \u2192 40 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [17-26]\n",
      "  \u2192 urgencias (CLINICAL_SERVICE) [29-38]\n",
      "  \u2192 diagn\u00f3sticos (OCURRENCE_EVENT) [43-55]\n",
      "  \u2192 CA mama bilateral (CANCER_CONCEPT) [69-86]\n",
      "  \u2192 estadio IV (STAGE) [87-97]\n",
      "  \u2192 CDI (CANCER_CONCEPT) [115-118]\n",
      "  \u2192 ypT2 N2a (TNM) [119-127]\n",
      "\n",
      "Texto: RRHH -, Her2 negativo.\n",
      "  \u2192 RRHH - (BIOMARKER) [0-6]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [8-21]\n",
      "\n",
      "Texto: - Mama Derecha: CDI con afectaci\u00f3n axilar que actualmente es ypT0N0.\n",
      "  \u2192 CDI con afectaci\u00f3n axilar (CANCER_CONCEPT) [16-41]\n",
      "  \u2192 ypT0N0 (TNM) [61-67]\n",
      "\n",
      "Texto: Tratada con 3 ciclos de TAC + Mastectom\u00eda bilateral.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 3 ciclos (LINE_CICLE_NUMBER) [12-20]\n",
      "  \u2192 TAC (DRUG) [24-27]\n",
      "  \u2192 Mastectom\u00eda bilateral (SURGERY) [30-51]\n",
      "\n",
      "Texto: Tratada con RT + Tamoxifeno.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 RT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 Tamoxifeno (DRUG) [17-27]\n",
      "\n",
      "Texto: El 02/2015 Inicia Carboplatino + Gemcitabina, lleva 6 ciclos hasta 15/07/15.\n",
      "  \u2192 02/2015 (DATE) [3-10]\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [11-17]\n",
      "  \u2192 Carboplatino (DRUG) [18-30]\n",
      "  \u2192 Gemcitabina (DRUG) [33-44]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [52-60]\n",
      "  \u2192 15/07/15 (DATE) [67-75]\n",
      "\n",
      "Texto: El 02/2015 Inicia Carboplatino + Gemcitabina, lleva 6 ciclos hasta 15/07/15.\n",
      "  \u2192 02/2015 (DATE) [3-10]\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [11-17]\n",
      "  \u2192 Carboplatino (DRUG) [18-30]\n",
      "  \u2192 Gemcitabina (DRUG) [33-44]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [52-60]\n",
      "  \u2192 15/07/15 (DATE) [67-75]\n",
      "\n",
      "Texto: Mujer de 37 a\u00f1os que pasa a nivel I por derrame peric\u00e1rdico.\n",
      "  \u2192 37 a\u00f1os (AGE) [9-16]\n",
      "\n",
      "Texto: No ausculto soplos.\n",
      "  \u2192 No ausculto soplos (COMORBIDITY) [0-18]\n",
      "\n",
      "Texto: Carcinoma mamario pT2aN0, intervenido en agosto 2016 .\n",
      "  \u2192 Carcinoma mamario (CANCER_CONCEPT) [0-17]\n",
      "  \u2192 pT2aN0 (TNM) [18-24]\n",
      "  \u2192 intervenido (OCURRENCE_EVENT) [26-37]\n",
      "  \u2192 agosto 2016 (DATE) [41-52]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: No se palpan adenopat\u00edas axilares.\n",
      "  \u2192 No se palpan adenopat\u00edas axilares (COMORBIDITY) [0-33]\n",
      "\n",
      "Texto: EEII: No edema.\n",
      "\n",
      "Texto: PLAN: Observaci\u00f3n.\n",
      "\n",
      "Texto: Pte de ingreso.\n",
      "\n",
      "Texto: El servicio de Cardiolog\u00eda est\u00e1 al tanto del caso.\n",
      "  \u2192 Cardiolog\u00eda (CLINICAL_SERVICE) [15-26]\n",
      "\n",
      "Texto: Tras valoraci\u00f3n del caso por cardiolog\u00eda y la imposibilidad de realizar pericardiocentesis por parte de ellos aconsejan ingreso a oncolog\u00eda m\u00e9dica con seguimiento estrecho por su parte.\n",
      "  \u2192 cardiolog\u00eda (CLINICAL_SERVICE) [29-40]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [130-146]\n",
      "\n",
      "Texto: Probablemente se realizar\u00e1 ventana peric\u00e1rdica por parte de cirug\u00eda cardiaca.\n",
      "  \u2192 cirug\u00eda cardiaca (CLINICAL_SERVICE) [60-76]\n",
      "\n",
      "Texto: Juicio cl\u00ednico: Carcinoma ductal infiltrante de mama cT1pN1cM0 (estadio IIB) en 2010, RE +, HER2 +, Tratada con cisplatino + docetaxel (x 4) + cuadrantectom\u00eda + Tamoxifeno hace 5 a\u00f1os .\n",
      "  \u2192 Carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [16-52]\n",
      "  \u2192 cT1pN1cM0 (TNM) [53-62]\n",
      "  \u2192 estadio IIB (STAGE) [64-75]\n",
      "  \u2192 2010, (DATE) [80-85]\n",
      "  \u2192 RE + (BIOMARKER) [86-90]\n",
      "  \u2192 HER2 + (BIOMARKER) [92-98]\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [100-107]\n",
      "  \u2192 cisplatino (DRUG) [112-122]\n",
      "  \u2192 docetaxel (DRUG) [125-134]\n",
      "  \u2192 ( (LINE_CICLE_NUMBER) [135-136]\n",
      "  \u2192 x 4) (LINE_CICLE_NUMBER) [136-140]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [143-158]\n",
      "  \u2192 Tamoxifeno (DRUG) [161-171]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [172-183]\n",
      "\n",
      "Texto: Mujer diagnosticada con carcinoma de mama y tratada con cisplatino + docetaxel (x 4).\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [24-41]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [44-51]\n",
      "  \u2192 cisplatino (DRUG) [56-66]\n",
      "  \u2192 docetaxel (DRUG) [69-78]\n",
      "  \u2192 ( (LINE_CICLE_NUMBER) [79-80]\n",
      "  \u2192 x 4) (LINE_CICLE_NUMBER) [80-84]\n",
      "\n",
      "Texto: Paciente de 31 a\u00f1os con diagn\u00f3stico de carcinoma ductal infiltrante de mama izquierda ( regi\u00f3n periareolar ).\n",
      "  \u2192 31 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [24-35]\n",
      "  \u2192 carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [39-85]\n",
      "\n",
      "Texto: Multifocal ( focos muy pr\u00f3ximos de 14 mm y 7 mm ).\n",
      "\n",
      "Texto: Con componente intraductal asociado de grado nuclear intermedio de patr\u00f3n s\u00f3lido, sin necrosis y cancerizaci\u00f3n ductal que representa aproximadamente el 25 % de la masa tumoral .\n",
      "  \u2192 masa tumoral (CANCER_CONCEPT) [163-175]\n",
      "\n",
      "Texto: Infiltra dermis sin ulcerar epidermis.\n",
      "\n",
      "Texto: No se observa afectaci\u00f3n de la areola.\n",
      "\n",
      "Texto: - No se identifican im\u00e1genes de invasi\u00f3n linfovascular.\n",
      "\n",
      "Texto: - Se observa invasi\u00f3n perineural.\n",
      "\n",
      "Texto: -Bordes quir\u00fargicos definitivos: LIBRES DE AFECTACI\u00d3N: borde quir\u00fargico superficial (no cubierto por piel, CII) afecto en la pieza de mastectom\u00eda (borde libre en pieza de ampliaci\u00f3n: B13-20160).\n",
      "  \u2192 mastectom\u00eda (SURGERY) [134-145]\n",
      "\n",
      "Texto: Resto de m\u00e1rgenes a m\u00e1s de 1 cm.\n",
      "\n",
      "Texto: -ESTADIO GANGLIONAR: MACROMET\u00c1STASIS en ganglio centinela (B13-20154) .\n",
      "  \u2192 MACROMET\u00c1STASIS (CANCER_CONCEPT) [21-36]\n",
      "\n",
      "Texto: Ausencia de met\u00e1stasis en ganglios aislados en pieza de linfadenectom\u00eda .\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [12-22]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [56-71]\n",
      "\n",
      "Texto: TOTAL GANGLIONAR (1/16) Estadio : pT1c(m); pN1a (1/16), Mastectom\u00eda ahorradora con ampliaci\u00f3n de margen superficial y LA.\n",
      "  \u2192 pT1c(m); (TNM) [34-42]\n",
      "  \u2192 pN1a (TNM) [43-47]\n",
      "  \u2192 Mastectom\u00eda ahorradora con ampliaci\u00f3n de margen superficial (SURGERY) [56-115]\n",
      "  \u2192 LA (SURGERY) [118-120]\n",
      "\n",
      "Texto: Cirug\u00eda + QT + RT + Tamoxifeno pT1N1(1/13) M0.\n",
      "  \u2192 QT (TREATMENT_NAME) [10-12]\n",
      "  \u2192 RT (TREATMENT_NAME) [15-17]\n",
      "  \u2192 Tamoxifeno (DRUG) [20-30]\n",
      "  \u2192 pT1N1(1/13) (TNM) [31-42]\n",
      "  \u2192 M0 (TNM) [43-45]\n",
      "\n",
      "Texto: En Septiembre 2016: reca\u00edda \u00f3sea confirmacion PAAF ganglionar, HER2 negativa.\n",
      "  \u2192 Septiembre 2016 (DATE) [3-18]\n",
      "  \u2192 reca\u00edda \u00f3sea (PROGRESION) [20-32]\n",
      "  \u2192 HER2 negativa (BIOMARKER) [63-76]\n",
      "\n",
      "Texto: En Septiembre 2017: progresi\u00f3n \u00f3sea, inicia Capecitabina en Sept 2017.\n",
      "  \u2192 Septiembre 2017: (DATE) [3-19]\n",
      "  \u2192 progresi\u00f3n \u00f3sea (PROGRESION) [20-35]\n",
      "  \u2192 inicia (OCURRENCE_EVENT) [37-43]\n",
      "  \u2192 Capecitabina (DRUG) [44-56]\n",
      "  \u2192 Sept 2017. (DATE) [60-70]\n",
      "\n",
      "Texto: En julio 2018: sospecha de progresi\u00f3n \u00f3sea.\n",
      "  \u2192 julio 2018: (DATE) [3-14]\n",
      "  \u2192 progresi\u00f3n \u00f3sea (PROGRESION) [27-42]\n",
      "\n",
      "Texto: JUICIO DIAGN\u00d3STICO ACTUALIZADO: Paciente de 42 a\u00f1os diagnosticada con CARCINOMA INFILTRANTE de tipo histol\u00f3gico no espec\u00edfico de mama derecha, cT2m ( 5 cm de di\u00e1metro m\u00e1ximo en RM), cN1(sn).\n",
      "  \u2192 42 a\u00f1os (AGE) [44-51]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [52-65]\n",
      "  \u2192 CARCINOMA INFILTRANTE de tipo histol\u00f3gico no espec\u00edfico de mama derecha (CANCER_CONCEPT) [70-141]\n",
      "  \u2192 cT2m (TNM) [143-147]\n",
      "  \u2192 cN1(sn (TNM) [182-188]\n",
      "\n",
      "Texto: Ha sido tratada con quimioterapia con AC seguida de Paclitaxel, Herceptin y mastectom\u00eda y linfadenectom\u00eda con hallazgos histopatol\u00f3gicos.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [8-15]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [20-33]\n",
      "  \u2192 AC (DRUG) [38-40]\n",
      "  \u2192 Paclitaxel (DRUG) [52-62]\n",
      "  \u2192 Herceptin (DRUG) [64-73]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [76-87]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [90-105]\n",
      "\n",
      "Texto: Carcinoma infiltrante de mama derecha en 2010 pTxN0M0.\n",
      "  \u2192 Carcinoma infiltrante de mama derecha (CANCER_CONCEPT) [0-37]\n",
      "  \u2192 2010 (DATE) [41-45]\n",
      "  \u2192 pTxN0M0 (TNM) [46-53]\n",
      "\n",
      "Texto: - Carcinoma infiltrante de mama izquierda cT4b N2 M1 (estadio IV por afectaci\u00f3n \u00f3sea y pulmonar).\n",
      "  \u2192 Carcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [2-41]\n",
      "  \u2192 cT4b N2 M1 (TNM) [42-52]\n",
      "  \u2192 estadio IV (STAGE) [54-64]\n",
      "  \u2192 afectaci\u00f3n \u00f3sea y pulmonar (PROGRESION) [69-95]\n",
      "\n",
      "Texto: Rc estr\u00f3genos negativo, Rc progesterona 40 % , HER2 negativo.\n",
      "  \u2192 Rc estr\u00f3genos negativo (BIOMARKER) [0-22]\n",
      "  \u2192 Rc progesterona 40 % (BIOMARKER) [24-44]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [47-60]\n",
      "\n",
      "Texto: Ha recibido QT con Docetaxel + Capecitabina x 4.\n",
      "  \u2192 QT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 Docetaxel (DRUG) [19-28]\n",
      "  \u2192 Capecitabina (DRUG) [31-43]\n",
      "  \u2192 x 4. (LINE_CICLE_NUMBER) [44-48]\n",
      "\n",
      "Texto: Paclitaxel + Bevacizumab x 2 ciclos.\n",
      "  \u2192 Paclitaxel (DRUG) [0-10]\n",
      "  \u2192 Bevacizumab (DRUG) [13-24]\n",
      "  \u2192 x 2 ciclos (LINE_CICLE_NUMBER) [25-35]\n",
      "\n",
      "Texto: RESUMEN HISTORIA ONCOL\u00d3GICA: El 1 de mayo de 2006 se realiza tumorectom\u00eda y linfadenectom\u00eda axilar.\n",
      "  \u2192 1 de mayo de 2006 (DATE) [32-49]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [61-73]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [76-98]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de 2 cm de di\u00e1metro a 7 mm del borde resecci\u00f3n pr\u00f3ximo, con afectaci\u00f3n de ganglios aislados en el vaciamiento axilar.\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 resecci\u00f3n (SURGERY) [66-75]\n",
      "  \u2192 vaciamiento axilar (SURGERY) [127-145]\n",
      "\n",
      "Texto: Receptores de estr\u00f3geno y progest\u00e1genos positivos, HER-2 negativo, Ki67 positivo\n",
      "  \u2192 Receptores de estr\u00f3geno y progest\u00e1genos positivos (BIOMARKER) [0-49]\n",
      "  \u2192 HER-2 negativo (BIOMARKER) [51-65]\n",
      "  \u2192 Ki67 positivo (BIOMARKER) [67-80]\n",
      "\n",
      "Texto: Se realiz\u00f3 estudio de extensi\u00f3n que inclu\u00eda Rx de t\u00f3rax.\n",
      "\n",
      "Texto: El 1 de junio de 2006 inicia quimioterapia con Adriamicina, Ciclofosfamida y Docetaxel recibiendo 6 ciclos entre junio y octubre de 2006.\n",
      "  \u2192 1 de junio de 2006 (DATE) [3-21]\n",
      "  \u2192 inicia (OCURRENCE_EVENT) [22-28]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [29-42]\n",
      "  \u2192 Adriamicina (DRUG) [47-58]\n",
      "  \u2192 Ciclofosfamida (DRUG) [60-74]\n",
      "  \u2192 Docetaxel (DRUG) [77-86]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [98-106]\n",
      "  \u2192 junio (DATE) [113-118]\n",
      "  \u2192 octubre de 2006. (DATE) [121-137]\n",
      "\n",
      "Texto: Inicia radioterapia con 50 Gy hace 3 meses.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [7-19]\n",
      "  \u2192 50 Gy (DOSE) [24-29]\n",
      "  \u2192 hace 3 meses (IMPLICIT_DATE) [30-42]\n",
      "\n",
      "Texto: Ayer inici\u00f3 tratamiento quimioter\u00e1pico con Gemcitabina - carboplatino quincenal.\n",
      "  \u2192 Ayer (IMPLICIT_DATE) [0-4]\n",
      "  \u2192 inici\u00f3 (OCURRENCE_EVENT) [5-11]\n",
      "  \u2192 tratamiento quimioter\u00e1pico (TREATMENT_NAME) [12-38]\n",
      "  \u2192 Gemcitabina (DRUG) [43-54]\n",
      "  \u2192 carboplatino (DRUG) [57-69]\n",
      "  \u2192 quincenal (FREQ) [70-79]\n",
      "\n",
      "Texto: Juicio Cl\u00ednico:- Carcinoma metapl\u00e1sico triple negativo de mama izquierda con focos de diferenciaci\u00f3n escamosa ypT4bN2M0, estadio IIIB, tratado con mastectom\u00eda y linfadenectom\u00eda izquierda.\n",
      "  \u2192 Carcinoma metapl\u00e1sico triple negativo de mama izquierda con focos de diferenciaci\u00f3n escamosa (CANCER_CONCEPT) [17-109]\n",
      "  \u2192 ypT4bN2M0 (TNM) [110-119]\n",
      "  \u2192 estadio IIIB (STAGE) [121-133]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [135-142]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [147-158]\n",
      "  \u2192 linfadenectom\u00eda izquierda (SURGERY) [161-186]\n",
      "\n",
      "Texto: Inicio de tratamiento quimioter\u00e1pico de primera l\u00ednea con Carboplatino - Gemcitabina.\n",
      "  \u2192 Inicio (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 tratamiento quimioter\u00e1pico (TREATMENT_NAME) [10-36]\n",
      "  \u2192 primera l\u00ednea (LINE_CICLE_NUMBER) [40-53]\n",
      "  \u2192 Carboplatino (DRUG) [58-70]\n",
      "  \u2192 Gemcitabina (DRUG) [73-84]\n",
      "\n",
      "Texto: Inici\u00f3 quimioterapia con Carboplatino + Gemcitabina x 4 hasta junio 2016.\n",
      "  \u2192 Inici\u00f3 (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [7-20]\n",
      "  \u2192 Carboplatino (DRUG) [25-37]\n",
      "  \u2192 Gemcitabina (DRUG) [40-51]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [52-55]\n",
      "  \u2192 junio 2016. (DATE) [62-73]\n",
      "\n",
      "Texto: Ingreso URPA: Mujer de 40 a\u00f1os que ingresa procedente de Qx para mastectom\u00eda radical izda + Linfadenectom\u00eda + reconstrucci\u00f3n con dorsal ancho (+injerto de muslo dcho) bajo anestesia general.\n",
      "  \u2192 URPA (CLINICAL_SERVICE) [8-12]\n",
      "  \u2192 40 a\u00f1os (AGE) [23-30]\n",
      "  \u2192 ingresa (OCURRENCE_EVENT) [35-42]\n",
      "  \u2192 mastectom\u00eda radical izda (SURGERY) [65-89]\n",
      "  \u2192 Linfadenectom\u00eda (SURGERY) [92-107]\n",
      "  \u2192 reconstrucci\u00f3n con dorsal ancho (SURGERY) [110-141]\n",
      "\n",
      "Texto: AP: Alergia a diclofenaco.\n",
      "  \u2192 Alergia a diclofenaco (ALLERGIES) [4-25]\n",
      "\n",
      "Texto: Meningitis en la infancia, ca mama.\n",
      "  \u2192 Meningitis en la infancia (COMORBIDITY) [0-25]\n",
      "  \u2192 ca mama (CANCER_CONCEPT) [27-34]\n",
      "\n",
      "Texto: A la llegada HD estable, buenas saturaciones con GN a 33.\n",
      "\n",
      "Texto: Pasando SSF de Qx, comienzo STP pautada: Rnger-L a 6 ml/h.\n",
      "  \u2192 Rnger-L (DRUG) [41-48]\n",
      "  \u2192 6 ml/h (DOSE) [51-57]\n",
      "\n",
      "Texto: SV, orina clara.\n",
      "\n",
      "Texto: Mujer con cancer de mama.\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [10-24]\n",
      "\n",
      "Texto: Inicia Capecitabina 1250 mg/m2 cada 12 horas 14 d\u00edas seguido de una semana de descanso.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 Capecitabina (DRUG) [7-19]\n",
      "  \u2192 1250 mg/m2 (DOSE) [20-30]\n",
      "  \u2192 cada 12 horas (FREQ) [31-44]\n",
      "\n",
      "Texto: Mujer de 40 a\u00f1os diagnosticada de un carcinoma de mama triple negativo estadio IV por extensa afectaci\u00f3n cutanea, sin respuesta a quimioterapia.\n",
      "  \u2192 40 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 carcinoma de mama triple negativo (CANCER_CONCEPT) [37-70]\n",
      "  \u2192 estadio IV (STAGE) [71-81]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [130-143]\n",
      "\n",
      "Texto: Acude derivada de RT donde la han suspendido el tratamiento por progresi\u00f3n local.\n",
      "  \u2192 derivada (OCURRENCE_EVENT) [6-14]\n",
      "  \u2192 RT (TREATMENT_NAME) [18-20]\n",
      "  \u2192 han (OCURRENCE_EVENT) [30-33]\n",
      "  \u2192 suspendido el tratamiento (OCURRENCE_EVENT) [34-59]\n",
      "  \u2192 progresi\u00f3n local (PROGRESION) [64-80]\n",
      "\n",
      "Texto: Vista en RT: Aunque ser\u00eda pronto para excluir una respuesta local a la irradiaci\u00f3n, estando hasta ahora aparentemente sin cambios significativos, la progresi\u00f3n a otros niveles, hacen pensar que continuar la irradiaci\u00f3n no reportar\u00eda beneficio para la paciente.\n",
      "  \u2192 RT (TREATMENT_NAME) [9-11]\n",
      "\n",
      "Texto: Acude la paciente.\n",
      "\n",
      "Texto: Cl\u00ednicamente muy molesta por dolor secundario al linfedema.\n",
      "\n",
      "Texto: Ajusto tratamiento analg\u00e9sico: Aumento los parches de Durogesic de 50 a 75 mg/7 horas y la dosis de rescate de Effentora de 100 a 200.\n",
      "  \u2192 parches de Durogesic (DRUG) [43-63]\n",
      "  \u2192 50 a 75 mg (DOSE) [67-77]\n",
      "  \u2192 /7 horas (FREQ) [77-85]\n",
      "  \u2192 Effentora (DRUG) [111-120]\n",
      "  \u2192 100 a 200 (DOSE) [124-133]\n",
      "\n",
      "Texto: A pesar de que tiene reciente una radiograf\u00eda de t\u00f3rax y una ecograf\u00eda abdominal solicito un PET como estudio de extensi\u00f3n.\n",
      "\n",
      "Texto: Hablo con ellos y se lo hacen el 08/08/2013 por lo que decido iniciar QT.\n",
      "  \u2192 08/08/2013 (DATE) [33-43]\n",
      "  \u2192 iniciar (OCURRENCE_EVENT) [62-69]\n",
      "  \u2192 QT (TREATMENT_NAME) [70-72]\n",
      "\n",
      "Texto: Propongo: Capecitabina 1250 mg/m2 cada 12 horas 14 d\u00edas seguido de una semana de descanso.\n",
      "  \u2192 Capecitabina (DRUG) [10-22]\n",
      "  \u2192 1250 mg/m2 (DOSE) [23-33]\n",
      "  \u2192 cada 12 horas (FREQ) [34-47]\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA:Intervenida mediante mastectom\u00eda simple ahorradora de piel, identificada como mama derecha el 12/06/2017.\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [20-31]\n",
      "  \u2192 mastectom\u00eda simple ahorradora de piel (SURGERY) [41-78]\n",
      "  \u2192 mama derecha (CANCER_CONCEPT) [98-110]\n",
      "  \u2192 12/06/2017 (DATE) [114-124]\n",
      "\n",
      "Texto: Hematoma y alteraciones inflamatorias y reparativas inespec\u00edficas secundarias a la toma previa de biopsia asistida por vac\u00edo (BAV) en el cuadrante inferoexterno.\n",
      "  \u2192 biopsia (SURGERY) [98-105]\n",
      "\n",
      "Texto: 2) CARCINOMA LOBULILLAR INFILTRANTE PLEOM\u00d3RFICO:- Un foco de 5,5 mil\u00edmetros de di\u00e1metro m\u00e1ximo, localizado en el cuadrante inferoexterno, adyacente al hematoma y a las alteraciones reparativas e inflamatorias inespec\u00edficas descritas en el apartado\n",
      "  \u2192 CARCINOMA LOBULILLAR INFILTRANTE (CANCER_CONCEPT) [3-35]\n",
      "  \u2192 PLEOM\u00d3RFICO (CANCER_CONCEPT) [36-47]\n",
      "\n",
      "Texto: Grado histol\u00f3gico de Nottingham: 2 (formaci\u00f3n de estructuras ductales / acinares en menos del 1 % del tumor: 3; intenso pleomorfismo nuclear: 3; hasta 6 mitosis en 10 campos 40 X de 0,55 mil\u00edmetros de di\u00e1metro:\n",
      "  \u2192 Grado histol\u00f3gico de Nottingham: 2 (STAGE) [0-34]\n",
      "  \u2192 tumor (CANCER_CONCEPT) [102-107]\n",
      "\n",
      "Texto: No se identifica invasi\u00f3n tumoral linfovascular.\n",
      "  \u2192 invasi\u00f3n tumoral linfovascular (CANCER_CONCEPT) [17-47]\n",
      "\n",
      "Texto: - No se observa infiltraci\u00f3n tumoral perineural.\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [29-36]\n",
      "\n",
      "Texto: - No contacta con los bordes quir\u00fargicos.\n",
      "\n",
      "Texto: Dista 5 mil\u00edmetros del borde quir\u00fargico profundo y se encuentra m\u00e1s alejado del resto de los bordes.\n",
      "\n",
      "Texto: CARCINOMA LOBULILLAR PLEOM\u00d3RFICO IN SITU:- Variantes cl\u00e1sica y pleom\u00f3rfica.\n",
      "  \u2192 CARCINOMA LOBULILLAR PLEOM\u00d3RFICO IN SITU (CANCER_CONCEPT) [0-40]\n",
      "\n",
      "Texto: - La variante pleom\u00f3rfica es de de alto grado nuclear, con patr\u00f3n de crecimiento s\u00f3lido, con comedonecrosis focal y asociado a escasas microcalcificaciones.\n",
      "  \u2192 come (CANCER_CONCEPT) [93-97]\n",
      "  \u2192 cro (CANCER_CONCEPT) [101-104]\n",
      "\n",
      "Texto: La variante cl\u00e1sica dista menos de 1 mil\u00edmetro del borde profundo en el centro de la pieza; y menos de 1 mil\u00edmetro del borde superficial, en una zona de 4 mil\u00edmetros de extensi\u00f3n situada a las 7 horas y entre 3 mil\u00edmetros y 7 mil\u00edmetros por debajo del borde inferior del huso de piel.\n",
      "  \u2192 a las 7 horas (IMPLICIT_DATE) [187-200]\n",
      "\n",
      "Texto: Carcinoma infiltrante:- Receptores de estr\u00f3genos: NEGATIVO ( 0 ).\n",
      "  \u2192 Carcinoma infiltrante (CANCER_CONCEPT) [0-21]\n",
      "  \u2192 Receptores de estr\u00f3genos: NEGATIVO ( 0 (BIOMARKER) [24-62]\n",
      "\n",
      "Texto: Receptores de progesterona: NEGATIVO ( 0 ).\n",
      "  \u2192 Receptores de progesterona: NEGATIVO ( 0 (BIOMARKER) [0-40]\n",
      "\n",
      "Texto: \u00cdndice proliferativo (Ki67): alrededor del 3 % - E-cadherina: negativo (indica que se trata de una lesi\u00f3n de origen lobulillar).\n",
      "  \u2192 \u00cdndice proliferativo (Ki67): alrededor del 3 % (BIOMARKER) [0-46]\n",
      "  \u2192 E-cadherina: negativo (BIOMARKER) [49-70]\n",
      "\n",
      "Texto: -HER2 positivo.\n",
      "  \u2192 - (BIOMARKER) [0-1]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [1-14]\n",
      "\n",
      "Texto: Carcinoma lobulillar in situ:- Expresi\u00f3n irregular de receptores de estr\u00f3genos: positivos en las zonas cl\u00e1sicas y en algunas pleom\u00f3rficas y negativos en algunas de las zonas pleom\u00f3rficas.- E-cadherina: negativo (indica que se trata de una lesi\u00f3n de origen lobulillar).\n",
      "  \u2192 Carcinoma lobulillar in situ (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 receptores de estr\u00f3genos: positivos (BIOMARKER) [54-89]\n",
      "  \u2192 E-cadherina: negativo (BIOMARKER) [189-210]\n",
      "\n",
      "Texto: Diagn\u00f3sticos:Carcinoma lobulillar infiltrante pT1b pN0(i+) cMx (al menos estadio IA) grado 2 sin invasion linfovascular ni perineural, RH negativos HER2 positivo.\n",
      "  \u2192 Diagn\u00f3sticos (OCURRENCE_EVENT) [0-12]\n",
      "  \u2192 Carcinoma lobulillar infiltrante (CANCER_CONCEPT) [13-45]\n",
      "  \u2192 pT1b pN0(i+) cMx (TNM) [46-62]\n",
      "  \u2192 estadio IA (STAGE) [73-83]\n",
      "  \u2192 grado 2 (STAGE) [85-92]\n",
      "  \u2192 RH negativos (BIOMARKER) [135-147]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [148-161]\n",
      "\n",
      "Texto: Motivo de consulta: derivada de onco medica por cefalea en paciente con AP de metastasis cerebral.\n",
      "  \u2192 derivada (OCURRENCE_EVENT) [20-28]\n",
      "  \u2192 onco medica (CLINICAL_SERVICE) [32-43]\n",
      "  \u2192 metastasis cerebral (CANCER_CONCEPT) [78-97]\n",
      "\n",
      "Texto: Antecedentes personales: NO RAMC Historia oncol\u00f3gica: Carcinoma ductal infiltrante mama izquierda cT3m cN1 cM0 (estadio IIIA).\n",
      "  \u2192 NO RAMC (ALLERGIES) [25-32]\n",
      "  \u2192 Carcinoma ductal infiltrante mama izquierda (CANCER_CONCEPT) [54-97]\n",
      "  \u2192 cT3m cN1 cM0 (TNM) [98-110]\n",
      "  \u2192 estadio IIIA (STAGE) [112-124]\n",
      "\n",
      "Texto: HER2 positivo, Ki67 40 % .\n",
      "  \u2192 HER2 positivo (BIOMARKER) [0-13]\n",
      "  \u2192 Ki67 40 % (BIOMARKER) [15-24]\n",
      "\n",
      "Texto: Inicia EC con LAPATINIB 1250 mg + DOCETAXEL X 11 ciclos hace 3 semanas.\n",
      "  \u2192 Inicia EC (OCURRENCE_EVENT) [0-9]\n",
      "  \u2192 LAPATINIB (DRUG) [14-23]\n",
      "  \u2192 1250 mg (DOSE) [24-31]\n",
      "  \u2192 DOCETAXEL (DRUG) [34-43]\n",
      "  \u2192 X 11 ciclos (LINE_CICLE_NUMBER) [44-55]\n",
      "  \u2192 hace 3 semanas (IMPLICIT_DATE) [56-70]\n",
      "\n",
      "Texto: CICLO 25 de CARBOPLATINO - GEMCITABINA - TRASTUZUMAB en Mujer de 44 a\u00f1os con carcinoma ductal infiltrante mama izquierda cT3m , cN1 cM0 (estadio IIIA).\n",
      "  \u2192 CICLO 25 (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 CARBOPLATINO (DRUG) [12-24]\n",
      "  \u2192 GEMCITABINA (DRUG) [27-38]\n",
      "  \u2192 TRASTUZUMAB (DRUG) [41-52]\n",
      "  \u2192 44 a\u00f1os (AGE) [65-72]\n",
      "  \u2192 carcinoma ductal infiltrante mama izquierda (CANCER_CONCEPT) [77-120]\n",
      "  \u2192 cT3m (TNM) [121-125]\n",
      "  \u2192 cN1 cM0 (TNM) [128-135]\n",
      "  \u2192 estadio IIIA (STAGE) [137-149]\n",
      "\n",
      "Texto: HER2 positivo, Ki67 40 % .\n",
      "  \u2192 HER2 positivo (BIOMARKER) [0-13]\n",
      "  \u2192 Ki67 40 % (BIOMARKER) [15-24]\n",
      "\n",
      "Texto: Mastectom\u00eda el 15.05.2013 + Radioterapia entre el 03-07-2013 y 06-08-2013.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [0-11]\n",
      "  \u2192 15.05.2013 (DATE) [15-25]\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [28-40]\n",
      "  \u2192 03-07-2013 (DATE) [50-60]\n",
      "  \u2192 06-08-2013 (DATE) [63-73]\n",
      "\n",
      "Texto: Tratamiento con HERCEPT\u00cdN hasta el 12.04.14 + TAMOXIFENO (desde feb 14)- Marzo 2016: progresi\u00f3n hep\u00e1tica.\n",
      "  \u2192 HERCEPT\u00cdN (DRUG) [16-25]\n",
      "  \u2192 12.04.14 (DATE) [35-43]\n",
      "  \u2192 TAMOXIFENO (DRUG) [46-56]\n",
      "  \u2192 feb 14 (DATE) [64-70]\n",
      "  \u2192 Marzo 2016 (DATE) [73-83]\n",
      "  \u2192 progresi\u00f3n hep\u00e1tica (PROGRESION) [85-104]\n",
      "\n",
      "Texto: Juicio cl\u00ednico: Carcinoma infiltrante de mama izquierda pT2 N0 Mx (al menos estadio IIA).\n",
      "  \u2192 Carcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [16-55]\n",
      "  \u2192 pT2 N0 Mx (TNM) [56-65]\n",
      "  \u2192 estadio IIA (STAGE) [76-87]\n",
      "\n",
      "Texto: RS riesgo intermedio.\n",
      "\n",
      "Texto: Ha recibido AC por 4 RT y Tamoxifeno.\n",
      "  \u2192 AC (DRUG) [12-14]\n",
      "  \u2192 por 4 (LINE_CICLE_NUMBER) [15-20]\n",
      "  \u2192 RT (TREATMENT_NAME) [21-23]\n",
      "  \u2192 Tamoxifeno (DRUG) [26-36]\n",
      "\n",
      "Texto: REVISI\u00d3N PROGRAMADA: 42 a\u00f1os.\n",
      "  \u2192 42 a\u00f1os (AGE) [21-28]\n",
      "\n",
      "Texto: Met\u00e1stasis parasagital frontal dcha frontal y cortical frontal izda.\n",
      "  \u2192 Met\u00e1stasis (CANCER_CONCEPT) [0-10]\n",
      "\n",
      "Texto: Ca de mama (HER2 positivo).\n",
      "  \u2192 Ca de mama (CANCER_CONCEPT) [0-10]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [12-25]\n",
      "\n",
      "Texto: Esta en tratamiento con QT : Carboplatino + Gemcitabina + Traztuzumab, lleva 2 ciclos.\n",
      "  \u2192 QT (TREATMENT_NAME) [24-26]\n",
      "  \u2192 Carboplatino (DRUG) [29-41]\n",
      "  \u2192 Gemcitabina (DRUG) [44-55]\n",
      "  \u2192 Traztuzumab (DRUG) [58-69]\n",
      "  \u2192 2 ciclos (LINE_CICLE_NUMBER) [77-85]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha pT2N0Mx tratado mediante tumorectom\u00eda y posterior mastectom\u00eda con BSGC, RE y RP positivos, Her2 negativo en mujer premenopausica.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 pT2N0Mx (TNM) [45-52]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [53-60]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [70-82]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [95-106]\n",
      "  \u2192 RE y RP positivos (BIOMARKER) [117-134]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [136-149]\n",
      "  \u2192 premenopausica (GINECOLOGICAL_HISTORY) [159-173]\n",
      "\n",
      "Texto: Diciembre del 2010: Recibio tto con TC por 4 ciclos y tamoxifeno en septiembre de 2011.\n",
      "  \u2192 Diciembre del 2010 (DATE) [0-18]\n",
      "  \u2192 Recibio (OCURRENCE_EVENT) [20-27]\n",
      "  \u2192 tto (OCURRENCE_EVENT) [28-31]\n",
      "  \u2192 TC (DRUG) [36-38]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [43-51]\n",
      "  \u2192 tamoxifeno (DRUG) [54-64]\n",
      "  \u2192 septiembre de 2011. (DATE) [68-87]\n",
      "\n",
      "Texto: Mama derecha : carcinoma lobulillar infiltrante multifocal cT2 cN1 M0, HER2 positivo.\n",
      "  \u2192 carcinoma lobulillar infiltrante multifocal (CANCER_CONCEPT) [15-58]\n",
      "  \u2192 cT2 cN1 M0 (TNM) [59-69]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [71-84]\n",
      "\n",
      "Texto: Mama izquierda: carcinoma infiltrante inespec\u00edfico cT1b cN1 M0, HER2 positivo.\n",
      "  \u2192 carcinoma infiltrante inespec\u00edfico (CANCER_CONCEPT) [16-50]\n",
      "  \u2192 cT1b cN1 M0 (TNM) [51-62]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [64-77]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre con cancer de pr\u00f3stata hace 20 a\u00f1os.\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 cancer de pr\u00f3stata (CANCER_CONCEPT) [35-53]\n",
      "  \u2192 hace 20 a\u00f1os (IMPLICIT_DATE) [54-66]\n",
      "\n",
      "Texto: Madre diagnosticada con cancer de mama hace 5 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [0-5]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [24-38]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [39-50]\n",
      "\n",
      "Texto: Antecentes personales: No HTA, padece diabetes mellitus.\n",
      "  \u2192 No HTA (COMORBIDITY) [23-29]\n",
      "  \u2192 diabetes mellitus (COMORBIDITY) [38-55]\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA: En septiembre de 2011, biopsia incisional de lesi\u00f3n tumoral en cuero cabelludo, interparietal, con AP de carcinoma basocelular variante querat\u00f3sica y pigmentada con m\u00e1rgenes afectos.\n",
      "  \u2192 septiembre de 2011, (DATE) [24-43]\n",
      "  \u2192 lesi\u00f3n tumoral en cuero cabelludo (CANCER_CONCEPT) [66-99]\n",
      "  \u2192 carcinoma basocelular (CANCER_CONCEPT) [126-147]\n",
      "\n",
      "Texto: El 3/11/2011 se hace ampliaci\u00f3n de m\u00e1rgenes, que resultan libres.\n",
      "  \u2192 3/11/2011 (DATE) [3-12]\n",
      "\n",
      "Texto: En septiembre del 2015, biopsia de mama derecha con carcinoma lobulillar infiltrante con reacci\u00f3n desmopl\u00e1sica y un foco de carcinoma in situ.\n",
      "  \u2192 septiembre del 2015, (DATE) [3-23]\n",
      "  \u2192 carcinoma lobulillar infiltrante (CANCER_CONCEPT) [52-84]\n",
      "  \u2192 carcinoma in situ (CANCER_CONCEPT) [124-141]\n",
      "\n",
      "Texto: HER2 negativo, Ki 67 del 1 %.\n",
      "  \u2192 HER2 negativo (BIOMARKER) [0-13]\n",
      "  \u2192 Ki 67 del 1 %. (BIOMARKER) [15-29]\n",
      "\n",
      "Texto: Citolog\u00eda de ganglio axilar derecho positiva para adenocarcinoma.\n",
      "  \u2192 adenocarcinoma (CANCER_CONCEPT) [50-64]\n",
      "\n",
      "Texto: TAC enero 2017 con dos peque\u00f1as adenopat\u00edas en ventana aortopulmonar inespec\u00edficas.\n",
      "  \u2192 enero 2017 (DATE) [4-14]\n",
      "  \u2192 adenopat\u00edas en ventana aortopulmonar inespec\u00edficas (COMORBIDITY) [32-82]\n",
      "\n",
      "Texto: Actualmente mantiene letrozol, triptorelina y bifosfonatos.\n",
      "  \u2192 letrozol (DRUG) [21-29]\n",
      "  \u2192 triptorelina (DRUG) [31-43]\n",
      "  \u2192 bifosfonatos (DRUG) [46-58]\n",
      "\n",
      "Texto: Paciente de 45 a\u00f1os con el diagnostico de c\u00e1ncer de mama, HER2 positivo, RH positivo, pT3 (m); pN2a en noviembre 2012.\n",
      "  \u2192 45 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnostico (OCURRENCE_EVENT) [27-38]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [42-56]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [58-71]\n",
      "  \u2192 RH positivo (BIOMARKER) [73-84]\n",
      "  \u2192 pT3 (TNM) [86-89]\n",
      "  \u2192 pN2a (TNM) [95-99]\n",
      "  \u2192 noviembre 2012. (DATE) [103-118]\n",
      "\n",
      "Texto: Cirugia y reconstruccion mamaria en este hospital.\n",
      "  \u2192 reconstruccion mamaria (SURGERY) [10-32]\n",
      "\n",
      "Texto: El 29/10/2012 se realiza ampliaci\u00f3n de mastectomia derecha.\n",
      "  \u2192 29/10/2012 (DATE) [3-13]\n",
      "  \u2192 mastectomia derecha (SURGERY) [39-58]\n",
      "\n",
      "Texto: Pieza de resecci\u00f3n de reconstrucci\u00f3n mamaria con dorsal ancho y pr\u00f3tesis de silicona sin evidencia de neoplasia residual.\n",
      "  \u2192 reconstrucci\u00f3n mamaria (SURGERY) [22-44]\n",
      "  \u2192 neoplasia residual (CANCER_CONCEPT) [102-120]\n",
      "\n",
      "Texto: Bordes quir\u00fargicos libres de tumor.\n",
      "  \u2192 tumor (CANCER_CONCEPT) [29-34]\n",
      "\n",
      "Texto: Se completa estudio con:TAC de t\u00f3rax (2012-11-19): Conclusi\u00f3n:Pr\u00f3tesis mamaria derecha con tejido inflamatorio periprot\u00e9sico.\n",
      "  \u2192 2012-11-19) (DATE) [38-49]\n",
      "\n",
      "Texto: Imagen sugestiva de gasoma en regi\u00f3n axilar derecha. Lesiones l\u00edticas en cuerpos vertebrales de D12 y y L2 sugestivas de met\u00e1stasis.\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [121-131]\n",
      "\n",
      "Texto: Dado el diagn\u00f3stico de estadio IV se plantea tratamiento con Docetaxel , carboplatino y trastuzumab cada 21 d\u00edas y posteriomente si respuesta mantenimiento con trastuzumab y hormonoterapia.\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [8-19]\n",
      "  \u2192 estadio IV (STAGE) [23-33]\n",
      "  \u2192 Docetaxel (DRUG) [61-70]\n",
      "  \u2192 carboplatino (DRUG) [73-85]\n",
      "  \u2192 trastuzumab (DRUG) [88-99]\n",
      "  \u2192 cada 21 d\u00edas (FREQ) [100-112]\n",
      "  \u2192 trastuzumab (DRUG) [160-171]\n",
      "  \u2192 hormonoterapia (TREATMENT_NAME) [174-188]\n",
      "\n",
      "Texto: Ha recibido quimioterapia esquema CTH (6 ciclos) del 21/11/12 hasta el 7/3/2013.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [12-25]\n",
      "  \u2192 TH (DRUG) [35-37]\n",
      "  \u2192 (6 ciclos (LINE_CICLE_NUMBER) [38-47]\n",
      "  \u2192 21/11/12 (DATE) [53-61]\n",
      "  \u2192 7/3/2013 (DATE) [71-79]\n",
      "\n",
      "Texto: Con Reevaluaci\u00f3n:PET (2013-01-24) y PET (2013-04-10) SIN EVIDENCIA DE TEJIDO TUMORAL VIABLE CON AFINIDAD POR LA 18F-FDG.\n",
      "  \u2192 2013-01-24) (DATE) [22-33]\n",
      "  \u2192 2013-04-10) (DATE) [41-52]\n",
      "  \u2192 TEJIDO TUMORAL (CANCER_CONCEPT) [70-84]\n",
      "\n",
      "Texto: HALLAZGOS EN AXILA DERECHA SUGESTIVOS DE COLECCI\u00d3N POSTQUIR\u00daRGICA.\n",
      "\n",
      "Texto: RT de pared y cadenas: El tratamiento se ha realizado entre los d\u00edas 29/05/13 al 8/07/13 con dosis de 50 Gy.\n",
      "  \u2192 RT (TREATMENT_NAME) [0-2]\n",
      "  \u2192 29/05/13 (DATE) [69-77]\n",
      "  \u2192 8/07/13 (DATE) [81-88]\n",
      "  \u2192 50 Gy (DOSE) [102-107]\n",
      "\n",
      "Texto: Se mantiene tratamiento con herceptin y tamoxifeno.\n",
      "  \u2192 herceptin (DRUG) [28-37]\n",
      "  \u2192 tamoxifeno (DRUG) [40-50]\n",
      "\n",
      "Texto: - En oct 2015 en RM: Lesi\u00f3n en el ped\u00edculo izquierdo de D10 sugestiva de afectaci\u00f3n metast\u00e1sica.\n",
      "  \u2192 oct 2015 (DATE) [5-13]\n",
      "  \u2192 afectaci\u00f3n metast\u00e1sica (CANCER_CONCEPT) [73-95]\n",
      "\n",
      "Texto: Impronta en el canal vertebral sin contactar con el cord\u00f3n medular.\n",
      "\n",
      "Texto: No lesiones de partes blandas paravertebrales asociadas.\n",
      "\n",
      "Texto: Lesi\u00f3n en cuerpo esternal tambi\u00e9n sospechosa de afectaci\u00f3n metast\u00e1sica.\n",
      "  \u2192 afectaci\u00f3n metast\u00e1sica (CANCER_CONCEPT) [48-70]\n",
      "\n",
      "Texto: Paciente de 45 a\u00f1os diagnosticada de c\u00e1ncer de mama, HER2 positivo hace tres semanas.\n",
      "  \u2192 45 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [20-33]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [37-51]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [53-66]\n",
      "  \u2192 hace tres semanas (IMPLICIT_DATE) [67-84]\n",
      "\n",
      "Texto: Carcinoma infiltrante de mama izquierda (intercuadrantes superioores), Estadio: pT1c (20 mm) N2aM0.\n",
      "  \u2192 Carcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [0-39]\n",
      "  \u2192 pT1c (TNM) [80-84]\n",
      "  \u2192 N2aM0 (TNM) [93-98]\n",
      "\n",
      "Texto: RE 100 % y RP 100 % ; HER2 negativo, Ki67 10 % .\n",
      "  \u2192 RE 100 % (BIOMARKER) [0-8]\n",
      "  \u2192 RP 100 % (BIOMARKER) [11-19]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [22-35]\n",
      "  \u2192 Ki67 10 % (BIOMARKER) [37-46]\n",
      "\n",
      "Texto: Mastectom\u00eda con linfadenectom\u00eda realizada el 12/01/16.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [0-11]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [16-31]\n",
      "  \u2192 12/01/16 (DATE) [45-53]\n",
      "\n",
      "Texto: Adyuvancia con QT seg\u00fan esquema AC x 4 ciclos y Docetaxel x 4 ciclos (\u00faltimo ciclo el 19/07).\n",
      "  \u2192 Adyuvancia con (TREATMENT_NAME) [0-14]\n",
      "  \u2192 QT (TREATMENT_NAME) [15-17]\n",
      "  \u2192 AC (DRUG) [32-34]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [35-45]\n",
      "  \u2192 Docetaxel (DRUG) [48-57]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [58-68]\n",
      "  \u2192 \u00faltimo (OCURRENCE_EVENT) [70-76]\n",
      "  \u2192 ciclo (LINE_CICLE_NUMBER) [77-82]\n",
      "  \u2192 19/07 (DATE) [86-91]\n",
      "\n",
      "Texto: - TRATAMIENTO RADIOTER\u00c1PICO: La dosis total administrada ha sido de 50 Gy sobre el lecho de mastectom\u00eda izquierda.\n",
      "  \u2192 TRATAMIENTO RADIOTER\u00c1PICO (TREATMENT_NAME) [2-27]\n",
      "  \u2192 50 Gy (DOSE) [68-73]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [92-113]\n",
      "\n",
      "Texto: El fraccionamiento utilizado ha sido de 2 Gy al d\u00eda.\n",
      "  \u2192 2 Gy (DOSE) [40-44]\n",
      "  \u2192 d\u00eda (FREQ) [48-51]\n",
      "\n",
      "Texto: El tratamiento se inici\u00f3 el 18/08/16 y finaliza 28/09/2016.\n",
      "  \u2192 inici\u00f3 (OCURRENCE_EVENT) [18-24]\n",
      "  \u2192 18/08/16 (DATE) [28-36]\n",
      "  \u2192 finaliza (OCURRENCE_EVENT) [39-47]\n",
      "  \u2192 28/09/2016 (DATE) [48-58]\n",
      "\n",
      "Texto: - En tto por Tamoxifeno en nov/16, Intervenida el 24/01/18 de tumorectomia de necrosi grasa en intercuadrantes superiores.\n",
      "  \u2192 Tamoxifeno (DRUG) [13-23]\n",
      "  \u2192 nov/16 (DATE) [27-33]\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [35-46]\n",
      "  \u2192 24/01/18 (DATE) [50-58]\n",
      "  \u2192 tumorectomia (SURGERY) [62-74]\n",
      "\n",
      "Texto: AP: Fragmentos de tejido fibroconectivo con fibrosis,calcificaciones focales, inflamaci\u00f3n cr\u00f3nica y necrosis grasa.\n",
      "\n",
      "Texto: Rx t\u00f3rax: 2019-06-13 Asimetr\u00eda mamaria izquierda.\n",
      "  \u2192 2019-06-13 (DATE) [10-20]\n",
      "\n",
      "Texto: Clips quir\u00fargicos en pared tor\u00e1cica izquierda.\n",
      "\n",
      "Texto: CONCLUSI\u00d3N:Sin evidencia de afectaci\u00f3n \u00f3sea secundaria.\n",
      "  \u2192 afectaci\u00f3n \u00f3sea secundaria (PROGRESION) [28-54]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os ingresada en oncolgo\u00eda m\u00e9dica por Carcinoma lobulillar infiltrante mama derecha pT3 pN0 en 2011, HER2 negativo.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [17-26]\n",
      "  \u2192 oncolgo\u00eda m\u00e9dica (CLINICAL_SERVICE) [30-46]\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [51-96]\n",
      "  \u2192 pT3 pN0 (TNM) [97-104]\n",
      "  \u2192 2011, (DATE) [108-113]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [114-127]\n",
      "\n",
      "Texto: * Mastectom\u00eda seguido de Tamoxifeno hasta 2013.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [2-13]\n",
      "  \u2192 Tamoxifeno (DRUG) [25-35]\n",
      "  \u2192 2013. (DATE) [42-47]\n",
      "\n",
      "Texto: Mujer de 37 a\u00f1os, remitida por ca de mama derecha.\n",
      "  \u2192 37 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [18-26]\n",
      "  \u2192 ca de mama derecha (CANCER_CONCEPT) [31-49]\n",
      "\n",
      "Texto: Refiere n\u00f3dulo en mama derecha desde hace 6 meses que no se ha modificado no doloroso.\n",
      "  \u2192 hace 6 meses (IMPLICIT_DATE) [37-49]\n",
      "\n",
      "Texto: Antecedentes Familiares: T\u00eda materna ca mama a los 50 a\u00f1os.\n",
      "  \u2192 T\u00eda materna (FAMILY) [25-36]\n",
      "  \u2192 ca mama (CANCER_CONCEPT) [37-44]\n",
      "  \u2192 50 a\u00f1os (AGE) [51-58]\n",
      "\n",
      "Texto: Abuela materna diagnosticada con ca de colon a los 80 a\u00f1os.\n",
      "  \u2192 Abuela materna (FAMILY) [0-14]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [15-28]\n",
      "  \u2192 ca de colon (CANCER_CONCEPT) [33-44]\n",
      "  \u2192 80 a\u00f1os (AGE) [51-58]\n",
      "\n",
      "Texto: Mamas de tama\u00f1o medio, sim\u00e9tricas.\n",
      "\n",
      "Texto: En MD CIE gran n\u00f3dulo m\u00f3vil de bordes lisos de unos 3-4 cm aprox.\n",
      "\n",
      "Texto: DIAGN\u00d3STICO ANATOMOPAT\u00d3GICO: CARCINOMA INFILTRANTE.\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 CARCINOMA INFILTRANTE (CANCER_CONCEPT) [29-50]\n",
      "\n",
      "Texto: Receptores de Estr\u00f3genos : negativos, receptores de Progesterona : negativos, \u00edndice proliferativo ki67 : positivo en un 60 %, CK 19 : positiva, HER 2 negativo.\n",
      "  \u2192 Receptores de Estr\u00f3genos : negativos (BIOMARKER) [0-36]\n",
      "  \u2192 receptores de Progesterona : negativos (BIOMARKER) [38-76]\n",
      "  \u2192 \u00edndice proliferativo ki67 : positivo en un 60 % (BIOMARKER) [78-125]\n",
      "  \u2192 CK 19 : positiva (BIOMARKER) [127-143]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [145-159]\n",
      "\n",
      "Texto: AP: ces\u00e1rea, no enfermedades de einter\u00e9s, no RAMC.\n",
      "  \u2192 RAMC (ALLERGIES) [45-49]\n",
      "\n",
      "Texto: Menarquia 13 a\u00f1os, FUR: 6/12/2011.\n",
      "  \u2192 Menarquia (GINECOLOGICAL_HISTORY) [0-9]\n",
      "  \u2192 13 a\u00f1os (AGE) [10-17]\n",
      "  \u2192 FUR (GINECOLOGICAL_HISTORY) [19-22]\n",
      "  \u2192 6/12/2011 (DATE) [24-33]\n",
      "\n",
      "Texto: Diagnosticada de fibroadenoma mama izda hace 10 a\u00f1os.\n",
      "  \u2192 Diagnosticada (OCURRENCE_EVENT) [0-13]\n",
      "  \u2192 fibroadenoma mama izda (CANCER_CONCEPT) [17-39]\n",
      "  \u2192 hace 10 a\u00f1os (IMPLICIT_DATE) [40-52]\n",
      "\n",
      "Texto: AF: madre con ca de mama a los 45 a\u00f1os, t\u00eda paterna con linfoma.\n",
      "  \u2192 madre (FAMILY) [4-9]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [14-24]\n",
      "  \u2192 45 a\u00f1os (AGE) [31-38]\n",
      "  \u2192 t\u00eda paterna (FAMILY) [40-51]\n",
      "  \u2192 linfoma (CANCER_CONCEPT) [56-63]\n",
      "\n",
      "Texto: Volvemos a valorar.\n",
      "\n",
      "Texto: Paciente diagnosticada con Carcinoma lobulillar infiltrante, T2N1M0.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [9-22]\n",
      "  \u2192 Carcinoma lobulillar infiltrante (CANCER_CONCEPT) [27-59]\n",
      "  \u2192 T2N1M0 (TNM) [61-67]\n",
      "\n",
      "Texto: Diagnostico con HER2 negativo.\n",
      "  \u2192 Diagnostico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [16-29]\n",
      "\n",
      "Texto: Acude a revision.\n",
      "\n",
      "Texto: Ciclos regulares.\n",
      "  \u2192 Ciclos regulares (GINECOLOGICAL_HISTORY) [0-16]\n",
      "\n",
      "Texto: Paciente tratada Tamoxifeno y Carboplatino.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Tamoxifeno (DRUG) [17-27]\n",
      "  \u2192 Carboplatino (DRUG) [30-42]\n",
      "\n",
      "Texto: Exploracion:GE y V leucorrea inespecifica.\n",
      "\n",
      "Texto: Cx de nulipara bien epitelizado.\n",
      "\n",
      "Texto: Utero y ovarios normales.\n",
      "\n",
      "Texto: Eco TV: Normales.\n",
      "\n",
      "Texto: Mamas: Sin hallazgos patol\u00f3gicos.\n",
      "\n",
      "Texto: Tiene solicitada mamografia para el proximo a\u00f1o.\n",
      "\n",
      "Texto: Alta de Ginecologia Oncol\u00f3gica.\n",
      "  \u2192 Ginecologia Oncol\u00f3gica (CLINICAL_SERVICE) [8-30]\n",
      "\n",
      "Texto: Seguimiento anual con mamografia y exploracion mamariay cribado de ca de cervix por AP.\n",
      "  \u2192 ca de cervix (CANCER_CONCEPT) [67-79]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre con cancer de pr\u00f3stata hace 20 a\u00f1os.\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 cancer de pr\u00f3stata (CANCER_CONCEPT) [35-53]\n",
      "  \u2192 hace 20 a\u00f1os (IMPLICIT_DATE) [54-66]\n",
      "\n",
      "Texto: Mujer de 46 a\u00f1os diagnosticada de Carcinoma de mama estadio IV, HER2 positivo con receptores hormonales negativos.\n",
      "  \u2192 46 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [34-51]\n",
      "  \u2192 estadio IV (STAGE) [52-62]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [64-77]\n",
      "  \u2192 receptores hormonales negativos (BIOMARKER) [82-113]\n",
      "\n",
      "Texto: - Cl\u00ednica en probable relaci\u00f3n con empoeramiento radiologico de patolog\u00eda de base en SNC conocida con abundante edema que provoca colapso ventricular occipital y desplazameinto de linea media.\n",
      "\n",
      "Texto: - Sintomas compatibles con crisis parciales visuales y dudoso episodio de crisis parcial compleja.\n",
      "\n",
      "Texto: - Marcado aumento del edema vasog\u00e9nico occipitoparietal izquierdo en resonancia.\n",
      "\n",
      "Texto: - Ocasionales anomal\u00edas epileptiformes sin crisis epil\u00e9pticas registradas en EEG.\n",
      "\n",
      "Texto: Al pase buen estado general.\n",
      "\n",
      "Texto: Refiere que ha presentado dos mareos sin giro de objetos.\n",
      "\n",
      "Texto: Uno de ellos tras realizar esfuerzo defecatorio, con inestabilidad, sin giro de objetos, no nauseas ni v\u00f3mitos, y que se ha recuperado tras aprox 20 min.\n",
      "\n",
      "Texto: Mujer diagnosticada de carcinoma de mama hace 5 dias.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [23-40]\n",
      "  \u2192 hace 5 dias (IMPLICIT_DATE) [41-52]\n",
      "\n",
      "Texto: Mujer diagnosticada con Carcinoma ductal infiltrante de mama derecha T1cN0M0, con RH positivos y HER2 negativo.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [24-68]\n",
      "  \u2192 T1cN0M0 (TNM) [69-76]\n",
      "  \u2192 RH positivos (BIOMARKER) [82-94]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [97-110]\n",
      "\n",
      "Texto: Mujer premenopausica, tratada con tumorectomia bilateral ( en la mama izq solo cambios fibroquisticos) , RT y TAMOXIFENO desde Enero del 2012.\n",
      "  \u2192 premenopausica (GINECOLOGICAL_HISTORY) [6-20]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [22-29]\n",
      "  \u2192 tumorectomia bilateral (SURGERY) [34-56]\n",
      "  \u2192 RT (TREATMENT_NAME) [105-107]\n",
      "  \u2192 TAMOXIFENO (DRUG) [110-120]\n",
      "  \u2192 Enero del 2012. (DATE) [127-142]\n",
      "\n",
      "Texto: Acude a revisi\u00f3n rutinaria.\n",
      "\n",
      "Texto: EXploiracion: tumorectomia derecha, No adenocpatias.\n",
      "  \u2192 tumorectomia derecha (SURGERY) [14-34]\n",
      "  \u2192 No adenocpatias (COMORBIDITY) [36-51]\n",
      "\n",
      "Texto: Mama izquierda sin alteraciones con parenquima glandular algo engrosado.\n",
      "\n",
      "Texto: CICLO 9 CAPECITABINA, Carcinoma lobulillar infiltrante mama derecha pT3 pN0 en 2011, RE 40 % , RP 90 % , HER2 negativo.\n",
      "  \u2192 CICLO 9 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 CAPECITABINA (DRUG) [8-20]\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [22-67]\n",
      "  \u2192 pT3 pN0 (TNM) [68-75]\n",
      "  \u2192 2011, (DATE) [79-84]\n",
      "  \u2192 RE 40 % (BIOMARKER) [85-92]\n",
      "  \u2192 RP 90 % (BIOMARKER) [95-102]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [105-118]\n",
      "\n",
      "Texto: Mastectom\u00eda seguido de Tamoxifeno hasta 2013.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [0-11]\n",
      "  \u2192 Tamoxifeno (DRUG) [23-33]\n",
      "  \u2192 2013. (DATE) [40-45]\n",
      "\n",
      "Texto: * Abril 2013: histerectom\u00eda con doble anexectom\u00eda por carcinoma lobulillar.\n",
      "  \u2192 Abril 2013 (DATE) [2-12]\n",
      "  \u2192 histerectom\u00eda con doble anexectom\u00eda (SURGERY) [14-49]\n",
      "  \u2192 carcinoma lobulillar (CANCER_CONCEPT) [54-74]\n",
      "\n",
      "Texto: Docetaxel y Ciclofosfamida x 4 ciclos.\n",
      "  \u2192 Docetaxel (DRUG) [0-9]\n",
      "  \u2192 Ciclofosfamida (DRUG) [12-26]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [27-37]\n",
      "\n",
      "Texto: * Junio 2013: met\u00e1stasis \u00f3seas m\u00faltiples.\n",
      "  \u2192 Junio 2013 (DATE) [2-12]\n",
      "  \u2192 met\u00e1stasis \u00f3seas m\u00faltiples (CANCER_CONCEPT) [14-40]\n",
      "\n",
      "Texto: Mujer tratada con Letrozol hasta abril 2016.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [6-13]\n",
      "  \u2192 Letrozol (DRUG) [18-26]\n",
      "  \u2192 abril 2016. (DATE) [33-44]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os ingresada en oncolgo\u00eda m\u00e9dica por Carcinoma lobulillar infiltrante mama derecha pT3 pN0 en 2011, RE 40 % RP 90 % HER2 negativo.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [17-26]\n",
      "  \u2192 oncolgo\u00eda m\u00e9dica (CLINICAL_SERVICE) [30-46]\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [51-96]\n",
      "  \u2192 pT3 pN0 (TNM) [97-104]\n",
      "  \u2192 2011, (DATE) [108-113]\n",
      "  \u2192 RE 40 % (BIOMARKER) [114-121]\n",
      "  \u2192 RP 90 % (BIOMARKER) [122-129]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [130-143]\n",
      "\n",
      "Texto: * Mastectom\u00eda seguido de Tamoxifeno hasta 2013.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [2-13]\n",
      "  \u2192 Tamoxifeno (DRUG) [25-35]\n",
      "  \u2192 2013. (DATE) [42-47]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os diagnosticada con Carcinoma lobulillar infiltrante mama derecha, estadio IV, HER2 negativo, hace 3 meses.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma lobulillar infiltrante mama derecha (CANCER_CONCEPT) [35-80]\n",
      "  \u2192 estadio IV (STAGE) [82-92]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [94-107]\n",
      "  \u2192 hace 3 meses (IMPLICIT_DATE) [109-121]\n",
      "\n",
      "Texto: Diagn\u00f3stico principal: Paciente de 45 a\u00f1os diagnosticada de carcinoma lobulillar infiltrante de mama izquierda (Cuadrante infero externo e intercuadrantes superiores que se extiende hacia la regi\u00f3n retroareolar pero sin afectar la areola ni el pez\u00f3n), pT3 (12 cm) N0 (0/14).\n",
      "  \u2192 45 a\u00f1os (AGE) [35-42]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [43-56]\n",
      "  \u2192 carcinoma lobulillar infiltrante de mama izquierda (CANCER_CONCEPT) [60-110]\n",
      "  \u2192 pT3 (TNM) [252-255]\n",
      "  \u2192 N0 (TNM) [264-266]\n",
      "\n",
      "Texto: Presencia de invasi\u00f3n vascular.\n",
      "\n",
      "Texto: Respeta todos los bordes de resecci\u00f3n quir\u00fargica (el m\u00e1s cercano el \u00e1ntero-inferior a 4 mm).\n",
      "\n",
      "Texto: Se observa extensi\u00f3n neopl\u00e1sica pagetoide (in situ) en un ducto galact\u00f3foro.\n",
      "  \u2192 neopl\u00e1sica pagetoide (CANCER_CONCEPT) [21-41]\n",
      "\n",
      "Texto: Paciente de 45 a\u00f1os con diagn\u00f3stico de Carcinoma, estadio patol\u00f3gico: pT3pN0.\n",
      "  \u2192 45 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 con diagn\u00f3stico (OCURRENCE_EVENT) [20-35]\n",
      "  \u2192 Carcinoma (CANCER_CONCEPT) [39-48]\n",
      "  \u2192 pT3pN0 (TNM) [70-76]\n",
      "\n",
      "Texto: RECEPTORES DE ESTR\u00d3GENOS: positivos.\n",
      "  \u2192 RECEPTORES DE ESTR\u00d3GENOS: positivos (BIOMARKER) [0-35]\n",
      "\n",
      "Texto: RECEPTORES DE PROGESTERONA: positivos.\n",
      "  \u2192 RECEPTORES DE PROGESTERONA: positivos (BIOMARKER) [0-37]\n",
      "\n",
      "Texto: Ki67: positivo (40 %).\n",
      "  \u2192 Ki67: positivo (40 %) (BIOMARKER) [0-21]\n",
      "\n",
      "Texto: P53: negativa, Her2 negativo.\n",
      "  \u2192 P53: negativa (BIOMARKER) [0-13]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [15-28]\n",
      "\n",
      "Texto: Se realiza historia cl\u00ednica detallada, exploraci\u00f3n f\u00edsica completa y se explican al paciente/familiar la necesidad de plantear tratamiento con radioterapia sobre el lecho de mastectom\u00eda izquierda.\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [143-155]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [174-195]\n",
      "\n",
      "Texto: Le explicamos a la paciente los beneficios y posibles efectos secundarios derivados del mismo.\n",
      "\n",
      "Texto: Se toma la decisi\u00f3n terap\u00e9utica en sesi\u00f3n cl\u00ednica, se propone al paciente/familiar y se solicita la firma del consentimiento informado. Una vez firmado se inicia la preparaci\u00f3n del tratamiento.\n",
      "\n",
      "Texto: TRATAMIENTO RADIOTER\u00c1PICO: Se decide efectuar la radioterapia de un volumen que incluye el lecho de mastectom\u00eda izquierda y las cadenas ganglionares axilo, claviculares izquierdas.\n",
      "  \u2192 TRATAMIENTO RADIOTER\u00c1PICO (TREATMENT_NAME) [0-25]\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [49-61]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [100-121]\n",
      "\n",
      "Texto: Se efect\u00faa la planificaci\u00f3n en 3D, previa realizaci\u00f3n de TAC de planificaci\u00f3n y utilizaci\u00f3n de sistemas de inmovilizaci\u00f3n adecuados.\n",
      "\n",
      "Texto: El tratamiento se ha realizado en acelerador lineal con fotones de 6 MV y 15 MV.\n",
      "\n",
      "Texto: La dosis total administrada ha sido de 50 Gy sobre el lecho de mastectom\u00eda izquierda y cadenas ganglionares axiloclaviculares izquierdas mediante la aplicaci\u00f3n de campos tangenciales.\n",
      "  \u2192 50 Gy (DOSE) [39-44]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [63-84]\n",
      "\n",
      "Texto: El fraccionamiento utilizado ha sido de 2 Gy al d\u00eda.\n",
      "  \u2192 2 Gy (DOSE) [40-44]\n",
      "  \u2192 d\u00eda (FREQ) [48-51]\n",
      "\n",
      "Texto: El tratamiento se inici\u00f3 el 14/01/2013 y est\u00e1 previsto finalizar ma\u00f1ana 15/02/2013.\n",
      "  \u2192 inici\u00f3 (OCURRENCE_EVENT) [18-24]\n",
      "  \u2192 14/01/2013 (DATE) [28-38]\n",
      "  \u2192 finalizar (OCURRENCE_EVENT) [55-64]\n",
      "  \u2192 ma\u00f1ana (IMPLICIT_DATE) [65-71]\n",
      "  \u2192 15/02/2013 (DATE) [72-82]\n",
      "\n",
      "Texto: RECOMENDACIONES: Acudir\u00e1 a consulta de Oncolog\u00eda M\u00e9dica seg\u00fan lo previsto.\n",
      "  \u2192 Oncolog\u00eda M\u00e9dica (CLINICAL_SERVICE) [39-55]\n",
      "\n",
      "Texto: Primera linea de tratamiento con Carboplatino en paciente diagnosticada con cancer de mama.\n",
      "  \u2192 Primera linea (LINE_CICLE_NUMBER) [0-13]\n",
      "  \u2192 Carboplatino (DRUG) [33-45]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [58-71]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [76-90]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante pT1c (m: dos n\u00f3dulos de iguales caracter\u00edsticas) pN0M0, estadio IA.\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 pT1c (TNM) [29-33]\n",
      "  \u2192 pN0M0 (TNM) [78-83]\n",
      "  \u2192 estadio IA (STAGE) [85-95]\n",
      "\n",
      "Texto: Carcinoma ductal in situ de alto grado nuclear con comedonecrosis asociado.\n",
      "  \u2192 Carcinoma ductal in situ de alto grado nuclear (CANCER_CONCEPT) [0-46]\n",
      "\n",
      "Texto: Mujer tratada con Mastectom\u00eda derecha el 3-11-2011.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [6-13]\n",
      "  \u2192 Mastectom\u00eda derecha (SURGERY) [18-37]\n",
      "  \u2192 3-11-2011 (DATE) [41-50]\n",
      "\n",
      "Texto: Quimioterapia AC x 4 (1er ciclo: 2-12-11 y el 4\u00ba ciclo: 10-2-12).\n",
      "  \u2192 Quimioterapia AC (TREATMENT_NAME) [0-16]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [17-20]\n",
      "  \u2192 (1er ciclo (LINE_CICLE_NUMBER) [21-31]\n",
      "  \u2192 2-12-11 (DATE) [33-40]\n",
      "  \u2192 4o ciclo (LINE_CICLE_NUMBER) [46-54]\n",
      "  \u2192 10-2-12 (DATE) [56-63]\n",
      "\n",
      "Texto: AP: adenocarcinoma infiltrante ductal de mama derecha, HER2 negativo.\n",
      "  \u2192 adenocarcinoma infiltrante ductal de mama derecha (CANCER_CONCEPT) [4-53]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [55-68]\n",
      "\n",
      "Texto: No adenopat\u00edas palpables.\n",
      "  \u2192 No adenopat\u00edas palpables (COMORBIDITY) [0-24]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre fallecido de cancer de pr\u00f3stata.\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 fallecido (OCURRENCE_EVENT) [31-40]\n",
      "  \u2192 cancer de pr\u00f3stata (CANCER_CONCEPT) [44-62]\n",
      "\n",
      "Texto: Fumadora de 10 cigarrillos al dia.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [0-8]\n",
      "  \u2192 10 cigarrillos (HABIT-QUANTITY) [12-26]\n",
      "  \u2192 al dia (FREQ) [27-33]\n",
      "\n",
      "Texto: Mujer de 49 a\u00f1os diagnosticada en 2010 de cancer de mama derecha, T1cN0M0, Ki67 30 % , Her2 negativo.\n",
      "  \u2192 49 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 2010 (DATE) [34-38]\n",
      "  \u2192 cancer de mama derecha (CANCER_CONCEPT) [42-64]\n",
      "  \u2192 T1cN0M0 (TNM) [66-73]\n",
      "  \u2192 Ki67 30 % (BIOMARKER) [75-84]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [87-100]\n",
      "\n",
      "Texto: Paciente operada el d\u00eda 22/11/2010, con mastectom\u00eda simple.\n",
      "  \u2192 operada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 22/11/2010 (DATE) [24-34]\n",
      "  \u2192 mastectom\u00eda simple (SURGERY) [40-58]\n",
      "\n",
      "Texto: AC x 4 entre 29/12/2010 y 09/03/2011 + Tamoxifeno desde 04/2011, suspendido hace 5 meses.\n",
      "  \u2192 AC (DRUG) [0-2]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [3-6]\n",
      "  \u2192 29/12/2010 (DATE) [13-23]\n",
      "  \u2192 09/03/2011 (DATE) [26-36]\n",
      "  \u2192 Tamoxifeno (DRUG) [39-49]\n",
      "  \u2192 04/2011 (DATE) [56-63]\n",
      "  \u2192 suspendido (OCURRENCE_EVENT) [65-75]\n",
      "  \u2192 hace 5 meses (IMPLICIT_DATE) [76-88]\n",
      "\n",
      "Texto: No ha sido vista en Oncologia m\u00e9dica desde 2016 y en ginecologia desde 2012.\n",
      "  \u2192 Oncologia m\u00e9dica (CLINICAL_SERVICE) [20-36]\n",
      "  \u2192 2016 (DATE) [43-47]\n",
      "  \u2192 ginecologia (CLINICAL_SERVICE) [53-64]\n",
      "  \u2192 2012. (DATE) [71-76]\n",
      "\n",
      "Texto: Ultima mamograf\u00eda que consta es del a\u00f1o 2014.\n",
      "  \u2192 2014. (DATE) [40-45]\n",
      "\n",
      "Texto: Exp: Ge y V normales.\n",
      "\n",
      "Texto: No sangrado. eco TV: \u00datero en nate regular conendoemtrio de 4 mm.\n",
      "\n",
      "Texto: Ovarios normales.\n",
      "\n",
      "Texto: No l\u00edquido libre.\n",
      "\n",
      "Texto: exp mama: mamam izquierda CAP normal.\n",
      "\n",
      "Texto: No palpo nodulos.\n",
      "\n",
      "Texto: No adenopat\u00edas axilares ni SCV.\n",
      "  \u2192 No adenopat\u00edas axilares (COMORBIDITY) [0-23]\n",
      "\n",
      "Texto: Mujer de 45 a\u00f1os diagnosticada en 2013 de Carcinoma ductal infiltrante de mama izquierda, pT1c(m) pN0(sn); estadio II.\n",
      "  \u2192 45 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 2013 (DATE) [34-38]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [42-88]\n",
      "  \u2192 pT1c(m) pN0(sn (TNM) [90-104]\n",
      "  \u2192 estadio II (STAGE) [107-117]\n",
      "\n",
      "Texto: Premenop\u00e1usica.\n",
      "  \u2192 Premenop\u00e1usica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "\n",
      "Texto: Recibi\u00f3 tratamiento con Tumorectom\u00eda en agosto de 2013, posteriormente AC x 4 + Paclitaxel x 12 y RADIOTERAPIA posterior (50 Gy ).\n",
      "  \u2192 Tumorectom\u00eda (SURGERY) [24-36]\n",
      "  \u2192 agosto de 2013, (DATE) [40-55]\n",
      "  \u2192 AC (DRUG) [71-73]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [74-77]\n",
      "  \u2192 Paclitaxel (DRUG) [80-90]\n",
      "  \u2192 x 12 (LINE_CICLE_NUMBER) [91-95]\n",
      "  \u2192 RADIOTERAPIA (TREATMENT_NAME) [98-110]\n",
      "  \u2192 (50 Gy (DOSE) [121-127]\n",
      "\n",
      "Texto: Reca\u00edda en oct/2015 a nivel hep\u00e1tico, pulmonar, ganglionar y \u00f3sea.\n",
      "  \u2192 Reca\u00edda (PROGRESION) [0-7]\n",
      "  \u2192 oct/2015 (DATE) [11-19]\n",
      "\n",
      "Texto: Inici\u00f3 Carboplatino + Gemcitabina x 4 en monoterapia x 4 (hasta junio 2016).\n",
      "  \u2192 Inici\u00f3 (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 Carboplatino (DRUG) [7-19]\n",
      "  \u2192 Gemcitabina (DRUG) [22-33]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [34-37]\n",
      "  \u2192 monoterapia (TREATMENT_NAME) [41-52]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [53-56]\n",
      "  \u2192 junio 2016) (DATE) [64-75]\n",
      "\n",
      "Texto: En marzo/16 recibi\u00f3 tratamiento RT (30 Gy) sobre met\u00e1stasis en tibia derecha.\n",
      "  \u2192 marzo/16 (DATE) [3-11]\n",
      "  \u2192 RT (TREATMENT_NAME) [32-34]\n",
      "  \u2192 (30 Gy (DOSE) [35-41]\n",
      "  \u2192 met\u00e1stasis en tibia derecha (CANCER_CONCEPT) [49-76]\n",
      "\n",
      "Texto: JDCO: CDI mama derecha G1, pT2(4,8 cm) N1mi (1sn/11: 8% ) M0.\n",
      "  \u2192 CDI mama derecha (CANCER_CONCEPT) [6-22]\n",
      "  \u2192 G1 (STAGE) [23-25]\n",
      "  \u2192 pT2 (TNM) [27-30]\n",
      "  \u2192 N1mi (TNM) [39-43]\n",
      "  \u2192 M0 (TNM) [58-60]\n",
      "\n",
      "Texto: RE y RP 10 % .\n",
      "  \u2192 RE y RP 10 % (BIOMARKER) [0-12]\n",
      "\n",
      "Texto: Her 2: negativo. Ki67: \u00edndice proliferativo de 55 .\n",
      "  \u2192 Her 2: negativo (BIOMARKER) [0-15]\n",
      "  \u2192 Ki67: \u00edndice proliferativo de 55 (BIOMARKER) [17-49]\n",
      "\n",
      "Texto: Intervenido el 24/04/2012 mediante mastectomia derecha ahorradora de piel, con vaciamiento axilar y reconstrucci\u00f3n con dorsal ancho m\u00e1s pr\u00f3tesis.\n",
      "  \u2192 Intervenido (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 24/04/2012 (DATE) [15-25]\n",
      "  \u2192 mastectomia derecha ahorradora de piel (SURGERY) [35-73]\n",
      "  \u2192 vaciamiento axilar (SURGERY) [79-97]\n",
      "  \u2192 reconstrucci\u00f3n con dorsal ancho m\u00e1s pr\u00f3tesis (SURGERY) [100-144]\n",
      "\n",
      "Texto: Fin RT 3/1/13.\n",
      "  \u2192 Fin (OCURRENCE_EVENT) [0-3]\n",
      "  \u2192 RT (TREATMENT_NAME) [4-6]\n",
      "  \u2192 3/1/13 (DATE) [7-13]\n",
      "\n",
      "Texto: Mujer con carcinoma ductual de la mama derecha.\n",
      "  \u2192 carcinoma ductual de la mama derecha (CANCER_CONCEPT) [10-46]\n",
      "\n",
      "Texto: CONTROL TRATAMIENTO: Carcinoma ductal infiltrante de mama derecha, pT1c (13 mm), pN0M0.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [21-65]\n",
      "  \u2192 pT1c (TNM) [67-71]\n",
      "  \u2192 pN0M0 (TNM) [81-86]\n",
      "\n",
      "Texto: No invasion linfovascular, ni perineural, CIS extenso alto grado, m\u00e1rgenes libres el m\u00e1s pr\u00f3ximoel profundo a menos de 1 mm.\n",
      "\n",
      "Texto: Ki67: 12 %, HER2 positivo.\n",
      "  \u2192 Ki67: 12 % (BIOMARKER) [0-10]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [12-25]\n",
      "\n",
      "Texto: El 31/10/2019 se realiza tumorectom\u00eda.\n",
      "  \u2192 31/10/2019 (DATE) [3-13]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [25-37]\n",
      "\n",
      "Texto: Inicia el 12/12/2019 primer ciclo de QT seg\u00fan esquema FEC.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 12/12/2019 (DATE) [10-20]\n",
      "  \u2192 primer ciclo (LINE_CICLE_NUMBER) [21-33]\n",
      "  \u2192 QT (TREATMENT_NAME) [37-39]\n",
      "  \u2192 FEC (DRUG) [54-57]\n",
      "\n",
      "Texto: Recibe 6 ciclos, \u00faltimo ciclo el 26.03.2020.\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [7-15]\n",
      "  \u2192 \u00faltimo ciclo (LINE_CICLE_NUMBER) [17-29]\n",
      "  \u2192 26.03.2020 (DATE) [33-43]\n",
      "\n",
      "Texto: SERVICIO: Urgencias Generales FECHA INGRESO: 29/08/2017 17:57 FECHA ALTA: 29/08/2017 21:46 .\n",
      "  \u2192 Urgencias Generales (CLINICAL_SERVICE) [10-29]\n",
      "  \u2192 FECHA INGRESO (OCURRENCE_EVENT) [30-43]\n",
      "  \u2192 29/08/2017 (DATE) [45-55]\n",
      "  \u2192 FECHA ALTA (OCURRENCE_EVENT) [62-72]\n",
      "  \u2192 29/08/2017 (DATE) [74-84]\n",
      "\n",
      "Texto: Fumadora de 10-15 cigarrillos diarios hace 3 a\u00f1os.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [0-8]\n",
      "  \u2192 10-15 cigarrillos (HABIT-QUANTITY) [12-29]\n",
      "  \u2192 diario (FREQ) [30-36]\n",
      "  \u2192 s (HABIT-QUANTITY) [36-37]\n",
      "  \u2192 hace 3 a\u00f1os (IMPLICIT_DATE) [38-49]\n",
      "\n",
      "Texto: Motivo de consulta Dolor cadera.\n",
      "\n",
      "Texto: Antecedentes personales: No HTA, no DM2, No dislipemia.\n",
      "  \u2192 No HTA (COMORBIDITY) [25-31]\n",
      "  \u2192 no DM2 (COMORBIDITY) [33-39]\n",
      "  \u2192 No dislipemia (COMORBIDITY) [41-54]\n",
      "\n",
      "Texto: No bebedora.\n",
      "  \u2192 No bebedora (TOXIC_HABITS) [0-11]\n",
      "\n",
      "Texto: Anatomia patologica: Adenopatia hiliar izquierda : Puncion aspiracion de ganglio linfatico NEGATIVA para celulas tumorales malignas.\n",
      "  \u2192 Adenopatia hiliar izquierda (COMORBIDITY) [21-48]\n",
      "  \u2192 celulas tumorales malignas (CANCER_CONCEPT) [105-131]\n",
      "\n",
      "Texto: El dia 27 de junio iniciamos tratamiento con quimioterapia segun esquema CARBOPLATINO - PEMETREXED.\n",
      "  \u2192 27 de junio (DATE) [7-18]\n",
      "  \u2192 iniciamos tratamiento (OCURRENCE_EVENT) [19-40]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [45-58]\n",
      "  \u2192 CARBOPLATINO (DRUG) [73-85]\n",
      "  \u2192 PEMETREXED (DRUG) [88-98]\n",
      "\n",
      "Texto: EGFR no mutado, ALK no traslocado, ROS1 no traslocado, HER2 negativo.\n",
      "  \u2192 EGFR no mutado (BIOMARKER) [0-14]\n",
      "  \u2192 ALK no traslocado (BIOMARKER) [16-33]\n",
      "  \u2192 ROS1 no traslocado (BIOMARKER) [35-53]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [55-68]\n",
      "\n",
      "Texto: HER2 negativo.\n",
      "  \u2192 HER2 negativo (BIOMARKER) [0-13]\n",
      "\n",
      "Texto: No se observan adenopatias patologicas hipermetabolicas en hilios mamarios.\n",
      "  \u2192 No se observan adenopatias patologicas hipermetabolicas (COMORBIDITY) [0-55]\n",
      "\n",
      "Texto: Hipotiroidismo subclinico EA: Acude a revision programada.\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [0-14]\n",
      "\n",
      "Texto: Diabetes tipo 2 con control metabolico suboptimo e IMC Plan Decidimos mantener tratamiento sin cambios.\n",
      "  \u2192 Diabetes tipo 2 (COMORBIDITY) [0-15]\n",
      "\n",
      "Texto: No HTA, ni DM ni DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 ni DM (COMORBIDITY) [8-13]\n",
      "  \u2192 ni DL (COMORBIDITY) [14-19]\n",
      "\n",
      "Texto: Antecedentes personales: Tia con cancer de mama hace 10 a\u00f1os.\n",
      "  \u2192 Tia (FAMILY) [25-28]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [33-47]\n",
      "  \u2192 hace 10 a\u00f1os (IMPLICIT_DATE) [48-60]\n",
      "\n",
      "Texto: Ex fumadora de 30 cg al dia hace 5 a\u00f1os.\n",
      "  \u2192 Ex fumadora (TOXIC_HABITS) [0-11]\n",
      "  \u2192 30 cg (HABIT-QUANTITY) [15-20]\n",
      "  \u2192 al dia (FREQ) [21-27]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [28-39]\n",
      "\n",
      "Texto: Ex fumadora de 30 cg al dia hace 5 a\u00f1os.\n",
      "  \u2192 Ex fumadora (TOXIC_HABITS) [0-11]\n",
      "  \u2192 30 cg (HABIT-QUANTITY) [15-20]\n",
      "  \u2192 al dia (FREQ) [21-27]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [28-39]\n",
      "\n",
      "Texto: No palpo adenopatias.\n",
      "  \u2192 No palpo adenopatias (COMORBIDITY) [0-20]\n",
      "\n",
      "Texto: PAAF Adenopatia subcarinal: Citologia POSITIVA para Carcinoma.\n",
      "  \u2192 Adenopatia subcarinal (COMORBIDITY) [5-26]\n",
      "  \u2192 Carcinoma (CANCER_CONCEPT) [52-61]\n",
      "\n",
      "Texto: NO RAMC - Niega HTA, DM2 o Dislipemia.\n",
      "  \u2192 NO RAMC (ALLERGIES) [0-7]\n",
      "  \u2192 Niega HTA, DM2 o Dislipemia (COMORBIDITY) [10-37]\n",
      "\n",
      "Texto: Carcinoma mamario pT2aN0: intervenido en agosto 2016\n",
      "  \u2192 Carcinoma mamario (CANCER_CONCEPT) [0-17]\n",
      "  \u2192 pT2aN0 (TNM) [18-24]\n",
      "  \u2192 intervenido (OCURRENCE_EVENT) [26-37]\n",
      "  \u2192 agosto 2016 (DATE) [41-52]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: No se palpan adenopat\u00edas axilares.\n",
      "  \u2192 No se palpan adenopat\u00edas axilares (COMORBIDITY) [0-33]\n",
      "\n",
      "Texto: Paciente con antecedentes de Hipertensi\u00f3n arterial y diabetes mellitus en tratamiento.\n",
      "  \u2192 Hipertensi\u00f3n arterial (COMORBIDITY) [29-50]\n",
      "  \u2192 diabetes mellitus (COMORBIDITY) [53-70]\n",
      "\n",
      "Texto: Abuela materna con ca de mama fallecida hace 12 a\u00f1os.\n",
      "  \u2192 Abuela materna (FAMILY) [0-14]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [19-29]\n",
      "  \u2192 fallecida (OCURRENCE_EVENT) [30-39]\n",
      "  \u2192 hace 12 a\u00f1os (IMPLICIT_DATE) [40-52]\n",
      "\n",
      "Texto: Paciente con adenopatias hiliares ipsilaterales.\n",
      "  \u2192 adenopatias hiliares ipsilaterales (COMORBIDITY) [13-47]\n",
      "\n",
      "Texto: Mujer de 75 a\u00f1os diagnosticada con Carcinoma lobulillar invasivo.\n",
      "  \u2192 75 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma lobulillar invasivo (CANCER_CONCEPT) [35-64]\n",
      "\n",
      "Texto: Mujer de 75 a\u00f1os diagnosticada con Carcinoma lobulillar invasivo.\n",
      "  \u2192 75 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma lobulillar invasivo (CANCER_CONCEPT) [35-64]\n",
      "\n",
      "Texto: Mujer de 75 a\u00f1os diagnosticada con Carcinoma lobulillar invasivo.\n",
      "  \u2192 75 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma lobulillar invasivo (CANCER_CONCEPT) [35-64]\n",
      "\n",
      "Texto: Paciente que a parte se le ha diagnosticado de un tumor de prostata T2cN0.\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [30-43]\n",
      "  \u2192 tumor de prostata (CANCER_CONCEPT) [50-67]\n",
      "  \u2192 T2cN0 (TNM) [68-73]\n",
      "\n",
      "Texto: Paciente con HTA, No DM2, ni Dislipemias.\n",
      "  \u2192 HTA (COMORBIDITY) [13-16]\n",
      "  \u2192 No DM2 (COMORBIDITY) [18-24]\n",
      "  \u2192 ni Dislipemias (COMORBIDITY) [26-40]\n",
      "\n",
      "Texto: Paciente con HTA, No DM2, ni Dislipemias.\n",
      "  \u2192 HTA (COMORBIDITY) [13-16]\n",
      "  \u2192 No DM2 (COMORBIDITY) [18-24]\n",
      "  \u2192 ni Dislipemias (COMORBIDITY) [26-40]\n",
      "\n",
      "Texto: Paciente con HTA, No DM2, ni Dislipemias.\n",
      "  \u2192 HTA (COMORBIDITY) [13-16]\n",
      "  \u2192 No DM2 (COMORBIDITY) [18-24]\n",
      "  \u2192 ni Dislipemias (COMORBIDITY) [26-40]\n",
      "\n",
      "Texto: Carcinoma lobulillar de mama, cT2a cN2 cM1c, estadio IVB por afectacion hepatica y osea.\n",
      "  \u2192 Carcinoma lobulillar de mama (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 cT2a cN2 cM1c (TNM) [30-43]\n",
      "  \u2192 estadio IVB (STAGE) [45-56]\n",
      "\n",
      "Texto: Mujer de 41 a\u00f1os diagnosticada con Carcinoma infiltrante de mama izquierda, pT2pN1cM0, receptores hormonales positivos, HER2 negativo, premenop\u00e1usica.\n",
      "  \u2192 41 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [35-74]\n",
      "  \u2192 pT2pN1cM0 (TNM) [76-85]\n",
      "  \u2192 receptores hormonales positivos (BIOMARKER) [87-118]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [120-133]\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [135-149]\n",
      "\n",
      "Texto: Paciente tratada con Mastectom\u00eda m\u00e1s linfadenectomia.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [21-32]\n",
      "  \u2192 linfadenectomia (SURGERY) [37-52]\n",
      "\n",
      "Texto: Linfoma folicular estadio IV tratado con Carboplatino hace dos a\u00f1os.\n",
      "  \u2192 Linfoma folicular (CANCER_CONCEPT) [0-17]\n",
      "  \u2192 estadio IV (STAGE) [18-28]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [29-36]\n",
      "  \u2192 Carboplatino (DRUG) [41-53]\n",
      "  \u2192 hace dos a\u00f1os (IMPLICIT_DATE) [54-67]\n",
      "\n",
      "Texto: Tamoxifeno desde octubre del 2016.\n",
      "  \u2192 Tamoxifeno (DRUG) [0-10]\n",
      "  \u2192 octubre del 2016. (DATE) [17-34]\n",
      "\n",
      "Texto: Paciente que acude a oncologia m\u00e9dica para revisi\u00f3n.\n",
      "  \u2192 oncologia m\u00e9dica (CLINICAL_SERVICE) [21-37]\n",
      "\n",
      "Texto: REVISI\u00d3N: CARCINOMA LOBULILLAR INFILTRANTE de mama derecha, pT3m (n\u00f3dulo mayor de 53 mm) pN1a (1 de 29 con extensi\u00f3n extracapsular).\n",
      "  \u2192 CARCINOMA LOBULILLAR INFILTRANTE de mama derecha (CANCER_CONCEPT) [10-58]\n",
      "  \u2192 pT3m (TNM) [60-64]\n",
      "  \u2192 pN1a (TNM) [89-93]\n",
      "\n",
      "Texto: RE positivos, Ki67 del 18 % ; HER2 negativo.\n",
      "  \u2192 RE positivos (BIOMARKER) [0-12]\n",
      "  \u2192 Ki67 del 18 % (BIOMARKER) [14-27]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [30-43]\n",
      "\n",
      "Texto: Mujer tratada con Mastectom\u00eda y linfadenectom\u00eda el 10-12-14; observ\u00e1ndose contacto con la tinta en el borde superior en cuadrantes externos y en interno, en el que tambi\u00e9n afecta al borde posterior: ampliaci\u00f3n sin tumor residual en las piezas de ampliaci\u00f3n.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [6-13]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [18-29]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [32-47]\n",
      "  \u2192 10-12-14 (DATE) [51-59]\n",
      "  \u2192 tumor residual (CANCER_CONCEPT) [214-228]\n",
      "\n",
      "Texto: Quimioterapia AC x 4 seguido de Docetaxel x 4 el 10-7-2015 .\n",
      "  \u2192 Quimioterapia (TREATMENT_NAME) [0-13]\n",
      "  \u2192 AC (DRUG) [14-16]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [17-20]\n",
      "  \u2192 Docetaxel (DRUG) [32-41]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [42-45]\n",
      "  \u2192 10-7-2015 (DATE) [49-58]\n",
      "\n",
      "Texto: Ha recibido RT entre los d\u00edas 11-08-2015 y 15-09-2015, irradiaci\u00f3n de pared tor\u00e1cica derecha y de \u00e1reas ganglionares supraclaviculares, interpectorales, infraclaviculares y axilares .\n",
      "  \u2192 RT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 11-08-2015 (DATE) [30-40]\n",
      "  \u2192 15-09-2015 (DATE) [43-53]\n",
      "\n",
      "Texto: Mujer de 59 a\u00f1os, ca ductal infiltrante de mama derecha T1N1M0, tratada con cuadrantectom\u00eda, radioterapia y quimioterapia.\n",
      "  \u2192 59 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ca ductal infiltrante de mama derecha (CANCER_CONCEPT) [18-55]\n",
      "  \u2192 T1N1M0 (TNM) [56-62]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [64-71]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [76-91]\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [93-105]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [108-121]\n",
      "\n",
      "Texto: Ca ductal infiltrante de mama izquierda T1N0Mx, postmenopa\u00fasica, HER2 positivo, intervenida mediante cuadrantectom\u00eda en diciembre del 2008.\n",
      "  \u2192 Ca ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-39]\n",
      "  \u2192 T1N0Mx (TNM) [40-46]\n",
      "  \u2192 postmenopa\u00fasica (GINECOLOGICAL_HISTORY) [48-63]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [65-78]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [80-91]\n",
      "  \u2192 cuadrantectom\u00eda (SURGERY) [101-116]\n",
      "  \u2192 diciembre del 2008. (DATE) [120-139]\n",
      "\n",
      "Texto: Tratada con Doxorrubicina y Ciclofosfamida x 4 ciclos, Radioterapia y Trastuzumab posterior.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 Doxorrubicina (DRUG) [12-25]\n",
      "  \u2192 Ciclofosfamida (DRUG) [28-42]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [43-53]\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [55-67]\n",
      "  \u2192 Trastuzumab (DRUG) [70-81]\n",
      "\n",
      "Texto: Paciente remitida desde Oncologia m\u00e9dica por amenorrea en paciente con ca de mama ductal infiltrante pT1apN0M0 tratado con cirug\u00eda conservadora.\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [9-17]\n",
      "  \u2192 Oncologia m\u00e9dica (CLINICAL_SERVICE) [24-40]\n",
      "  \u2192 amenorrea (GINECOLOGICAL_HISTORY) [45-54]\n",
      "  \u2192 ca de mama ductal infiltrante (CANCER_CONCEPT) [71-100]\n",
      "  \u2192 pT1apN0M0 (TNM) [101-110]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [111-118]\n",
      "  \u2192 cirug\u00eda conservadora (SURGERY) [123-143]\n",
      "\n",
      "Texto: Paciente mujer de 41 a\u00f1os remtitida desde Ginecolog\u00eda por c\u00e1ncer de mama.\n",
      "  \u2192 41 a\u00f1os (AGE) [18-25]\n",
      "  \u2192 remtitida (OCURRENCE_EVENT) [26-35]\n",
      "  \u2192 Ginecolog\u00eda (CLINICAL_SERVICE) [42-53]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [58-72]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES: No DM, no dislipemias.\n",
      "  \u2192 No DM (COMORBIDITY) [25-30]\n",
      "  \u2192 no dislipemias (COMORBIDITY) [32-46]\n",
      "\n",
      "Texto: Antecedentes familiares oncol\u00f3gicos: Tia materna con ca de mama sobre 45 a\u00f1os.\n",
      "  \u2192 Tia materna (FAMILY) [37-48]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [53-63]\n",
      "  \u2192 45 a\u00f1os (AGE) [70-77]\n",
      "\n",
      "Texto: TRATAMIENTO HABITUAL: Enalapril 12.5 mg cada 8 horas.\n",
      "  \u2192 Enalapril (DRUG) [22-31]\n",
      "  \u2192 12.5 mg (DOSE) [32-39]\n",
      "  \u2192 cada 8 horas (FREQ) [40-52]\n",
      "\n",
      "Texto: En tratamiento actual con Tamoxifeno hace 2 a\u00f1os y Goserelina trimestral, suspendido en enero 2012.\n",
      "  \u2192 Tamoxifeno (DRUG) [26-36]\n",
      "  \u2192 hace 2 a\u00f1os (IMPLICIT_DATE) [37-48]\n",
      "  \u2192 Goserelina (DRUG) [51-61]\n",
      "  \u2192 trimestral (FREQ) [62-72]\n",
      "  \u2192 suspendido (OCURRENCE_EVENT) [74-84]\n",
      "  \u2192 enero 2012. (DATE) [88-99]\n",
      "\n",
      "Texto: Her2 positivo.\n",
      "  \u2192 Her2 positivo (BIOMARKER) [0-13]\n",
      "\n",
      "Texto: Contin\u00faa con sofocos intensos\n",
      "\n",
      "Texto: Antecedentes ginecologicos: menaruqia a los 11 a\u00f1os, tipo mesntrual normal.\n",
      "  \u2192 menaruqia (GINECOLOGICAL_HISTORY) [28-37]\n",
      "  \u2192 11 a\u00f1os (AGE) [44-51]\n",
      "  \u2192 tipo mesntrual normal (GINECOLOGICAL_HISTORY) [53-74]\n",
      "\n",
      "Texto: Nuligesta con relaciones sexuales.\n",
      "  \u2192 Nuligesta (GINE_OBSTETRICS) [0-9]\n",
      "\n",
      "Texto: Expl: GE y vagina normales, c\u00e9rvix de nul\u00edpara, normal, \u00fatero en ante, normal, m\u00f3vil.\n",
      "\n",
      "Texto: ECO TV: \u00fatero en ante, normal, ambos anejos visualizados, normales.\n",
      "\n",
      "Texto: Explico posibilidad de bloqueo ov\u00e1rico residual e imposibilidad de predecir pr\u00f3xima regla.\n",
      "\n",
      "Texto: Utiliza anticoncepci\u00f3n.\n",
      "  \u2192 Utiliza anticoncepci\u00f3n (GINECOLOGICAL_HISTORY) [0-22]\n",
      "\n",
      "Texto: Doy cuestionario de s\u00edntomas vasomotores y planteo tratamiento con venlafaxina.\n",
      "  \u2192 venlafaxina (DRUG) [67-78]\n",
      "\n",
      "Texto: Mujer de 46 a\u00f1os ingresada en oncolog\u00eda m\u00e9dica por Carcinoma ductal infiltrante de mama derecha pT2 pN1 cM0, estadio IIB.\n",
      "  \u2192 46 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [17-26]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [30-46]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [51-95]\n",
      "  \u2192 pT2 pN1 cM0 (TNM) [96-107]\n",
      "  \u2192 estadio IIB (STAGE) [109-120]\n",
      "\n",
      "Texto: RH +, HER2 negativo en 2010.\n",
      "  \u2192 RH + (BIOMARKER) [0-4]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [6-19]\n",
      "  \u2192 2010. (DATE) [23-28]\n",
      "\n",
      "Texto: CICLO 1: Capecitabina 2000 mg cada 12 horas (dosis total) durante 14 d\u00edas y descansar 7 d\u00edas.\n",
      "  \u2192 CICLO 1: (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 Capecitabina (DRUG) [9-21]\n",
      "  \u2192 2000 mg (DOSE) [22-29]\n",
      "  \u2192 cada 12 horas (FREQ) [30-43]\n",
      "  \u2192 durante 14 d\u00edas (DURATION) [58-73]\n",
      "\n",
      "Texto: Paciente con Carcinoma ductal infiltrante HER2 positivo .\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [13-41]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [42-55]\n",
      "\n",
      "Texto: DIAGN\u00d3STICO ANATOMOPAT\u00d3GICO-Partes blandas y hueso infiltrados por un adenocarcinoma, morfol\u00f3gicamente compatible con su primario conocido (carcinoma ductal infiltrante de mama, seg\u00fan datos de la historia cl\u00ednica).\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 adenocarcinoma (CANCER_CONCEPT) [70-84]\n",
      "  \u2192 primario (CANCER_CONCEPT) [121-129]\n",
      "  \u2192 carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [140-176]\n",
      "\n",
      "Texto: Bordes libres.\n",
      "\n",
      "Texto: Recidiva de la enfermedad en junio de 2016, confirmada con AP, por lo que se inicia tratamiento con Carboplatino el 1/7/2016 durante 10 ciclos.\n",
      "  \u2192 Recidiva de la enfermedad (PROGRESION) [0-25]\n",
      "  \u2192 junio de 2016, (DATE) [29-43]\n",
      "  \u2192 inicia tratamiento (OCURRENCE_EVENT) [77-95]\n",
      "  \u2192 Carboplatino (DRUG) [100-112]\n",
      "  \u2192 1/7/2016 (DATE) [116-124]\n",
      "  \u2192 durante 10 (DURATION) [125-135]\n",
      "  \u2192 ciclo (LINE_CICLE_NUMBER) [136-141]\n",
      "  \u2192 s (DURATION) [141-142]\n",
      "\n",
      "Texto: Inicia tratamiento con Capecitabina el 27/12/2018 recibiendo un total de 6 ciclos que se suspenden por progresi\u00f3n de la enfermedad a nivel cut\u00e1neo axilar.\n",
      "  \u2192 Inicia tratamiento (OCURRENCE_EVENT) [0-18]\n",
      "  \u2192 Capecitabina (DRUG) [23-35]\n",
      "  \u2192 27/12/2018 (DATE) [39-49]\n",
      "  \u2192 6 ciclos (LINE_CICLE_NUMBER) [73-81]\n",
      "  \u2192 suspenden (OCURRENCE_EVENT) [89-98]\n",
      "\n",
      "Texto: Inicia tratamiento con Abraxane el 4/5/2018 (\u00faltimo ciclo el 26/7/2018).\n",
      "  \u2192 Inicia tratamiento (OCURRENCE_EVENT) [0-18]\n",
      "  \u2192 Abraxane (DRUG) [23-31]\n",
      "  \u2192 4/5/2018 (DATE) [35-43]\n",
      "  \u2192 \u00faltimo ciclo (LINE_CICLE_NUMBER) [45-57]\n",
      "  \u2192 26/7/2018) (DATE) [61-71]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha pT2N1M0, tratado con mastectom\u00eda m\u00e1s linfadenectom\u00eda en enero 2011.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 pT2N1M0 (TNM) [45-52]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [54-61]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [66-77]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [82-97]\n",
      "  \u2192 enero 2011. (DATE) [101-112]\n",
      "\n",
      "Texto: Receptores de estr\u00f3genos y progesterona positivos, HER-2 negativo.\n",
      "  \u2192 Receptores de estr\u00f3genos y progesterona positivos (BIOMARKER) [0-49]\n",
      "  \u2192 HER-2 negativo (BIOMARKER) [51-65]\n",
      "\n",
      "Texto: Paciente tratado con Capecitabina 1800 mg cada 12h el 07-12-2016.\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Capecitabina (DRUG) [21-33]\n",
      "  \u2192 1800 mg (DOSE) [34-41]\n",
      "  \u2192 cada 12h (FREQ) [42-50]\n",
      "  \u2192 07-12-2016 (DATE) [54-64]\n",
      "\n",
      "Texto: 2\u00ba ciclo reducido el 28-12-16.\n",
      "  \u2192 2o ciclo (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 reducido (OCURRENCE_EVENT) [9-17]\n",
      "  \u2192 28-12-16 (DATE) [21-29]\n",
      "\n",
      "Texto: Diarrea G2-3EmesisSindrome mano-pie G2.\n",
      "\n",
      "Texto: 3\u00ba CICLO CAPECITABINA + HERCEPTIN +/- PERTUZUMAB VISITA CONTROL DIA 7\u00ba DEL CICLO.\n",
      "  \u2192 3o CICLO (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 CAPECITABINA (DRUG) [9-21]\n",
      "  \u2192 HERCEPTIN (DRUG) [24-33]\n",
      "  \u2192 PERTUZUMAB (DRUG) [38-48]\n",
      "\n",
      "Texto: Acude, se encuentra bien.\n",
      "\n",
      "Texto: Mujer de 74 a\u00f1os diagnosticada con Carcinoma de mama derecha, pT1b pN0 (mol-) (sn) cM0, estadio IA, tratada Tumorectom\u00eda 10/05/2016.\n",
      "  \u2192 74 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 Carcinoma de mama derecha (CANCER_CONCEPT) [35-60]\n",
      "  \u2192 pT1b pN0 (TNM) [62-70]\n",
      "  \u2192 cM0 (TNM) [83-86]\n",
      "  \u2192 estadio IA (STAGE) [88-98]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [100-107]\n",
      "  \u2192 Tumorectom\u00eda (SURGERY) [108-120]\n",
      "  \u2192 10/05/2016 (DATE) [121-131]\n",
      "\n",
      "Texto: Ampliaci\u00f3n m\u00e1rgenes el 21/06, *Adyuvancia con taxotere + ciclofosfamida x 3.\n",
      "  \u2192 21/06 (DATE) [23-28]\n",
      "  \u2192 Adyuvancia (TREATMENT_NAME) [31-41]\n",
      "  \u2192 taxotere (DRUG) [46-54]\n",
      "  \u2192 ciclofosfamida (DRUG) [57-71]\n",
      "  \u2192 x 3. (LINE_CICLE_NUMBER) [72-76]\n",
      "\n",
      "Texto: Carcinoma de mama derecha estadio pT1b pN0 (mol-) (sn) cM0, estadio IA.\n",
      "  \u2192 Carcinoma de mama derecha (CANCER_CONCEPT) [0-25]\n",
      "  \u2192 pT1b pN0 (TNM) [34-42]\n",
      "  \u2192 estadio IA (STAGE) [60-70]\n",
      "\n",
      "Texto: Mujer 44 a\u00f1os con carcinoma ductal infiltrante T1N0M0 triple negativo .\n",
      "  \u2192 44 a\u00f1os (AGE) [6-13]\n",
      "  \u2192 carcinoma ductal infiltrante (CANCER_CONCEPT) [18-46]\n",
      "  \u2192 T1N0M0 (TNM) [47-53]\n",
      "  \u2192 triple negativo (CANCER_CONCEPT) [54-69]\n",
      "\n",
      "Texto: - Tratado con tumorectomia y docetaxel - ciclofosfamida x 4 adyuvante.\n",
      "  \u2192 Tratado (OCURRENCE_EVENT) [2-9]\n",
      "  \u2192 tumorectomia (SURGERY) [14-26]\n",
      "  \u2192 docetaxel (DRUG) [29-38]\n",
      "  \u2192 ciclofosfamida (DRUG) [41-55]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [56-59]\n",
      "  \u2192 adyuvante (TREATMENT_NAME) [60-69]\n",
      "\n",
      "Texto: - RT finalizada el 12/06/2017.\n",
      "  \u2192 RT (TREATMENT_NAME) [2-4]\n",
      "  \u2192 finalizada (OCURRENCE_EVENT) [5-15]\n",
      "  \u2192 12/06/2017 (DATE) [19-29]\n",
      "\n",
      "Texto: Situaci\u00f3n actual:Cuenta astenia y sofocos.\n",
      "\n",
      "Texto: Fragilidad ungueal.\n",
      "\n",
      "Texto: Mamograf\u00eda y anal\u00edtica en septiembre de 2017.\n",
      "  \u2192 septiembre de 2017. (DATE) [26-45]\n",
      "\n",
      "Texto: CICLO 2 DOXORRUBICINA 90 MG CICLOFOSFAMIDA 895 MG Carcinoma infiltrante tipo inespec\u00edfico, en CII de mama derecha.\n",
      "  \u2192 CICLO 2 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 DOXORRUBICINA (DRUG) [8-21]\n",
      "  \u2192 90 MG (DOSE) [22-27]\n",
      "  \u2192 CICLOFOSFAMIDA (DRUG) [28-42]\n",
      "  \u2192 895 MG (DOSE) [43-49]\n",
      "  \u2192 Carcinoma infiltrante tipo inespec\u00edfico (CANCER_CONCEPT) [50-89]\n",
      "  \u2192 CII de mama derecha (CANCER_CONCEPT) [94-113]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha estadio IV (G3 RE -, RP -, HER2 negativo , Ki67: 40 % ).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 estadio IV (G3 (STAGE) [45-59]\n",
      "  \u2192 RE - (BIOMARKER) [60-64]\n",
      "  \u2192 RP - (BIOMARKER) [66-70]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [72-85]\n",
      "  \u2192 Ki67: 40 % (BIOMARKER) [88-98]\n",
      "\n",
      "Texto: Con progresi\u00f3n pleural y tubo de drenaje pleural en octubre 2016.\n",
      "  \u2192 progresi\u00f3n pleural (PROGRESION) [4-22]\n",
      "  \u2192 octubre 2016. (DATE) [52-65]\n",
      "\n",
      "Texto: Infiltraci\u00f3n cut\u00e1nea.\n",
      "\n",
      "Texto: Ciclo de QT con Eribulina el 2/06/17.\n",
      "  \u2192 QT (TREATMENT_NAME) [9-11]\n",
      "  \u2192 Eribulina (DRUG) [16-25]\n",
      "  \u2192 2/06/17 (DATE) [29-36]\n",
      "\n",
      "Texto: Ciclo de QT con Eribulina el 2/06/17.\n",
      "  \u2192 QT (TREATMENT_NAME) [9-11]\n",
      "  \u2192 Eribulina (DRUG) [16-25]\n",
      "  \u2192 2/06/17 (DATE) [29-36]\n",
      "\n",
      "Texto: Teniendo en cuenta la situaci\u00f3n epidemiol\u00f3gica actual no doy volante de PET-TC (enfermedad en respuesta en el anterio), en la pr\u00f3xima visita, valorar dar PET-TC (lo dejo hecho).\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda cT2 pN1cMx, Her2 Positivo en septiembre de 2014.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 cT2 pN1cMx (TNM) [47-57]\n",
      "  \u2192 Her2 Positivo (BIOMARKER) [59-72]\n",
      "  \u2192 septiembre de 2014. (DATE) [76-95]\n",
      "\n",
      "Texto: Recibi\u00f3 tratamiento neoadyuvante en ensayo clinico con repuesta parcial ypT1ypN0+M0.\n",
      "  \u2192 Recibi\u00f3 (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 neoadyuvante (TREATMENT_NAME) [20-32]\n",
      "  \u2192 ypT1ypN0+M0 (TNM) [72-83]\n",
      "\n",
      "Texto: Complet\u00f3 adyuvancia con AC y Trastuzumab sc.\n",
      "  \u2192 adyuvancia con AC (TREATMENT_NAME) [9-26]\n",
      "  \u2192 Trastuzumab (DRUG) [29-40]\n",
      "\n",
      "Texto: Paciente tratada con Mastectom\u00eda izda + linfadenectom\u00eda izda.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Mastectom\u00eda izda (SURGERY) [21-37]\n",
      "  \u2192 linfadenectom\u00eda izda (SURGERY) [40-60]\n",
      "\n",
      "Texto: QT + RT posterior.\n",
      "  \u2192 QT (TREATMENT_NAME) [0-2]\n",
      "  \u2192 RT (TREATMENT_NAME) [5-7]\n",
      "\n",
      "Texto: En la actualidad en tto con Herceptin.\n",
      "  \u2192 Herceptin (DRUG) [28-37]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha CT3N1M0 tratada con neoadyuvancia AC-TH y estadiaje pT1N0M0 postratamiento, HER2 positivo.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 CT3N1M0 (TNM) [45-52]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [53-60]\n",
      "  \u2192 neoadyuvancia (TREATMENT_NAME) [65-78]\n",
      "  \u2192 AC-TH (DRUG) [79-84]\n",
      "  \u2192 pT1N0M0 (TNM) [97-104]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [121-134]\n",
      "\n",
      "Texto: El 06/07/2017 se realiza mastectomia radical modificada derecha + LA.\n",
      "  \u2192 06/07/2017 (DATE) [3-13]\n",
      "  \u2192 mastectomia radical modificada derecha (SURGERY) [25-63]\n",
      "  \u2192 LA (SURGERY) [66-68]\n",
      "\n",
      "Texto: En tto con ZOLADEX + EXEMESTANO + TRASTUZUMAb adyuvante que finaliza en Abril del 2018.\n",
      "  \u2192 ZOLADEX (DRUG) [11-18]\n",
      "  \u2192 EXEMESTANO (DRUG) [21-31]\n",
      "  \u2192 TRASTUZUMAb (DRUG) [34-45]\n",
      "  \u2192 adyuvante (TREATMENT_NAME) [46-55]\n",
      "  \u2192 finaliza (OCURRENCE_EVENT) [60-68]\n",
      "  \u2192 Abril del 2018. (DATE) [72-87]\n",
      "\n",
      "Texto: Vista y explorada hoy en Ginecologia, Revision en 6 meses.\n",
      "  \u2192 Ginecologia (CLINICAL_SERVICE) [25-36]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante T4N3Mx , HER2 positivo.\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 T4N3Mx (TNM) [29-35]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [38-51]\n",
      "\n",
      "Texto: Actualmente en tto con PERTUZUMAB + TRASTUZUMAB + PACLITAXEL.\n",
      "  \u2192 PERTUZUMAB (DRUG) [23-33]\n",
      "  \u2192 TRASTUZUMAB (DRUG) [36-47]\n",
      "  \u2192 PACLITAXEL (DRUG) [50-60]\n",
      "\n",
      "Texto: Actualmente en tto con PERTUZUMAB + TRASTUZUMAB + PACLITAXEL.\n",
      "  \u2192 PERTUZUMAB (DRUG) [23-33]\n",
      "  \u2192 TRASTUZUMAB (DRUG) [36-47]\n",
      "  \u2192 PACLITAXEL (DRUG) [50-60]\n",
      "\n",
      "Texto: CICLO 2 DOXORRUBICINA 90 MG, CICLOFOSFAMIDA 895 MG, Carcinoma infiltrante tipo inespec\u00edfico de mama derecha, pT1c cN1a (mi) cM0 (estadio IB).\n",
      "  \u2192 CICLO 2 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 DOXORRUBICINA (DRUG) [8-21]\n",
      "  \u2192 90 MG (DOSE) [22-27]\n",
      "  \u2192 CICLOFOSFAMIDA (DRUG) [29-43]\n",
      "  \u2192 895 MG (DOSE) [44-50]\n",
      "  \u2192 Carcinoma infiltrante tipo inespec\u00edfico de mama derecha (CANCER_CONCEPT) [52-107]\n",
      "  \u2192 pT1c cN1a (TNM) [109-118]\n",
      "  \u2192 cM0 (TNM) [124-127]\n",
      "  \u2192 estadio IB (STAGE) [129-139]\n",
      "\n",
      "Texto: Paciente tratada con Mastectom\u00eda + Linfadenectom\u00eda derechas 11/09/2017.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [21-32]\n",
      "  \u2192 Linfadenectom\u00eda derechas (SURGERY) [35-59]\n",
      "  \u2192 11/09/2017 (DATE) [60-70]\n",
      "\n",
      "Texto: Paciente mujer de 43 a\u00f1os ingresada con carcinoma de mama derecha pT2N0M0 (estadio IIA), RH +, Her2 negativo, diagnosticada en 2010 en mujer premenopa\u00fasica, tratado mediante mastectom\u00eda con reconstrucci\u00f3n.\n",
      "  \u2192 43 a\u00f1os (AGE) [18-25]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [26-35]\n",
      "  \u2192 carcinoma de mama derecha (CANCER_CONCEPT) [40-65]\n",
      "  \u2192 pT2N0M0 (TNM) [66-73]\n",
      "  \u2192 estadio IIA (STAGE) [75-86]\n",
      "  \u2192 RH + (BIOMARKER) [89-93]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [95-108]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [110-123]\n",
      "  \u2192 2010 (DATE) [127-131]\n",
      "  \u2192 premenopa\u00fasica (GINECOLOGICAL_HISTORY) [141-155]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [157-164]\n",
      "  \u2192 mastectom\u00eda con reconstrucci\u00f3n (SURGERY) [174-204]\n",
      "\n",
      "Texto: Derrame pleural derecho de nueva aparici\u00f3n en probable relaci\u00f3n a progresi\u00f3n de la enfermedad oncol\u00f3gica de base.\n",
      "\n",
      "Texto: Mal control del dolor en relaci\u00f3n a lo previo.\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA: Mujer de 43 a\u00f1os que acude en enero de 2010 por notar un bulto en mama izquierda.\n",
      "  \u2192 43 a\u00f1os (AGE) [30-37]\n",
      "  \u2192 enero de 2010 (DATE) [51-64]\n",
      "\n",
      "Texto: Se hab\u00eda realizado mamograf\u00eda en septiembre de 2009, que se hab\u00eda informado como : sin hallazgos patol\u00f3gicos.\n",
      "  \u2192 septiembre de 2009, (DATE) [33-52]\n",
      "\n",
      "Texto: Acude en enero al Hospital Ruber y le realizan mamograf\u00eda, en la que se objetiva una lesi\u00f3n sospechosa de malignidad.\n",
      "  \u2192 enero (DATE) [9-14]\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [106-116]\n",
      "\n",
      "Texto: Se realiza biopsia de la lesi\u00f3n con diagn\u00f3stico: carcinoma ductal infiltrante.\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [36-47]\n",
      "  \u2192 carcinoma ductal infiltrante (CANCER_CONCEPT) [49-77]\n",
      "\n",
      "Texto: El 16/03/2010 se realiza mastectom\u00eda radical modificada m\u00e1s linfadenectom\u00eda por ganglio centinela positivo.\n",
      "  \u2192 16/03/2010 (DATE) [3-13]\n",
      "  \u2192 mastectom\u00eda radical modificada (SURGERY) [25-55]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [60-75]\n",
      "\n",
      "Texto: Aporta informe de anatom\u00eda patol\u00f3gica: carcinoma ductal infiltrante de 8.6 cm, estadio II, con invasi\u00f3n vascular.\n",
      "  \u2192 carcinoma ductal infiltrante (CANCER_CONCEPT) [39-67]\n",
      "  \u2192 estadio II (STAGE) [79-89]\n",
      "\n",
      "Texto: Paciente con HER2 negativo.\n",
      "  \u2192 HER2 negativo (BIOMARKER) [13-26]\n",
      "\n",
      "Texto: Mujer diagnosticada con carcinoma ductal infiltrante T3N3aM0, en quimioterapia el 26/04/2010 con 4 ciclos de Epirrubicina y Genoxal y Taxol.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 carcinoma ductal infiltrante (CANCER_CONCEPT) [24-52]\n",
      "  \u2192 T3N3aM0 (TNM) [53-60]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [65-78]\n",
      "  \u2192 26/04/2010 (DATE) [82-92]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [97-105]\n",
      "  \u2192 Epirrubicina (DRUG) [109-121]\n",
      "  \u2192 Genoxal (DRUG) [124-131]\n",
      "  \u2192 Taxol (DRUG) [134-139]\n",
      "\n",
      "Texto: Despu\u00e9s radioterapia desde el 26/10/2010 hasta el 01/12/2010 en mastectom\u00eda izquierda.\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [8-20]\n",
      "  \u2192 26/10/2010 (DATE) [30-40]\n",
      "  \u2192 01/12/2010 (DATE) [50-60]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [64-85]\n",
      "\n",
      "Texto: Despu\u00e9s Tamoxifeno 20 mg al d\u00eda.\n",
      "  \u2192 Tamoxifeno (DRUG) [8-18]\n",
      "  \u2192 20 mg (DOSE) [19-24]\n",
      "  \u2192 al d\u00eda (FREQ) [25-31]\n",
      "\n",
      "Texto: REVISI\u00d3N: Carcinoma ductal infiltrante de uni\u00f3n de cuadrantes superiores de mama derecha cT2N1, ypTisN0, RE negativos, RP negativos, Her2 positiva, m\u00e1rgenes libres.\n",
      "  \u2192 Carcinoma ductal infiltrante de uni\u00f3n de cuadrantes superiores de mama derecha (CANCER_CONCEPT) [10-88]\n",
      "  \u2192 cT2N1, (TNM) [89-95]\n",
      "  \u2192 ypTisN0 (TNM) [96-103]\n",
      "  \u2192 RE negativos (BIOMARKER) [105-117]\n",
      "  \u2192 RP negativos (BIOMARKER) [119-131]\n",
      "  \u2192 Her2 positiva (BIOMARKER) [133-146]\n",
      "\n",
      "Texto: Her2 positiva para m\u00e1rgenes libres.\n",
      "  \u2192 Her2 positiva (BIOMARKER) [0-13]\n",
      "\n",
      "Texto: Tratamiento: Entre los d\u00edas 19.04.2018 y 4.05.2018 recibe tratamiento radioter\u00e1pico adyuvante concomitante con Trastuzumab.\n",
      "  \u2192 19.04.2018 (DATE) [28-38]\n",
      "  \u2192 4.05.2018 (DATE) [41-50]\n",
      "  \u2192 tratamiento radioter\u00e1pico adyuvante concomitante (TREATMENT_NAME) [58-106]\n",
      "  \u2192 Trastuzumab (DRUG) [111-122]\n",
      "\n",
      "Texto: Previa simulaci\u00f3n con TAC y posterior planificaci\u00f3n 3D, se procedi\u00f3 a la irradiaci\u00f3n de un volumen comprendido por mama izda con \u00e1reas ganglionares niveles axilares con m\u00e1rgenes adecuados, administr\u00e1ndose una dosis de 50 Gy en 25 sesiones a 2 Gy.\n",
      "  \u2192 50 Gy (DOSE) [218-223]\n",
      "  \u2192 25 sesiones (LINE_CICLE_NUMBER) [227-238]\n",
      "  \u2192 2 Gy (DOSE) [241-245]\n",
      "\n",
      "Texto: Posteriormente se continu\u00f3 con una sobreimpresi\u00f3n con m\u00e1rgenes adecuados, administr\u00e1ndose una dosis de 13.3 Gy en 5 sesiones a 2.66 Gy.\n",
      "  \u2192 13.3 Gy (DOSE) [103-110]\n",
      "  \u2192 5 sesiones (LINE_CICLE_NUMBER) [114-124]\n",
      "  \u2192 2.66 Gy (DOSE) [127-134]\n",
      "\n",
      "Texto: Buena tolerancia al tratamiento.\n",
      "\n",
      "Texto: EXPLORACI\u00d3N F\u00cdSICA: No se palpan adenopat\u00edas laterocervicales, supraclaviculares ni axilares.\n",
      "  \u2192 No se palpan adenopat\u00edas laterocervicales, supraclaviculares ni axilares (COMORBIDITY) [20-92]\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA: Mujer de 40 a\u00f1os de edad que acude al servicio de ginecolog\u00eda en enero de 2013 por aparici\u00f3n de n\u00f3dulo en mama izquierda de 2 meses de evoluci\u00f3n.\n",
      "  \u2192 40 a\u00f1os (AGE) [30-37]\n",
      "  \u2192 ginecolog\u00eda (CLINICAL_SERVICE) [71-82]\n",
      "  \u2192 enero de 2013 (DATE) [86-99]\n",
      "\n",
      "Texto: A la exploraci\u00f3n se describe una lesi\u00f3n de 4 cm.\n",
      "\n",
      "Texto: Se solicita estudio con:- Mamograf\u00eda (28/01/2013): Lesi\u00f3n radial de 4.5 cm de tama\u00f1o en intercuadrantes superiores de mama izquierda, muy sospechosa de malignidad.\n",
      "  \u2192 (28/01/2013 (DATE) [37-48]\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [152-162]\n",
      "\n",
      "Texto: Ante dichos hallazgos se realiza biopsia de ambas mamas:-BAG MAMA IZQUIERDA: Carcinoma lobulillar infiltrante, HER2 negativo.\n",
      "  \u2192 Carcinoma lobulillar infiltrante (CANCER_CONCEPT) [77-109]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [111-124]\n",
      "\n",
      "Texto: -BAG MAMA DERECHA: carcinoma lobulillar infiltrante, Receptores hormonales 80 %, HER2 negativo, Ki67: 20 % .\n",
      "  \u2192 carcinoma lobulillar infiltrante (CANCER_CONCEPT) [19-51]\n",
      "  \u2192 Receptores hormonales 80 % (BIOMARKER) [53-79]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [81-94]\n",
      "  \u2192 Ki67: 20 % (BIOMARKER) [96-106]\n",
      "\n",
      "Texto: Paciente de 45 a\u00f1os diagnosticada de c\u00e1ncer de mama, estadio IV; HER2 positivo, RH positivos .\n",
      "  \u2192 45 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [20-33]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [37-51]\n",
      "  \u2192 estadio IV (STAGE) [53-63]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [65-78]\n",
      "  \u2192 RH positivos (BIOMARKER) [80-92]\n",
      "\n",
      "Texto: El 29/10/2012 se realiza mastectomia derecha.\n",
      "  \u2192 29/10/2012 (DATE) [3-13]\n",
      "  \u2192 mastectomia derecha (SURGERY) [25-44]\n",
      "\n",
      "Texto: Mujer diagnosticada de cancer de mama, estadio IV.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 cancer de mama (CANCER_CONCEPT) [23-37]\n",
      "  \u2192 estadio IV (STAGE) [39-49]\n",
      "\n",
      "Texto: Se plantea tratamiento con Docetaxel, Carboplatino y Trastuzumab cada 21 d\u00edas y posteriomente si respuesta mantenimiento con Trastuzumab.\n",
      "  \u2192 Docetaxel (DRUG) [27-36]\n",
      "  \u2192 Carboplatino (DRUG) [38-50]\n",
      "  \u2192 Trastuzumab (DRUG) [53-64]\n",
      "  \u2192 cada 21 d\u00edas (FREQ) [65-77]\n",
      "  \u2192 Trastuzumab (DRUG) [125-136]\n",
      "\n",
      "Texto: Mujer premenop\u00e1usica con Adenocarcinoma infiltrante de mama izquierda estadio IIB, pT2pN1cM0, receptores hormonales positivos, Ki 12 %, HER2 negativo.\n",
      "  \u2192 premenop\u00e1usica (GINECOLOGICAL_HISTORY) [6-20]\n",
      "  \u2192 Adenocarcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [25-69]\n",
      "  \u2192 estadio IIB (STAGE) [70-81]\n",
      "  \u2192 pT2pN1cM0 (TNM) [83-92]\n",
      "  \u2192 receptores hormonales positivos (BIOMARKER) [94-125]\n",
      "  \u2192 Ki 12 % (BIOMARKER) [127-134]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [136-149]\n",
      "\n",
      "Texto: Paciente de 55 a\u00f1os con antecedentes personales de: No RAMC.\n",
      "  \u2192 55 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 No RAMC (ALLERGIES) [52-59]\n",
      "\n",
      "Texto: No HTA, No DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 No DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: Hipotiroidismo en tto con Eutirox hace 10 a\u00f1os.\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [0-14]\n",
      "  \u2192 Eutirox (DRUG) [26-33]\n",
      "  \u2192 hace 10 a\u00f1os (IMPLICIT_DATE) [34-46]\n",
      "\n",
      "Texto: Fumadora de 10 cigarrillos diarios hace 5 a\u00f1os.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [0-8]\n",
      "  \u2192 10 cigarrillos (HABIT-QUANTITY) [12-26]\n",
      "  \u2192 diario (FREQ) [27-33]\n",
      "  \u2192 s (HABIT-QUANTITY) [33-34]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [35-46]\n",
      "\n",
      "Texto: Menarquia a los 13 a\u00f1os.\n",
      "  \u2192 Menarquia (GINECOLOGICAL_HISTORY) [0-9]\n",
      "  \u2192 13 a\u00f1os (AGE) [16-23]\n",
      "\n",
      "Texto: Antecedentes familiares: T\u00eda materna con ca de mama y posteriormente leucemia.\n",
      "  \u2192 T\u00eda materna (FAMILY) [25-36]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [41-51]\n",
      "  \u2192 leucemia (CANCER_CONCEPT) [69-77]\n",
      "\n",
      "Texto: Antecedentes familiares: Padre con 65 a\u00f1os, Madre viva con 60 a\u00f1os, sana.\n",
      "  \u2192 Padre (FAMILY) [25-30]\n",
      "  \u2192 65 a\u00f1os (AGE) [35-42]\n",
      "  \u2192 Madre (FAMILY) [44-49]\n",
      "  \u2192 60 a\u00f1os (AGE) [59-66]\n",
      "\n",
      "Texto: Tia paterna con ca de mama a los 60 a\u00f1os.\n",
      "  \u2192 Tia paterna (FAMILY) [0-11]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [16-26]\n",
      "  \u2192 60 a\u00f1os (AGE) [33-40]\n",
      "\n",
      "Texto: T\u00eda paterna cancer epidermoide.\n",
      "  \u2192 T\u00eda paterna (FAMILY) [0-11]\n",
      "  \u2192 cancer epidermoide (CANCER_CONCEPT) [12-30]\n",
      "\n",
      "Texto: Tratada en quimioterapia con Docetaxel + Ciclofosfamida.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [11-24]\n",
      "  \u2192 Docetaxel (DRUG) [29-38]\n",
      "  \u2192 Ciclofosfamida (DRUG) [41-55]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha pT2 pN1 cM0, estadio IIB.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 pT2 pN1 cM0 (TNM) [45-56]\n",
      "  \u2192 estadio IIB (STAGE) [58-69]\n",
      "\n",
      "Texto: RH positivos, HER2 negativo en 2010.\n",
      "  \u2192 RH positivos (BIOMARKER) [0-12]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [14-27]\n",
      "  \u2192 2010. (DATE) [31-36]\n",
      "\n",
      "Texto: Paciente tratada con Mastectom\u00eda + linfadenectom\u00eda hace un a\u00f1o.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [21-32]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [35-50]\n",
      "  \u2192 hace un a\u00f1o (IMPLICIT_DATE) [51-62]\n",
      "\n",
      "Texto: Reca\u00edda hep\u00e1tica y pulmonar en 2016.\n",
      "  \u2192 Reca\u00edda hep\u00e1tica y pulmonar (PROGRESION) [0-27]\n",
      "  \u2192 2016. (DATE) [31-36]\n",
      "\n",
      "Texto: Recibe QT con Capecitabina x 2 con mala tolerancia, Paclitaxel en pauta de desensibilizaci\u00f3n x 7.\n",
      "  \u2192 QT (TREATMENT_NAME) [7-9]\n",
      "  \u2192 Capecitabina (DRUG) [14-26]\n",
      "  \u2192 x 2 (LINE_CICLE_NUMBER) [27-30]\n",
      "  \u2192 Paclitaxel (DRUG) [52-62]\n",
      "  \u2192 x 7. (LINE_CICLE_NUMBER) [93-97]\n",
      "\n",
      "Texto: Antecedentes personales:- No alergias medicamentosas conocidas.\n",
      "  \u2192 No alergias medicamentosas conocidas (ALLERGIES) [26-62]\n",
      "\n",
      "Texto: Fumadora 10-15 cigarrillos desde los 16 a\u00f1os hasta la actualidad, no bebedora.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [0-8]\n",
      "  \u2192 10-15 cigarrillos (HABIT-QUANTITY) [9-26]\n",
      "  \u2192 desde los 16 a\u00f1os hasta la actualidad (DURATION) [27-64]\n",
      "  \u2192 no bebedora (TOXIC_HABITS) [66-77]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: No cirug\u00edas.\n",
      "\n",
      "Texto: No tratamiento habitual.\n",
      "\n",
      "Texto: Mujer con Carcinoma multifocal de mama izquierda cT1c pN1 Mx, receptores de estr\u00f3genos positivos.\n",
      "  \u2192 Carcinoma multifocal de mama izquierda (CANCER_CONCEPT) [10-48]\n",
      "  \u2192 cT1c pN1 Mx (TNM) [49-60]\n",
      "  \u2192 receptores de estr\u00f3genos positivos (BIOMARKER) [62-96]\n",
      "\n",
      "Texto: Receptores de progesterona negativos, Ki-67: negativo , HER 2 negativo.\n",
      "  \u2192 Receptores de progesterona negativos (BIOMARKER) [0-36]\n",
      "  \u2192 Ki-67: negativo (BIOMARKER) [38-53]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [56-70]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: El 8/08/2017 es intervenida qx realiz\u00e1ndose tumorectom\u00eda.\n",
      "  \u2192 8/08/2017 (DATE) [3-12]\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [16-27]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [44-56]\n",
      "\n",
      "Texto: Se administra el radiotrazador en regi\u00f3n periareolar en ICS de mama izquierda.\n",
      "\n",
      "Texto: En las im\u00e1genes planares (proyecciones anterior y lateral) se identifica un intenso dep\u00f3stio axilar izquierdo que interpretamos como ganglio centinela y marcamos sobre la piel de la paciente con una cruz.\n",
      "\n",
      "Texto: Se realiza estudio tomogr\u00e1fico (SPET/TC) en el que se observa un ganglio de 12 mm situado en nivel II de Berg de axila izquierda, proximo al borde externo del pectoral menor.\n",
      "\n",
      "Texto: Est\u00e1 a unos 1,7 cm de la superficie cut\u00e1nea.\n",
      "\n",
      "Texto: Se observa un segundo dep\u00f3sito de muy leve intensidad en regi\u00f3n supraclavicular izquierda sugerente de ganglios secundario, ya que se observa trayecto desde el ganglio de mayor intensidad hasta \u00e9l.\n",
      "\n",
      "Texto: RESUMEN E INTERPRETACION CLINICA, Detecci\u00f3n gammagr\u00e1fica de un ganglio centinela axilar izquierdo localizado en nivel II de Berg.\n",
      "\n",
      "Texto: Ganglio secundario supraclavicular izquierdo.\n",
      "\n",
      "Texto: A GANGLIO LINFATICO (NEOM) Biopsia intraoperatoria.\n",
      "\n",
      "Texto: DESCRIPCI\u00d3N MACROSC\u00d3PICA: Se recibe en fresco para estudio intraoperatorio de ganglio centinela axilar que mide 1,8 cm de di\u00e1metro m\u00e1ximo y pesa 720 mg.\n",
      "\n",
      "Texto: Se toman improntas citol\u00f3gicas con resultado negativo.\n",
      "\n",
      "Texto: Mujer de 75 a\u00f1os diagnosticada en julio de 2019 de un carcinoma lobular invasivo de mama cT4cN2cM0, estadio IIIB .\n",
      "  \u2192 75 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [17-30]\n",
      "  \u2192 julio de 2019 (DATE) [34-47]\n",
      "  \u2192 carcinoma lobular invasivo de mama (CANCER_CONCEPT) [54-88]\n",
      "  \u2192 cT4cN2cM0 (TNM) [89-98]\n",
      "  \u2192 estadio IIIB (STAGE) [100-112]\n",
      "\n",
      "Texto: Mujer diagnosticada con Adenocarcinoma infiltrante de mama derecha en 1997, N0 cM0, IHQ?.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 Adenocarcinoma infiltrante de mama derecha (CANCER_CONCEPT) [24-66]\n",
      "  \u2192 1997 (DATE) [70-74]\n",
      "  \u2192 N0 cM0 (TNM) [76-82]\n",
      "\n",
      "Texto: Paciente tratada con Tumorectom\u00eda y Tamoxifeno.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Tumorectom\u00eda (SURGERY) [21-33]\n",
      "  \u2192 Tamoxifeno (DRUG) [36-46]\n",
      "\n",
      "Texto: AP con receptores hormonales positivos, HER 2 negativo.\n",
      "  \u2192 receptores hormonales positivos (BIOMARKER) [7-38]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [40-54]\n",
      "\n",
      "Texto: Tratamiento: Epirrubicina y Docetaxel + Letrozol, enfermedad estable.\n",
      "  \u2192 Epirrubicina (DRUG) [13-25]\n",
      "  \u2192 Docetaxel (DRUG) [28-37]\n",
      "  \u2192 Letrozol (DRUG) [40-48]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda (retroareolar - CSE), pT2N2a.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 pT2N2a (TNM) [69-75]\n",
      "\n",
      "Texto: Estadio patol\u00f3gico: pT2N2a, No se observa invasi\u00f3n linfovascular ni perineural.\n",
      "  \u2192 pT2N2a (TNM) [20-26]\n",
      "\n",
      "Texto: Piel y complejo areola-pez\u00f3n sin afectaci\u00f3n.\n",
      "\n",
      "Texto: Met\u00e1stasis en ganglios linf\u00e1ticos..\n",
      "  \u2192 Met\u00e1stasis en ganglios linf\u00e1ticos (CANCER_CONCEPT) [0-33]\n",
      "\n",
      "Texto: M\u00e1rgenes quir\u00fargicos libres a m\u00e1s de 1 cm.\n",
      "\n",
      "Texto: RH: positivos, Her2 negativo.\n",
      "  \u2192 RH: positivos (BIOMARKER) [0-13]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [15-28]\n",
      "\n",
      "Texto: Mujer tratada con Mastectom\u00eda radical modificada el 21/07/2017.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [6-13]\n",
      "  \u2192 Mastectom\u00eda radical modificada (SURGERY) [18-48]\n",
      "  \u2192 21/07/2017 (DATE) [52-62]\n",
      "\n",
      "Texto: No va a recibir quimioterapia.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [16-29]\n",
      "\n",
      "Texto: Iniciar\u00e1 tratamiento hormonal tras finalizar la radioterapia.\n",
      "  \u2192 tratamiento hormonal (TREATMENT_NAME) [9-29]\n",
      "  \u2192 tras finalizar (OCURRENCE_EVENT) [30-44]\n",
      "  \u2192 radioterapia (TREATMENT_NAME) [48-60]\n",
      "\n",
      "Texto: TRATAMIENTO RADIOTER\u00c1PICO: Se decide efectuar la irradiaci\u00f3n de un volumen que incluye el lecho de mastectom\u00eda izquierda, cadenas ganglionares axiloclaviculares izquierdas.\n",
      "  \u2192 TRATAMIENTO RADIOTER\u00c1PICO (TREATMENT_NAME) [0-25]\n",
      "  \u2192 mastectom\u00eda izquierda (SURGERY) [99-120]\n",
      "\n",
      "Texto: La dosis total administrada ha sido de 50 Gy.\n",
      "  \u2192 50 Gy (DOSE) [39-44]\n",
      "\n",
      "Texto: Resumen: Mastectom\u00eda izquierda.\n",
      "  \u2192 Mastectom\u00eda izquierda (SURGERY) [9-30]\n",
      "\n",
      "Texto: Mujer de 46 a\u00f1os que ingresa en oncolog\u00eda m\u00e9dica por Carcinoma ductal infiltrante de mama triple negativo, estadio IV (pulm\u00f3n, pleura, hueso y probable afectaci\u00f3n hep\u00e1tica), diagnosticado en mayo de 2012.\n",
      "  \u2192 46 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresa (OCURRENCE_EVENT) [21-28]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [32-48]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama triple negativo (CANCER_CONCEPT) [53-105]\n",
      "  \u2192 estadio IV (STAGE) [107-117]\n",
      "  \u2192 afectaci\u00f3n hep\u00e1tica (PROGRESION) [152-171]\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [174-187]\n",
      "  \u2192 mayo de 2012. (DATE) [191-204]\n",
      "\n",
      "Texto: Mastectom\u00eda y linfadenectom\u00eda el 20-8-12 ypT1cN1a (3/8 G+).\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [0-11]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [14-29]\n",
      "  \u2192 20-8-12 (DATE) [33-40]\n",
      "  \u2192 ypT1cN1a (TNM) [41-49]\n",
      "\n",
      "Texto: Taxol x 4 ciclos.\n",
      "  \u2192 Taxol (DRUG) [0-5]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [6-16]\n",
      "\n",
      "Texto: Recibe quimioterapia con Cisplatino semanal desde el 30-11-2015.\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [7-20]\n",
      "  \u2192 Cisplatino (DRUG) [25-35]\n",
      "  \u2192 semanal (FREQ) [36-43]\n",
      "  \u2192 30-11-2015 (DATE) [53-63]\n",
      "\n",
      "Texto: Mujer de 44 a\u00f1os derivada de oncologia m\u00e9dica para valroaci\u00f3n de tratamiento.\n",
      "  \u2192 44 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 derivada (OCURRENCE_EVENT) [17-25]\n",
      "  \u2192 oncologia m\u00e9dica (CLINICAL_SERVICE) [29-45]\n",
      "\n",
      "Texto: Antecedentes t\u00f3xicos: Fumadora de 5 cigarrillos diarios.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [22-30]\n",
      "  \u2192 5 cigarrillos (HABIT-QUANTITY) [34-47]\n",
      "  \u2192 diarios (FREQ) [48-55]\n",
      "\n",
      "Texto: Actualmente exfumadora hace 3 meses.\n",
      "  \u2192 hace 3 meses (IMPLICIT_DATE) [23-35]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: Antecedentes familiares: t\u00edo materno con c\u00e1ncer cerebral, abuela materna con c\u00e1ncer de ri\u00f1\u00f3n.\n",
      "  \u2192 t\u00edo materno (FAMILY) [25-36]\n",
      "  \u2192 c\u00e1ncer cerebral (CANCER_CONCEPT) [41-56]\n",
      "  \u2192 abuela materna (FAMILY) [58-72]\n",
      "  \u2192 c\u00e1ncer de ri\u00f1\u00f3n (CANCER_CONCEPT) [77-92]\n",
      "\n",
      "Texto: Paciente diagnosticada con Carcinoma lobulillar infiltrante, T2N1M0.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [9-22]\n",
      "  \u2192 Carcinoma lobulillar infiltrante (CANCER_CONCEPT) [27-59]\n",
      "  \u2192 T2N1M0 (TNM) [61-67]\n",
      "\n",
      "Texto: Tratada con TAMOXIFENO en septiembre de 2012.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 TAMOXIFENO (DRUG) [12-22]\n",
      "  \u2192 septiembre de 2012. (DATE) [26-45]\n",
      "\n",
      "Texto: Se encuentra bien.\n",
      "\n",
      "Texto: Importantes sofocos.\n",
      "\n",
      "Texto: Todo normal.\n",
      "\n",
      "Texto: A\u00f1ado colono por antec de ca de colon en padre hace 10 a\u00f1os.\n",
      "  \u2192 ca de colon (CANCER_CONCEPT) [26-37]\n",
      "  \u2192 padre (FAMILY) [41-46]\n",
      "  \u2192 hace 10 a\u00f1os (IMPLICIT_DATE) [47-59]\n",
      "\n",
      "Texto: Mama derecha : carcinoma lobulillar infiltrante multifocal cT2 cN1 M0, HER2 negativo.\n",
      "  \u2192 carcinoma lobulillar infiltrante multifocal (CANCER_CONCEPT) [15-58]\n",
      "  \u2192 cT2 cN1 M0 (TNM) [59-69]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [71-84]\n",
      "\n",
      "Texto: Mama izquierda: carcinoma infiltrante inespec\u00edfico cT1b cN1 M0, HER2 negativo.\n",
      "  \u2192 carcinoma infiltrante inespec\u00edfico (CANCER_CONCEPT) [16-50]\n",
      "  \u2192 cT1b cN1 M0 (TNM) [51-62]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [64-77]\n",
      "\n",
      "Texto: Antedentes familiares: Madre diagnosticada con ca de mama hace 5 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [23-28]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [29-42]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [47-57]\n",
      "  \u2192 hace 5 a\u00f1os (IMPLICIT_DATE) [58-69]\n",
      "\n",
      "Texto: Tratamiento: CICLO 1 VINORELBINA cada 4 d\u00edas.\n",
      "  \u2192 CICLO 1 (LINE_CICLE_NUMBER) [13-20]\n",
      "  \u2192 VINORELBINA (DRUG) [21-32]\n",
      "  \u2192 cada 4 d\u00edas (FREQ) [33-44]\n",
      "\n",
      "Texto: Es intervenida el d\u00eda 19/01/2011 de mastectom\u00eda m\u00e1s linfadenectom\u00eda axilar derechas.\n",
      "  \u2192 intervenida (OCURRENCE_EVENT) [3-14]\n",
      "  \u2192 19/01/2011 (DATE) [22-32]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [36-47]\n",
      "  \u2192 linfadenectom\u00eda axilar derechas (SURGERY) [52-83]\n",
      "\n",
      "Texto: Carcinima mamario, pT2 pN1, HER-2 NEGATIVO.\n",
      "  \u2192 Carcinima mamario (CANCER_CONCEPT) [0-17]\n",
      "  \u2192 pT2 pN1 (TNM) [19-26]\n",
      "  \u2192 HER-2 NEGATIVO (BIOMARKER) [28-42]\n",
      "\n",
      "Texto: Rreceptores de Estr\u00f3genos: positivos en un 99 % .\n",
      "  \u2192 Rreceptores de Estr\u00f3genos: positivos en un 99 % (BIOMARKER) [0-47]\n",
      "\n",
      "Texto: Tratamiento con 4 ciclos de esquema AC, precisando soporte con G-CSF por neutropenia y posteriormente 4 ciclos con Docetaxel trisemanal hasta agosto del 2011.\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [16-24]\n",
      "  \u2192 AC (DRUG) [36-38]\n",
      "  \u2192 neutropenia (COMORBIDITY) [73-84]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [102-110]\n",
      "  \u2192 Docetaxel (DRUG) [115-124]\n",
      "  \u2192 trisemanal (FREQ) [125-135]\n",
      "  \u2192 agosto del 2011. (DATE) [142-158]\n",
      "\n",
      "Texto: Inicia Cisplatino semanal el d\u00eda 25/05/2017, del que recibe 5 ciclos hasta el 13/07/2017.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 Cisplatino (DRUG) [7-17]\n",
      "  \u2192 semanal (FREQ) [18-25]\n",
      "  \u2192 25/05/2017 (DATE) [33-43]\n",
      "  \u2192 5 ciclos (LINE_CICLE_NUMBER) [60-68]\n",
      "  \u2192 13/07/2017 (DATE) [78-88]\n",
      "\n",
      "Texto: Inicia Cisplatino semanal el d\u00eda 25/05/2017, del que recibe 5 ciclos hasta el 13/07/2017.\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 Cisplatino (DRUG) [7-17]\n",
      "  \u2192 semanal (FREQ) [18-25]\n",
      "  \u2192 25/05/2017 (DATE) [33-43]\n",
      "  \u2192 5 ciclos (LINE_CICLE_NUMBER) [60-68]\n",
      "  \u2192 13/07/2017 (DATE) [78-88]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama, triple negativo, estadio IV (pulm\u00f3n, pleura, hueso y probable afectaci\u00f3n hep\u00e1tica).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [0-36]\n",
      "  \u2192 triple negativo (CANCER_CONCEPT) [38-53]\n",
      "  \u2192 estadio IV (STAGE) [55-65]\n",
      "  \u2192 ci\u00f3n hep\u00e1tica (PROGRESION) [106-119]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama, triple negativo, estadio IV (pulm\u00f3n, pleura, hueso y probable afectaci\u00f3n hep\u00e1tica).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [0-36]\n",
      "  \u2192 triple negativo (CANCER_CONCEPT) [38-53]\n",
      "  \u2192 estadio IV (STAGE) [55-65]\n",
      "  \u2192 ci\u00f3n hep\u00e1tica (PROGRESION) [106-119]\n",
      "\n",
      "Texto: -Tto neoady AC x 4 (18-5 al 27-7-12): respuesta parcial cl\u00ednica.\n",
      "  \u2192 Tto neoady (TREATMENT_NAME) [1-11]\n",
      "  \u2192 AC (DRUG) [12-14]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [15-18]\n",
      "  \u2192 (18-5 (DATE) [19-24]\n",
      "  \u2192 27-7-12 (DATE) [28-35]\n",
      "\n",
      "Texto: - Mastectom\u00eda y linfadenectom\u00eda el 20-8-12 ypT1cN1a (3/8 G+) - Taxotere x 4 ciclos.\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [2-13]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [16-31]\n",
      "  \u2192 20-8-12 (DATE) [35-42]\n",
      "  \u2192 ypT1cN1a (TNM) [43-51]\n",
      "  \u2192 Taxotere (DRUG) [63-71]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [72-82]\n",
      "\n",
      "Texto: - Mastectom\u00eda y linfadenectom\u00eda el 20-8-12 ypT1cN1a - Taxotere x 4 ciclos .\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [2-13]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [16-31]\n",
      "  \u2192 20-8-12 (DATE) [35-42]\n",
      "  \u2192 ypT1cN1a (TNM) [43-51]\n",
      "  \u2192 Taxotere (DRUG) [54-62]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [63-73]\n",
      "\n",
      "Texto: RT ady (10-01 al 13-02-2013) - Lenta progresi\u00f3n pulmonar desde octubre de 2013.\n",
      "  \u2192 RT ady (TREATMENT_NAME) [0-6]\n",
      "  \u2192 (10-01 (DATE) [7-13]\n",
      "  \u2192 13-02-2013 (DATE) [17-27]\n",
      "  \u2192 progresi\u00f3n pulmonar (PROGRESION) [37-56]\n",
      "  \u2192 octubre de 2013. (DATE) [63-79]\n",
      "\n",
      "Texto: - Mayo 2015 progresi\u00f3n en SNC: cerebelosa izquierda y parietal derecha.\n",
      "  \u2192 Mayo 2015 (DATE) [2-11]\n",
      "  \u2192 progresi\u00f3n en SNC: cerebelosa izquierda y parietal derecha (PROGRESION) [12-70]\n",
      "\n",
      "Texto: - Craniotom\u00eda suboccipital mediana en 29/05/2015.\n",
      "  \u2192 Craniotom\u00eda suboccipital mediana (SURGERY) [2-34]\n",
      "  \u2192 29/05/2015 (DATE) [38-48]\n",
      "\n",
      "Texto: RM postquir\u00fargico: Se objetivan otras tres lesiones supratentoriales de tama\u00f1o mil\u00edmetro.\n",
      "\n",
      "Texto: - RT holocraneal (01/07 al 21/07/15).\n",
      "  \u2192 RT holocraneal (TREATMENT_NAME) [2-16]\n",
      "  \u2192 01/07 (DATE) [18-23]\n",
      "  \u2192 21/07/15) (DATE) [27-36]\n",
      "\n",
      "Texto: - Progresi\u00f3n pulmonar, pleural y \u00f3sea, y dudosa hep\u00e1tica (agosto-15).\n",
      "  \u2192 Progresi\u00f3n pulmonar, pleural y \u00f3sea (PROGRESION) [2-37]\n",
      "  \u2192 y dudosa hep\u00e1tica (PROGRESION) [39-56]\n",
      "  \u2192 agosto-15 (DATE) [58-67]\n",
      "\n",
      "Texto: - Vinorelbina oral (12-8-15 al 28-10-2015 ciclo 4\u00ba)\n",
      "  \u2192 Vinorelbina (DRUG) [2-13]\n",
      "  \u2192 (12-8-15 (DATE) [19-27]\n",
      "  \u2192 28-10-2015 (DATE) [31-41]\n",
      "  \u2192 ciclo 4o (LINE_CICLE_NUMBER) [42-50]\n",
      "\n",
      "Texto: Infecci\u00f3n respiratoriaMal control del dolor.\n",
      "  \u2192 Infecci\u00f3n respiratoria (COMORBIDITY) [0-22]\n",
      "\n",
      "Texto: Empeoramiento del perfil hep\u00e1tico (hiperbilirrubinemia)\n",
      "  \u2192 hiperbilirrubinemia (COMORBIDITY) [35-54]\n",
      "\n",
      "Texto: Anemia microc\u00edtica.\n",
      "  \u2192 Anemia microc\u00edtica (COMORBIDITY) [0-18]\n",
      "\n",
      "Texto: Hiponatremia leve.\n",
      "  \u2192 Hiponatremia leve (COMORBIDITY) [0-17]\n",
      "\n",
      "Texto: Mujer con Carcinoma ductal infiltrante de mama, estadio IV.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [10-46]\n",
      "  \u2192 estadio IV (STAGE) [48-58]\n",
      "\n",
      "Texto: Motivo de consulta: Paciente con disnea derivada del nivel 3.\n",
      "\n",
      "Texto: Antecedentes personales: No alergias medicamentosas conocidas.\n",
      "  \u2192 No alergias medicamentosas conocidas (ALLERGIES) [25-61]\n",
      "\n",
      "Texto: Hipertensi\u00f3n arterial, No diabetes mellitus ni dislipemias .\n",
      "  \u2192 Hipertensi\u00f3n arterial (COMORBIDITY) [0-21]\n",
      "  \u2192 diabetes mellitus (COMORBIDITY) [26-43]\n",
      "  \u2192 ni dislipemias (COMORBIDITY) [44-58]\n",
      "\n",
      "Texto: Adenocarcinoma de mama estadio IV en tratamiento con XELODA (sexto ciclo).\n",
      "  \u2192 Adenocarcinoma de mama (CANCER_CONCEPT) [0-22]\n",
      "  \u2192 estadio IV (STAGE) [23-33]\n",
      "  \u2192 XELODA (DRUG) [53-59]\n",
      "  \u2192 sexto ciclo (LINE_CICLE_NUMBER) [61-72]\n",
      "\n",
      "Texto: Acude el 19-10-2015 a urgencias por Derrame pleural izquierdo paraneopl\u00e1sico que condiciona disnea pero no desaturaci\u00f3n.\n",
      "  \u2192 19-10-2015 (DATE) [9-19]\n",
      "  \u2192 urgencias (CLINICAL_SERVICE) [22-31]\n",
      "\n",
      "Texto: Hipertensi\u00f3n arterial, diabetes mellitus tipo II, no dislipemia.\n",
      "  \u2192 Hipertensi\u00f3n arterial (COMORBIDITY) [0-21]\n",
      "  \u2192 diabetes mellitus tipo II (COMORBIDITY) [23-48]\n",
      "  \u2192 no dislipemia (COMORBIDITY) [50-63]\n",
      "\n",
      "Texto: H\u00e1bitos t\u00f3xicos: no fumadora, no bebedora habitual.\n",
      "  \u2192 fumadora (TOXIC_HABITS) [20-28]\n",
      "  \u2192 bebedora habitual (TOXIC_HABITS) [33-50]\n",
      "\n",
      "Texto: Carcinoma de recto de 4 cm en 2001 tratada con cirug\u00eda amputaci\u00f3n abdominal.\n",
      "  \u2192 Carcinoma de recto (CANCER_CONCEPT) [0-18]\n",
      "  \u2192 2001 (DATE) [30-34]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [35-42]\n",
      "  \u2192 cirug\u00eda amputaci\u00f3n abdominal (SURGERY) [47-75]\n",
      "\n",
      "Texto: Antecedentes familiares oncol\u00f3gicos: Hermana c\u00e1ncer de \u00fatero (no sabe precisar) con 62 a\u00f1os.\n",
      "  \u2192 Hermana (FAMILY) [37-44]\n",
      "  \u2192 c\u00e1ncer de \u00fatero (CANCER_CONCEPT) [45-60]\n",
      "  \u2192 62 a\u00f1os (AGE) [84-91]\n",
      "\n",
      "Texto: Abuelo materno, cancer de nariz (epitelioma/basalioma ??), fallecido de otra cosa.\n",
      "  \u2192 Abuelo materno (FAMILY) [0-14]\n",
      "  \u2192 cancer de nariz (CANCER_CONCEPT) [16-31]\n",
      "  \u2192 epitelioma (CANCER_CONCEPT) [33-43]\n",
      "  \u2192 basalioma (CANCER_CONCEPT) [44-53]\n",
      "  \u2192 fallecido (OCURRENCE_EVENT) [59-68]\n",
      "\n",
      "Texto: T\u00edo materno, c\u00e1ncer de est\u00f3mago, con 43 a\u00f1os.\n",
      "  \u2192 T\u00edo materno (FAMILY) [0-11]\n",
      "  \u2192 c\u00e1ncer de est\u00f3mago (CANCER_CONCEPT) [13-31]\n",
      "  \u2192 43 a\u00f1os (AGE) [37-44]\n",
      "\n",
      "Texto: T\u00edo materno, c\u00e1ncer de pr\u00f3stata.\n",
      "  \u2192 T\u00edo materno (FAMILY) [0-11]\n",
      "  \u2192 c\u00e1ncer de pr\u00f3stata (CANCER_CONCEPT) [13-31]\n",
      "\n",
      "Texto: No antecedentes de c\u00e1ncer de mama.\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [19-33]\n",
      "\n",
      "Texto: Mujer de 45 a\u00f1os ingresada en oncolog\u00eda m\u00e9dica por: -Carcinoma ductal infiltrante 2012 IV (mts pulmoneres).\n",
      "  \u2192 45 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [17-26]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [30-46]\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [53-81]\n",
      "  \u2192 2012 (DATE) [82-86]\n",
      "  \u2192 IV (STAGE) [87-89]\n",
      "\n",
      "Texto: HER 2 negativo.\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [0-14]\n",
      "\n",
      "Texto: ** QT adyuvante AC (x 4 ciclos) 18/05-20/07/12)\n",
      "  \u2192 QT adyuvante (TREATMENT_NAME) [3-15]\n",
      "  \u2192 AC (DRUG) [16-18]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [20-30]\n",
      "  \u2192 18/05-20/07/12) (DATE) [32-47]\n",
      "\n",
      "Texto: ** Mastectom\u00eda con LA y reconstrucci\u00f3n 20/08/12\n",
      "  \u2192 Mastectom\u00eda con LA (SURGERY) [3-21]\n",
      "  \u2192 reconstrucci\u00f3n (SURGERY) [24-38]\n",
      "  \u2192 20/08/12 (DATE) [39-47]\n",
      "\n",
      "Texto: QT adyuvante Taxotere 19/09-20/11/12.\n",
      "  \u2192 QT adyuvante (TREATMENT_NAME) [0-12]\n",
      "  \u2192 Taxotere (DRUG) [13-21]\n",
      "  \u2192 19/09-20/11/12 (DATE) [22-36]\n",
      "\n",
      "Texto: Seguimiento con TAC de n\u00f3dulos pulmonares lento crecimiento -LOE cerebelosa izquierda con edema y LOE parietal derecha.\n",
      "\n",
      "Texto: -N\u00e1useas secundarias a lo previo, resueltasEvoluci\u00f3n: Buen estado general, asintom\u00e1tica.\n",
      "\n",
      "Texto: Diagn\u00f3stico: Mujer de 45 a\u00f1os ingresada en oncolog\u00eda m\u00e9dica por: Carcinoma ductal infiltrante IV (mts pulmoneres).\n",
      "  \u2192 Diagn\u00f3stico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 45 a\u00f1os (AGE) [22-29]\n",
      "  \u2192 ingresada (OCURRENCE_EVENT) [30-39]\n",
      "  \u2192 oncolog\u00eda m\u00e9dica (CLINICAL_SERVICE) [43-59]\n",
      "  \u2192 Carcinoma ductal infiltrante IV (CANCER_CONCEPT) [65-96]\n",
      "\n",
      "Texto: ** QT adyuvante AC (x 4 ciclos) 18/05-20/07/12) ** Mastectom\u00eda con LA y reconstrucci\u00f3n 20/08/12 ** QT adyuvante Taxotere 19/09-20/11/12.\n",
      "  \u2192 QT adyuvante (TREATMENT_NAME) [3-15]\n",
      "  \u2192 AC (DRUG) [16-18]\n",
      "  \u2192 x 4 ciclos (LINE_CICLE_NUMBER) [20-30]\n",
      "  \u2192 18/05-20/07/12) (DATE) [32-47]\n",
      "  \u2192 Mastectom\u00eda con LA (SURGERY) [51-69]\n",
      "  \u2192 reconstrucci\u00f3n (SURGERY) [72-86]\n",
      "  \u2192 20/08/12 (DATE) [87-95]\n",
      "  \u2192 QT adyuvante (TREATMENT_NAME) [99-111]\n",
      "  \u2192 Taxotere (DRUG) [112-120]\n",
      "  \u2192 19/09-20/11/12 (DATE) [121-135]\n",
      "\n",
      "Texto: Plan: Neurocirug\u00eda programar\u00e1 resecci\u00f3n de lesi\u00f3n cerebelosa la semana que viene.\n",
      "  \u2192 Neurocirug\u00eda (CLINICAL_SERVICE) [6-18]\n",
      "  \u2192 resecci\u00f3n de lesi\u00f3n cerebelosa (SURGERY) [30-60]\n",
      "\n",
      "Texto: Pendiente de ECO transtor\u00e1cico. Por nuestra parte, haremos seguimiento diario.\n",
      "\n",
      "Texto: CONSEJO GENETICO: No mutaciones en BRCA 1 y 2.\n",
      "  \u2192 No (BIOMARKER) [18-20]\n",
      "  \u2192 mutaciones en BRCA 1 y 2. (BIOMARKER) [21-46]\n",
      "\n",
      "Texto: Mujer de 36 a\u00f1os que acude para valoraci\u00f3n de riesgo de c\u00e1ncer de mama familiar.\n",
      "  \u2192 36 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 c\u00e1ncer de mama (CANCER_CONCEPT) [56-70]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES Primer periodo menstrual: 13 a\u00f1os.\n",
      "  \u2192 Primer periodo menstrual: (GINECOLOGICAL_HISTORY) [24-49]\n",
      "  \u2192 13 a\u00f1os (AGE) [50-57]\n",
      "\n",
      "Texto: \u00daltimo periodo menstrual octubre 2013.\n",
      "  \u2192 \u00daltimo periodo menstrual (GINECOLOGICAL_HISTORY) [0-24]\n",
      "  \u2192 octubre 2013. (DATE) [25-38]\n",
      "\n",
      "Texto: No anticoncepci\u00f3n hormonal.\n",
      "  \u2192 No (GINECOLOGICAL_HISTORY) [0-2]\n",
      "  \u2192 anticoncepci\u00f3n hormonal (GINECOLOGICAL_HISTORY) [3-26]\n",
      "\n",
      "Texto: A los 35 a\u00f1os: Carcinoma ductal infiltrante de mama derecha, multifocal, grado 3 de Nottingham; Ki67: 40%.\n",
      "  \u2192 35 a\u00f1os (AGE) [6-13]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [15-59]\n",
      "  \u2192 grado 3 de Nottingham (STAGE) [73-94]\n",
      "  \u2192 Ki67: 40% (BIOMARKER) [96-105]\n",
      "\n",
      "Texto: Estadio IIA.\n",
      "  \u2192 Estadio IIA (STAGE) [0-11]\n",
      "\n",
      "Texto: Receptores hormonales positivos, Her 2 negativo.\n",
      "  \u2192 Receptores hormonales positivos (BIOMARKER) [0-31]\n",
      "  \u2192 Her 2 negativo (BIOMARKER) [33-47]\n",
      "\n",
      "Texto: Premenop\u00e1usica.\n",
      "  \u2192 Premenop\u00e1usica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "\n",
      "Texto: ANTECEDENTES FAMILIARES: Abuela paterna diagnosticada de c\u00e1ncer g\u00e1strico con 86 a\u00f1os.\n",
      "  \u2192 Abuela paterna (FAMILY) [25-39]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [40-53]\n",
      "  \u2192 c\u00e1ncer g\u00e1strico (CANCER_CONCEPT) [57-72]\n",
      "  \u2192 86 a\u00f1os (AGE) [77-84]\n",
      "\n",
      "Texto: T\u00edo paterno diagnosticado de c\u00e1ncer urotelial con 67 a\u00f1os.\n",
      "  \u2192 T\u00edo paterno (FAMILY) [0-11]\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [12-25]\n",
      "  \u2192 c\u00e1ncer urotelial (CANCER_CONCEPT) [29-45]\n",
      "  \u2192 67 a\u00f1os (AGE) [50-57]\n",
      "\n",
      "Texto: Se ha realizado estudio gen\u00e9tico BRCA 1 y 2, no detectando ninguna mutaci\u00f3n (ver informe del laboratorio).\n",
      "  \u2192 BRCA 1 y 2 (BIOMARKER) [33-43]\n",
      "  \u2192 no detectando ninguna mutaci\u00f3n (BIOMARKER) [45-75]\n",
      "\n",
      "Texto: A la vista de este resultado y despu\u00e9s de volver comentar las posibilidades de reducci\u00f3n del riesgo apropiadas al caso se recomiendan las siguientes alternativas a los miembros de la familia, como paciente de alto riesgo.\n",
      "\n",
      "Texto: - Para las mujeres (a consensuar con su ginec\u00f3logo): o Autoexamen mamario mensual o Exploraci\u00f3n f\u00edsica ginecol\u00f3gica semestral a partir de los 25 a\u00f1os.\n",
      "  \u2192 mensual (FREQ) [74-81]\n",
      "  \u2192 semestral (FREQ) [116-125]\n",
      "  \u2192 25 a\u00f1os (AGE) [142-149]\n",
      "\n",
      "Texto: Ecograf\u00eda transvaginal ginecol\u00f3gica y determinaci\u00f3n del marcador tumoral Ca 125 de forma semestral tras los 35 a\u00f1os de edad, de acuerdo con su ginec\u00f3logo, o Mamograf\u00eda / Resonancia magn\u00e9tica mamaria de forma anual a partir de los 25 a\u00f1os.\n",
      "  \u2192 marcador tumoral Ca 125 (BIOMARKER) [56-79]\n",
      "  \u2192 semestral (FREQ) [89-98]\n",
      "  \u2192 35 a\u00f1os (AGE) [108-115]\n",
      "  \u2192 25 a\u00f1os (AGE) [230-237]\n",
      "\n",
      "Texto: La paciente seguir\u00e1 las recomendaciones de seguimiento indicadas por su onc\u00f3logo y/o ginec\u00f3logo.\n",
      "\n",
      "Texto: Paciente estable, sin incidencias de inter\u00e9s, se encuentra bien en todo momento y ella quiere irse a casa.\n",
      "\n",
      "Texto: Cumple los criterios de alta, se va a su domicilio.\n",
      "\n",
      "Texto: Tiene el informe m\u00e9dico, doy recomendaciones postquir\u00fargicas y la medicaci\u00f3n pautada.\n",
      "\n",
      "Texto: Diagn\u00f3stico: TUMOR MALIGNO DE LA MAMA PARTE NO ESPECIFICADA.\n",
      "  \u2192 Diagn\u00f3stico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 TUMOR MALIGNO DE LA MAMA PARTE NO ESPECIFICADA (CANCER_CONCEPT) [13-59]\n",
      "\n",
      "Texto: Subjetivo: Paciente femenina de 74 a\u00f1os, hemodinamicamente estable.\n",
      "  \u2192 74 a\u00f1os (AGE) [32-39]\n",
      "\n",
      "Texto: Paciente de 74 a\u00f1os con Ca ductal infiltrante de mama izquierda T1N0Mx, postmenopa\u00fasica, RE y RP negativos, HER2 positivo.\n",
      "  \u2192 74 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 Ca ductal infiltrante de mama izquierda (CANCER_CONCEPT) [24-63]\n",
      "  \u2192 T1N0Mx (TNM) [64-70]\n",
      "  \u2192 postmenopa\u00fasica (GINECOLOGICAL_HISTORY) [72-87]\n",
      "  \u2192 RE y RP negativos (BIOMARKER) [89-106]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [108-121]\n",
      "\n",
      "Texto: Paciente tratada con Doxorrubicina y Ciclofosfamida x 4, Radioterapia y Trastuzumab posterior.\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 Doxorrubicina (DRUG) [21-34]\n",
      "  \u2192 Ciclofosfamida (DRUG) [37-51]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [52-55]\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [57-69]\n",
      "  \u2192 Trastuzumab (DRUG) [72-83]\n",
      "\n",
      "Texto: Ha recibido tto con QT ( Carbo - paclitaxel ) por 4 ( 1\u00aa linea con carboplatino ) .\n",
      "  \u2192 QT (TREATMENT_NAME) [20-22]\n",
      "  \u2192 Carbo (DRUG) [25-30]\n",
      "  \u2192 paclitaxel (DRUG) [33-43]\n",
      "  \u2192 por 4 (LINE_CICLE_NUMBER) [46-51]\n",
      "  \u2192 1a linea (LINE_CICLE_NUMBER) [54-62]\n",
      "  \u2192 carboplatino (DRUG) [67-79]\n",
      "\n",
      "Texto: Paciente tratado con CICLO 1 d\u00eda + 1: CARBOPLATINO AUC 4 d\u00eda 1 y Gemcitabina 1000 mg/m2 d\u00edas 1 y 8, ciclos cada 21 d\u00edas.\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [9-16]\n",
      "  \u2192 CICLO 1 (LINE_CICLE_NUMBER) [21-28]\n",
      "  \u2192 CARBOPLATINO (DRUG) [38-50]\n",
      "  \u2192 AUC (DOSE) [51-54]\n",
      "  \u2192 Gemcitabina (DRUG) [65-76]\n",
      "  \u2192 1000 mg/m2 (DOSE) [77-87]\n",
      "  \u2192 ciclos (LINE_CICLE_NUMBER) [100-106]\n",
      "  \u2192 cada 21 d\u00edas (FREQ) [107-119]\n",
      "\n",
      "Texto: - Carcinoma ductal infiltrante, G2, RE 95 %; RP 75 %; HER2 positivo.\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [2-30]\n",
      "  \u2192 G2 (STAGE) [32-34]\n",
      "  \u2192 RE 95 % (BIOMARKER) [36-43]\n",
      "  \u2192 RP 75 % (BIOMARKER) [45-52]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [54-67]\n",
      "\n",
      "Texto: Tratamiento quimioter\u00e1pico adyuvante con Adriamicina y Ciclofosfamida, 4 ciclos entre Junio y Agosto de 2008.\n",
      "  \u2192 Tratamiento quimioter\u00e1pico adyuvante (TREATMENT_NAME) [0-36]\n",
      "  \u2192 Adriamicina (DRUG) [41-52]\n",
      "  \u2192 Ciclofosfamida (DRUG) [55-69]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [71-79]\n",
      "  \u2192 Junio (DATE) [86-91]\n",
      "  \u2192 Agosto de 2008. (DATE) [94-109]\n",
      "\n",
      "Texto: Tratamiento hormonal adyuvante con tamoxifeno durante 5 a\u00f1os.\n",
      "  \u2192 Tratamiento hormonal adyuvante (TREATMENT_NAME) [0-30]\n",
      "  \u2192 tamoxifeno (DRUG) [35-45]\n",
      "  \u2192 durante 5 a\u00f1os (DURATION) [46-60]\n",
      "\n",
      "Texto: Radioterapia en el Hospital La Paz en Noviembre de 2008.\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [0-12]\n",
      "  \u2192 Noviembre de 2008. (DATE) [38-56]\n",
      "\n",
      "Texto: Pauto tratamiento.\n",
      "\n",
      "Texto: Cita en 1 semana.\n",
      "\n",
      "Texto: Tratamiento:- Dexametasona 4 mg cada 12 horas los dos d\u00edas siguientes al tratamiento con carboplatino-gemcitabina.\n",
      "  \u2192 Dexametasona (DRUG) [14-26]\n",
      "  \u2192 4 mg (DOSE) [27-31]\n",
      "  \u2192 cada 12 horas (FREQ) [32-45]\n",
      "  \u2192 carboplatino-gemcitabina (DRUG) [89-113]\n",
      "\n",
      "Texto: Ondansetron 4 mg cada 12 horas los dos d\u00edas siguientes al tratamiento con carboplatino-gemcitabina.\n",
      "  \u2192 Ondansetron (DRUG) [0-11]\n",
      "  \u2192 4 mg (DOSE) [12-16]\n",
      "  \u2192 cada 12 horas (FREQ) [17-30]\n",
      "  \u2192 carboplatino-gemcitabina (DRUG) [74-98]\n",
      "\n",
      "Texto: Posteriormente si persisten n\u00e1useas o v\u00f3mitos:- Metoclopramida 10 mg cada 8 horas.\n",
      "  \u2192 Metoclopramida (DRUG) [48-62]\n",
      "  \u2192 10 mg (DOSE) [63-68]\n",
      "  \u2192 cada 8 horas (FREQ) [69-81]\n",
      "\n",
      "Texto: Si persisten a pesar de metoclopramida: ondansetron 4 mg cada 8 horas.\n",
      "  \u2192 metoclopramida (DRUG) [24-38]\n",
      "  \u2192 ondansetron (DRUG) [40-51]\n",
      "  \u2192 4 mg (DOSE) [52-56]\n",
      "  \u2192 cada 8 horas (FREQ) [57-69]\n",
      "\n",
      "Texto: Juicio Cl\u00ednico: Mujer de 43 a\u00f1os con adenocarcinoma infiltrante de mama izquierda CCII: cT2 (tumor de 3.2 cm)N0 M0, G3, RE + (< 5% ), RP (-), HER 2: negativo, GC (nov/2013).\n",
      "  \u2192 43 a\u00f1os (AGE) [25-32]\n",
      "  \u2192 adenocarcinoma infiltrante de mama izquierda (CANCER_CONCEPT) [37-81]\n",
      "  \u2192 cT2 (TNM) [88-91]\n",
      "  \u2192 N0 M0 (TNM) [109-114]\n",
      "  \u2192 G3 (STAGE) [116-118]\n",
      "  \u2192 RE + (BIOMARKER) [120-124]\n",
      "  \u2192 RP (- (BIOMARKER) [134-139]\n",
      "  \u2192 HER 2: negativo (BIOMARKER) [142-157]\n",
      "  \u2192 nov/2013 (DATE) [163-171]\n",
      "\n",
      "Texto: Con 2 ganglios sin met\u00e1stasis pero si con IL (Se observa un vaso linf\u00e1tico aferente a uno de los ganglios con un peque\u00f1o \u00e9mbolo tumoral de unas 10 c\u00e9lulas) tratado con QT neoadyuvante (finalizada el 30-04-2014) + tumorectom\u00eda (03-06-2014).\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [19-29]\n",
      "  \u2192 tumor (CANCER_CONCEPT) [128-133]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [156-163]\n",
      "  \u2192 QT neoadyuvante (TREATMENT_NAME) [168-183]\n",
      "  \u2192 finalizada (OCURRENCE_EVENT) [185-195]\n",
      "  \u2192 30-04-2014 (DATE) [199-209]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [213-225]\n",
      "  \u2192 03-06-2014 (DATE) [227-237]\n",
      "\n",
      "Texto: Eco TV: normal.\n",
      "\n",
      "Texto: No medicaci\u00f3n.EF: CyC: no adenopat\u00edas.\n",
      "  \u2192 no adenopat\u00edas (COMORBIDITY) [23-37]\n",
      "\n",
      "Texto: T\u00f3rax: Mama derecha sin hallazgos.\n",
      "\n",
      "Texto: Mama izquierda sigue hiperpigmentaci\u00f3n zona del lecho (\u00e1rea que le duele) sin otros hallazgos. Mamograf\u00eda bilateral en 2016-05-05.\n",
      "  \u2192 2016-05-05 (DATE) [119-129]\n",
      "\n",
      "Texto: REVISI\u00d3N:45 a\u00f1os pre-menopausica con ca ductal de mama derecha cT2N0 ypT1cN0, HER2 negativo y ki67 6 %.\n",
      "  \u2192 :45 a\u00f1os (AGE) [8-16]\n",
      "  \u2192 pre-menopausica (GINECOLOGICAL_HISTORY) [17-32]\n",
      "  \u2192 ca ductal de mama derecha (CANCER_CONCEPT) [37-62]\n",
      "  \u2192 cT2N0 ypT1cN0 (TNM) [63-76]\n",
      "  \u2192 HER2 negativo (BIOMARKER) [78-91]\n",
      "  \u2192 ki67 6 %. (BIOMARKER) [94-103]\n",
      "\n",
      "Texto: Tratado con QT neoadyuvante ( AC x 4 + Taxotere x 4) + mastectom\u00eda radical con reconstrucci\u00f3n con pr\u00f3tesis + linfadenectom\u00eda en Octubre 2010.\n",
      "  \u2192 Tratado (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 QT neoadyuvante (TREATMENT_NAME) [12-27]\n",
      "  \u2192 AC (DRUG) [30-32]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [33-36]\n",
      "  \u2192 Taxotere (DRUG) [39-47]\n",
      "  \u2192 x 4) (LINE_CICLE_NUMBER) [48-52]\n",
      "  \u2192 mastectom\u00eda radical con reconstrucci\u00f3n con pr\u00f3tesis (SURGERY) [55-106]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [109-124]\n",
      "  \u2192 Octubre 2010. (DATE) [128-141]\n",
      "\n",
      "Texto: Mujer con carcinoma ductual de mama derecha.\n",
      "  \u2192 carcinoma ductual de mama derecha (CANCER_CONCEPT) [10-43]\n",
      "\n",
      "Texto: En seguimiento tras finalizar tratamiento, no se consider\u00f3 candidata a RT porque no exist\u00edan datos de extensi\u00f3n tumoral > 5 cm antes de QT neoadyuvante ni afectaci\u00f3n ganglionar inicial.\n",
      "  \u2192 tras finalizar tratamiento (OCURRENCE_EVENT) [15-41]\n",
      "  \u2192 RT (TREATMENT_NAME) [71-73]\n",
      "  \u2192 tumoral (CANCER_CONCEPT) [112-119]\n",
      "  \u2192 QT neoadyuvante (TREATMENT_NAME) [136-151]\n",
      "  \u2192 afectaci\u00f3n ganglionar inicial (PROGRESION) [155-184]\n",
      "\n",
      "Texto: Se encuentra bien.\n",
      "\n",
      "Texto: Le han colocado TENS en la Unidad del Dolor.\n",
      "\n",
      "Texto: En Hospital Santa Cristina, se ha realizado recambio de pr\u00f3tesis derecha y cirug\u00eda est\u00e9tica de mama izquierda hace 1 mes, por desplazamiento de pr\u00f3stesis.\n",
      "  \u2192 recambio de pr\u00f3tesis derecha (SURGERY) [44-72]\n",
      "  \u2192 cirug\u00eda est\u00e9tica de mama izquierda (SURGERY) [75-109]\n",
      "  \u2192 hace 1 mes (IMPLICIT_DATE) [110-120]\n",
      "\n",
      "Texto: Sin complicaciones. Sigue en tratamiento con Tamoxifeno.\n",
      "  \u2192 Tamoxifeno (DRUG) [45-55]\n",
      "\n",
      "Texto: Revisi\u00f3n ginecol\u00f3gica: OK.\n",
      "\n",
      "Texto: EXPLORACI\u00d3N F\u00cdSICA:C y c: Car\u00f3tidas rr y ss.\n",
      "\n",
      "Texto: No ausculto soplos.\n",
      "  \u2192 No ausculto soplos (COMORBIDITY) [0-18]\n",
      "\n",
      "Texto: PVY a 45\u00ba no elevada. No palpo bocio ni adenopat\u00edas laterocervicales ni supraclaviculares. T\u00d3RAX: AC: R\u00edtmica a 70 lpm. No ausculto soplos.\n",
      "  \u2192 ni adenopat\u00edas laterocervicales ni supraclaviculares (COMORBIDITY) [37-89]\n",
      "  \u2192 No ausculto soplos (COMORBIDITY) [120-138]\n",
      "\n",
      "Texto: AP: MVCABDOMEN: Blando, no doloroso a la palpaci\u00f3n superficial ni profunda. No masas ni megalias. No signos de irritaci\u00f3n peritoneal. RHA+.\n",
      "  \u2192 RHA+ (BIOMARKER) [134-138]\n",
      "\n",
      "Texto: MAMAS:Mama derecha: pr\u00f3tesis con cicatriz en buen estado. No nodularidad. Turgente.Mama izquierda: cicatriz inferior de mamoplastia. No nodularidad.\n",
      "  \u2192 Ma (FAMILY) [83-85]\n",
      "  \u2192 mamoplastia (SURGERY) [120-131]\n",
      "\n",
      "Texto: Areola-pez\u00f3n sin hallazgos.\n",
      "\n",
      "Texto: No se palpan adenopat\u00edas axilares.\n",
      "  \u2192 No se palpan adenopat\u00edas axilares (COMORBIDITY) [0-33]\n",
      "\n",
      "Texto: PPCC:Aporta anal\u00edtica realizada el d\u00eda 29/02/2012:Hemograma: Hb: 13.5. Fe: 75.3. Ferritina: 28.7. Bioqu\u00edmica: sin alteraciones.\n",
      "  \u2192 29/02/2012 (DATE) [39-49]\n",
      "\n",
      "Texto: PLAN:No ha tenido cita todav\u00eda en H. La Princesa con su Onc\u00f3logo, pediente por lo tanto, de mamograf\u00edas.\n",
      "  \u2192 Onc\u00f3logo (CLINICAL_SERVICE) [56-64]\n",
      "\n",
      "Texto: Acudir\u00e1 cuando las tenga para revisar im\u00e1genes.\n",
      "\n",
      "Texto: Se citar\u00e1 de nuevo para aportar im\u00e1genes.\n",
      "\n",
      "Texto: Mujer de 36 a\u00f1os con dx de carcinoma de mama que acude a consulta para valoraci\u00f3n de tratamiento neoadyuvante.\n",
      "  \u2192 36 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 dx (OCURRENCE_EVENT) [21-23]\n",
      "  \u2192 carcinoma de mama (CANCER_CONCEPT) [27-44]\n",
      "  \u2192 tratamiento neoadyuvante (TREATMENT_NAME) [85-109]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES: No RAMC.\n",
      "  \u2192 No RAMC (ALLERGIES) [25-32]\n",
      "\n",
      "Texto: No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 no DM (COMORBIDITY) [8-13]\n",
      "  \u2192 no DL (COMORBIDITY) [15-20]\n",
      "\n",
      "Texto: Alergia al epitelio de los gatos.\n",
      "  \u2192 Alergia al epitelio de los gatos (ALLERGIES) [0-32]\n",
      "\n",
      "Texto: Menarquia a los 13 a\u00f1os.\n",
      "  \u2192 Menarquia (GINECOLOGICAL_HISTORY) [0-9]\n",
      "  \u2192 13 a\u00f1os (AGE) [16-23]\n",
      "\n",
      "Texto: Embarazo 2012.\n",
      "  \u2192 Embarazo (GINE_OBSTETRICS) [0-8]\n",
      "  \u2192 2012. (GINE_OBSTETRICS) [9-14]\n",
      "\n",
      "Texto: Lactancia materna durante 9 meses.\n",
      "  \u2192 Lactancia materna (GINE_OBSTETRICS) [0-17]\n",
      "  \u2192 durante 9 meses (DURATION) [18-33]\n",
      "\n",
      "Texto: Asma con el ejercicio. Profesora de profesi\u00f3n.\n",
      "\n",
      "Texto: Medicaci\u00f3n actual Broncodilatadores si precisa.\n",
      "\n",
      "Texto: T\u00eda paterna Ca de mama a los 42 a\u00f1os .\n",
      "  \u2192 T\u00eda paterna (FAMILY) [0-11]\n",
      "  \u2192 Ca de mama (CANCER_CONCEPT) [12-22]\n",
      "  \u2192 42 a\u00f1os (AGE) [29-36]\n",
      "\n",
      "Texto: Abuelo paterno ca de pulm\u00f3n.\n",
      "  \u2192 Abuelo paterno (FAMILY) [0-14]\n",
      "  \u2192 ca de pulm\u00f3n (CANCER_CONCEPT) [15-27]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama estadio IV en progresi\u00f3n.* 03/2010: Mastectom\u00eda + reconstrucci\u00f3n (pT2N0M0).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama (CANCER_CONCEPT) [0-36]\n",
      "  \u2192 estadio IV (STAGE) [37-47]\n",
      "  \u2192 progresi\u00f3n (PROGRESION) [51-61]\n",
      "  \u2192 03/2010 (DATE) [64-71]\n",
      "  \u2192 Mastectom\u00eda (SURGERY) [73-84]\n",
      "  \u2192 reconstrucci\u00f3n (SURGERY) [87-101]\n",
      "  \u2192 pT2N0M0) (TNM) [103-111]\n",
      "\n",
      "Texto: * AC 4c y posteriormente TMX.\n",
      "  \u2192 AC (DRUG) [2-4]\n",
      "  \u2192 4c (LINE_CICLE_NUMBER) [5-7]\n",
      "  \u2192 TMX (DRUG) [25-28]\n",
      "\n",
      "Texto: * 12/2014: Reca\u00edda \u00f3sea y pulmonar (No confirmaci\u00f3n histol\u00f3gica).\n",
      "  \u2192 12/2014 (DATE) [2-9]\n",
      "  \u2192 Reca\u00edda \u00f3sea y pulmonar (PROGRESION) [11-34]\n",
      "\n",
      "Texto: * 01/2015: Inicia Zoladex + Aromasil + Zometa.\n",
      "  \u2192 01/2015 (DATE) [2-9]\n",
      "  \u2192 Inicia (OCURRENCE_EVENT) [11-17]\n",
      "  \u2192 Zoladex (DRUG) [18-25]\n",
      "  \u2192 Aromasil (DRUG) [28-36]\n",
      "  \u2192 Zometa (DRUG) [39-45]\n",
      "\n",
      "Texto: * 03/2015: Derrame pleural derecho, talcaje 21/marzo.\n",
      "  \u2192 03/2015 (DATE) [2-9]\n",
      "  \u2192 21/marzo (DATE) [44-52]\n",
      "\n",
      "Texto: Progresi\u00f3n hep\u00e1tica, BX positiva.\n",
      "  \u2192 Progresi\u00f3n hep\u00e1tica (PROGRESION) [0-19]\n",
      "  \u2192 BX positiva (BIOMARKER) [21-32]\n",
      "\n",
      "Texto: Inicio QT paliativa con paclitaxel semanal 16/04/15.\n",
      "  \u2192 Inicio (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 QT paliativa (TREATMENT_NAME) [7-19]\n",
      "  \u2192 paclitaxel (DRUG) [24-34]\n",
      "  \u2192 semanal (FREQ) [35-42]\n",
      "  \u2192 16/04/15 (DATE) [43-51]\n",
      "\n",
      "Texto: Inicio QT paliativa con paclitaxel semanal 16/04/15.\n",
      "  \u2192 Inicio (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 QT paliativa (TREATMENT_NAME) [7-19]\n",
      "  \u2192 paclitaxel (DRUG) [24-34]\n",
      "  \u2192 semanal (FREQ) [35-42]\n",
      "  \u2192 16/04/15 (DATE) [43-51]\n",
      "\n",
      "Texto: Inicio QT paliativa con paclitaxel semanal 16/04/15.\n",
      "  \u2192 Inicio (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 QT paliativa (TREATMENT_NAME) [7-19]\n",
      "  \u2192 paclitaxel (DRUG) [24-34]\n",
      "  \u2192 semanal (FREQ) [35-42]\n",
      "  \u2192 16/04/15 (DATE) [43-51]\n",
      "\n",
      "Texto: -Disnea secundaria a aumento derrame pleural sobre todoizquierdo ya conocido.\n",
      "\n",
      "Texto: JUICIO CLINICO: Carcinoma ductal infiltrante multicentrico en mama derecha T1cN1a y carcinoma ductal in situ con micrometastasis en BSCG en mama izquierda.\n",
      "  \u2192 Carcinoma ductal infiltrante multicentrico en mama derecha (CANCER_CONCEPT) [16-74]\n",
      "  \u2192 T1cN1a (TNM) [75-81]\n",
      "  \u2192 carcinoma ductal in situ (CANCER_CONCEPT) [84-108]\n",
      "  \u2192 micrometastasis (CANCER_CONCEPT) [113-128]\n",
      "\n",
      "Texto: Receptores de Estr\u00f3genos : positivos en un 99%, receptores de Progesterona : positivos en un 9 %, \u00edndice HER2- Negativo.\n",
      "  \u2192 Receptores de Estr\u00f3genos : positivos en un 99% (BIOMARKER) [0-46]\n",
      "  \u2192 receptores de Progesterona : positivos en un 9 % (BIOMARKER) [48-96]\n",
      "  \u2192 HER2- Negativo (BIOMARKER) [105-119]\n",
      "\n",
      "Texto: Mastectomia bilateral en Octubre del 2011.\n",
      "  \u2192 Mastectomia bilateral (SURGERY) [0-21]\n",
      "  \u2192 Octubre del 2011. (DATE) [25-42]\n",
      "\n",
      "Texto: Tratamiento con AC Docetaxel que finaliza en Abril el 2012.\n",
      "  \u2192 AC (DRUG) [16-18]\n",
      "  \u2192 Docetaxel (DRUG) [19-28]\n",
      "  \u2192 finaliza (OCURRENCE_EVENT) [33-41]\n",
      "  \u2192 Abril el 2012. (DATE) [45-59]\n",
      "\n",
      "Texto: No toma medicacion hormonal.\n",
      "\n",
      "Texto: AF: Padre ca colon, Tia paterna linfoma.\n",
      "  \u2192 Padre (FAMILY) [4-9]\n",
      "  \u2192 ca colon (CANCER_CONCEPT) [10-18]\n",
      "  \u2192 Tia paterna (FAMILY) [20-31]\n",
      "  \u2192 linfoma (CANCER_CONCEPT) [32-39]\n",
      "\n",
      "Texto: AP: M: Litiasis renal, Ca mama derecho .\n",
      "  \u2192 Litiasis renal (COMORBIDITY) [7-21]\n",
      "  \u2192 Ca mama derecho (CANCER_CONCEPT) [23-38]\n",
      "\n",
      "Texto: En marzo se 2012: mastectomia y BSGC con micromet\u00e1stasis.\n",
      "  \u2192 marzo se 2012 (DATE) [3-16]\n",
      "  \u2192 mastectomia (SURGERY) [18-29]\n",
      "  \u2192 micromet\u00e1stasis (CANCER_CONCEPT) [41-56]\n",
      "\n",
      "Texto: Reconstrucci\u00f3n inmediata.\n",
      "  \u2192 Reconstrucci\u00f3n inmediata (SURGERY) [0-24]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha pT2N0Mx tratado mediante tumorectom\u00eda y posterior mastectom\u00eda con BSGC, RE y RP positivos, her2 negativo en mujer premenopausica.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 pT2N0Mx (TNM) [45-52]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [53-60]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [70-82]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [95-106]\n",
      "  \u2192 RE y RP positivos (BIOMARKER) [117-134]\n",
      "  \u2192 her2 negativo (BIOMARKER) [136-149]\n",
      "  \u2192 premenopausica (GINECOLOGICAL_HISTORY) [159-173]\n",
      "\n",
      "Texto: Diciembre del 2010.\n",
      "  \u2192 Diciembre del 2010. (DATE) [0-19]\n",
      "\n",
      "Texto: Recibio tto con TC por 4 ciclos y tamoxifeno desde 2011.\n",
      "  \u2192 TC (DRUG) [16-18]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [23-31]\n",
      "  \u2192 tamoxifeno (DRUG) [34-44]\n",
      "  \u2192 2011. (DATE) [51-56]\n",
      "\n",
      "Texto: Mujer con CA MAMA.\n",
      "  \u2192 CA MAMA (CANCER_CONCEPT) [10-17]\n",
      "\n",
      "Texto: Se ha practicado Cuadrantectomia Y RT, Ahora en tratamiento con Tamoxifemo.\n",
      "  \u2192 Cuadrantectomia (SURGERY) [17-32]\n",
      "  \u2192 RT (TREATMENT_NAME) [35-37]\n",
      "  \u2192 Tamoxifemo (DRUG) [64-74]\n",
      "\n",
      "Texto: Mujer con cancer de mama derecha.\n",
      "  \u2192 cancer de mama derecha (CANCER_CONCEPT) [10-32]\n",
      "\n",
      "Texto: RX : PIES NO VEO INTERES TOBILLOS PINZAMINETO ASTRAGLO CALCANEO POSTERIOR DERECHO CON OSTEOFITO DE 0,9 CMS PLANTEO INFILTRACION QUE ACEPTAACUDIRA A CONSULTA EL 11 DE MAYO.\n",
      "  \u2192 11 DE MAYO (DATE) [160-170]\n",
      "\n",
      "Texto: Paciente diagnosticada de Carcinoma ductal infiltrante de mama izquierda cT3 cN1 Mx (Al menos estad\u00edo IIIA).\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [9-22]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [26-72]\n",
      "  \u2192 cT3 cN1 Mx (TNM) [73-83]\n",
      "  \u2192 estad\u00edo IIIA (STAGE) [94-106]\n",
      "\n",
      "Texto: HER2 positivo con resp parcial radiologica cT2N0.\n",
      "  \u2192 HER2 positivo (BIOMARKER) [0-13]\n",
      "  \u2192 cT2N0 (TNM) [43-48]\n",
      "\n",
      "Texto: Ha recibido QT Paclitaxel, trastuzumab y pertuzumab.\n",
      "  \u2192 QT (TREATMENT_NAME) [12-14]\n",
      "  \u2192 Paclitaxel (DRUG) [15-25]\n",
      "  \u2192 trastuzumab (DRUG) [27-38]\n",
      "  \u2192 pertuzumab (DRUG) [41-51]\n",
      "\n",
      "Texto: Radioterapia hace dos meses con Dosis de 50 Gy en pared izquierda y cadenas con DIBH.\n",
      "  \u2192 Radioterapia (TREATMENT_NAME) [0-12]\n",
      "  \u2192 hace dos meses (IMPLICIT_DATE) [13-27]\n",
      "  \u2192 50 Gy (DOSE) [41-46]\n",
      "\n",
      "Texto: Tratamiento de quimiotrapia con Carboplatino y Paclitaxel.\n",
      "  \u2192 quimiotrapia (TREATMENT_NAME) [15-27]\n",
      "  \u2192 Carboplatino (DRUG) [32-44]\n",
      "  \u2192 Paclitaxel (DRUG) [47-57]\n",
      "\n",
      "Texto: Diagn\u00f3stico principal: Paciente de 37 a\u00f1os diagnosticada de Carcinoma ductal infiltrante de mama izquierda.\n",
      "  \u2192 37 a\u00f1os (AGE) [35-42]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [43-56]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [60-106]\n",
      "\n",
      "Texto: Diagn\u00f3stico principal: Paciente de 37 a\u00f1os diagnosticada de Carcinoma ductal infiltrante de mama izquierda.\n",
      "  \u2192 37 a\u00f1os (AGE) [35-42]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [43-56]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [60-106]\n",
      "\n",
      "Texto: Pieza de linfadenectom\u00eda axilar en B14-14952 con 15 ganglios linf\u00e1ticos sin met\u00e1stasis, Estadio patol\u00f3gico pTNM pT2.\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [9-31]\n",
      "  \u2192 met\u00e1stasis (CANCER_CONCEPT) [76-86]\n",
      "  \u2192 pTNM pT2. (TNM) [107-116]\n",
      "\n",
      "Texto: Diagn\u00f3stico principal: Paciente de 37 a\u00f1os diagnosticada de Carcinoma ductal infiltrante de mama izquierda.\n",
      "  \u2192 37 a\u00f1os (AGE) [35-42]\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [43-56]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [60-106]\n",
      "\n",
      "Texto: TRATAMIENTO RADIOTER\u00c1PICO:Se decide efectuar la irradiaci\u00f3n de un volumen que incluye la mama izquierda, axila y regi\u00f3n supraclavicular izquierda y posteriormente sobreimpresi\u00f3n del lecho quir\u00fargico.\n",
      "  \u2192 TRATAMIENTO RADIOTER\u00c1PICO (TREATMENT_NAME) [0-25]\n",
      "\n",
      "Texto: La dosis total administrada ha sido de 50 Gy.\n",
      "  \u2192 50 Gy (DOSE) [39-44]\n",
      "\n",
      "Texto: Posteriormente se ha realizado sobreimpresi\u00f3n del lecho quir\u00fargico administrando una dosis de 10 Gy .\n",
      "  \u2192 10 Gy (DOSE) [94-99]\n",
      "\n",
      "Texto: El fraccionamiento utilizado ha sido de 2 Gy al d\u00eda.\n",
      "  \u2192 2 Gy (DOSE) [40-44]\n",
      "  \u2192 d\u00eda (FREQ) [48-51]\n",
      "\n",
      "Texto: Actualmente en tratamiento con Herceptin y Tamoxifeno.\n",
      "  \u2192 Herceptin (DRUG) [31-40]\n",
      "  \u2192 Tamoxifeno (DRUG) [43-53]\n",
      "\n",
      "Texto: \u00daltimo herceptin el 1/09/2019.\n",
      "  \u2192 \u00daltimo (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 herceptin (DRUG) [7-16]\n",
      "  \u2192 1/09/2019 (DATE) [20-29]\n",
      "\n",
      "Texto: El pr\u00f3ximo le corresponde el 23/09.\n",
      "  \u2192 23/09 (DATE) [29-34]\n",
      "\n",
      "Texto: No d\u00e9ficit motor ni sensitivo.\n",
      "\n",
      "Texto: No incontinencia de esf\u00ednteres.\n",
      "  \u2192 No incontinencia de esf\u00ednteres (COMORBIDITY) [0-30]\n",
      "\n",
      "Texto: Tambi\u00e9n presenta dolor en parrilla costal izquierda de car\u00e1cter mec\u00e1nico, no es constante, no ha tomado AINES por estar en estudio de alergia por recci\u00f3n a antibi\u00f3tico pero no quiere tomar mdicaci\u00f3n.\n",
      "  \u2192 alergia por recci\u00f3n a antibi\u00f3tico (ALLERGIES) [134-167]\n",
      "\n",
      "Texto: 1er ciclo Docetaxel 75 mg/m2 - ciclofosfamida 600 mg/m2 Carcinoma mioepitelial infiltrante de mama derecha pT1cN0M0 (estadio IA TNM 8\u00aa ed), G3.\n",
      "  \u2192 1er ciclo (LINE_CICLE_NUMBER) [0-9]\n",
      "  \u2192 Docetaxel (DRUG) [10-19]\n",
      "  \u2192 75 mg/m2 (DOSE) [20-28]\n",
      "  \u2192 ciclofosfamida (DRUG) [31-45]\n",
      "  \u2192 600 mg/m2 (DOSE) [46-55]\n",
      "  \u2192 Carcinoma mioepitelial infiltrante de mama derecha (CANCER_CONCEPT) [56-106]\n",
      "  \u2192 pT1cN0M0 (TNM) [107-115]\n",
      "  \u2192 estadio IA (STAGE) [117-127]\n",
      "  \u2192 G3 (STAGE) [140-142]\n",
      "\n",
      "Texto: Tumorectom\u00eda + BSGC 19/9/2018.\n",
      "  \u2192 Tumorectom\u00eda (SURGERY) [0-12]\n",
      "  \u2192 BSGC (SURGERY) [15-19]\n",
      "  \u2192 19/9/2018 (DATE) [20-29]\n",
      "\n",
      "Texto: Se encuentra bien.\n",
      "\n",
      "Texto: Anal\u00edtica el otro d\u00eda normal.\n",
      "\n",
      "Texto: Plan: VIENE A INICIAR ADYUVANCIA.\n",
      "  \u2192 INICIAR (OCURRENCE_EVENT) [14-21]\n",
      "  \u2192 ADYUVANCIA (TREATMENT_NAME) [22-32]\n",
      "\n",
      "Texto: Se propone tratamiento segun esquema TC x4.\n",
      "  \u2192 TC (DRUG) [37-39]\n",
      "  \u2192 x4 (LINE_CICLE_NUMBER) [40-42]\n",
      "\n",
      "Texto: Se va a revisar caso en sesi\u00f3n de anatom\u00eda patol\u00f3gica del lunes.\n",
      "\n",
      "Texto: Tomar\u00e1 ondansetron 4 mg antes de las comidas principales durante 3 d\u00edas tras la quimioterapia.\n",
      "  \u2192 ondansetron (DRUG) [7-18]\n",
      "  \u2192 4 mg (DOSE) [19-23]\n",
      "  \u2192 antes de las comidas principales (FREQ) [24-56]\n",
      "  \u2192 durante 3 d\u00edas (DURATION) [57-71]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [80-93]\n",
      "\n",
      "Texto: ANAMNESIS Motivo de consulta: Me Mandaron Enfermedad actual: DERMATOLOGIA GENERAL.\n",
      "  \u2192 DERMATOLOGIA GENERAL (CLINICAL_SERVICE) [61-81]\n",
      "\n",
      "Texto: Mujer 72 a\u00f1os, Separada, sin hijos.\n",
      "  \u2192 72 a\u00f1os (AGE) [6-13]\n",
      "  \u2192 sin hijos (GINE_OBSTETRICS) [25-34]\n",
      "\n",
      "Texto: Diagnostico: Carcinoma ductal infiltrante mama derecha 2004.\n",
      "  \u2192 Diagnostico (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 Carcinoma ductal infiltrante mama derecha (CANCER_CONCEPT) [13-54]\n",
      "  \u2192 2004. (DATE) [55-60]\n",
      "\n",
      "Texto: Tratamiento: Cuadrantectomia + QT + RT.\n",
      "  \u2192 Cuadrantectomia (SURGERY) [13-28]\n",
      "  \u2192 QT (TREATMENT_NAME) [31-33]\n",
      "  \u2192 RT (TREATMENT_NAME) [36-38]\n",
      "\n",
      "Texto: Actualmente en remision, Tratamiento con Verapamilo 120 mg cada 12 horas, Losartan 500 mg cada 12 horas Levotiroxina 50 mcg cada 24 horas Sulfato ferroso 300 mg cada 24 horas Calcio + Vitamina D cada 24 horas Acido folico 1 mg cada 24 horas.\n",
      "  \u2192 Verapamilo (DRUG) [41-51]\n",
      "  \u2192 120 mg (DOSE) [52-58]\n",
      "  \u2192 cada 12 horas (FREQ) [59-72]\n",
      "  \u2192 Losartan (DRUG) [74-82]\n",
      "  \u2192 500 mg (DOSE) [83-89]\n",
      "  \u2192 cada 12 horas (FREQ) [90-103]\n",
      "  \u2192 Levotiroxina (DRUG) [104-116]\n",
      "  \u2192 50 mcg (DOSE) [117-123]\n",
      "  \u2192 cada 24 horas (FREQ) [124-137]\n",
      "  \u2192 Sulfato ferroso (DRUG) [138-153]\n",
      "  \u2192 300 mg (DOSE) [154-160]\n",
      "  \u2192 cada 24 horas (FREQ) [161-174]\n",
      "  \u2192 Calcio (DRUG) [175-181]\n",
      "  \u2192 Vitamina D (DRUG) [184-194]\n",
      "  \u2192 cada 24 horas (FREQ) [195-208]\n",
      "  \u2192 Acido folico (DRUG) [209-221]\n",
      "  \u2192 1 mg (DOSE) [222-226]\n",
      "  \u2192 cada 24 horas (FREQ) [227-240]\n",
      "\n",
      "Texto: Indica que la remitio el hematologo para valoracion de lesion en mama derecha REVISI\u00d3N POR SISTEMAS Revisi\u00f3n F\u00edsica: Piel y anexos: Fototipo Iv EXAMEN F\u00cdSICO.\n",
      "  \u2192 hematologo (CLINICAL_SERVICE) [25-35]\n",
      "\n",
      "Texto: Examen F\u00edsico:Piel y anexos Piel y anexos : Fototipo IV .\n",
      "\n",
      "Texto: Multiples placas ocres en torax anterior.\n",
      "\n",
      "Texto: SE valora mamas sin encontrar ganglios, masas, nodulos, quistes, unicamente con cicatriz quirurgica con retraccion secundaria.\n",
      "\n",
      "Texto: Diagn\u00f3sticos activos despu\u00e9s de la nota: C509 - TUMOR MALIGNO DE LA MAMA PARTE NO ESPECIFICADA, Origen: Primario, Fecha de diagn\u00f3stico: 15/07/2019, Edad al diagn\u00f3stico: 72 A\u00f1os, D649.\n",
      "  \u2192 Diagn\u00f3sticos (OCURRENCE_EVENT) [0-12]\n",
      "  \u2192 TUMOR MALIGNO DE LA MAMA PARTE NO ESPECIFICADA (CANCER_CONCEPT) [48-94]\n",
      "  \u2192 Primario (CANCER_CONCEPT) [104-112]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [123-134]\n",
      "  \u2192 15/07/2019 (DATE) [136-146]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [156-167]\n",
      "  \u2192 72 A\u00f1os (AGE) [169-176]\n",
      "\n",
      "Texto: ANEMIA DE TIPO NO ESPECIFICADO (En Estudio), Fecha de diagn\u00f3stico: 15/07/2019, Edad al diagn\u00f3stico: 72 A\u00f1os.\n",
      "  \u2192 ANEMIA DE TIPO NO ESPECIFICADO (COMORBIDITY) [0-30]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [54-65]\n",
      "  \u2192 15/07/2019 (DATE) [67-77]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [87-98]\n",
      "  \u2192 72 A\u00f1os (AGE) [100-107]\n",
      "\n",
      "Texto: Paciente con Anemia hace 3 meses.\n",
      "  \u2192 Anemia (COMORBIDITY) [13-19]\n",
      "  \u2192 hace 3 meses (IMPLICIT_DATE) [20-32]\n",
      "\n",
      "Texto: AN\u00c1LISIS DEL CASO Y PLAN DE MANEJO Cita de control: No Incapacidad: .\n",
      "\n",
      "Texto: An\u00e1lisis del caso: Paciente con antecedente de Ca de Mama derecha en seguimiento por oncologia, en el momento sin lesiones en piel sugestivas de malignidad se da cita abierta por dermatologia en caso de considerar por parte de oncologia lesion que requiera estudio, en el momento no se palpan lesiones sugestivas de malignidad en mama segun lo descrito por Oncologia.\n",
      "  \u2192 Ca de Mama derecha (CANCER_CONCEPT) [47-65]\n",
      "  \u2192 oncologia (CLINICAL_SERVICE) [85-94]\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [145-155]\n",
      "  \u2192 dermatologia (CLINICAL_SERVICE) [179-191]\n",
      "  \u2192 oncologia (CLINICAL_SERVICE) [227-236]\n",
      "  \u2192 malignidad (CANCER_CONCEPT) [316-326]\n",
      "  \u2192 Oncologia (CLINICAL_SERVICE) [357-366]\n",
      "\n",
      "Texto: CICLO 2 PACLITAXEL ( dia 1 y 8 ), Carcinoma de mama estadio IV por afectaci\u00f3n osea y hep\u00e1tica en tartamiento con Paclitaxel.\n",
      "  \u2192 CICLO 2 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 PACLITAXEL (DRUG) [8-18]\n",
      "  \u2192 dia 1 y 8 (FREQ) [21-30]\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [34-51]\n",
      "  \u2192 estadio IV (STAGE) [52-62]\n",
      "  \u2192 Paclitaxel (DRUG) [113-123]\n",
      "\n",
      "Texto: Carcinoma lobulillar de mama T3N2Mo en el 2014 tratado con neoadyuvancia sin respuetsa, AC-P , RT y Tamoxifeno Buena tolerancia.\n",
      "  \u2192 Carcinoma lobulillar de mama (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 T3N2Mo (TNM) [29-35]\n",
      "  \u2192 2014 (DATE) [42-46]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [47-54]\n",
      "  \u2192 neoadyuvancia (TREATMENT_NAME) [59-72]\n",
      "  \u2192 AC-P (DRUG) [88-92]\n",
      "  \u2192 RT (TREATMENT_NAME) [95-97]\n",
      "  \u2192 Tamoxifeno (DRUG) [100-110]\n",
      "\n",
      "Texto: Sin toxicidad.\n",
      "\n",
      "Texto: Amenorrea desde el 2014.\n",
      "  \u2192 Amenorrea desde el 2014. (GINECOLOGICAL_HISTORY) [0-24]\n",
      "\n",
      "Texto: Antecedentes.\n",
      "\n",
      "Texto: AF: Madre ca de mama 53 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [4-9]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [10-20]\n",
      "  \u2192 53 a\u00f1os (AGE) [21-28]\n",
      "\n",
      "Texto: Abuela materna con cancer ginecologico (utero) pero desconoce de cervix o endometrio.\n",
      "  \u2192 Abuela materna (FAMILY) [0-14]\n",
      "  \u2192 cancer ginecologico (CANCER_CONCEPT) [19-38]\n",
      "\n",
      "Texto: Madre tratada en Hospital Puerta de Hierro hace 14 a\u00f1os.\n",
      "  \u2192 Madre (FAMILY) [0-5]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [6-13]\n",
      "  \u2192 hace 14 a\u00f1os (IMPLICIT_DATE) [43-55]\n",
      "\n",
      "Texto: AP: Adenocarcinoma ductal infiltrante de mama izquierda, cuadrante superoexterno, estadio cT2 cN0 MO (IIa).\n",
      "  \u2192 Adenocarcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [4-55]\n",
      "  \u2192 cT2 cN0 MO (TNM) [90-100]\n",
      "  \u2192 IIa (STAGE) [102-105]\n",
      "\n",
      "Texto: Tratamiento inicial con quimioterapia de neoadyyvancia.\n",
      "  \u2192 quimioterapia de neoadyyvancia (TREATMENT_NAME) [24-54]\n",
      "\n",
      "Texto: Hipotiroidismo, en tratamiento con Eutirox 112,5 y S y D 100.\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [0-14]\n",
      "  \u2192 Eutirox (DRUG) [35-42]\n",
      "  \u2192 2,5 (DOSE) [45-48]\n",
      "\n",
      "Texto: No alergias a medicamentos conocidas.\n",
      "  \u2192 No alergias a medicamentos conocidas (ALLERGIES) [0-36]\n",
      "\n",
      "Texto: H\u00e1bitos t\u00f3xicos: Fumadora 1-2 cada dia.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [17-25]\n",
      "  \u2192 1-2 (HABIT-QUANTITY) [26-29]\n",
      "  \u2192 cada dia (FREQ) [30-38]\n",
      "\n",
      "Texto: Cerveza diaria.\n",
      "  \u2192 Cerveza (TOXIC_HABITS) [0-7]\n",
      "  \u2192 diaria (FREQ) [8-14]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda MULTIFOCAL (y)pT3(m)N3a (10/13)M0, operada mediante mastectom\u00eda radical modificada izquierda el d\u00eda 26/03/2013.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda MULTIFOCAL (CANCER_CONCEPT) [0-57]\n",
      "  \u2192 y)pT3(m)N3a (TNM) [59-70]\n",
      "  \u2192 (10/13 (DATE) [71-77]\n",
      "  \u2192 )M0 (TNM) [77-80]\n",
      "  \u2192 operada (OCURRENCE_EVENT) [82-89]\n",
      "  \u2192 mastectom\u00eda radical modificada izquierda (SURGERY) [99-139]\n",
      "  \u2192 26/03/2013 (DATE) [147-157]\n",
      "\n",
      "Texto: RH positivos, HER 2 negativo.\n",
      "  \u2192 RH positivos (BIOMARKER) [0-12]\n",
      "  \u2192 HER 2 negativo (BIOMARKER) [14-28]\n",
      "\n",
      "Texto: Bordes libres uno de ellos (inferoexterno) a menos de 1 mm.\n",
      "\n",
      "Texto: Quimioterapia neoadyuvante AC x 4 y posteriormente tras la cirug\u00eda recibe 4 ciclos de taxotere y RT locoregional.\n",
      "  \u2192 Quimioterapia neoadyuvante (TREATMENT_NAME) [0-26]\n",
      "  \u2192 AC (DRUG) [27-29]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [30-33]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [74-82]\n",
      "  \u2192 taxotere (DRUG) [86-94]\n",
      "  \u2192 RT (TREATMENT_NAME) [97-99]\n",
      "\n",
      "Texto: Tamoxifeno desde: 09/10/2013.- Mastectom\u00eda profilactica derecha en 2014 - Recidiva local resecada en enero de 2018.\n",
      "  \u2192 Tamoxifeno (DRUG) [0-10]\n",
      "  \u2192 09/10/2013 (DATE) [18-28]\n",
      "  \u2192 Mastectom\u00eda profilactica derecha (SURGERY) [31-63]\n",
      "  \u2192 2014 (DATE) [67-71]\n",
      "  \u2192 Recidiva local resecada (PROGRESION) [74-97]\n",
      "  \u2192 enero de 2018. (DATE) [101-115]\n",
      "\n",
      "Texto: - En febrero de 2018 cambio a letrozol por sospecha de progresi\u00f3n pulmonar.\n",
      "  \u2192 febrero de 2018 (DATE) [5-20]\n",
      "  \u2192 cambio (OCURRENCE_EVENT) [21-27]\n",
      "  \u2192 letrozol (DRUG) [30-38]\n",
      "  \u2192 progresi\u00f3n pulmonar (PROGRESION) [55-74]\n",
      "\n",
      "Texto: - Sustituido letrzol por faslodex por rotura tendon de aquiles en febrero 2019.\n",
      "  \u2192 Sustituido (OCURRENCE_EVENT) [2-12]\n",
      "  \u2192 letrzol (DRUG) [13-20]\n",
      "  \u2192 faslodex (DRUG) [25-33]\n",
      "  \u2192 ro (SURGERY) [38-40]\n",
      "  \u2192 febrero 2019. (DATE) [66-79]\n",
      "\n",
      "Texto: Progresion de la enfermedad a expensas sobre todo de afectacion pleural.\n",
      "  \u2192 Progresion de la enfermedad (PROGRESION) [0-27]\n",
      "\n",
      "Texto: La paciente refiere disnea d moderados esfuerzos.\n",
      "\n",
      "Texto: Se compara con PET-TAC previo del 12/02/2020 y con TAC del 24/10/2019. Mastectom\u00eda izquierda, cambios post tratamiento en regi\u00f3n mamaria y axilar izquierdas.\n",
      "  \u2192 12/02/2020 (DATE) [34-44]\n",
      "  \u2192 24/10/2019 (DATE) [59-69]\n",
      "  \u2192 Mastectom\u00eda izquierda (SURGERY) [71-92]\n",
      "\n",
      "Texto: Imagen nodular en regi\u00f3n interna mamaria izquierda, en \u00edntimo contacto con plano muscular, de 2 cm, estable.\n",
      "\n",
      "Texto: Aumento en el n\u00famero y tama\u00f1o de los m\u00faltiples implantes pleurales izquierdos y aumento del derrame pleural izquierdo.\n",
      "\n",
      "Texto: Aparici\u00f3n y crecimiento de m\u00faltiples n\u00f3dulos milim\u00e9tricos en cisura mayor derecha, inespec\u00edficos (peque\u00f1os ganglios paracisurales?, implantes pleurales?...)\n",
      "\n",
      "Texto: Adenopat\u00eda en regi\u00f3n prevascular izquierda, de 2 x 1,9 cm que parece haber crecido discretamente con respecto al PET-TAC previo.\n",
      "  \u2192 Adenopat\u00eda en regi\u00f3n prevascular izquierda (COMORBIDITY) [0-42]\n",
      "\n",
      "Texto: Se objetiva crecimiento de otras adenopat\u00edas localizadas tambi\u00e9n en regi\u00f3n prevascular izquierda (todas ellas de eje corto inferior al cent\u00edmetro) y de peque\u00f1as adenopat\u00edas en regi\u00f3n cardio- fr\u00e9nica bilateral.\n",
      "  \u2192 otras (COMORBIDITY) [27-32]\n",
      "  \u2192 adenopat\u00edas (COMORBIDITY) [33-44]\n",
      "  \u2192 peque\u00f1a (COMORBIDITY) [152-159]\n",
      "  \u2192 adenopat\u00edas (COMORBIDITY) [161-172]\n",
      "\n",
      "Texto: Estabilidad del resto de los ganglios hilio-mediast\u00ednicos.\n",
      "\n",
      "Texto: Estabilidad respecto a TC previo de n\u00f3dulo perif\u00e9rico en l\u00f3bulo inferior izquierdo (7 mm).\n",
      "\n",
      "Texto: Aumento de tama\u00f1o del tronco de la arteria pulmonar, valorar hipertensi\u00f3n pulmonar.\n",
      "  \u2192 hipertensi\u00f3n pulmonar (COMORBIDITY) [61-82]\n",
      "\n",
      "Texto: Hemitiroidectom\u00eda izquierda.\n",
      "  \u2192 Hemitiroidectom\u00eda izquierda (SURGERY) [0-27]\n",
      "\n",
      "Texto: Crecimiento del l\u00f3bulo tiroideo derecho con componente intrator\u00e1cico, improntando pared traqueal.\n",
      "\n",
      "Texto: V\u00eda a\u00e9rea principal permeable.\n",
      "\n",
      "Texto: Engrosamiento generalizado de paredes bronquiales.\n",
      "\n",
      "Texto: En los cortes incluidos de abdomen superior se aprecia LOE hep\u00e1tica izquierda compatible con quiste y colelitiasis.\n",
      "  \u2192 colelitiasis (COMORBIDITY) [102-114]\n",
      "\n",
      "Texto: Mujer de 65 a\u00f1os con diagn\u00f3stico de ca de mama izquierdo multic\u00e9ntrico que ingresa el d\u00eda 17/2/20 para cirug\u00eda programada consistenteen mastectomia izquierda post neoadyuvancia.\n",
      "  \u2192 65 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [21-32]\n",
      "  \u2192 ca de mama izquierdo multic\u00e9ntrico (CANCER_CONCEPT) [36-70]\n",
      "  \u2192 17/2/20 (DATE) [90-97]\n",
      "  \u2192 mastectomia izquierda (SURGERY) [136-157]\n",
      "  \u2192 neoadyuvancia (TREATMENT_NAME) [163-176]\n",
      "\n",
      "Texto: Antecedentes familiares: prima materna cree cancer de ovario con 40 a\u00f1os.\n",
      "  \u2192 prima materna (FAMILY) [25-38]\n",
      "  \u2192 cancer de ovario (CANCER_CONCEPT) [44-60]\n",
      "  \u2192 40 a\u00f1os (AGE) [65-72]\n",
      "\n",
      "Texto: .- Antecedentes personales: Dislipemia.\n",
      "  \u2192 Dislipemia (COMORBIDITY) [28-38]\n",
      "\n",
      "Texto: No alergias medicamentosas conocidas.\n",
      "  \u2192 No alergias medicamentosas conocidas (ALLERGIES) [0-36]\n",
      "\n",
      "Texto: - Intervenciones quir\u00fargicas: 5 legrados.\n",
      "\n",
      "Texto: Refiere disficultad por parte de anestesia de despertarla de la sedaci\u00f3n.\n",
      "  \u2192 anestesia (CLINICAL_SERVICE) [33-42]\n",
      "\n",
      "Texto: - Fumadora 7 cig/ d\u00eda hasta hace 4 d\u00edas.\n",
      "  \u2192 Fumadora (TOXIC_HABITS) [2-10]\n",
      "  \u2192 7 cig (HABIT-QUANTITY) [11-16]\n",
      "  \u2192 d\u00eda (FREQ) [18-21]\n",
      "  \u2192 hace 4 d\u00edas (IMPLICIT_DATE) [28-39]\n",
      "\n",
      "Texto: - Tratamiento habitual: Atorvastatina 20 mg/d\u00eda\n",
      "  \u2192 Atorvastatina (DRUG) [24-37]\n",
      "  \u2192 20 mg/ (DOSE) [38-44]\n",
      "  \u2192 d\u00eda (FREQ) [44-47]\n",
      "\n",
      "Texto: - Antecedentes gineco-obst\u00e9tricos: Menarquia: 14.\n",
      "  \u2192 Menarquia: 14. (GINECOLOGICAL_HISTORY) [35-49]\n",
      "\n",
      "Texto: Menopausia: 51 a\u00f1os.\n",
      "  \u2192 Menopausia (GINECOLOGICAL_HISTORY) [0-10]\n",
      "  \u2192 51 a\u00f1os (AGE) [12-19]\n",
      "\n",
      "Texto: DIAGN\u00d3STICO ANATOMOPATOL\u00d3GICO: BAG de mama izquierda con CARCINOMA INFILTRANTE;- tipo histol\u00f3gico (pendiente de estudio inmunohistoqu\u00edmico);- grado histol\u00f3gico 3 sobre 3 de Nottingham por puntuaci\u00f3n de 8: formaci\u00f3n de t\u00fabulos 3 + pleomorfismo nuclear 3 + mitosis por mm2 1 (2 mitosis / 10 CGA para un CGA de 0.625 mm).\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 CARCINOMA INFILTRANTE (CANCER_CONCEPT) [57-78]\n",
      "  \u2192 3 sobre 3 de Nottingham (STAGE) [160-183]\n",
      "\n",
      "Texto: DIAGN\u00d3STICO ANATOMOPATOL\u00d3GICO: BAG de mama izquierda con CARCINOMA INFILTRANTE;- tipo histol\u00f3gico: NO ESPEC\u00cdFICO (ductal, NOS);- grado histol\u00f3gico 1 sobre 3 de Nottingham por puntuaci\u00f3n de 5: formaci\u00f3n de t\u00fabulos 2 + pleomorfismo nuclear 2 + mitosis por mm2 1 (1 mitosis / 10 CGA para un CGA de 0.625 mm).\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 CARCINOMA INFILTRANTE (CANCER_CONCEPT) [57-78]\n",
      "  \u2192 1 sobre 3 de Nottingham (STAGE) [147-170]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda, pT1c N1a M0 (estadio IIA).\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 pT1c N1a M0 (TNM) [48-59]\n",
      "  \u2192 estadio IIA (STAGE) [61-72]\n",
      "\n",
      "Texto: Intervenida con mastectom\u00eda y linfadenectom\u00eda.\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [16-27]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [30-45]\n",
      "\n",
      "Texto: DIAGN\u00d3STICO ANATOMOPAT\u00d3GICO: Pieza de mastectom\u00eda ahorradora de piel, identificada como izquierda con CARCINOMA DUCTAL INFILTRANTE.\n",
      "  \u2192 DIAGN\u00d3STICO (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 mastectom\u00eda ahorradora de piel (SURGERY) [38-68]\n",
      "  \u2192 CARCINOMA DUCTAL INFILTRANTE (CANCER_CONCEPT) [102-130]\n",
      "\n",
      "Texto: MULTIFOCAL, con cuatro focos, todos ellos en los cuadrantes externos, de borde externo hacia pez\u00f3n: 1\u00ba, mide 19 x 16 mm y est\u00e1 a 2,8 mm del borde profundo, 3 mm del borde superficial, 8 mm del borde externo.\n",
      "\n",
      "Texto: 2\u00ba, mide 4 mm, est\u00e1 a mas de 5 mm de todos los bordes, 3\u00ba, mide 6 mm, est\u00e1 a menos de 1 mm del borde superficial y 4\u00ba, mide 4 mm, est\u00e1 a m\u00e1s de 5 mm de todos los bordes.\n",
      "\n",
      "Texto: Grado histol\u00f3gico 2 de Nottingham, moderadamente diferenciado (diferenciaci\u00f3n tubular, 2; grado nuclear, 2; 21 mitosis en 10 cga, 3)- respeta todos los m\u00e1rgenes quir\u00fargicos (ver informe B13-04276 para borde superficial definitivo)- no se identifica invasi\u00f3n de vasos sangu\u00edneos.\n",
      "  \u2192 Grado histol\u00f3gico 2 de Nottingham (STAGE) [0-33]\n",
      "\n",
      "Texto: ESTADIO PATOL\u00d3GICO (UICC, 7\u00aa ed.): pT1c(4) N1a, en conjunto con estudio de ganglio centinela B13-04199 y linfadenectom\u00eda axilar B13-04276.\n",
      "  \u2192 pT1c(4) (TNM) [35-42]\n",
      "  \u2192 N1a (TNM) [43-46]\n",
      "  \u2192 linfadenectom\u00eda axilar (SURGERY) [105-127]\n",
      "\n",
      "Texto: En total 14 ganglios con 1 macromet\u00e1stasis y 2 micromet\u00e1stasis.\n",
      "  \u2192 macromet\u00e1stasis (CANCER_CONCEPT) [27-42]\n",
      "  \u2192 micromet\u00e1stasis (CANCER_CONCEPT) [47-62]\n",
      "\n",
      "Texto: Carcinoma ductual in situ, focal en la proximidad de dos de los focos de tumor infiltrante, con patr\u00f3n cribiforme, grado nuclear intermedio, sin comedonecrosis.\n",
      "  \u2192 Carcinoma ductual in situ (CANCER_CONCEPT) [0-25]\n",
      "  \u2192 tumor infiltrante (CANCER_CONCEPT) [73-90]\n",
      "  \u2192 comedonecrosis (CANCER_CONCEPT) [145-159]\n",
      "\n",
      "Texto: Mujer diagnosticada con Carcinoma ductal infiltrante hace dos a\u00f1os.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [6-19]\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [24-52]\n",
      "  \u2192 hace dos a\u00f1os (IMPLICIT_DATE) [53-66]\n",
      "\n",
      "Texto: Paciente mujer de 62 a\u00f1os: Carcinoma ductal infiltrante de mama derecha, grado 2, triple negativo, Ki67 30%: pT1c pN0 cM0 (estadio IA), 15 mm.\n",
      "  \u2192 62 a\u00f1os (AGE) [18-25]\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [27-71]\n",
      "  \u2192 grado 2 (STAGE) [73-80]\n",
      "  \u2192 triple negativo (CANCER_CONCEPT) [82-97]\n",
      "  \u2192 Ki67 30% (BIOMARKER) [99-107]\n",
      "  \u2192 pT1c pN0 cM0 (TNM) [109-121]\n",
      "  \u2192 estadio IA (STAGE) [123-133]\n",
      "\n",
      "Texto: Posmenop\u00e1usica * Tumorectom\u00eda de mama derecha + BSGC negativa 13/09/201.\n",
      "  \u2192 Posmenop\u00e1usica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "  \u2192 Tumorectom\u00eda de mama derecha (SURGERY) [17-45]\n",
      "  \u2192 13/09/201 (DATE) [62-71]\n",
      "\n",
      "Texto: Adyuvancia con adriamicina - ciclofosfamida.\n",
      "  \u2192 Adyuvancia (TREATMENT_NAME) [0-10]\n",
      "  \u2192 adriamicina (DRUG) [15-26]\n",
      "  \u2192 ciclofosfamida (DRUG) [29-43]\n",
      "\n",
      "Texto: 1\u00ba ciclo 17/10/2017.\n",
      "  \u2192 1o ciclo (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 17/10/2017 (DATE) [9-19]\n",
      "\n",
      "Texto: 4\u00ba ciclo el 26/12/2017.\n",
      "  \u2192 4o ciclo (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 26/12/2017 (DATE) [12-22]\n",
      "\n",
      "Texto: Hoy se encuentra mejor, m\u00e1s de 24 horas sin fiebre.\n",
      "  \u2192 Hoy (IMPLICIT_DATE) [0-3]\n",
      "\n",
      "Texto: Mujer de 50 a\u00f1os.\n",
      "  \u2192 50 a\u00f1os (AGE) [9-16]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante mama izquierda, grado 2, 34 mm, pT2 N1mi (micromet\u00e1stasis detectadas mediante OSNA en dos ganglios) + carcinoma ductal in situ, de grado citol\u00f3gico intermedio.\n",
      "  \u2192 Carcinoma ductal infiltrante mama izquierda (CANCER_CONCEPT) [0-43]\n",
      "  \u2192 grado 2 (STAGE) [45-52]\n",
      "  \u2192 pT2 N1mi (TNM) [61-69]\n",
      "  \u2192 micromet\u00e1stasis (CANCER_CONCEPT) [71-86]\n",
      "  \u2192 carcinoma ductal in situ (CANCER_CONCEPT) [131-155]\n",
      "\n",
      "Texto: Intervenida el 22/08/2012 mediante mastectom\u00eda simple izquierda ahorradora de piel + linfadenectomia (0/8 ganglios) + reconstrucci\u00f3n mamaria inmediata .\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [0-11]\n",
      "  \u2192 22/08/2012 (DATE) [15-25]\n",
      "  \u2192 mastectom\u00eda simple izquierda ahorradora de piel (SURGERY) [35-82]\n",
      "  \u2192 linfadenectomia (SURGERY) [85-100]\n",
      "  \u2192 reconstrucci\u00f3n mamaria inmediata (SURGERY) [118-150]\n",
      "\n",
      "Texto: Se administra tratamiento bajo esquema AC x 4 Taxotere x 4.\n",
      "  \u2192 AC (DRUG) [39-41]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [42-45]\n",
      "  \u2192 Taxotere (DRUG) [46-54]\n",
      "  \u2192 x 4. (LINE_CICLE_NUMBER) [55-59]\n",
      "\n",
      "Texto: Se administra tratamiento bajo esquema AC x 4 Taxotere x 4.\n",
      "  \u2192 AC (DRUG) [39-41]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [42-45]\n",
      "  \u2192 Taxotere (DRUG) [46-54]\n",
      "  \u2192 x 4. (LINE_CICLE_NUMBER) [55-59]\n",
      "\n",
      "Texto: Se administra tratamiento bajo esquema AC x 4 Taxotere x 4.\n",
      "  \u2192 AC (DRUG) [39-41]\n",
      "  \u2192 x 4 (LINE_CICLE_NUMBER) [42-45]\n",
      "  \u2192 Taxotere (DRUG) [46-54]\n",
      "  \u2192 x 4. (LINE_CICLE_NUMBER) [55-59]\n",
      "\n",
      "Texto: Actualmente con Tamoxifeno desde 03/2013.\n",
      "  \u2192 Tamoxifeno (DRUG) [16-26]\n",
      "  \u2192 03/2013 (DATE) [33-40]\n",
      "\n",
      "Texto: Inici\u00f3 Aromasil en octubre del 2016.\n",
      "  \u2192 Inici\u00f3 (OCURRENCE_EVENT) [0-6]\n",
      "  \u2192 Aromasil (DRUG) [7-15]\n",
      "  \u2192 octubre del 2016. (DATE) [19-36]\n",
      "\n",
      "Texto: Buena tolerancia, vida normal.\n",
      "\n",
      "Texto: Molestias osteomusculares, sobre todo en talones.\n",
      "\n",
      "Texto: Tuvo un spotting hace 2 meses, en caso de sangrado le indsito en que debe acudir a Ginecolog\u00eda.\n",
      "  \u2192 hace 2 meses (IMPLICIT_DATE) [17-29]\n",
      "  \u2192 Ginecolog\u00eda (CLINICAL_SERVICE) [83-94]\n",
      "\n",
      "Texto: EF: sin alteraciones.\n",
      "  \u2192 EF (BIOMARKER) [0-2]\n",
      "\n",
      "Texto: Mujer de 57 a\u00f1os con Carcinoma ductal infiltrante, HER2 positivo.\n",
      "  \u2192 57 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 Carcinoma ductal infiltrante (CANCER_CONCEPT) [21-49]\n",
      "  \u2192 HER2 positivo (BIOMARKER) [51-64]\n",
      "\n",
      "Texto: Tratamiento quimioter\u00e1pico con Adriamicina y Ciclofosfamida, 4 ciclos en Agosto de 2008 .\n",
      "  \u2192 Tratamiento quimioter\u00e1pico (TREATMENT_NAME) [0-26]\n",
      "  \u2192 Adriamicina (DRUG) [31-42]\n",
      "  \u2192 Ciclofosfamida (DRUG) [45-59]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [61-69]\n",
      "  \u2192 Agosto de 2008 (DATE) [73-87]\n",
      "\n",
      "Texto: Tratamiento hormonal adyuvante con tamoxifeno durante 5 a\u00f1os.\n",
      "  \u2192 Tratamiento hormonal adyuvante (TREATMENT_NAME) [0-30]\n",
      "  \u2192 tamoxifeno (DRUG) [35-45]\n",
      "  \u2192 durante 5 a\u00f1os (DURATION) [46-60]\n",
      "\n",
      "Texto: MC:Remitida de unidad de mama (ginecolog\u00eda) para valorar reconstrucci\u00f3n mamaria inmediata.\n",
      "  \u2192 Remitida (OCURRENCE_EVENT) [3-11]\n",
      "  \u2192 unidad de mama (CLINICAL_SERVICE) [15-29]\n",
      "  \u2192 ginecolog\u00eda (CLINICAL_SERVICE) [31-42]\n",
      "  \u2192 reconstrucci\u00f3n mamaria (SURGERY) [57-79]\n",
      "\n",
      "Texto: Antecedentes Personales: Tiroiditis de Hashimoto Intervenida de endometriosis.\n",
      "  \u2192 Tiroiditis de Hashimoto (COMORBIDITY) [25-48]\n",
      "  \u2192 Intervenida (OCURRENCE_EVENT) [49-60]\n",
      "  \u2192 endometriosis (COMORBIDITY) [64-77]\n",
      "\n",
      "Texto: Probable alergia a dexketoprofeno (pero no demostrada).\n",
      "  \u2192 alergia a dexketoprofeno (ALLERGIES) [9-33]\n",
      "\n",
      "Texto: Alergica a olivo y gram\u00edneas.\n",
      "  \u2192 Alergica a olivo y gram\u00edneas (ALLERGIES) [0-28]\n",
      "\n",
      "Texto: No fumadora.\n",
      "  \u2192 No fumadora (TOXIC_HABITS) [0-11]\n",
      "\n",
      "Texto: No f\u00e1rmacos.\n",
      "\n",
      "Texto: Historia actualTras una exploraci\u00f3n rutinaria se diagnostico una lesi\u00f3n en mama izquierda que fue biopsidad con el resultado de carcinoma in situ.\n",
      "  \u2192 diagnostico (OCURRENCE_EVENT) [49-60]\n",
      "  \u2192 carcinoma in situ (CANCER_CONCEPT) [128-145]\n",
      "\n",
      "Texto: Vista por ginecolog\u00eda le recomiendan mastectom\u00eda y bsgc.Exploraci\u00f3n.Mama de peque\u00f1o tama\u00f1o sin alteraciones cut\u00e1neas signficativas.\n",
      "  \u2192 ginecolog\u00eda (CLINICAL_SERVICE) [10-21]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [37-48]\n",
      "  \u2192 Ma (FAMILY) [68-70]\n",
      "\n",
      "Texto: Complejo areola pez\u00f3n de aspecto normal.\n",
      "\n",
      "Texto: Paniculo adiposo normal.\n",
      "\n",
      "Texto: Tejido abdominal donante con volumen justo para reconstrucci\u00f3n aut\u00f3loga pero suficiente para volumen de la mamaLa paciente no desea sacrificio del m\u00fasculo dorsal ancho en la reconstrucci\u00f3n mamaria.\n",
      "  \u2192 reconstrucci\u00f3n (SURGERY) [48-62]\n",
      "  \u2192 reconstrucci\u00f3n mamaria (SURGERY) [174-196]\n",
      "\n",
      "Texto: Se le plantea como soluci\u00f3n ideal el colgajo DIEP, si bien la paciente prefiere pens\u00e1rselo pues no descarta la realizaci\u00f3n de reconstrucci\u00f3n con expansor-protesis por la simplicidad de la t\u00e9cnica.\n",
      "  \u2192 reconstrucci\u00f3n con expansor-protesis (SURGERY) [126-162]\n",
      "\n",
      "Texto: Es fisioterapeuta de este centro y entiende las ventajas e inconvenientes de cada t\u00e9cnica.\n",
      "  \u2192 fisioterapeuta (CLINICAL_SERVICE) [3-17]\n",
      "\n",
      "Texto: Hago petici\u00f3n de BSGC e incluyo en lista de espera.\n",
      "\n",
      "Texto: Acudira el pr\u00f3ximo martes con la decisi\u00f3n concreta de la t\u00e9cnica reconstructiva.\n",
      "\n",
      "Texto: Motivo de Consulta:Traumatismo costal.\n",
      "\n",
      "Texto: Antecedentes Personales- No RAMC.\n",
      "  \u2192 No RAMC (ALLERGIES) [25-32]\n",
      "\n",
      "Texto: - No HTA, no DM, no DL.\n",
      "  \u2192 No HTA (COMORBIDITY) [2-8]\n",
      "  \u2192 no DM (COMORBIDITY) [10-15]\n",
      "  \u2192 no DL (COMORBIDITY) [17-22]\n",
      "\n",
      "Texto: Exfumadora de un m\u00e1x de 5 cig/d\u00eda, consumidora de 1 clara de cerveza cada 2 d\u00edas.\n",
      "  \u2192 Exfumadora (TOXIC_HABITS) [0-10]\n",
      "  \u2192 5 cig (HABIT-QUANTITY) [24-29]\n",
      "  \u2192 d\u00eda (FREQ) [30-33]\n",
      "  \u2192 consumidora (TOXIC_HABITS) [35-46]\n",
      "  \u2192 1 clara de cerveza (HABIT-QUANTITY) [50-68]\n",
      "  \u2192 cada 2 d\u00edas (FREQ) [69-80]\n",
      "\n",
      "Texto: Carcinoma de mama izquierda tratada con mastectom\u00eda + BSGC en 10/2016.\n",
      "  \u2192 Carcinoma de mama izquierda (CANCER_CONCEPT) [0-27]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [28-35]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [40-51]\n",
      "  \u2192 10/2016 (DATE) [62-69]\n",
      "\n",
      "Texto: Adenocarcinoma de endometrio, tipo histol\u00f3gico endometrioide, grado histol\u00f3gico 2 (FIGO), intervenido.\n",
      "  \u2192 Adenocarcinoma de endometrio (CANCER_CONCEPT) [0-28]\n",
      "  \u2192 grado histol\u00f3gico 2 (STAGE) [62-81]\n",
      "\n",
      "Texto: Gastritis H. pylori positiva tratada, sin confirmar erradicaci\u00f3n.\n",
      "  \u2192 Gastritis H. pylori positiva (COMORBIDITY) [0-28]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [29-36]\n",
      "\n",
      "Texto: Pacientee con Hipotiroidismo en tratamiento.\n",
      "  \u2192 Hipotiroidismo (COMORBIDITY) [14-28]\n",
      "\n",
      "Texto: Con Osteoporosis en tratamiento, aplastamientos vertebrales.\n",
      "  \u2192 Osteoporosis (COMORBIDITY) [4-16]\n",
      "\n",
      "Texto: En tratamiento con Forsteo durante 2 a\u00f1os.\n",
      "  \u2192 Forsteo (DRUG) [19-26]\n",
      "  \u2192 durante 2 a\u00f1os (DURATION) [27-41]\n",
      "\n",
      "Texto: Paciente diagnosticado con adenocarcinoma de endometrio.\n",
      "  \u2192 diagnosticado (OCURRENCE_EVENT) [9-22]\n",
      "  \u2192 adenocarcinoma de endometrio (CANCER_CONCEPT) [27-55]\n",
      "\n",
      "Texto: Me avisan para valoraci\u00f3n de mujer de 91 a\u00f1os con episodio de desconexi\u00f3n del medio.\n",
      "  \u2192 91 a\u00f1os (AGE) [38-45]\n",
      "\n",
      "Texto: Antecedentes personales- Alergia a penicilina.\n",
      "  \u2192 Alergia a penicilina (ALLERGIES) [25-45]\n",
      "\n",
      "Texto: No otras RAMc.\n",
      "  \u2192 No otras RAMc (ALLERGIES) [0-13]\n",
      "\n",
      "Texto: HTA, DM2.\n",
      "  \u2192 HTA (COMORBIDITY) [0-3]\n",
      "  \u2192 DM2. (COMORBIDITY) [5-9]\n",
      "\n",
      "Texto: No DL.\n",
      "  \u2192 No DL (COMORBIDITY) [0-5]\n",
      "\n",
      "Texto: H\u00e1bitos t\u00f3xicos: no fumadora, no bebedora habitual.\n",
      "  \u2192 fumadora (TOXIC_HABITS) [20-28]\n",
      "  \u2192 bebedora habitual (TOXIC_HABITS) [33-50]\n",
      "\n",
      "Texto: Antecedentes personales: Carcinoma de mama en 2016,\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [25-42]\n",
      "  \u2192 2016, (DATE) [46-51]\n",
      "\n",
      "Texto: Carcinoma de recto de 4 cm en 2001 tratada con cirug\u00eda amputaci\u00f3n abdominal, histerectom\u00eda y doble anexectom\u00eda, estadio B.\n",
      "  \u2192 Carcinoma de recto (CANCER_CONCEPT) [0-18]\n",
      "  \u2192 2001 (DATE) [30-34]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [35-42]\n",
      "  \u2192 cirug\u00eda amputaci\u00f3n abdominal (SURGERY) [47-75]\n",
      "  \u2192 histerectom\u00eda (SURGERY) [77-90]\n",
      "  \u2192 doble anexectom\u00eda (SURGERY) [93-110]\n",
      "  \u2192 estadio B (STAGE) [112-121]\n",
      "\n",
      "Texto: Anatom\u00eda patol\u00f3gica: adenocarcinoma de recto de 5,3 cm, invasi\u00f3n hasta muscular profunda, bordes libres, a 1.7 cm de l\u00ednea pect\u00ednea, 17 ganglios negativos.\n",
      "  \u2192 adenocarcinoma de recto (CANCER_CONCEPT) [21-44]\n",
      "\n",
      "Texto: Niega episodios previos de desconexi\u00f3n del medio, automatismos ni clon\u00edas.\n",
      "\n",
      "Texto: Tamposo episodios previos de focalidad.\n",
      "\n",
      "Texto: No cuenta palpitaciones ni dolor tor\u00e1cico actual.\n",
      "\n",
      "Texto: A mi valoraci\u00f3n, nerviosa por lo sucedido, pero se encuentra bien y cl\u00ednicamente asintom\u00e1tica.\n",
      "\n",
      "Texto: Comenta que la bolsa de colostom\u00eda se encontraba llena de heces con abundante gas, y la recambi\u00f3 antes de venir al hospital.\n",
      "  \u2192 colostom\u00eda (SURGERY) [24-34]\n",
      "\n",
      "Texto: MMII: no edema ni signos de TVP.\n",
      "  \u2192 TVP (COMORBIDITY) [28-31]\n",
      "\n",
      "Texto: Paciente que derivan de Hospital Quir\u00f3n con diagn\u00f3stico de carcinoma ductal infiltrante de mama izquierda metast\u00e1sico (\u00f3seas y m.o.) en febrero de 2009, tras tratamiento con Taxol + Hercept\u00edn, en tratamiento actual con xeloda + lapatinib, que su sociedad m\u00e9dica ha dejado de cubrir.\n",
      "  \u2192 derivan (OCURRENCE_EVENT) [13-20]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [44-55]\n",
      "  \u2192 carcinoma ductal infiltrante de mama izquierda metast\u00e1sico (CANCER_CONCEPT) [59-117]\n",
      "  \u2192 febrero de 2009, (DATE) [136-152]\n",
      "  \u2192 tras tratamiento (OCURRENCE_EVENT) [153-169]\n",
      "  \u2192 Taxol (DRUG) [174-179]\n",
      "  \u2192 Hercept\u00edn (DRUG) [182-191]\n",
      "  \u2192 xeloda (DRUG) [219-225]\n",
      "  \u2192 lapatinib (DRUG) [228-237]\n",
      "\n",
      "Texto: ANTECEDENTES PERSONALES - ALERGIA A AMOXICILINA.\n",
      "  \u2192 ALERGIA A AMOXICILINA (ALLERGIES) [26-47]\n",
      "\n",
      "Texto: Intolerancia a lactosa, fructosa y edulcorantes.\n",
      "\n",
      "Texto: Edad del primer embarazo 37 a\u00f1os.\n",
      "  \u2192 primer embarazo (GINE_OBSTETRICS) [9-24]\n",
      "  \u2192 37 a\u00f1os (AGE) [25-32]\n",
      "\n",
      "Texto: Premenopausica.\n",
      "  \u2192 Premenopausica (GINECOLOGICAL_HISTORY) [0-14]\n",
      "\n",
      "Texto: HISTORIA ONCOL\u00d3GICA Paciente diagnosticada de CDI de mama izquierda estadio IV (\u00f3seas y MO) en febrero de 2009.\n",
      "  \u2192 diagnosticada (OCURRENCE_EVENT) [29-42]\n",
      "  \u2192 CDI de mama izquierda (CANCER_CONCEPT) [46-67]\n",
      "  \u2192 estadio IV (STAGE) [68-78]\n",
      "  \u2192 febrero de 2009. (DATE) [95-111]\n",
      "\n",
      "Texto: Cl\u00ednica al diagn\u00f3stico: Dolor \u00f3seo y masa palpable en mama izquierda con adenopat\u00edas axilares.\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [11-22]\n",
      "  \u2192 adenopat\u00edas axilares (COMORBIDITY) [73-93]\n",
      "\n",
      "Texto: Recibi\u00f3 al diagn\u00f3stico tratamiento de quimioterapia con TAXOL - AVAST\u00cdN semanal recibiendo una s\u00f3la dosis por TEP y por precesos infecciosos graves m\u00faltiples.\n",
      "  \u2192 Recibi\u00f3 (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [11-22]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [38-51]\n",
      "  \u2192 TAXOL (DRUG) [56-61]\n",
      "  \u2192 AVAST\u00cdN (DRUG) [64-71]\n",
      "  \u2192 semanal (FREQ) [72-79]\n",
      "\n",
      "Texto: Tras confirmar positividad HER-2 se inicia tratamiento con HERCEPT\u00cdN semanal presentando excelente respuesta cl\u00ednica con desaparici\u00f3n completa de la masa de la mama izquierda y adenopat\u00edas palpables axilares.\n",
      "  \u2192 Tras confirmar (OCURRENCE_EVENT) [0-14]\n",
      "  \u2192 positividad HER-2 (BIOMARKER) [15-32]\n",
      "  \u2192 inicia tratamiento (OCURRENCE_EVENT) [36-54]\n",
      "  \u2192 HERCEPT\u00cdN (DRUG) [59-68]\n",
      "  \u2192 semanal (FREQ) [69-76]\n",
      "  \u2192 adenopat\u00edas palpables axilares (COMORBIDITY) [177-207]\n",
      "\n",
      "Texto: Inicia tratamiento con Taxol semanal (1\u00aa dosis 12.06.2009), que finaliza el d\u00eda 13-04-2010.\n",
      "  \u2192 Inicia tratamiento (OCURRENCE_EVENT) [0-18]\n",
      "  \u2192 Taxol (DRUG) [23-28]\n",
      "  \u2192 semanal (FREQ) [29-36]\n",
      "  \u2192 (1a dosis (DOSE) [37-46]\n",
      "  \u2192 12.06.2009 (DATE) [47-57]\n",
      "  \u2192 finaliza (OCURRENCE_EVENT) [64-72]\n",
      "  \u2192 13-04-2010 (DATE) [80-90]\n",
      "\n",
      "Texto: Est\u00e1 con Tamoxifeno desde el 10 de mayo.\n",
      "  \u2192 Tamoxifeno (DRUG) [9-19]\n",
      "  \u2192 10 de mayo (DATE) [29-39]\n",
      "\n",
      "Texto: Tambi\u00e9n ha recibido RT sobre las met\u00e1stasis \u00f3seas en columna cervical de 50 Gy.\n",
      "  \u2192 RT (TREATMENT_NAME) [20-22]\n",
      "  \u2192 met\u00e1stasis \u00f3seas (CANCER_CONCEPT) [33-49]\n",
      "  \u2192 50 Gy (DOSE) [73-78]\n",
      "\n",
      "Texto: Juicio cl\u00ednico: - Carcinoma Ductal infiltrante de mama derecha T2N0M0.\n",
      "  \u2192 Carcinoma Ductal infiltrante de mama derecha (CANCER_CONCEPT) [18-62]\n",
      "  \u2192 T2N0M0 (TNM) [63-69]\n",
      "\n",
      "Texto: Mujer Premenopausica, Her2 negativo.\n",
      "  \u2192 Premenopausica (GINECOLOGICAL_HISTORY) [6-20]\n",
      "  \u2192 Her2 negativo (BIOMARKER) [22-35]\n",
      "\n",
      "Texto: Paciente de 47 a\u00f1os remitida de su centro de salud por cefalea.\n",
      "  \u2192 47 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 remitida (OCURRENCE_EVENT) [20-28]\n",
      "\n",
      "Texto: Antecedentes personales- Niega reacciones al\u00e9rgicas o medicamentosas conocidas.\n",
      "  \u2192 Niega reacciones al\u00e9rgicas o medicamentosas conocidas (ALLERGIES) [25-78]\n",
      "\n",
      "Texto: - No t\u00f3xicos.\n",
      "\n",
      "Texto: No HTA, No DM2 ni Dislipemias.\n",
      "  \u2192 No HTA (COMORBIDITY) [0-6]\n",
      "  \u2192 No DM2 (COMORBIDITY) [8-14]\n",
      "  \u2192 ni Dislipemias (COMORBIDITY) [15-29]\n",
      "\n",
      "Texto: Mujer con Carcinoma de mama pT1 (m) N0 M0 (estadio IA), G2 con RE y P positivo, HER-2 negativo.\n",
      "  \u2192 Carcinoma de mama (CANCER_CONCEPT) [10-27]\n",
      "  \u2192 pT1 (TNM) [28-31]\n",
      "  \u2192 N0 M0 (TNM) [36-41]\n",
      "  \u2192 estadio IA (STAGE) [43-53]\n",
      "  \u2192 G2 (STAGE) [56-58]\n",
      "  \u2192 RE y P positivo (BIOMARKER) [63-78]\n",
      "  \u2192 HER-2 negativo (BIOMARKER) [80-94]\n",
      "\n",
      "Texto: Ki67: 350 el mayor.\n",
      "  \u2192 Ki67: 350 (BIOMARKER) [0-9]\n",
      "\n",
      "Texto: Tratada con cirug\u00eda, QT ( 4 ciclos AC) y tamoxifeno - Quir\u00fargicos: hallux valgus derecho, varices, mastectom\u00eda con reconstrucci\u00f3n posterior.\n",
      "  \u2192 Tratada (OCURRENCE_EVENT) [0-7]\n",
      "  \u2192 cirug\u00eda (SURGERY) [12-19]\n",
      "  \u2192 QT (TREATMENT_NAME) [21-23]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [26-34]\n",
      "  \u2192 AC (DRUG) [35-37]\n",
      "  \u2192 tamoxifeno (DRUG) [41-51]\n",
      "  \u2192 hallux valgus derecho (SURGERY) [67-88]\n",
      "  \u2192 varices (SURGERY) [90-97]\n",
      "  \u2192 mastectom\u00eda con reconstrucci\u00f3n posterior (SURGERY) [99-139]\n",
      "\n",
      "Texto: Medicaci\u00f3n actual: Tamoxifeno desde hace 1 a\u00f1os\n",
      "  \u2192 Tamoxifeno (DRUG) [19-29]\n",
      "  \u2192 hace 1 a\u00f1os (IMPLICIT_DATE) [36-47]\n",
      "\n",
      "Texto: Vida activa.\n",
      "\n",
      "Texto: Historia actual:: Desde hace 1 semana presenta cuadro de cefalea retroocular y occipital constante que se irradia por el resto de la columna.\n",
      "  \u2192 hace 1 semana (IMPLICIT_DATE) [24-37]\n",
      "\n",
      "Texto: Se asocia a sensacion de parestesias en pies ( como si los tuviese acorchados), y nota p\u00e9rdida de fuerza y hormigueo en las manos , aunque no se le llegan a caer los objetos de las manos.\n",
      "\n",
      "Texto: Nota nauseas y ha tenido alg\u00fan v\u00f3mito bilioalimentario.\n",
      "\n",
      "Texto: No fiebre.\n",
      "\n",
      "Texto: Interrogada por \u00f3rganos y aparatos refiere haber notado un bulto en hipogastrio (pr\u00f3ximo a la cicatriz de donde se extrajo el colgajo para reconstrucci\u00f3n mamaria) desde hace un mes.\n",
      "  \u2192 reconstrucci\u00f3n mamaria (SURGERY) [139-161]\n",
      "  \u2192 hace un mes (IMPLICIT_DATE) [169-180]\n",
      "\n",
      "Texto: No s\u00edndrome miccional ni alteraci\u00f3n del ritmo intestinal.\n",
      "\n",
      "Texto: Exploraci\u00f3n f\u00edsicaTA 122/84 mmhg, FC 67 lpm, sato21 99 BEG, bien perfundida, eupneica, sobrepeso.\n",
      "  \u2192 sobrepeso (COMORBIDITY) [87-96]\n",
      "\n",
      "Texto: T\u00f3rax: AC: r\u00edtmica sin soplos, AP: murmullo vesicular conservado.\n",
      "  \u2192 sin soplos (COMORBIDITY) [19-29]\n",
      "\n",
      "Texto: Abdomen blando, no doloroso, se palpa masa redondeada de unos 5 cm de di\u00e1metro, duda en zona suprap\u00fabica.\n",
      "\n",
      "Texto: No signos inflamatorios.\n",
      "\n",
      "Texto: Previsto inicar Quimioteraia seg\u00fan esquema Doxorrubicina 60 mg/m2 dia 1 y Ciclofosfamida 600 mg/ m2 dia 1 cada 21 dias por 4 ciclos seguidos de PACLITAXEL 80 mg/ m2 dia 1 semanal por 12 semnas.\n",
      "  \u2192 Quimioteraia (TREATMENT_NAME) [16-28]\n",
      "  \u2192 Doxorrubicina (DRUG) [43-56]\n",
      "  \u2192 60 mg/m2 (DOSE) [57-65]\n",
      "  \u2192 Ciclofosfamida (DRUG) [74-88]\n",
      "  \u2192 600 mg/ m2 (DOSE) [89-99]\n",
      "  \u2192 cada 21 dias (FREQ) [106-118]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [123-131]\n",
      "  \u2192 PACLITAXEL (DRUG) [144-154]\n",
      "  \u2192 80 mg/ m2 (DOSE) [155-164]\n",
      "  \u2192 semanal (FREQ) [171-178]\n",
      "\n",
      "Texto: Se explican efectos secundarios y beneficios del tratamietno que entiende y acepta.\n",
      "\n",
      "Texto: Acompa\u00f1ada de su marido.\n",
      "\n",
      "Texto: Previsto inicar Quimioteraia seg\u00fan esquema Doxorrubicina 60 mg/m2 dia 1 y Ciclofosfamida 600 mg/ m2 dia 1 cada 21 dias por 4 ciclos seguidos de PACLITAXEL 80 mg/ m2 dia 1 semanal por 12 semanas.\n",
      "  \u2192 Quimioteraia (TREATMENT_NAME) [16-28]\n",
      "  \u2192 Doxorrubicina (DRUG) [43-56]\n",
      "  \u2192 60 mg/m2 (DOSE) [57-65]\n",
      "  \u2192 Ciclofosfamida (DRUG) [74-88]\n",
      "  \u2192 600 mg/ m2 (DOSE) [89-99]\n",
      "  \u2192 cada 21 dias (FREQ) [106-118]\n",
      "  \u2192 4 ciclos (LINE_CICLE_NUMBER) [123-131]\n",
      "  \u2192 PACLITAXEL (DRUG) [144-154]\n",
      "  \u2192 80 mg/ m2 (DOSE) [155-164]\n",
      "  \u2192 semanal (FREQ) [171-178]\n",
      "  \u2192 semanas (DURATION) [186-193]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha pT2N1M0, mastectom\u00eda m\u00e1s linfadenectom\u00eda en enero 2011.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 pT2N1M0 (TNM) [45-52]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [54-65]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [70-85]\n",
      "  \u2192 enero 2011. (DATE) [89-100]\n",
      "\n",
      "Texto: Receptores de estr\u00f3genos y progesterona positivos al 99%.\n",
      "  \u2192 Receptores de estr\u00f3genos y progesterona positivos al 99% (BIOMARKER) [0-56]\n",
      "\n",
      "Texto: HER-2 negativos.\n",
      "  \u2192 HER-2 negativos (BIOMARKER) [0-15]\n",
      "\n",
      "Texto: Reca\u00edda hep\u00e1tica y dudosa pulmonar confirmada histol\u00f3gicamente en diciembre 2016.\n",
      "  \u2192 Reca\u00edda hep\u00e1tica (PROGRESION) [0-16]\n",
      "  \u2192 diciembre 2016. (DATE) [66-81]\n",
      "\n",
      "Texto: Capecitabina 1800 mg/12h el 07-12-2016.\n",
      "  \u2192 Capecitabina (DRUG) [0-12]\n",
      "  \u2192 1800 mg/12h (DOSE) [13-24]\n",
      "  \u2192 07-12-2016 (DATE) [28-38]\n",
      "\n",
      "Texto: 2\u00ba ciclo reducido el 28-12-16.\n",
      "  \u2192 2o ciclo (LINE_CICLE_NUMBER) [0-8]\n",
      "  \u2192 reducido (OCURRENCE_EVENT) [9-17]\n",
      "  \u2192 28-12-16 (DATE) [21-29]\n",
      "\n",
      "Texto: Diarrea G2-3 Emesis Sindrome mano-pie G2.\n",
      "\n",
      "Texto: CONTROL DE TRATAMIENTOTuvo cefalea evaluada en Urgencias.\n",
      "  \u2192 Urgencias (CLINICAL_SERVICE) [47-56]\n",
      "\n",
      "Texto: S\u00edntomas de infecci\u00f3n respiratoria de v\u00edas altas.\n",
      "\n",
      "Texto: Ha tenido fiebre de 38 \u00baC.\n",
      "\n",
      "Texto: Hoy no fiebre.\n",
      "\n",
      "Texto: Diarrea.\n",
      "\n",
      "Texto: No dolor abdominal.\n",
      "\n",
      "Texto: Finaliz\u00f3 capecitabina el d\u00eda 07/02/2019, Para ciclos siguientes requerir\u00e1 dosis de tratamiento concomitante.\n",
      "  \u2192 Finaliz\u00f3 (OCURRENCE_EVENT) [0-8]\n",
      "  \u2192 capecitabina (DRUG) [9-21]\n",
      "  \u2192 07/02/2019 (DATE) [29-39]\n",
      "\n",
      "Texto: Dosis 6 Gy.\n",
      "  \u2192 is (DOSE) [3-5]\n",
      "  \u2192 6 Gy (DOSE) [6-10]\n",
      "\n",
      "Texto: CICLO 2 CAPECITABINA + ZOMETA Mejor del dolor .\n",
      "  \u2192 CICLO 2 (LINE_CICLE_NUMBER) [0-7]\n",
      "  \u2192 CAPECITABINA (DRUG) [8-20]\n",
      "  \u2192 ZOMETA (DRUG) [23-29]\n",
      "\n",
      "Texto: Paciente que ingresa desde consulta por derrame peric\u00e1rdico.\n",
      "\n",
      "Texto: Tx cardiaco hace 7 a\u00f1os.\n",
      "  \u2192 hace 7 a\u00f1os (IMPLICIT_DATE) [12-23]\n",
      "\n",
      "Texto: Actualmente afecta de Ca ductal de mama estad\u00edo IV con afectaci\u00f3n osea y ganglionar fundamentalmente, en tratamiento con capecitabina con mejor\u00eda de lesiones en PET TC \u00faltimo.\n",
      "  \u2192 Ca ductal de mama (CANCER_CONCEPT) [22-39]\n",
      "  \u2192 estad\u00edo IV (STAGE) [40-50]\n",
      "  \u2192 capecitabina (DRUG) [121-133]\n",
      "\n",
      "Texto: Actualmente afecta de Ca ductal de mama estad\u00edo IV con afectaci\u00f3n osea y ganglionar fundamentalmente, en tratamiento con capecitabina con mejor\u00eda de lesiones en PET TC \u00faltimo.\n",
      "  \u2192 Ca ductal de mama (CANCER_CONCEPT) [22-39]\n",
      "  \u2192 estad\u00edo IV (STAGE) [40-50]\n",
      "  \u2192 capecitabina (DRUG) [121-133]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os con antecedentes de Ca de Mama tratada con mastectom\u00eda, linfadenectom\u00eda(2011)y tamoxifeno (acab\u00f3 en 2016) que acude por diarrea y cefalea durante el d\u00eda de ayer.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 Ca de Mama (CANCER_CONCEPT) [37-47]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [48-55]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [60-71]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [73-88]\n",
      "  \u2192 2011 (DATE) [89-93]\n",
      "  \u2192 tamoxifeno (DRUG) [96-106]\n",
      "  \u2192 2016) (DATE) [117-122]\n",
      "  \u2192 ayer (IMPLICIT_DATE) [173-177]\n",
      "\n",
      "Texto: Mujer de 48 a\u00f1os con antecedentes de Ca de Mama tratada con mastectom\u00eda, linfadenectom\u00eda(2011)y tamoxifeno (acab\u00f3 en 2016) que acude por diarrea y cefalea durante el d\u00eda de ayer.\n",
      "  \u2192 48 a\u00f1os (AGE) [9-16]\n",
      "  \u2192 Ca de Mama (CANCER_CONCEPT) [37-47]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [48-55]\n",
      "  \u2192 mastectom\u00eda (SURGERY) [60-71]\n",
      "  \u2192 linfadenectom\u00eda (SURGERY) [73-88]\n",
      "  \u2192 2011 (DATE) [89-93]\n",
      "  \u2192 tamoxifeno (DRUG) [96-106]\n",
      "  \u2192 2016) (DATE) [117-122]\n",
      "  \u2192 ayer (IMPLICIT_DATE) [173-177]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama derecha G3 RRHH+ HER -, Ki 50%, inicialmente cT2 pN+ cM0 en mujer premenop\u00e1usica, tratado con QT neoadyuvante, con respuesta radiol\u00f3gica completa, se realiz\u00f3 tumorectom\u00eda y LA, ypTispNocM0, recibiendo posteriomente 25 sesiones RT.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [0-44]\n",
      "  \u2192 G3 (STAGE) [45-47]\n",
      "  \u2192 RRHH+ (BIOMARKER) [48-53]\n",
      "  \u2192 HER - (BIOMARKER) [54-59]\n",
      "  \u2192 Ki 50% (BIOMARKER) [61-67]\n",
      "  \u2192 cT2 pN+ cM0 (TNM) [82-93]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [119-126]\n",
      "  \u2192 QT neoadyuvante (TREATMENT_NAME) [131-146]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [195-207]\n",
      "  \u2192 LA (SURGERY) [210-212]\n",
      "  \u2192 ypTispNocM0 (TNM) [214-225]\n",
      "  \u2192 25 sesiones (DOSE) [252-263]\n",
      "  \u2192 RT (TREATMENT_NAME) [264-266]\n",
      "\n",
      "Texto: Actualmente en tratamiento con tamoxifeno desde 2012 (Zoladex durante el primer a\u00f1o).\n",
      "  \u2192 tamoxifeno (DRUG) [31-41]\n",
      "  \u2192 2012 (DATE) [48-52]\n",
      "  \u2192 Zoladex (DRUG) [54-61]\n",
      "\n",
      "Texto: Actualmente en tratamiento con tamoxifeno desde 2012.\n",
      "  \u2192 tamoxifeno (DRUG) [31-41]\n",
      "  \u2192 2012. (DATE) [48-53]\n",
      "\n",
      "Texto: Juicio diagn\u00f3stico: carcinoma infiltrante de mama patron mixto (tubulo-lobulillar) pT2N1M0 (septiembre 2009) tratada con mastectomia, quimioterapia y tamoxifeno posterior.\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [7-18]\n",
      "  \u2192 carcinoma infiltrante de mama patron mixto (CANCER_CONCEPT) [20-62]\n",
      "  \u2192 pT2N1M0 (TNM) [83-90]\n",
      "  \u2192 septiembre 2009) (DATE) [92-108]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [109-116]\n",
      "  \u2192 mastectomia (SURGERY) [121-132]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [134-147]\n",
      "  \u2192 tamoxifeno (DRUG) [150-160]\n",
      "\n",
      "Texto: Juicio diagn\u00f3stico: carcinoma infiltrante de mama patron mixto (tubulo-lobulillar) pT2N1M0 (septiembre 2009) tratada con mastectomia, quimioterapia y tamoxifeno posterior.\n",
      "  \u2192 diagn\u00f3stico (OCURRENCE_EVENT) [7-18]\n",
      "  \u2192 carcinoma infiltrante de mama patron mixto (CANCER_CONCEPT) [20-62]\n",
      "  \u2192 pT2N1M0 (TNM) [83-90]\n",
      "  \u2192 septiembre 2009) (DATE) [92-108]\n",
      "  \u2192 tratada (OCURRENCE_EVENT) [109-116]\n",
      "  \u2192 mastectomia (SURGERY) [121-132]\n",
      "  \u2192 quimioterapia (TREATMENT_NAME) [134-147]\n",
      "  \u2192 tamoxifeno (DRUG) [150-160]\n",
      "\n",
      "Texto: Ca de mama ductal infiltrante T3N2M0, Her2 positivo.\n",
      "  \u2192 Ca de mama ductal infiltrante (CANCER_CONCEPT) [0-29]\n",
      "  \u2192 T3N2M0 (TNM) [30-36]\n",
      "  \u2192 Her2 positivo (BIOMARKER) [38-51]\n",
      "\n",
      "Texto: Ca de mama ductal infiltrante T3N2M0, Her2 +.\n",
      "  \u2192 Ca de mama ductal infiltrante (CANCER_CONCEPT) [0-29]\n",
      "  \u2192 T3N2M0 (TNM) [30-36]\n",
      "  \u2192 Her2 + (BIOMARKER) [38-44]\n",
      "\n",
      "Texto: Carcinoma ductal infiltrante de mama izquierda, en mayo 2012, pT1c N0(sn) M0.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama izquierda (CANCER_CONCEPT) [0-46]\n",
      "  \u2192 mayo 2012, (DATE) [51-61]\n",
      "  \u2192 pT1c N0(sn) M0 (TNM) [62-76]\n",
      "\n",
      "Texto: RH+.\n",
      "  \u2192 RH+ (BIOMARKER) [0-3]\n",
      "\n",
      "Texto: Her 2 negativo.\n",
      "  \u2192 Her 2 negativo (BIOMARKER) [0-14]\n",
      "\n",
      "Texto: Tamoxifeno (desde 14/8/12).\n",
      "  \u2192 Tamoxifeno (DRUG) [0-10]\n",
      "  \u2192 14/8/12 (DATE) [18-25]\n",
      "\n",
      "Texto: Fuma 10 cig/d\u00eda por estres ocasionado por el ca de mama.\n",
      "  \u2192 Fuma (TOXIC_HABITS) [0-4]\n",
      "  \u2192 10 cig (HABIT-QUANTITY) [5-11]\n",
      "  \u2192 d\u00eda (FREQ) [12-15]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [45-55]\n",
      "\n",
      "Texto: No quiere ayuda de psicologos.\n",
      "\n",
      "Texto: Acude se encuentra bien asintmatica, solo que persisten molestias en la cicatriz.\n",
      "\n",
      "Texto: Tiene reglas irregulares.\n",
      "  \u2192 reglas irregulares (GINECOLOGICAL_HISTORY) [6-24]\n",
      "\n",
      "Texto: Revision en 6 meses.\n",
      "\n",
      "Texto: Paciente de 47 a\u00f1os con antecedentes de -ca de mama , hasta hace 3 a\u00f1os en tratamiento con tamoxifeno, hace una semana le cambiaron el tratamiento.\n",
      "  \u2192 47 a\u00f1os (AGE) [12-19]\n",
      "  \u2192 -ca de mama (CANCER_CONCEPT) [40-51]\n",
      "  \u2192 hace 3 a\u00f1os (IMPLICIT_DATE) [60-71]\n",
      "  \u2192 tamoxifeno (DRUG) [91-101]\n",
      "  \u2192 hace una semana (IMPLICIT_DATE) [103-118]\n",
      "\n",
      "Texto: Antecedentes personales:- Niega reacciones al\u00e9rgicas o medicamentosas conocidas.\n",
      "  \u2192 Niega reacciones al\u00e9rgicas o medicamentosas conocidas (ALLERGIES) [26-79]\n",
      "\n",
      "Texto: Niega HTA, DM2 o Dislipemias.\n",
      "  \u2192 Niega HTA, DM2 o Dislipemias (COMORBIDITY) [0-28]\n",
      "\n",
      "Texto: Migra\u00f1a, Hernia discal lumbar .\n",
      "  \u2192 Migra\u00f1a (COMORBIDITY) [0-7]\n",
      "  \u2192 Hernia discal lumbar (COMORBIDITY) [9-29]\n",
      "\n",
      "Texto: Quir\u00fargicos: Resecci\u00f3n de quiste tirogloso, tumorectom\u00eda de mama derecha.\n",
      "  \u2192 Resecci\u00f3n de quiste tirogloso (SURGERY) [13-42]\n",
      "  \u2192 tumorectom\u00eda de mama derecha (SURGERY) [44-72]\n",
      "\n",
      "Texto: Toxicol\u00f3gicos: Exfumadora desde hace 8 a\u00f1os.\n",
      "  \u2192 Exfumadora (TOXIC_HABITS) [15-25]\n",
      "  \u2192 hace 8 a\u00f1os (IMPLICIT_DATE) [32-43]\n",
      "\n",
      "Texto: Medicaci\u00f3n actual: Magnesio BOI 2 com/d\u00eda.\n",
      "  \u2192 Magnesio BOI (DRUG) [19-31]\n",
      "  \u2192 2 com (DOSE) [32-37]\n",
      "  \u2192 d\u00eda (FREQ) [38-41]\n",
      "\n",
      "Texto: Situaci\u00f3n basal: IABVD.\n",
      "\n",
      "Texto: Antecedentes oncol\u00f3gicos familiares: Padre con ca de pr\u00f3stata a los 62 a\u00f1os.\n",
      "  \u2192 Padre (FAMILY) [37-42]\n",
      "  \u2192 ca de pr\u00f3stata (CANCER_CONCEPT) [47-61]\n",
      "  \u2192 62 a\u00f1os (AGE) [68-75]\n",
      "\n",
      "Texto: T\u00eda materna con ca de mama a los 70 a\u00f1os.\n",
      "  \u2192 T\u00eda materna (FAMILY) [0-11]\n",
      "  \u2192 ca de mama (CANCER_CONCEPT) [16-26]\n",
      "  \u2192 70 a\u00f1os (AGE) [33-40]\n",
      "\n",
      "Texto: Abuela materna fallecida de ca de endometrio.\n",
      "  \u2192 Abuela materna (FAMILY) [0-14]\n",
      "  \u2192 fallecida (OCURRENCE_EVENT) [15-24]\n",
      "  \u2192 ca de endometrio (CANCER_CONCEPT) [28-44]\n",
      "\n",
      "Texto: Acude a control sucesivo mujer de 45 a\u00f1os.\n",
      "  \u2192 45 a\u00f1os (AGE) [34-41]\n",
      "\n",
      "Texto: Mujerr con Carcinoma ductal infiltrante de mama derecha, pT1c N0 M0 (Estadio IA) tratado con tumorectom\u00eda en Mayo 2013.\n",
      "  \u2192 Carcinoma ductal infiltrante de mama derecha (CANCER_CONCEPT) [11-55]\n",
      "  \u2192 pT1c N0 M0 (TNM) [57-67]\n",
      "  \u2192 Estadio IA (STAGE) [69-79]\n",
      "  \u2192 tratado (OCURRENCE_EVENT) [81-88]\n",
      "  \u2192 tumorectom\u00eda (SURGERY) [93-105]\n",
      "  \u2192 Mayo 2013. (DATE) [109-119]\n",
      "\n",
      "Texto: Seguimiento por OM y ORT.\n",
      "  \u2192 OM (CLINICAL_SERVICE) [16-18]\n",
      "  \u2192 ORT (CLINICAL_SERVICE) [21-24]\n",
      "\n",
      "Texto: Asintom\u00e1tica salvo las molestias en genitales pese a los tratamientos.\n",
      "\n",
      "Texto: No ha realizado ningun tto en la ultima semana\n",
      "\n",
      "Texto: FUR: 10/09/2016. Ultima citologia no recuerda.\n",
      "  \u2192 FUR (GINECOLOGICAL_HISTORY) [0-3]\n",
      "  \u2192 10/09/2016 (DATE) [5-15]\n",
      "\n",
      "Texto: Refiere reglas normales, quiz\u00e1s mas cortas y escasas.\n",
      "  \u2192 reglas normales (GINECOLOGICAL_HISTORY) [8-23]\n",
      "\n",
      "Texto: Citologia HPV negativa en 2017.\n",
      "  \u2192 2017. (DATE) [26-31]\n",
      "\n",
      "Texto: Exploracion:Ge eritematosos. Vagina normal.\n",
      "\n",
      "Texto: Cx de mult\u00edpara de caracteristicas normales.\n"
     ]
    }
   ]
  },
  {
   "cell_type": "code",
   "source": [],
   "metadata": {
    "id": "wxAjqNIPegl0"
   },
   "execution_count": null,
   "outputs": []
  }
 ]
}
